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ABSTRACT 
Pain, although subjective, is an unpleasant sensation caused by a noxious stimulus, that 
effects millions of people every year. Currently, the most frequently prescribed class of 
analgesics for moderate to severe acute and sometime chronic pain are opioid analgesics, most 
commonly µ-opioid receptor (MOP) agonists, such as oxycodone, morphine, and fentanyl. 
Although these drugs provide significant pain relief, they are also associated with unwelcome 
side effects such as constipation, addiction, physical dependence, respiratory depression, and 
physiological tolerance that leads to hyperalgesia. Receptor desensitization due to excessive 
receptor activation by an agonist is but one source of physiological tolerance; it can also develop 
through the activation of homeostasis-regulating endogenous anti-opioid systems. One of these 
anti-opioid systems, the neuropeptide FF (NPFF) system, which is comprised of two receptor 
subtypes NPFF1 and NPFF2, is a member of the RFamide family and has been shown to 
modulate opioid activity. Although, currently, there are limited numbers of reported NPFFR 
ligands, it has been indicated that antagonism of NPFFR leads to the attenuation of physiological 
tolerance. Currently, many of these ligands are peptidic in structure and are not considered ideal 
candidates for drug development. However, the design and synthesis of small molecule, dual-
acting ligands that act as MOP agonists and NPFF antagonists are a viable approach to opioid 
analgesics. These ligands would provide the necessary opportunity to provide analgesia, while 
also blocking a physiological tolerance development center, thus preventing the development of 
hyperalgesia as well as provide an opioid drug class with reduced side effect liabilities.  
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CHAPTER 1 
BACKGROUND OF ANALGESIA AND TOLERANCE 
 
1.1: Analgesic Mechanisms 
 Analgesia by definition is the insensibility to pain without the loss of consciousness, but, 
pain in itself can be hard to define due to it being viewed as a subjective sensation.1 Pain 
currently is seen as an unpleasant sensory and emotional experience attributed to damaged or 
potentially damaged tissue, however, pain is biased due to the varying nature of an individual’s 
physical and psychological state.1 The perception of pain is also known as nociception. 
Nociception is the process by which a painful or harmful stimulus is relayed through nociceptor 
neurons from the point of noxious stimulation to the central nervous system (CNS). 
1.1.1: Acute Pain 
 Most nociceptor neurons consist of unmyelinated, small diameter afferent fiber axons 
called C-fibers, which are bundled together and surrounded by Schwann cells, to help support 
necessary conduction velocities from the periphery to the CNS.2, 3 These fibers are attached to 
peripheral tissues and project to the superficial laminae I and II of the dorsal horn, which is 
located in the back of the spinal cord and consists of gray matter. The C-fibers can be activated 
by mechanical, thermal, and chemical stimuli, however are typically activated only in the 
presence of stimulus of noxious intensity.4 For fast-onset pain, conduction is mediated through 
A-fiber nociceptor neurons, which are also attached to peripheral tissue.4 However, A-fibers are 
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projected to the superficial laminae I and V of the dorsal horn, different from the C-fiber 
projections.2 Neurons located within the laminae I and V provide major output from the dorsal 
horn to the brain due to being at the origin of multiple ascending pathways that carry pain 
messages to the brainstem and thalamus.5 Nociceptor neurons are classified as primary 
somatosensory neurons and are split into two segments. These segments send a peripheral axon 
to the dermis and a central axon to synapse on second-order neurons positioned in the spinal 
cord, more specifically, the dorsal horn.5, 6 The information from the segmented nociceptors acts 
on projected neurons that relay the information of the location and intensity of the stimulus to the 
somatosensory cortex by way of the thalamus.5 The cognition of pain comes from projection 
neurons activating the cingulate and insular cortices by way of connections in the parabrachial 
nucleus and the amygdala.5 The ascending information through the brainstem, accesses neurons 
in the rostral ventral medulla (RVM) and the midbrain periaqueductal gray (PAG), which 
provides a descending feedback system that will in turn regulate the output from the spinal cord 
(Figure 1).  
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Figure 1. Pain Pathway Physiology 
 
*Interpreted from Basbaum, A. I.; Bautista, D. M.; Scherrer, G.; Julius, 
D. Cellular and Molecular Mechanisms of Pain. Cell 2009, 139, 267-284 
  
When tissue cells are damaged, they release arachidonic acid, a 20-carbon unsaturated 
fatty acid, which will bind to cyclooxygenase-1 (COX-1), also known as prostaglandin 
endoperoxide H synthase (PHGS) 1, and cyclooxygenase-2 (COX-2), also called PHGS-2, 
enzymes, which are upregulated when inflammation is present.7-9 COX-1 and COX-2 will 
convert arachidonic acid into prostaglandin H2 (PGH2).7 PGH2 is a member of the prostaglandin 
family, whose biosynthesis is drastically increased in injured tissue and plays a crucial role in 
inflammatory response.10 PGH2 can then be converted into four biologically significant 
molecules: prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostacyclin (PGI2), and 
thromboxane A2 (TXA2). PGD2 is produced by mast cells, also known as white blood cells, and 
plays a role in contracting bronchial airways, regulating body temperature, and vasodilation. 
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PGE2 exerts a wide array of effects on tissue homeostasis through inflammation, cell 
proliferation, apoptosis, and the immune system.11, 12 PGI2 is produced by vascular endothelium 
and when present, will inhibit platelet aggregation, while also acting as a vasodilator.13, 14 TXA2, 
which is produced by blood platelets, acts opposite to PGI2 and stimulates the activation and 
aggregation of new platelets, while also causing vasoconstriction.14 These bioactive molecules 
are all produced to achieve or maintain bodily homeostasis.10  
 In order to treat mild to moderate acute pain, a nonsteroidal anti-inflammatory drug 
(NSAID) or acetaminophen will be used as a first-line agent.15 There are 3 major NSAIDs: that 
are available over-the-counter (OTC): Aspirin (1), naproxen (2), and ibuprofen (3), and the 
common analgesic/antipyretic acetaminophen (4), which does not fall into the NSAID 
pharmacological class. Although these medications are used for acute pain, their 
pharmacological activities differ. 
Figure 2.  Common Over-the-Counter Pain Medications 
 
Aspirin (1) 
 
Naproxen (2) 
 
Ibuprofen (3) 
 
Acetaminophen (4) 
Salicylic acid was isolated from willow bark over 100 years ago, however its mechanism 
of action was not determined until 1971.16, 17 Aspirin (1), also known as acetylsalicylic acid, is 
considered a weak analgesic and is beneficial for low to moderate clinical pain, but is not used 
for high intense or severe pain. Aspirin (1) has also shown no effectiveness against nociception 
in experimental models involving mice, rats, and guinea pigs.18, 19 Aspirin (1) acts by selectively 
acetylating the hydroxy group on the Serine (Ser) 529 residue of COX-1.20, 21 This acetylation 
irreversibly inhibits COX-1, thus hindering the binding of arachidonic acid.18, 20-22 In COX-2, 
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aspirin (1) binds to Ser 516, acetylating the COX-2 active site, however due to the binding 
pocket size being larger than COX-1, arachidonic acid can still be converted into 15-
hydroxyeicosatetraenoic acid (15-R-HETE).23 Pharmaceuticals, such as celecoxib (Celebrex®) 
and meloxicam (Mobic®), have been developed to act similar to aspirin (1), however are able to 
prevent arachidonic acid from binding at COX-2.24, 25 The use of aspirin (1) in several studies 
showed patients had a higher risk of gastrointestinal bleeds, thus alternative OTC medications 
are preferred.26	
Another very commonly used OTC NSAID is naproxen (2), also known as Aleve®, 
which is taken to alleviate pain and some arthritis symptoms.27 Naproxen (2) is listed as an OTC 
non-selective COX-1 and COX-2 inhibitor. The inhibition of COX-1 leads to gastrointestinal 
bleeding and the inhibition of COX-2 provides analgesic, anti-inflammatory, and antipyretic 
effects.28 Its selectivity for COX-1 over COX-2 is not known, thus other selective COX-2 
pharmaceuticals have been synthesized, but have shown heightened cardiovascular risks.29 This 
is because COX-2, is upregulated during inflammation, and causes vasodilation, whereas COX-1 
leads to TXA2-mediated vasoconstriction and platelet aggregation; under normal biological 
functions this process is balanced.30 However, if a patient with preexisting cardiovascular disease 
takes a COX-2 selective drug, the balance is disrupted and vasodilation inhibited.30 
Vasoconstriction then increases blood pressure and consequently increases a patient’s risk of a 
major cardiovascular event.30 Although naproxen (2) is listed to have gastrointestinal and 
cardiovascular side effects, it and low-dose ibuprofen (3) have shown to have the lowest risk for 
cardiovascular events.15, 27, 31, 32 
Ibuprofen (3) goes by many names but two well-known OTC names are Advil® and 
Motrin® and is used for its anti-inflammatory, pain-relieving, and antipyretic properties.33 
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Ibuprofen (3) is metabolized almost completely by CYP2C9 and its metabolites are excreted 
through the urinary system.34-36 Ibuprofen’s main mechanism of action is through reversible, 
non-selective inhibition of COX-1 and COX-2, which in turn inhibits prostanoid synthesis, like 
that of aspirin (1), thus providing many of its effects.34, 36 It has side effects similar to other 
NSAIDs, the most noteworthy are cardiovascular and serious gastrointestinal complications and 
when used at higher doses, these risks are increased.36 Although these are the most common side 
effects, ibuprofen (3) is commonly used in pediatric patients because it has a better safety profile 
compared to aspirin (1) and has better efficacy than acetaminophen (APAP) (4).33 Although 
ibuprofen (3) is classified as a relatively safe OTC, it is associated with irreversible kidney 
damage due to acute toxicity; ibuprofen (3) decreases the production of intrarenal prostaglandins, 
diminishes the kidneys filtration rate efficiency, and also reduces renal blood flow.37 Ibuprofen 
(3) and APAP (4) have the same tolerability when used at their approved OTC doses.26 However, 
when ibuprofen (3) is used at its prescription doses, its antipyretic and analgesic effects are 
greater when compared to APAP (4).38 Since both ibuprofen (3) and APAP (4) are both 
successful in their pharmacologic effects, they are often prescribed together, however, in most 
cases they must be taken at separate time intervals. One group utilized the tablet, Maxigesic®, 
which comprises of appropriate doses of ibuprofen (3) and APAP (4) in a single dosage regimen, 
for pain relief following oral surgery; the results showed excellent pain relief after the surgery 
compared with ibuprofen (3) and APAP (4) alone.39 
 APAP (4) is related but doesn’t fall into the class of NSAIDs, has been shown to relieve 
some mild to moderate acute pain and is the most used OTC in the world.40 It has shown to have 
good digestive absorption, minimal first pass metabolism and high oral bioavailability, but has 
potential for accidental overdose and can lead to hepatotoxicity, if not managed properly.26, 41 It 
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is readily metabolized by cytochrome P450, which is located in the liver, and is quickly removed 
from the body.41	 However, APAP’s mechanism of action is poorly understood, but several 
mechanisms have been hypothesized, as detailed below.42 
One hypothesis involves the eicosanoid system. The COX enzyme consists of two 
binding sites, COX and peroxidase (POX). Although the reactions occur at different locations on 
the enzyme, the two sites are linked mechanistically and electronically.9 When there is a 
reduction of peroxides, a heme group will be oxidized in the POX site, which will form a 
tyrosine radical in the COX site and the radical will take a hydrogen atom from arachidonic acid 
during the initial step of COX catalysis.9 It has been noted that in order for COX activity to 
occur, it must be in its oxidized form, however, it is thought that when APAP (4) binds to POX it 
lessens the oxidized form of COX, thus decreasing COX’s activity.9, 42, 43 However, a more 
recent theory that was suggested in the mid 2000s was that APAP (4) is acting through a third 
COX isoform (COX-3). APAP was shown to induce hypothermia in C57/BL6 mice, while also 
reducing PGE2 in the brain. By engineering COX-1 and COX-2 gene-deleted mice and 
subjecting them to a writhing test along with APAP treatment, APAP produced little to no 
hypothermic response, which suggested the hypothermic and analgesic effects are mediated 
through COX-3.44 Although APAP’s analgesic and antipyretic activity is focused on COX, its 
lack of anti-inflammatory or inhibition of TXAs give rise to the suspicion of multifaceted 
mechanisms.45 Other hypotheses find connections in the cannabinoid, serotonergic, and 
opioidergic systems. 
A second theory stems from evidence that APAP (4) is metabolized into p-aminophenol, 
which is further metabolized into N-arachidonoyl-phenolamine (AM404). AM404, an antagonist 
against COX-1 and COX-2, has been found to act on the endocannabinoid system along with 
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transient receptor potential vanilloid type 1 (TRPV1), all of which are involved in pain and 
thermoregulatory pathways.46 While one group hypothesized that the endocannabinoid and 
serotonin systems are interconnected, others believe APAP (4) itself is modulating the serotonin 
system.47, 48 
Yet another theory is that APAP (4) is modulating the descending serotonergic (5-
hydroxytryptamine or 5-HT) pathway, which extends from the nucleus raphe magnus (NRM) to 
the dorsal horn, particularly the substantia gelatinosa.48, 49 Behavioral in vivo testing of mice was 
performed, using the hot-plate model as well as a formalin test.48 The hot-plate test is used to 
study the analgesic effect of drugs at the level of the spine and is considered to be a supraspinal 
response, all while minimizing the involvement of prostaglandins.50 The formalin test is a 
commonly used model that focuses on chronic pain at two different stages: the neurogenic phase 
and inflammation phase.50 Experiments showed significant analgesic effects in both models and 
supported the idea that APAP (4) acts peripherally and centrally.48 To better understand the 
APAP (4) results, Karandika et al. administered fluoxetine, a selective serotonin reuptake 
inhibitor (SSRI), with APAP as well as APAP with buspirone (5-HT1A agonist).48 Results 
showed that the SSRI + APAP provided higher analgesic activity, whereas buspirone + APAP 
decreased pain threshold which coincides with the notion that nociception is involved.48, 49 Pini et 
al. found that after treatment of APAP in rats, 5-HT levels were increased in several CNS 
locations and concurred that changes in the 5-HT system are associated with antinociception.42, 
49, 51 One assumption made, based off of behavioral studies, was the serotonergic and opioidergic 
systems could interact in a functional-like relationship, modulating each other, thus emitting 
changes in nociception and other behavioral changes.42, 52, 53 Morphine (5) and other	 µ-opioid 
receptor (MOP) agonists have been shown to exert analgesic effects through the serotonergic 
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system, which increases the release of serotonin in the brain.54-56 Data comparing differences of 
non-inflammatory pain between repeated administrations of APAP (4) and morphine (5) showed 
that APAP (4)	 retained analgesic effect and decreased the number MOP receptors, while 
morphine (5) lost its effect and physiological tolerance developed.56 APAP (4) with a weak 
opioid, typically codeine (13), can be prescribed for moderately severe acute pain.57 Although 
APAP data shows a correlation to antinociception while providing analgesic effects, APAP (4) 
should not be used to treat severe acute or chronic pain due to an increased risk of APAP-
induced acute liver failure.42, 58  
A common example of moderate to severe acute chronic pain is after an invasive surgery 
where nerves and tissues have been severed, however, other examples are broken bones and 
childbirth. When tissue is severely damaged, nociceptors are activated and a cascade of immune 
cells along with an inflammatory response begins.59 This cascade will trigger and activate 
dormant nociceptors or will increase the nociceptor sensation.59 There are a few common routes 
of moderate to severe acute pain treatment: NSAIDs and APAP, prescription opioid medications, 
local anesthetics, and adrenergic agonists.59 As mentioned above, most NSAIDs are weak 
analgesics and are not equip enough to relieve severe acute pain.15 However, NSAIDs will be 
used as a first line agent; if relief does not occur, a second line agent, typically an opioid will be 
prescribed.15, 60 
Prescription opioid medications (morphine (5), hydrocodone (6)) although strong and 
provide sufficient pain relief in acute pain patients, have several issues surrounding their use.60 
Most opioid pain medications, which are opioid receptor agonists, are seen as addictive 
substances.61 (Details regarding the opioid system and its neurobiological processes will be 
described in further detail in section 1.2.) Research has shown that long-term use of opioid 
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prescriptions will cause physiological tolerance, opioid-induced hyperalgesia (OIH), and 
dependence, but also has an increased risk of addiction and respiratory depression.62, 63 OIH is 
defined as a condition of nociceptive sensitization caused by opioid exposure.64 Opioids will also 
cause opioid-induced constipation (OIC) over long-term use. Another option for severe acute 
pain treatment, is through local anesthetics, which have low associated risk and are commonly 
known as neural blockades.59 Nerve block administrations can be beneficial to patients with pain 
in a specific site or region and if used in combination with opioid prescriptions, can offset some 
of the opioid associated risks.65, 66 Nerve blockades can be extended and intensified through the 
administration of clonidine (7), an	α2 adrenergic agonist.59 Research has also found that the use 
of adrenergic agonists, such as clonidine (7), produces analgesia when administered 
systemically, epidurally, or intrathecally.67 Although	α2 agonists, including dexmedetomidine 
(8), are successful in achieving analgesia, the side effects associated with them, such as 
hypotension, sympatholysis, bradycardia, and sedation, limit their clinical effectiveness in severe 
acute pain treatment.59, 67, 68 Steroid injections, most commonly corticosteroids, that utilize 
ultrasonography-guiding techniques have also been proven effective in acute pain treatment, 
although studies have shown pain relief is short lived and typically last 1-3 months.69 Long-term 
use of steroid injections when used in patients with osteoarthritis of the knee has shown 
correlations to faster cartilage deterioration, while producing insignificant alterations in knee 
pain.70 
Severe acute and chronic pain can be difficult to differentiate between. Severe acute pain 
can range anywhere from hours to weeks or even months; whereas chronic pain’s duration is 
anything lasting longer than 6 months and is seen more as a disease state.71 However, there have 
been cases where severe acute pain will rapidly advance into chronic pain.59 
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1.1.2: Chronic Pain 
Unlike acute pain, that has a biological purpose, chronic pain will remain long after 
normal healing time and has no resolve or purpose.72 Chronic pain’s pathophysiological 
mechanisms are poorly understood, but are thought to be associated with abnormalities of the 
normal physiological pain pathway that give rise to various types of hypersensitivity such as 
allodynia and hyperalgesia.57 Allodynia is when a normally innocuous stimulus is perceived as 
painful and is typically associated with nerve damage.73 Hyperalgesia is having an increased 
sensitivity to pain and most commonly associated with OIH; extended periods of hyperalgesia 
can cause damage to nociceptors an peripheral nerves (more details on OIH development in 
1.2.3.2).74 
One factor believed to play a role in chronic pain is the redistribution and overexpression 
of voltage-gated sodium (Na+) channels in damaged sensory neurons.57, 75 Na+ channels involved 
in the intracellular signaling pathways in damaged sensory neurons, have been found to have 
alterations in their function and expression, which leads to heightened neuronal excitability and 
pain.76 There have been cases of neuropathic pain and chronic regional pain syndrome (CRPS) 
that have had some sympathetic nervous system mediation, thus creating a more complex clinical 
understanding of chronic pain.77 In sympathetically mediated pain (SMP), damaged sensory 
neurons express α-adrenoceptors, which become sensitive to norepinephrine and produce strong 
stimuli through the sympathetic nervous system.57 After severe injury, allodynia, cold or hot 
hyperalgesia, and spontaneous burning pain appear as symptoms of SMP.78 It is possible to use 
some OTC medications such as naproxen (2) to relieve chronic pain from arthritis; for more 
severe chronic pain it is difficult to treat with currently established analgesic drugs.57 
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Due to the difficulty of chronic pain treatment, prescribers have started utilizing tricyclic 
antidepressants (TCAs), SSRIs, anticonvulsants, and opioids to fight chronic pain.79 TCAs were 
first prescribed due to their long history of treating multiple types of pain conditions and were 
found to use a lower dosage than those used for depression.79 However, there are known 
cardiovascular and overdose risks associated with TCAs.79 SSRIs have also been found to work 
with chronic pain; however, they appear to have weaker effects when compared to TCAs.79, 80 
One commonly prescribed SSRI for pain relief is duloxetine (Cymbalta®) (9), which is approved 
for neuropathic pain, chronic musculoskeletal pain, and fibromyalgia.81 It is not known how it 
relieves pain, but it is thought to involve norepinephrine and 5-HT in the brain.82 Interestingly, 
anticonvulsants like gabapentin (Neurontin®) (10) and pregabalin (Lyrica®) (11) are often 
prescribed to patients suffering from neuropathic pain and neuralgia and are shown to have 
similar efficacies when compared to nortriptyline (12), a common TCA.83-86 Gabapentin and 
pregabalin inhibit the release of excitatory neurotransmitters involved in pain, by binding to 
calcium channels in the brain and dorsal horn of the spinal cord.79 Anticonvulsants also exert 
common side effects such as peripheral oedema, concentration issues, and dizziness to name a 
few, but also have abuse potential.84, 87, 88 There have been some cases of TCAs or 
anticonvulsants being used in combination with opioid medications, although there is not 
extensive research into the effectiveness and current information shows no significant changes 
from monotherapies.89, 90 Opioid medications, although strong, give little sensation relief and 
have heightened risks of tolerance development, OIH, withdrawal, and abuse liabilities.57, 63 The 
TROUP study, which used a “claims-based” approach, focused on patients with chronic pain that 
were prescribed opioids for long-term use; their results showed a small percentage of patients 
had an opioid abuse/dependence diagnosis.62 However they found a correlation, between patient 
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characteristics as well as the opioid therapy itself, and having a heightened the risk of abuse and 
dependence, and believe the actual opioid prescription misuse is under-estimated.62 It is clear 
that treatments are needed for severe acute and chronic pain with limited liabilities related to 
physiological tolerance, hyperalgesia, and dependence. Since opioid prescriptions are still seen 
as the “gold standard” among pain medications, the avenue of synthetic opioid derivatives, with 
limited liabilities, remains a goal of the research community.91, 92 
Figure 3. Common Prescription Medications for Severe Acute and Chronic Pain 
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1.2: Opioid System 
 The terms, opioid and opiate, are commonly confused and misused. An opioid refers to 
any substance, natural or synthetic, that acts on opioid receptors, whereas an opiate is an opium 
derivative that is based from the natural product. Opiates originated from the juice of the opium 
poppy, Papaver somniferum, and were used for their analgesic and psychotropic properties for 
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thousands of years.93 It wasn’t until the early 1800s before the most abundant alkaloid in opium, 
morphine (5) (originally termed ‘Morphium’ after the Greek god of sleep and dreams), was 
extracted from poppy seed juice by Friedrich Serturner, and was found to have analgesic, 
sedative, and euphoric properties.94-97 Over time, other alkaloids, including codeine (15), were 
isolated from opium; however, morphine (5) remained the main area of interest.98, 99 The 
structure of morphine (5) was not determined until the early 1900s and it was not synthesized 
until the 1950s.100, 101  
1.2.1: Discovery of the Endogenous Opioid Peptides and Receptors 
Prior to its discovery, scientists hypothesized that there was a physiological receptor 
system that was capable of binding the unique structures of morphine (5) and diacetylmorphine 
(heroin) (16).102-104 Binding studies using radiolabeled opioid drugs, such as [3H]-naloxone and 
[3H]-etorphine, showed specific opioid receptors did exist.105, 106 Isolation of endogenous opioid 
peptides, showed three distinct precursor molecule families: the proenkephalins, the 
proopiomelanocortins, and the prodynorphins.57, 107 In 1975, members of the proenkephalin 
family, Met-enkephalin (MET) and Leu-enkephalin (LEU), were the first discovered and isolated 
opioid peptides, which were found in porcine brains.108, 109In 1976, β-endorphin, a 
proopiomelanocortin member, was isolated from camel and human pituitary glands, and found to 
share a homology sequence with MET.108-111 In 1979, from the prodynorphin precursor, 
dynorphin-A was isolated from porcine pituitary and shown to have a similar homology to 
LEU.112 The newly discovered neuropeptides demonstrated opioid receptor activity.113 However, 
due to the differences in pharmacological structure and activity of the peptides, evidence 
suggested that there was potential for multiple opioid receptors that consisted of differing 
functions (Table 1).114  
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The study of “cross tolerance”, through the use of the high affinity drugs: morphine, 
ketocyclazocine, and N-allylnormetazocine, analyzed the behavioral and neurophysiological 
properties, which suggested three separate “classical” opioid receptors: µ/OP3 (MOP), κ/OP2 
(KOP), and δ/OP1 (DOP).115, 116 The endogenous peptides that had been previously discovered 
(i.e. the enkephalins, β-endorphin, and the dynorphins) were able to be matched with their 
corresponding receptor(s): enkephalins were nonselective for DOP and MOP, β-endorphin 
preferred DOP, but consisted of some MOP activity, and both dynorphins were selective for 
KOP. It wasn’t until 1997, where Zadina et al. isolated endomorphins-1 (Tyr-Pro-Trp-Phe-NH2) 
and -2 (Try-Pro-Phe-Phe-NH2) from mammalian brain extract, and found them to be selective 
MOP endogenous peptides.117 Endomorphin-1 possesses picomolar affinity for MOP and 
excessive preference for MOP vs. DOP and KOP (4,000-fold and 15,000-fold, respectively).117 
Some have suggested that endomorphin-2 is an arrestin-biased agonist because it has been shown 
to promote efficient phosphorylation of MOP.118 The three ‘classical’ opioid receptors were not 
cloned until the early 1990s, whereas in 1994, the cDNA of a fourth receptor, human Opioid 
Receptor-Like 1 (ORL-1) or nociceptin receptor (NOP, OP4), was isolated and cloned by three 
separate investigators: Mollereau et al., Evans et al., and Yu et al.119-122 A year later, the 
endogenous peptide of ORL-1/NOP, nociceptin/orphanin FQ (N/OFQ), was isolated and the 
structure was determined to be a heptadecapeptide with pro-nociceptive properties.123 Several 
investigators proposed the idea of ORL-1/NOP as a KOP subtype based off its similar homology, 
however, the current scientific consensus is that ORL-1/NOP is a separate opioid receptor family 
member, not only because it does not have affinity for the other opioid endogenous peptides, but 
its functional, behavioral, and pain modulatory properties are different.124-127   
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Table 1. Opioid Receptor Type Classification128 
Current 
Nomenclature 
Previous 
Nomenclature 
Presumed Endogenous Peptides 
δ, delta, or DOP DOR, OP1 β-endorphin (not selective) 
enkephalins (not selective) 
κ, kappa, or KOP KOR, OP2 α-neoendorphin 
dynorphin A 
dynorphin B 
µ, mu, or MOP MOR, OP3 β-endorphin (not selective) 
endomorphin-1 
endomorphin-2 
enkephalins (not selective) 
NOP or ORL-1 OP4 nociceptin/orphanin FQ (N/OFQ) 
 
1.2.2: Pharmacology and Cloning of the Opioid Receptors 
 Research showed that the inhibition of second messenger, cyclic AMP (cAMP), was 
mediated by all four opioid receptors, which indicated the receptors utilized a G-protein enzyme, 
thus placing the receptors into the G-protein coupled receptor (GPCR) family.129, 130 A GPCR is 
a seven trans-membrane receptor that is coupled to a trimeric signal-transducing G-protein, 
which sends a signal to G-protein effectors, also known as second messengers.130, 131 When a 
GPCR is inactive, it has a Gα, β, and γ subunit complex bound to it; the Gα is also bound to 
guanosine diphosphate (GDP). When a molecule binds to the GPCR, a conformational change 
occurs causing the Gα, β and γ subunits to disperse. An exchange of nucleotides (GDP à 
guanosine triphosphate (GTP)) occurs on Gα	to activate the receptor, sending a signal to second 
messengers (Figure 3). GTPase hydrolyzes the GTP into GDP, thus the	 Gα, β and γ subunits 
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rebind to the GPCR.131 It was later determined that each receptor could activate specific second 
messengers. When MOP or DOP are activated, there is an increase in K+ out of the cell, a 
decrease in Ca2+ entry, and decrease in intracellular cAMP, all of which produces 
hyperpolarization of the neurons thus inhibiting the generation of action potentials; whereas, 
KOP activation inhibits synaptic transmission through the inhibition of Ca2+.119 
Figure 4. Activation of a G-Protein Coupled Receptor. 
 
In order to clone the receptors, initial efforts attempted to purify the receptors from 
tissues, but failed due to the low density of the opioid receptors.119 Through the use of cDNA 
probes and radioligand binding, the DOP in mice was the first cloned opioid receptor.132, 133 The 
cloned DOP was subsequently followed by the cloning of MOP and KOP, in rats, and promptly 
resulted in their human counter parts.134-138 The results from tissue studies and clonal cell lines 
showed high ligand binding affinities and cohesion between their pharmacological properties.119  
 The best way to incorporate pharmacophoric structural elements into a compound is to 
first examine the target receptor protein structure and understand its pharmacological properties. 
Knowledge of the receptor’s active structure provides a template, which aids in the advancement 
Gα Gα
γ
β
β γ
GDP GTPG-Protein Coupled Receptor
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of drug design. In order to determine the 3-dimensional structure of a receptor protein a 
technique called x-ray crystallography is employed.  To perform this technique, a reliable protein 
source and a high quality purification or concentration protocol must be available.139 The 
purified protein is then crystallized in high concentrations and the crystals are exposed to an x-
ray beam.139 When the x-ray beam come in contact with the crystals, the beam is diffracted into 
patterns; the structure of the protein is then determined based off the intensities of the diffraction 
spots.139 X-ray crystallography has been vital for the advancement of opioid research; by 
determining the 3-dimensional structure of active opioid receptors, scientists are able to collect 
fundamental structural features necessary for more detailed designs of opioid ligands. To date, 
crystal structures of ORL-1/NOP, DOP, MOP, and KOP have all been established in their 
inactive form through the binding of antagonists; however, only the crystal structures for MOP 
and KOP receptors in their active states have been established.140-145 
Figure 5. Crystal structure of active MOP receptor bound to agonist BU72.144 
 
 
BU72 (13) 
 
Buprenorphine (14) 
*MOP X-ray crystal structure was provided by the RCSB Protein Data Bank. 
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 In 2015, BU72 (13) was co-crystallized with the active receptor form of MOP. BU72 13 
was designed for the treatment of opioid abuse and dependence as a derivative of buprenorphine 
(14) through a bridged pyrrolidinomorphinan system, but displayed too much potency for human 
use.146 BU72 (13) in vitro displayed nonselective properties with a high affinity and efficacy for 
MOP, full agonism at KOP, and also partial agonism at DOP; in animal models, however, not 
only did BU72 (13) provide potent analgesia, but also after its agonist effects had diminished it 
attenuated morphine antinociception.146 The use of BU72 (13) for the stabilization of MOP 
unveiled the arrangement of three conserved amino acids located within the MOP core; it also 
showed an extensive polar network between the cytoplasmic domains and the binding pocket, 
which plays a role in signal transmission.144 
Figure 6. Crystal structure of active KOP receptor through nanobody-stabilization of 
MP1104.145 
 
 
MP1104 (15) 
*KOP X-ray crystal structure was provided by the RCSB Protein Data Bank. 
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 This crystal structure (figure 6), published in January 2018 by Roth et al., is of the 
elusive KOP receptor in its active form; it was crystallized through the use of an active-state-
stabilizing nanobody, MP1104 (15).145, 147 Inactive states of KOP have been crystallized prior to 
this advancement, however, the active form provided insight into how substantial the 
conformational changes within the binding pocket as well as the intracellular and extracellular 
regions are between the two states.145, 148 Because of this development, key residues involved in 
structural rearrangements and binding have been discovered and in turn have provided 
comprehensive KOP structural pharmacology, which have revealed KOP is involved in biased 
signaling.145 In general, crystal structures provide a better understanding into the necessary 
structural frameworks that contribute to a more detailed focus in the design and development of 
safe and effective therapeutics. 
 Originally all GPCRs were thought to work in a linear-like fashion through the signaling 
cascade of G proteins, however, as mentioned above KOP has been found to be involved in 
biased signaling, which involves another signaling pathway through β-arrestins. Initially, β-
arrestins were thought to only play important roles in receptor internalization and desensitization, 
but in recent years it has been discovered that β-arrestins can act as signal transducers and 
mediators of GPCR signaling when there is an absence of G protein interactions, this is the 
concept of biased signaling. Biased agonism is when a ligand is able to selectively control the 
downstream activity towards one pathway or another. When the ligand binds to a GPCR, a 
cascade that begins with phosphorylation of the active GPCR by a kinase (second messenger-
dependent or a GPCR kinase).149, 150 This phosphorylation then triggers the recruitment of β-
arrestin to the phosphorylated receptor, which causes a conformational change and uncouples the 
G proteins from the GPCR.150 Once the G proteins have dissociated, they are no longer able to 
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signal, however, β-arrestin-dependent signaling pathways are then employed and have been 
found to activate G protein-independent downstream signaling effectors such as mitogen-
activated protein kinase (MAPK) cascades, c-Jun N-terminal kinase 2 (JNK3), components of 
the extracellular signal-regulated kinase 1/2 (ERK 1/2), and Akt to name a few.151-153 Biased 
signaling has shown the potential to provide safer and more effective therapeutics devoid the 
undesirable side effects associated with G protein-dependent signaling.154 
1.2.3: Opioid Receptor Locations and Functions 
The opioid system is critical for our physiological functioning, because of its major role 
in pain behavior and antinociception modulation.155 Opioid receptors are located throughout the 
CNS and the peripheral nervous system (PNS) and when activated, receptors can inhibit spinal 
cord pain transmission through the inhibition of neurons.155-157 Genetic variations within the 
opioid system have been investigated through the study of functional single-nucleotide 
polymorphisms (SNPs).158 Studies have shown that SNPs play roles in individual variations in 
neurotransmitter function surrounding pain, but also in cognitive-emotional influence regulation, 
also known as the placebo effect.158 SNPs are not the only genetic variations within the opioid 
system.158 It was later determined that not only in animals but in humans, each opioid receptor 
subtype consisted of splice variants, MOP: µ1, µ2, µ3; KOP: κ1a, κ1b, κ2a, κ2b; and DOP: δ1, δ2.159-
162 A splice variant is made when a single gene gives rise to multiple protein products, also 
known as alternative splicing.163 Alternative splicing, which occurs during DNA transcription, is 
when exons are combined together in different combinations, thus providing a greater diversity 
of proteins.163 Several studies have shown that the knock-out of a single opioid receptor gene in 
mice, removes any function that receptor showed.164 Although opioid receptors are dispersed 
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throughout the body, the distributions, locations, and functions differ based on the subtype and 
possibly their splice variants and polymorphisms.165 
DOP is not as diversely distributed in the body as MOP and KOP.166 DOP are found 
distributed in peripheral sensory neurons, the spinal cord, and in the brain.164 Within the brain, 
there are specific areas that contain a much higher density of DOP: the cerebral cortex, the 
amygdala, and the dorsal striatum, which consists of the caudate nucleus and the putamen.166 
Although there is two described splice variants, there are few details regarding their specific 
location distributions and their specific duties.164 In general, DOP has been found to play a role 
in cardioprotection, thermoregulation, and analgesia but has also been linked to convulsant 
effects when agonized.164, 167 
KOP are also found within peripheral sensory neurons and the CNS. However, its densest 
locations differ from DOP; within the CNS its specific location distributions have been in the 
brainstem, midbrain, and the forebrain, specifically the hippocampus and thalamus.164, 166 KOP 
has been found to elicit analgesic, antidepressant, and anti-addictive effects, however, due to its 
dysphoria causing nature, kappa-specific agonists are not currently considered ideal drug 
candidates.168 Scientists have suggested that selective peripherally restricted KOP agonists could 
be a viable breakthrough to treat chronic pain analgesics through peripheral mechanisms, without 
the CNS associated dysphoric and psychotropic effects.169 Now that there is a more clear picture 
of the KOP receptor through its crystal structure, the option for peripheral-acting KOP 
therapeutics are more possible than ever. 
MOPs are the most studied of the opioid receptors due to their well-established analgesic 
effects; they are found throughout the CNS and PNS. Although MOP is known for its analgesic 
properties, it is also known to cause biological tolerance, OIH, respiratory depression, and 
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gastrointestinal tract issues, such as OIC.164, 170 The general function of MOPs splice variants has 
been discussed and suggested OIH is attributed to the µ1 splice and µ2 is considered to play a 
major role in the gastrointestinal and respiratory depression effects.164, 171 However, splice-
specific compounds have not been heavily studied, but due to the success of MOP analgesia a 
different approach is necessary in order to eliminate the current liabilities.172 
1.2.3.1: Opioid Agonists and Current Applications 
 Morphine (5) and several of its derivatives such as codeine (16), hydrocodone (6), 
oxycodone (17), and hydromorphone (18) are widely utilized in clinical practice. Heroin (19) 
was originally developed in the early 1900s by Felix Hoffman at Bayer Pharmaceuticals with a 
goal to make codeine (16), but acetylation of morphine (5) increased the potency 2-4x.173, 174 
Codeine (16) is most commonly found in cough medicines; the difference between it and the 
structure of morphine (5) is it consists of an ether at C3 on ring A, which makes it less addictive 
and decreases its strength to 1/5 of morphine.57, 175 However, bond saturation between C7 and 
C8, gives hydrocodone (6) the same potency as oral morphine, but hydroxylation of the C9 
hydrogen, oxycodone (17) supersedes the potency of morphine.175 Furthermore, the saturation of 
C7 and C8 as well as the ketone at C6 provides hydromorphone (18) with 5-6x the strength of 
morphine.176 Morphine (5), hydrocodone (6), oxycodone (17) and hydromorphone (18) are most 
commonly used for severe acute pain.57 A synthetic analog, fentanyl (20), was developed for 
cancer pain and was found to be 300x more potent than that of morphine (5), while a fentanyl 
derivative, carfentanyl (21), is 10,000x.177 All of these agonists are classified as addictive and 
some such as heroin (19) and fentanyl (20) have become common street drugs with an increase 
in overdose potential; carfentanyl (21) however, is not considered a street drug due to its extreme 
potency, but it has been found laced into heroin and fentanyl.178 
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 Not always are opioid agonists used in clinical practices; DAMGO (22), DPDPE (23), 
and U69,543 (25) are all currently used in scientific research and are common radioligands used 
for in vitro binding studies. DAMGO (22) is a synthetic opioid ligand originally designed to bind 
to DOP, but was found to be a selective MOP agonist and was used as a probe to elucidate the 
functions of the opioid receptors before they were cloned.179 DPDPE (23) is also a synthetically 
derived opioid peptide, with structural modification based off of MET, that is used as a DOP 
selective agonist. U50,488 (24) was originally designed as a clinical KOP agonist by possessing 
morphine pharmacophoric features, such as system rigidification and the 6-membered 
cyclohexane ring non basic nitrogen (a fentanyl modification), but not superimposable on to 
morphine.180 Although U50,488 (24) proved KOP selectivity with its absence of morphine 
tolerance, respiratory depression, and constipation, it possessed negative side effects such as 
diuresis, sedation, and dysphoria, so an analog containing a spiro substitution was designed, 
U69,593 (25).180, 181 It yielded better affinity (IC50 = 9.5 nM) than U50,488 (24), but it still 
caused adverse effects, thus over time it garnered momentum as a research tool. 
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Figure 7. Selected Opioid Agonists 
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1.2.3.2: Opioid-Induced Hyperalgesia Development 
 OIH is classified as one of the common health implications associated with opioid use. 
Although it has been characterized in humans, its mechanisms of development are not 
completely understood, but several mechanisms have been theorized; below are a selected few of 
postulated mechanisms behind OIH development. One of the suggested development methods is 
thought to involve the MOP splice variants based from the fact that MOP can show two opposing 
effects: analgesia vs. hyperalgesia.64 The discovered MOP alternative splices have shown 1 
transmembrane (TM), 6TM and 7TM MOP receptor variants, however, the distribution and 
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expression levels have not extensively investigated.182-184 Studies have shown that activation of 
the 6TM receptor variants activate Gs, which induce excitatory cellular effects and activation of 
7TM in turn activates Gi, which inhibits neurons; interestingly silencing the receptor variant, in 
mice, showed a decrease in morphine-induced hyperalgesia.185 This resulted in Oladosu et al. to 
suggest that the MOP 6TM receptor variant is involved in OIH development and 7TM is 
associated with analgesia.171 Another suggested mechanism is through a MOP GPCR coupling 
shift from Gi to Gs, which would change the classical Gi-mediated analgesic pathway to the Gs 
coupling.186 Spinal nerve ligation-induced neuropathic pain showed an upregulation of MOP 
coupling to Gs, acute morphine-induced hyperalgesia also showed a similar MOP-Gs coupling.187 
Studies in other GPCRs, have shown that Gs-coupling reduces the activation threshold of Na+ 
channels via cAMP or PKA-dependent pathways which in turn, initiates an enhancement in 
nociceptor sensitization.188, 189 This indicates that the G proteins that are coupled with the MOP 
receptor play a possible role in OIH. 
Other OIH mechanisms of development surround other physiological systems such as 
other types of GPCRs and their intracellular pathways and various anti-opioid systems. In mice 
and genetic blockade studies, β2 adrenergic receptors were found to be involved in OIH 
development, whereas morphine-induced tolerance reduced astrocyte activation and 
proinflammatory cytokines but antagonism with a melanocortin 4 receptor antagonist, blocked 
analgesic tolerance and drug withdrawal hyperalgesia.190-192 Anti-opioid systems tend to have the 
most research surrounding their association with OIH development. The most studied systems 
and are cholecystokin (CCK), NOP, and neuropeptide FF (NPFF). In general, the blocking of 
these systems has shown lessened or blocked antinociceptive effects. When morphine is 
administered, it triggers a cascade that releases CCK from the spinal cord and cause 
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hyperalgesia, whereas CCK antagonists block hyperalgesia development.193-195 NOP and NPFF 
systems both induce hyperalgesia and reverse morphine analgesia via upregulation, which 
suggests that both of the peptides (N/OFQ; NPFF) consist of pro- and antinociceptive 
properties.196, 197 Studies have shown, in order to block NPFF-induced tolerance and OIH 
development, an NPFF antagonist must be administered at the same time as opioid 
administration.198 The mentioned mechanisms of development are mostly conjecture and theory, 
however, it is clear that OIH has multiple facets involved in its development. 
1.2.4: Opioid Tolerance Development 
 In recent years, opioid drug use, both medically and recreationally has exponentially 
increased, bringing with it increases in tolerance, dependence, and most notably, death.199-201 
Opioid tolerance development is a well-known phenomenon in which repeated administration of 
an exogenous opioid agonist (morphine (6), heroin (19), hydrocodone (6), etc.) causes a decrease 
in overall drug effectiveness.124, 202 Studies have shown that pain-induced analgesia is mediated 
through the mesolimbic (midbrain) reward system.203 Opioid agonists (most commonly MOP 
agonists) activate the pathway through the activation of the ventral tegmental area (VTA), which 
is located close to the floor of the midbrain.204, 205 This activation releases the neurotransmitter, 
dopamine (DA) from the nucleus accumbens (NAc), located in the basal forebrain, which in turn 
produces pleasurable feelings.204 The brain will then construct a memory, to associate the 
pleasantness of event with the environment in which it occurred, this is called a conditioned 
association.204, 205 The primary reason of opioid abuse is due to the mesolimbic reward pathways 
release of DA, which produces feelings of euphoria.204 However, over time physiological 
dependence and tolerance develops to where a higher dosage is necessary to achieve the same 
effect or one will be susceptible to symptoms of withdrawal.204, 205 This is due to the 
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desensitization of the opioid receptors, which will not stimulate the VTA nor release DA from 
the NAc.204, 205 High concentrations of an agonist that over stimulates a receptor, initiates 
desensitization, which results in receptor conformational changes to its active state.206 Receptor 
specific Ser/Thr residues located at the intracellular loops or C-terminus of the agonist-bound 
activated receptor are then phosphorylated by G protein-coupled receptor kinases (GRKs), thus 
increasing the receptor’s affinity for the inhibitory β-arrestin protein.206 This causes the Gα 
subunit to uncouple from the receptor, thus substantially diminishing receptor signaling.206 In 
order to produce the same level of pleasure, more of the drug must be taken.204 There is a strong 
agonist-dependent correlation between MOP agonists and receptor signaling and regulation, 
which could imply that there is a greater chance of drug addiction to occur.207 Although tolerance 
and dependence are seen in opioid use, not all who use drugs become addicted.124 
Desensitization is one form of tolerance development, however endogenous anti-opioid systems 
have been attributed to physiological tolerance. The neuropeptide FF (NPFF) system is one of 
these systems (others being CCK, nociceptin, and dynorphin) and is comprised of two GPCR 
receptor subtypes: NPFF receptor 1 (NPFF1R) and NPFF receptor 2 (NPFF2R), which were 
isolated from rat and human CNS tissues.208	
1.3: Neuropeptide FF System 
 NPFFRs belong to the RFamide family, which consists of various peptides all with 
variable length, but share an Arg-Phe-NH2 sequence at their carboxyl terminal.197 A 
cardioexcitatory tetrapeptide termed FMRF-amide was the first isolated RF-amide; it was 
sequenced from the ganglia of the clam Macrocallista nimbosa.209 The first two mammalian RF-
amides were NPFF, an octapeptide, and neuropeptide AF (NPAF), an octadecapeptide, which 
were both isolated from bovine brain and showed nociception effects.210 Both the NPFF and 
 29 
NPAF have high affinity for both NPFFRs.208, 211 Several other neuropeptides, NPSF and NPVF 
also known as RFRP-1 and RFRP-3, pyroglutamylated RFamide (QRFP), kisspeptin (Kp), and 
Prolactin (PRL)-releasing peptide (PrRP) were found to also activate NPFFRs and were 
presumed endogenous ligands involved in the NPFF system.212-216 All of the above 
neuropeptides have been discovered in humans.217-222 In humans, NPFFRs are located throughout 
the CNS, specifically in the dorsal horn of the spinal cord, the hypothalamus, and thalamic 
nuclei, but NPFF1R mRNA has been found to be more abundant in the spinal cord, which could 
indicate a greater role in sensory and pain modulation, particularly since these locations correlate 
with opioid receptors.208, 223 The dorsal horn and PAG are rich in MOP and KOP receptors while 
KOP receptors are also found in the hypothalamus and thalamic nuclei.224 
The NPFF system has shown involvement in several biological functions and systems 
surrounding hunger, thirst, the limbic, cardiovascular and endocrine systems, but is most well 
known for its modulation of the opioid system through tolerance and pain.225-229 Some believe 
that NPFF is modulating the other functions through the opioid system in some form or 
fashion.197  
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Table 2. Neuropeptide RFamide Family Peptide Sequences.222 
Peptides Sequences 
NPFF FLFQPQRF-NH2 
NPAF AGEGLNSQFWSLAAPQRF-NH2 
NPSF SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRF-NH2 
NPVF VPNLPQRF-NH2 
QRFP EDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRKKGGFSFRF-NH2 
Kp-10 YNWNSFGLRF-NH2 
Kp-13 LPNYNWNSFGLRF-NH2 
Kp-54 GTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF-NH2 
PrRP-20 TPDINPAWYASRGIRPVGRF-NH2 
PrRP-31 SRTHRHSMEIRTPDINPAWYASRGIRPVGRF-NH2 
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Table 3. Binding Data for NPFF and Related Peptides222 
  hNPFF1 hNPFF2 
Peptide Ki (nM) EC50 
(nM)a 
EC50 
(nM)b 
Ki (nM) EC50 
(nM)a 
EC50 (nM)b 
NPFF 0.29 ± 0.01 152 ± 55 510 ± 105 0.8 ± 0.1 79 ± 10 7 ± 2 
NPAF 3.1 ± 0.4 372 ± 13 1,350 ± 
320 
0.87 ± 
0.04 
89 ± 6 3 ± 1 
NPSF 0.58 ± 0.05 126 ± 15 20 ± 3 15 ± 2 163 ± 21 151 ± 68 
NPVF 0.20 ± 0.02 61 ± 15 9 ± 2 67 ± 3 284 ± 6 437 ± 94 
QRFP 84 ± 35 50 ± 8 > 10,000 131 ± 37 395 ± 133 > 10,000 
Kp-10 0.5 ± 0.1 181 ± 14 380 ± 95 1.6 ± 0.3 270 ± 130 292 ± 61 
Kp-13 0.7 ± 0.4 347 ± 31 830 ± 100 1.4 ± 0.3 225 ± 45 475 ± 107 
Kp-54 0.5 ± 0.2 821 ± 46 > 10,000 10.2 ± 1.3 550 ± 150 7,770 ± 2,600 
PrRP-20 4.7 ± 0.3 1,220 ± 
150 
9,280 ± 
1,180 
0.7 ± 0.1 94 ± 12 466 ± 147 
PrRP-31 11 ± 1 1,550 ± 
600 
> 10,000 0.4 ± 0.1 360 ± 270 240 ± 106 
*[3H]-FFRF-NH2 was used as radioligand for competition assays with both hNPFF1 and 
hNPFF2 receptors. 
aEC50 is the concentration of agonist that inhibits 50% of [35S]-GTPγS binding to membranes 
from CHO cells. 
bEC50 is the concentration of agonist that inhibits 50% of the intracellular cAMP production 
induced by 2 µM forskolin in CHO cells. 
Ki values, are expressed as the mean ± SEM 	
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1.3.1: Pharmacological Effects and Their Relationship to the Opioid System 
Research has shown that when an exogenous opioid agonist stimulates opioid receptors, a 
cascade of triggers activate anti-opioid systems; these systems in turn produce physiological 
tolerance, allodynia, and OIH, thus weakening the analgesic effect.229-231 Based on the research 
by Mollereau et al., NPFF is but one of these anti-opioid peptides; other peptides include 
dynorphin, cholecystokinin, nociceptin, and melanocyte inhibiting factor (MIF) related 
peptides.232 These peptides are classified as opioid modulating because they demonstrate both 
anti-opioid and pro-opioid activity. The NPFF system has clearly displayed involvement in the 
opioid system through its opioid-modulating properties.233 Chronic pain in rats has shown 
upregulated amounts of NPFF mRNA, as well as an increase in NPFF2R mRNA during early and 
late phase inflammatory hyperalgesia.234 
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1.3.2: Reported Compounds 
Figure 8. Selected NPFF1 and NPFF2 ligands 
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Due to a rather limited number of dipeptides and small molecules designed to probe and 
interact within the NPFF system, the definitive pharmacology surrounding the receptor subtypes 
is not fully established. However the compounds in figure 6 provide insight into the functional 
profiles necessary to antagonize the NPFF system through either one or both receptors. 
1.3.2.1: Original Lead NPFF Antagonists. 
The first reported NPFF antagonist, BIBP3226 (26), was originally designed as a potent 
and selective neuropeptide Y1 (NPY1) antagonist.232 The NPY (-QRYamide) endogenous ligand 
shares 30-35% homology with NPFF (-QRFamide) as well as similar C-terminal sequences and 
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consists of an arginine as well as an amidated aromatic residue necessary for receptor binding.208 
In binding assays using Chinese hamster ovary (CHO) cells transfected hNPFF1 and hNPFF2 
cells, BIBP3226 (26) displayed a Ki of 12 ± 1 nM and 84 ± 12 nM, respectively. However, when 
subjected to a cAMP functional assay to determine its agonistic ability, BIBP3226 (26) displayed 
an EC50 value of >10,000 nM at both NPFF receptors, thus demonstrating an antagonistic 
function. Derivatives of BIBP3226 were designed and synthesized, but provided weak binding 
and functional data.232 
RF9 (27), which gained notoriety for its ability to block OIH development (section 
1.3.3.1), has structural similarities to that of BIBP3226 (26); however, rather than the rigid 
diphenyl as in BIBP3226 (26), RF9 (27) contains a 3-dimensional, extremely lipophilic 
adamantine ring, which showed affinity for both NPFF receptors, but no selectivity. RF9 (27) 
also showed no agonistic effects in [35S]GTPγS functional assays at concentrations up to 100 µM 
and shifted the NPFF concentration-effect curve to the right, thus indicating antagonist 
properties.198 Compound 28, was designed to mimic RF9 (27), showed an almost 69-fold 
increase in affinity (Ki = 0.32 ± 0.02 nM) compared to RF9 (27) (Ki = 22 ± 5 nM), and a 2900-
fold preference for NPFF1 over NPFF2 (Ki = 920 ± 50 nM) through the exchange of the 
adamantine with a biphenyl ring system.235 Following suit, through the use of the biphenyl and 
RF9 (27) backbone, RF313 (29) was designed with a piperidine in place of the guanidine, which 
resulted in a 500-fold loss of activity at NPFF1 and slight gain of affinity for NPFF2 compared to 
28.235 
Compounds 30 and 31 are classified as NPFF2 selective compounds and were synthesized 
and reported by Acadia Pharmaceuticals. EC50 results for 30 reported the NPFF1 EC50 = 3980 
nM and NPFF2 EC50 = 501-1000 nM activity in cAMP functional assays.236 Whereas 31 
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displayed NPFF1 and NPFF2 functional activity at an EC50 = 3160 nM and EC50 = 501-1580 nM, 
respectively.236, 237 It was reported that 30 and 31 inhibited thermal hypersensitivity in rats, 
induced by carrageenan, however, there is no information regarding any possible off-target 
opioid activity, thus the in vivo information could be misrepresented.238 
Table 4. Binding Data for Original Lead NPFF Ligands. 
Name Ki hNPFF1 (nM)b Ki hNPFF2 (nM)b 
NPFFa 9.8 ± 0.8 0.2 ± 0.05 
BIBP3226 (26)a 12 ± 1 84 ± 12 
RF9 (27)b 58 ± 5 75 ± 9 
28b 0.32 ± 0.02 920 ± 50 
RF313 (29)b 172 ± 13 563 ± 164 
a[125I]YVP and [125I]Tyr-NPFF were used for hNPFF1 and NPFF2 
receptors, respectively. 
b[3H]-FFRF-NH2 was used as radioligand for competition assays 
with both hNPFF1 and hNPFF2, values are the means of at least 
two experiments.235 
 
1.3.2.2:  GJ Derivatives. 
The GJ derivatives (32-38) were designed based off of the BIBP3226 (26) and RF9 (27) 
scaffolds to produce ligands that would play a similar role to NPVF and its actions on NPFF 
receptors. Compounds 32, 33, and 38 consisted of the diphenyl ring system, similar to that of 
BIBP3226 (26) and showed high affinity for NPFF1. Compounds 32 and 33 consisted of an 80- 
to 54-fold preference for NPFF1 over NPFF2, respectively. While 38 had a 7-fold increase in 
affinity (Ki = 16.48 nM) for NPFF1, it also only had a 11-fold preference between NPFF1 and 
NPFF2 receptors. Compound 34 exchanged the diphenyl ring system for an adamantine ring, 
which consisted of a 72-fold loss of affinity for NPFF1 (Ki = 1887 nM). By retaining the 
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adamantine ring, but exchanging the amide at R2 for hydrogen, 36 and 37 proved to be beneficial 
in regaining NPFF1 receptor activity. Interestingly, the change in chirality of the arginine from L 
(36) to the D (37) only caused a 2.5-fold loss of NPFF1 activity (Ki = 268.6 nM) and yielded less 
NPFF2 receptor preference (Ki = 735.2 nM). By adding a large rigid system, 35, lost NPFF1 
receptor affinity. Compound 38 was tested in vivo to determine its effects on anxiogenic and 
stressor effects in mice. It was determined that 38 blocked NPVF from binding to NPFF1 
receptors and chronic administration of 38 delivered anxiogenic effects, which is contradictory to 
that of NFPV. It was determined that antagonists able to block NPVF from binding at the NPFF1 
receptor site will regulate stress and anxiety. Although 38 has the most affinity for NPFF1, it is 
still active at NPFF2, which ads the question, of the involvement of NPFF2 receptors in stress and 
anxiety. However, this further examines the reach of the NPFF system.239 
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Table 5. Binding Data for GJ Derivatives (32-38).239 
Cmpd. 
Code 
R1 R2 
Arg 
Chirality 
hNPFF1 
Ki (nM) 
hNPFF2 
Ki (nM) 
NPFF — 1.657 1.02 
RFRP-3 — 0.23 30.81 
RF9 (27) — 201.5 559 
GJ1 (32) 
 
H L 124 >10,000 
GJ2 (33) 
 
H D 184.5 >10,000 
GJ5 (34) 
  
L 1887 ND 
GJ6 (35) 
 
H L 546.8 ND 
GJ9 (36) 
 
H L 107.89 314.6 
GJ10 (37) 
 
H D 268.6 735.2 
GJ14 (38) 
 
 
L 16.48 187.9 
*Values are the mean equilibrium dissociation constants where Ki = IC50/[1+L/Kd]. 
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1.3.2.3: 4-Aminopiperidine Derivatives. 
The SAR of hNPFF residues established that the peptide binds to the receptor via the C-
terminal amide, the arginine (specifically the guanidine), and the phenylalanine aromatic ring.240 
This binding will proceed to determine the peptide’s affinity and functional activity. Research, 
accomplished by the McCurdy group, through the use of dipeptidic and small molecule ligands, 
founded that a minimum of one phenyl and a guanidine moiety are necessary for antagonistic 
binding.241 The 4-aminopiperidine scaffold was the starting point for 39-58 because the section 
in red (R2 = aromatic substitution) is known for binding to GPCR receptors, including opioid 
receptors, due to its mimicry of phenylalanine.241 The piperidine nitrogen (R1) tolerates lipophilic 
substitutions, while R3 provides a location to bind guanidine-containing moieties.241 
It was determined, based from experimental results of 39 through 43, for NPFF2 receptor 
activity it is necessary to have both a compact aromatic substitution at R1 and compact arginine 
at position R3. Since, 39 had a 2.2-fold preference for NPFF1 over NPFF2, subsequent 
compounds followed suit and consisted of a benzyl at R1 and varied the R2 and R3 moieties. 44, 
45, and 46 focused on the core structure at R3, whereas 44 investigated the linker length, 45 and 
46 looked into the rigidity. Results showed the 2-carbon linker length in 44 provided a 6-fold 
preference for NPFF1, but the rigidity of 45 and 46 lead to loss of NPFF activity. By further 
shortening the linker, 47, yielded a 1.5- and 2.6-fold increase in activity at NPFF1 and NPFF2, 
respectively, when compared to 39, however it lost receptor preference. To further investigate 
the SAR of 47, substitutions at R2 explored various aromatic substitutions. Results showed that 
compounds that consist of a hydrophobic group at R2, such as 48, 49, 50, and 51, increased 
overall affinity for NPFF1. However when 50 and 51 are compared to 48 and 49, the activity is 
less active at NPFF1, thus designating that additional hydrophobic interactions at R2 are only 
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advantageous for NPFF1 binding. To further establish SAR, moieties at R1 were exchanged with 
various lipophilic ring systems. Compounds 52, 53, and 54 lost NPFF1 activity but gained NPFF2 
activity when compared to 47. The results of 55 and 56 showed a 2.3-2.8-fold increase in NPFF1 
activity, whereas 57 remained similar to that of 47. The SAR information of these compounds 
was used to further develop and synthesize 58, which became a lead compound (Table 9). 
The removal and replacement of the methylene amide, with a reverse amide, compound 
58, was utilized to determine the methylene amides importance. In order to retain the same 
distance between the piperidine and the guanidine, a two-carbon linker between the amide and 
guanidine was used. These alterations provided not only a 4-fold increase in affinity for NPFF1, 
but also a 17.6-fold preference for NPFF1 over NPFF2. EC50 data from the forskolin-induced 
cAMP assay for NPFF1, showed 58 had antagonistic effects against 0.1 µM NPVF, thus 
indicating good affinity and preference for NPFF1. In vivo testing in mice showed that 
pretreatment of 58 prevented NPFF-induced hyperalgesic effects significantly in the warm-water 
tail-withdrawal assay.241 
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Table 6. Binding Data for 4-Aminopiperidine Derivatives (39-57).241  
Cmpd 
Code 
R1 R2 R3 
hNPFF1 
Ki (nM) 
hNPFF2 
Ki (nM) 
NPVF — 3.66 ± 0.95 — 
1DMe — 3.85 ± 0.42 0.47 ± 0.08 
39a 
   
487 ±117 1052 ± 32 
40a    
2906 ± 576 1694 ± 183 
41a 
   
479 ± 39 304 ± 14 
42a 
   
1880 ± 53 6616 ± 377 
43a    
2965 ± 112 2773 ± 470 
44a 
   
441 ± 14 2907 ± 216 
45a 
   
1623 ± 630 993 ± 87 
46a 
   
1966 ± 324 1620 ± 179 
47b 
   
319 ± 19 405 ± 56 
48b 
   
94 ± 24 309 ± 55 
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Cmpd 
Code 
R1 R2 R3 
hNPFF1 
Ki (nM) 
hNPFF2 
Ki (nM) 
49b 
   
114 ± 17 987 ± 65 
50b 
   
201 ± 35 884 ± 177 
51b 
   
191 ± 31 409 ± 39 
52b 
   
1638 ± 499 298 ± 14 
53b    
1057 ± 150 330 ± 28 
54b 
   
538 ± 40 129 ± 26 
55b 
   
141 ± 34 504 ± 95 
56b 
   
112 ± 11 454 ± 4 
57b 
   
340 ± 91 1513 ± 33 
aKi values were determined by using [125I]YVP and [125I]EYF for hNPFF1 and hNPFF2, 
respectively, and are the mean ± SEM from two to four experiments performed in 
duplicate. 
bKi values were determined by using [3H]NPVF and [3H]EYF for hNPFF1 and hNPFF2, 
respectively and are the mean ± SEM from two to four experiments performed in 
duplicate. 
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Table 7. Binding and Functional Data for 58.241 
 hNPFF1 hNPFF2 
Cmpd 
Code 
Ki (nM)a EC50 (nM)b Emax, % Ki (nM)a EC50 (nM)b Emax, % 
RF9 (27) 58 ± 5c 4700 ± 1200 c 79 ± 5 75 ± 9c d d 
58 81 ± 17 3520 ± 1420 68 ± 16 1426 ± 49 e e 
aKi values were determined by using [3H]NPVF and [3H]EYF for hNPFF1 and hNPFF2, 
respectively and are the mean ± SEM from two to four experiments performed in duplicate. 
bEC50 is the concentration that produces a 50% reversion of the NPVF (0.1 µM) or 1DMe 
(0.01 µM)-induced inhibition of forskolin-stimulated cAMP accumulation in CHO hNPFF1 
and hNPFF2 cells, respectively. 
cData taken from Simonin, Schmitt, Laulin, Laboureyras, Jhamandas, MacTavish, Matifas, 
Mollereau, Laurent, Parmentier, Kieffer, Bourguignon and Simonnet 198 dNot reported. eNot 
determined. 
 
1.3.2.4. Proline-Based Derivatives.242 
 The proline-based derivatives (59-66) were developed through the use of high throughput 
screening (HTS) against a library of GPCR-oriented compounds. The proline derivatives showed 
promising results with affinities for both NPFFRs while consisting of reasonable 
physicochemical properties. The group established a library of proline analogs to help with SAR 
and they first targeted the carboxamide region. Synthesized ligands were subjected to an assay 
called calcium mobilization, which is a more cost effective assay, beneficial for HTS, rather than 
GTPγS or cAMP assays. The assays were developed using CHO cells that overexpressed the 
Gα16 protein and had either NPFF1 or NPFF2 receptors. Clones of the cells were screened against 
10 µM of NPFF in order to identify that the receptors were functional; clones with the most 
potent and efficacious NPFF activity were tested with the synthesized ligands. Hit ligands were 
also subjected to cAMP and designated hit ligands to radioligand binding. The data from the 
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Ca2+ mobilization and cAMP assays were calculated as the apparent dissociation constant, Ke. 
The total number of reported ligands was 42, however, a selected number of ligands with more 
promising data are reported in Table 10. 
 It was quickly discovered that the carboxamide side chain of R was important for NPFF1 
antagonist functionality. Shorter chains were inactive and chains with n-hexyl or more also lost 
activity. It was found that the n-pentyl of 59 was the ideal length (NPFF1 Ke = 0.72 µM, NPFF2 
Ke = 3.09 µM); more bulky chains consisting of an s- or t-butyl or i-pentyl were also tested but it 
was determined that the linear chain lengths provided NPFF1 preference. To further study the 
regions spatial capabilities, compounds 60 and 61 focused on the aliphatic side chain with 
bulkier moieties at the terminal end. 60 consisted of a morpholinyl substitution and was less 
potent that 59, whereas the N,N-diethylaminoethyl side chains of 61 lost affinity at both 
NPFFRs, thus demonstrating heteroatoms are insufficient for the region. The replacement of the 
aliphatic groups at the terminal end with a phenyl to provide 62 (NPFF1 Ke = 0.85 µM, NPFF2 
Ke = 2.34 µM), increased NPFF1 activity while holding NPFF1 receptor preference. Lengthening 
the methylene linker of 62 to afford 63 eliminated all activity at NPFF1. Since the phenethyl 
substituent of 62 showed promising and potent results, various substituents substituted on the 
phenyl ring were then examined. Ligands with p-positioned electron-donating substituents 
showed a decrease in potency or were less tolerated, with the exception of the 4-methoxy 
derivative 64 (NPFF1 Ke = 0.67 µM, NPFF2 Ke = 1.75 µM), which showed high potency. 
Ligands with electron-withdrawing substituents were then employed and provided the most 
potent proline antagonist analog, 65 (NPFF1 Ke = 0.25 µM, NPFF2 Ke = 0.69 µM). The 4-nitro 
substituent indicated that NPFF1 antagonist affinity was attributed to strong electron-
withdrawing effects, thus a 3,4-difloro ligand 66, was synthesized. Although potent, 66 (NPFF1 
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Ke = 0.61 µM, NPFF2 Ke = 3.49 µM), did not have the same efficacy as 65, but it did provide 
more NPFF1 preference. The ligands that were selected for radioligand binding were 59, 62, 64, 
65, and 66, which showed good coordination between the three assays. The ligands that showed 
to be potent antagonists in the Ca2+ mobilization assay also showed antagonist potency in the 
cAMP assay and had affinity for NPFF1 and NPFF2 in the radioligand-binding assay. The most 
potent and successful ligands were 59 and 65, which were analyzed for their physicochemical 
properties and their in vivo applications. 
 Both 59 and 65 contain protonable nitrogen atoms, thus in their salt forms, they can 
partake enhanced solubility and bioavailability. 59 and 65 consisted of decent blood-brain 
permeability as well as good solubility (146.8 ± 6.9 µM and 45.9 ± 7.7 µM, respectively) within 
the range for feasible CNS ligand candidates. Both ligands were subjected to in vivo studies in 
fentanyl-induced hyperalgesic rats and both compounds reversed the fentanyl-induced 
hyperalgesia when administered intraperitoneally (i.p.). Although these ligands have 
submicromolar affinities and potencies, the proline-based derivatives suggest potential 
alternatives to standard guanidine moieties. 
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Table 8. Binding and Functional Data for Proline-Based Derivatives 59-66.242 
  Radioligand Bindinga Ca2+ mobilization 
assayb 
cAMP assayb 
Cmpd 
Code R 
NPFF1 Ki 
(µM) 
NPFF2 Ki 
(µM) 
NPFF1 Ke 
(µM) 
NPFF2 Ke 
(µM) 
NPFF1 Ke 
(µM) 
NPFF2 
Ke (µM) 
59 
 
0.89 ± 0.05 1.44 ± 0.13 0.72 ± 0.01 3.09 ± 0.58 0.36 ± 0.08 
2.15 ± 
0.36 
60 
 
N.D. N.D. 1.96 ± 0.07 c N.D. N.D. 
61 
 
N.D. N.D. >10 c N.D. N.D. 
62 
 
0.71 ± 0.02 1.23 ± 0.27 0.85 ± 0.14 2.34 ± 0.31 0.77 ± 0.13 
3.79 ± 
0.45 
63 
 
N.D. N.D. >10 2.60 ± 0.28 N.D. N.D. 
64 
 
0.92 ± 0.03 1.46 ± 0.05 0.67 ± 0.06a 1.75 ± 0.11 0.57 ± 0.15 
2.56 ± 
0.20 
65 
 
0.61 ± 0.03 1.67 ± 0.06 0.25 ± 0.06 0.69 ± 0.14 0.49 ± 0.09 
1.17 ± 
0.36 
66 
 
0.56 ± 0.04 1.49 ± 0.27 0.61 ± 0.13 3.49 ± 1.4 0.57 ± 0.17 
2.16 ± 
0.30 
aValues are the mean ± SEM of at least two independent experiments in duplicate. 
bValues are the mean ± SEM of at least three independent experiments in duplicate. 
cCompound was inactive in antagonist screen at 10 µM final  (N = 2). 
N.D., Potency was not determined. 
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1.3.3: RF9 and Heroin 
A synthetic pseudopeptide, synthesized by Simonin et al., titled RF9 (27), known as a 
selective NPFFR antagonist but was later reported to show nonselective agonism at NPFF1 and 
NPFF2, showed the first effects of human NPFF receptors (hNPFFR) when antagonized.198, 243 
RF9 (27) was designed to mimic BIBP3226 (26), an NPY1-selective antagonist, due to its 
structural similarities to RFamide derivatives.198, 244 In order to investigate the anti-opioid and 
pro-nociceptive effects, RF9 was co-administered with heroin and was shown to block OIH as 
well as counteract tolerance development in mice.198 To gain further insight of RF9 (27), it was 
also administered by itself without an opioid agonist and no effects were shown. This strongly 
suggested that the NPFF system is involved in the anti-opioid systems involved in tolerance and 
OIH.198 	 	
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CHAPTER 2 
ADVANCES IN DRUG DESIGN: POLYPHARMACOLOGY 
  
2.1: Stigma of ‘Dirty’ Drugs 
 Traditionally, drugs that are considered safe with favorable physicochemical and 
pharmacological properties are thought to have a single-target.245, 246 However, the human body 
is complex, and consists of intertwined and interconnected systems and pathways, which makes 
it difficult to target a specific site without one system modulating another in a down-stream 
cascade. Much research is aimed to avoid compounds classified as ‘dirty’ drugs, which have 
activity at multiple targets, even though many successful drugs actually do not have one single 
target.247 Mestres et al. found that out of 802 drugs and 480 targets there was a network of 4767 
unique interactions, which in turn showed one drug, interacts on average with six separate 
targets.248 Another group concurred Mestres et al.’s results after they examined currently 
approved FDA drugs and unearthed an abundance of off-target interactions.249 Also termed 
polypharmacology, there is a stigma that surrounds the use of multi-target compounds, which has 
evolved from cases where severe side effects and even fatalities have occurred, most likely due 
to off-target interactions.247 
Polypharmacology is a rather broad term that consists of two specific definitions: (1) the 
involvement of several drugs to act independently on separate targets, known as a drug cocktail 
or multicomponent drug, or (2) a single drug, which binds to two or more molecular targets 
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within a biological system.250 The second definition can be further defined to where either a 
single drug acts on multiple targets of a unique disease pathway or the multiple targets are 
associated with multiple disease pathways.251 In theory, polypharmacological drugs have the 
opportunity to provide better efficacy and decreased toxicity compared to a single-target mode of 
therapy. Not only could single-drug multi-target, polypharmacological therapy be more cost-
effective, but also provide better pharmacokinetic and metabolic profiles such as increase overall 
drug bioavailability, better intrinsic clearance, and contain minimal side effects.252-255 
Figure 9. Multi-target Therapy Options. 
 
(A) Drug cocktail: consists of two or more tablets with two or more agents; (B) multicomponent 
drug: contains two agents in one tablet; (C) multiple ligand: one tablet has one active agent that 
acts at 2 or more targets. *Interpreted from Morphy and Rankovic 256. 
2.2: Targeted Polypharmacology: Designed Multiple Ligands (DMLs) 
 The foundational goal in the design of polypharmacological ligands is to concentrate on 
multi-target compounds within a biological network, which can be modified to achieve 
advantageous clinical therapies. The design of multi-target ligands has shown to be a difficult 
task even though it does not consist of the same time restrictions and expenses as single drug 
treatments; there are many other factors that play a role in the rational design of 
polypharmacological therapies. In order to increase effectiveness, compounds are typically 
designed with overlapped or linker-connected pharmacophores. However, many times, ligands 
designed in this manner, lose ADME properties such as oral bioavailability and consist of a high 
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molecular weight.245 Traditionally, animal models are used as one of the first-lines in the 
screening process, since they can readily identify the compounds that exhibit the suitable 
pharmacokinetic (PK) and pharmacodynamics (PD) profiles. However, when compounds are 
inactive its difficult to establish if it was due to inactivity at the molecular target interaction or if 
it did not reach the site of action. 
 Many have been able to maneuver around this problem, through the utilization of 
screening-based methods such as computational chemistry, or systems biology, prior to the 
synthesis of the ligand. Milletti et al. compared binding pockets through structural similarities at 
the sub-pocket level to look closer at the various protein folds, which in turn provided a ‘map’-
like prediction of protein inhibition.257 Another more commonly used method called docking, 
binds designed compounds in silico with a 3-dimensional structure of the target protein to predict 
how they will bind in vitro and in vivo. An algorithm then organizes the ligands based on the in 
silico binding similarities, which indicates the most ideal ligand to be synthesized.258, 259 Duran-
Frigola et al. compared over 90,000 binding pockets in 3,700 proteins and determined there is at 
least one equivalent binding cavity in the 23,000 pairs of proteins.260 The fragment-based 
approach, an alternative in silico method, takes a library of small fragment-like molecules, MW 
<250 Da, and screens them against the intended targets. This approach provides an opportunity 
to optimize the lead ligands which in turn identifies efficient small drug-like molecules.261 
Although in silico methods used to predict ligand design are advantageous, in some cases they 
are not reliable. In silico methods need at least a 3D structure of the target protein(s), a crystal 
structure of an active receptor with a bound ligand is better, but if a receptor protein has yet to be 
crystallized or no 3-dimensional structure yet exists, these methods are inadequate. In this case, a 
knowledge-based approach is utilized. 
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 The knowledge-based approach must rely on existing in vitro and in vivo data from 
known ligands.256 Some groups that have large libraries of literature with diverse compound 
assortments utilize HTS to develop a hit compound. A more focused screening approach uses 
compounds with known robust activity at target A and screen them against target B; any activity, 
even weak, provides a foundation to develop a more rigorous SAR scaffold.256 The development 
of the SAR scaffold can fall into three different classifications: conjugate, fused, or merged. 
A conjugate framework consists of a higher molecular weight, because it’s comprised of the 
fundamental pharmacophores for the intended targets connected by a metabolically stable linker, 
such as a pseudopeptide linker. This linker can also be designed to be cleavable, most commonly 
ester-based; once metabolized the two ligands are released and are able to act independently at 
their intended targets. An example of this is 67, a heterodimeric conjugate that contains 
naltrindole (DOP antagonist) and ICI-199,441 (K1OP agonist) bridged by an oligoglycyl-based 
linker and demonstrated a selectivity and potency greater to that of its monomer counterparts.262 
Thus strengthening the evidence that there is a phenomenon surrounding the idea of opioid 
receptor heterooligomerization.256, 262, 263 A fused scaffold is when the linker is essentially 
nonexistent and the pharmacophores are in contact with each other, as in compound 70; where 
the hydrophilic pharmacophore of the histamine H2 antagonist 69 and the hydrophobic region of 
the gastrin antagonist 68 were superimposed onto peptide, N-acetyl-CCK-7.264 When a 
compound is designed to have the most common motifs of the initial compounds, but is compiled 
into a smaller and simpler molecule this becomes a merged scaffold. In order to establish an 
analgesic with limited liabilities, Montero et al. combined the MOP agonist fentanyl (20) with 
the I2-imidazoline receptor agonist (agmatine) to have a combined agonism at both GPCRs.265 
Although 73 had activity at both receptors, it was unbalanced and had a greater affinity for MOP, 
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whereas 74 had much better affinity balance.265, 266 It was determined that the alkyl chain of 73 
provided too much similarity to fentanyl (20) aniline system.265 
However, regardless of the type of scaffold, it is necessary to take into consideration 
three things when designing DMLs: are the potencies (agonist, antagonist, or both) relatively 
similar for both intended targets, what is the dose ratio necessary for the intended results, and the 
metabolism of the DML.256, 267 It is important to realize that the metabolism of DMLs will 
change, but the dose ratio will not. 
Figure 10. Framework Integration of Pharmacophores. 
 
*Interpreted from Morphy and Rankovic 256 
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2.2.1: Reported Compounds 
Figure 11. Dual-acting compounds with therapeutic importance. 
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2.2.1.1: Conjugate Ligands 
 Conjugate ligands can fall into two generalized categories: cleavable conjugates and 
conjugated pharmacophores.268 Pharmacophores can be connected using cleavable linkers (i.e. 
ester linker) or through the use of pseudopeptides that are more impervious to metabolic 
cleavage.268 In the case of cleavable conjugates that consist of ester linkers, when exposed to the 
blood, the ester linker is metabolized by esterases in the plasma, which in turn releases two 
individual drugs, that act independent of each other.268 Whereas conjugated pharmacophores use 
a pseudopeptide to facilitate a bridge between two monomer pharmacophores, which can 
improve potency and receptor selectivity.268 
 A conjugated ligand was designed to activate both A1 and A3 adenosine receptors for 
cardioprotective effects associated with myocardial ischemia.269 This ligand, MRS1741 (75), was 
created through covalent, thiourea-linked adenosine agonists selective for A1 and A3.269 
MRS1741 (75) was found to co-activate both target receptors concurrently while demonstrating 
that the expression of both receptors delivers full cardioprotection.269 
 Another example is NAPAP-PS (76), which was designed to combat thrombosis and 
hemostasis through the linkage of NAPAP, a thrombin antagonist, and a heparin 
pentassaccharide (PS)-analog, which inhibits factor Xa through activation of antithrombin III 
(ATIII).270, 271 NAPAP-PS (76) was designed to mimic the heparin inhibition sequences of a 10-
12 unit pentassaccharide domain, in order to form a ternary complex with thrombin and 
ATIII.270, 272 NAPAP-PS (76) displayed high anti-thrombin (IC50 = 0.35 µM) and ATIII-
mediated anti-Xa (885 U mg-1) activity in vitro.270 In vivo models revealed NAPAP-PS (76) had 
stronger inhibition than a combination of the separate monomers and demonstrated a extended 
half-life compared to NAPAP.270 
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The interactions between opioid receptors, was exposed after an investigation of morphine-
induced analgesia and the effects of LEU and MET, yielded different physiological functions.273 
As time progressed, the selective DOP antagonist, naltrindole (NTI, 89) was found to block 
morphine tolerance without weakening its antinociceptive efficacy.274 In cases as in KDAN-18 
(67) and MDAN-21 (77), these ligands comprise of a long linkers between the active opioid 
receptor pharmacophores. Since DPDPE (23) activates an allosterically coupled D1OP-K2OP 
heterodimer, a question surrounding D2OP and K1OP developed; thus the phenotypes were to be 
evaluated through a bridged concept of two pharmacophores one active at each target 
receptor.275, 276 The KDAN (67) series consisted of a varying number of oligoglycyl residues 
between NTI (89), and K1OP agonist, ICI-199,441.262 KDAN-18 (67) with an 18 member 
oligoglycyl-based linker, facilitated bridging between D2OP and K1OP phenotypes, which in turn 
provided the greatest selectivity out of the examined D2OP-K1OP ligands.262 Where KDAN-18 
(67) targeted KOP and DOP heterodimers, MDAN-21 (77) was designed to bridge the MOP and 
DOP heterodimers.277, 278 MDAN series was designed with NTI (89) and mu agonist 
oxymorphone bridged together with various spacer lengths; MDAN-21 (77), consisted of 21 
spacers, was found to be 50-fold more potent than morphine and displayed less dependence in 
mice when administered through intravenous (i.v.) route.278 When tested in rhesus monkeys, 
MDAN-21 (77) was capable of suppressing withdrawal symptoms, and was as effective as 
morphine in thermal allodynia assays (dose range of 0.032-0.32 mg/kg), but was unable to 
produce reliable antinociceptive effects.279 
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2.2.1.2: Fused Ligands 
 By fusing together pharmacophore moieties that specifically act at their target receptors, 
without the need of long cleavable or conjugated linkers, will typically allow for better PK and 
PD properties associated with a lower molecular weight.  
  70, was designed using a fused scaffold that consisted of antagonistic moieties for 
histamine H2 receptors (H2) and gastrin receptors (GA) superimposed onto peptide N-acetyl-
CCK-7 in order to combat peptic ulcers.264, 280 70 was designed from moieties on notable H2 
antagonists, famotidine (Pepcid AC®) and roxatidine, but with modifications, and a non-peptide 
GA moiety from the GA antagonist, L-365,260.264 This fused scaffold was shown to possess 
balanced activity at H2 and GA receptors; however, in vivo results of 70 in rat and canine, 
indicated poor bioavailability compared to L-365,260 itself.264 Although there was poor 
bioavailability, the modifications made improved H2 (pA2 = 6.6) and GA (IC50 = 136 nM) 
antagonistic activity, although it contained some cholecystokinin (CCK)-B activity (IC50 = 290 
nM).264  
 UFP-505 (78) is another fused ligand that contains 2 separate pharmacophores: 2’,6’-
dimethyl-L-tyrosine (Dmt) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) linked via 
a Gly-NH-CH2 linker.281 Dmt enhances affinity and bioactivity at MOP and DOP, whereas Tic 
promotes DOP antagonist activity.281-284 For example, when Dmt is inserted onto deltorphin B 
(selective DOP agonist) it intensifies both DOP and MOP affinities when compared deltorphin 
B, alone; endomorphins-1 and -2 also express added MOP affinity when compared to the Dmt-
free peptides.285, 286 It is suggested that Dmt facilitates ligand recognition for DOP and MOP 
receptors through an “address” role in the “message-address” concept.263, 287-289 This concept, 
designs a ligand to contain a “message” role, which is important for biological action, and an 
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“address” role, necessary for receptor binding.289, 290 Tic on the other hand, will establish DOP 
antagonism. An example of this is that when Tic is incorporated onto dynorphin A (KOP 
agonist), it becomes a selective DOP/KOP antagonist.291 A similar effect occurred with 
enkephalin (DOP agonist) and dermorphin (MOP agonist) were converted into DOP-selective 
antagonists.292 The synthesis of Dmt-Tic analogs were used to investigate the necessity of a 
“spacer” and a third aromatic center in order to establish ligands with DOP agonism or mixed 
DOP antagonism/MOP agonism from current DOP antagonists.281 Dmt-Tic analogs with various 
spacers were designed; the extra methylene on UFP-505 (78) Gly-NH-CH2-Ph linker was found 
to exhibit high affinity for DOP and MOP (Ki = 0.031 ± 0.002 nM and Ki = 0.16 ± 0.018 nM, 
respectively) and the most potent DOP antagonism (pA2, 9.25) and MOP agonism (pEC50 = 
8.57) out of the synthesized Dmt-Tic analogs.281 One study went a step further and compared 
UFP-505 (78) to fentanyl (20) and morphine (5), their results showed UFP-505 (78) consisted of 
full MOP agonist activity, similar to fentanyl (20), while also acting as a potent DOP 
antagonist.293 Recently, more in-depth in vivo experiments reported that UFP-505 (78) did not 
produce an adequate tolerance profile, and suggested tolerance results could be due to pain 
model-sensitivity or dose/method of administration.294 UFP-505 (78), did however produce 
prolonged antinociception in both the tail-flick and paw-pressure assays compared to that of 
morphine.294 
 Another avenue in the treatment of chronic and neuropathic pain with fused DMLs is 
through the design of opioid agonist/NOP antagonist approach.295-297 Guillemyn et al. fused an 
opioid pharmacophore with an ORL-1/NOP pharmacophore through a corresponding amide to 
yield 79.298 The un-fused opioid pharmacophore utilized a Dmt moiety, which enhanced its 
overall opioid receptor binding, and displayed only MOP, DOP, and KOP affinity with no 
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affinity for ORL-1/NOP (Ki > 10,000 nM), whereas the ORL-1/NOP parent pharmacophore 
showed low affinity for opioid receptors and high affinity for ORL-1/NOP (Ki = 0.53 ± 0.06 
nM).298 The fused DML 79 caused a slight loss in all-over receptor binding, however, 79 was 
able to maintain the opioid affinities in the low to moderate nanomolar range (MOP Ki = 5.0 ± 
1.7 nM, DOP Ki = 99 ± 4 nM, an KOP Ki = 33 ± 15 nM), while also displaying an adequate 
ORL-1/NOP affinity (Ki = 42 ± 6 nM).298 Although 79 displayed potent opioid agonism and 
weak ORL-1/NOP antagonism in vitro, in vivo assays displayed a prolonged increase in 
analgesic action compared to morphine when administered i.v., which suggested BBB 
penetration and thus coincided with BBB in vitro assay models.298 Not only did 79 have provide 
better antiallodynic and antihyperalgesic effects compared to morphine, but the primary dosages 
of 79 were low and its corresponding effects prolonged even after 180 minutes post-
administration.298 The initial in vivo assays for 79 showed it to display high analgesic potency in 
acute and neuropathic pain models; respiratory depression assays of 79 demonstrated no 
significant inhalation or exhalation issues, commonly seen with morphine.298 In all, opioid-NOP 
DMLs are able to provide analgesic activity without the associated respiratory depression.298  
2.2.1.3: Merged Ligands 
 In order to design merged ligands, structural motifs from selective or hit ligands are 
overlapped, then the specific receptor pharmacophores are integrated onto the scaffold.268 
 Cancer can be very difficult to treat due to all its complexities and entangled 
physiological pathways. The design and utilization of DMLs in cancer therapeutics has surged in 
recent years as alternatives to the traditional radiation and chemotherapies.299-301 A small 
molecule, merged ligand that recently hit market, is called lapatinib (80). Lapatinib (80) was 
designed with a 4-anilinoquinazoline core that allows for reversible dual-inhibition of epidermal 
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growth factor receptor (EGFR) and HER-2 breast cancers.302 By competing with ATP in the 
intracellular ATP-binding domain, lapatinib (80) binds in the cytoplasmic tail of the tyrosine 
kinase receptor thus blocking the phosphorylation of tyrosine kinase.302 The phosphorylation 
inhibition blocks signal transduction to the PI3K/Akt and Ras/Raf/MAPK (Erk1/2) pathways.302 
When PI3K/Akt pathway is upregulated and activated, it projects HER-2 positive breast cancers 
forward, whereas Ras/Raf/MAPK pathway is involved in cell division and proliferation.303 
 Recently, Cuadrado-Tejedor et al. designed a small molecule DML probe for the 
treatment of Alzheimer’s disease (AD).304 They suggested that because of ADs complexity, the 
upregulation of phosphodiesterase 5 (PDE5) and class I histone deacetylases (HDACs) might be 
important to modulate simultaneous inhibition.305-307 CM-414 (81) was designed through 
merging HDAC and PDE5 inhibiting pharmacophores onto one scaffold.304 In vitro studies 
showed CM-414 (81) to display potent HDAC6 and PDE5 inhibition, while exhibiting overall 
moderate inhibitions for HDAC class I.304 In AD mice, synaptic plasticity and cognitive 
impairment was prevented, while also displaying a drastic reduction in β-amyloid and tau 
phosphorylation levels.304 CM-414 (81) provided a new avenue for AD discovery through dual-
inhibition.304 
 Some groups have utilized functional groups from successful marketed drugs such as 
Celecoxib, to design merged ligands. Celecoxib (Celebrex®) is a COX-2 selective inhibitor that 
provides an enhanced gastrointestinal side-effect profile compared to nonselective COX-1 and 
COX-2 inhibitors (i.e. Aspirin (1), ibuprofen (3)). Celecoxib blocks hyperalgesia and 
inflammation from occurring through arachidonic acid-mediated prostaglandin formation.23, 308, 
309 However, arachidonic acid can also be metabolized thorough the lipoxygenase (LO) pathway 
and in turn generates pro-inflammatory leukotrienes (LTs).310, 311 Barbey et al. suggests that if 
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both arachidonic acid biosynthetic pathways are inhibited, patients suffering from arthritis, 
inflammation and hypersensitivity could achieve more relief.312 In order to reduce the 
inflammatory process, compounds were designed to inhibit COX-2 and 5-LO enzymes. The 
pyrazole of Celecoxib, was merged with a 5-LO inhibitor pharmacophore, 4-(3-fluoro-5-
oxy)phenyl-4-methoxytetrahydropyran, from Zeneca’s ZD-2138 to yield 82.312 82 displayed 
affinities for COX-2 and 5-LO (IC50 = 0.05 µM and IC50 = 0.003 µM, respectively) with over a 
200-fold selectivity for COX-2 over COX-1.312 In vivo experiments evaluated 82 on arachidonic 
acid-induced ear edema in rats; i.v. administration and oral administration of 82 produced a 
strong reduction of arachidonic acid-induced ear edema.312 
 UMB425 (83) is a uniquely designed DML that contains the structure of oxymorphone (a 
strong MOP agonist) with a 5’-hydroxymethyl substituent.313 In silico models predicted 
UMB425 (83) to contain mixed MOP agonism/DOP antagonism effects; the 5’-hydroxymethyl 
moiety provided enough spatial overlap similar to that of the C19 hydroxy group on orvinols, 
and thus can interact with receptors in a similar way to yield mixed activity.313 In vitro binding 
and functional assays with CHO cells exhibited the projected MOP agonist/DOP antagonist 
activity.313 In vivo studies showed UMB425 (83) maintains greater antinociceptive effects 
compared to morphine; its effects can be blocked by naloxone but not KOP antagonist 
norbinaltrophimine (norBNI, 90) which reinforces the fact that UMB425 (83) displays MOP 
activity rather than KOP activity.313 The findings of UMB425 (83) indicate that the classical 
DOP moieties on the C-ring are not always required as initially presumed.313  
 The above ligands are examples to establish the proof of concept and indicate that small 
molecule DMLs are viable approaches to novel therapeutics.  
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2.3: Therapeutic Applications of MOP-NPFF ligands. 
Figure 12. Compounds with MOP-NPFF therapeutic importance 
 
BN-9 (84) 
 
 
DN-9 (85) 
 
 Morphine (5) and other MOP agonists are commonly prescribed for the treatment of 
moderate to severe pain, however, these MOP agonists come with negative side effects such as 
hyperalgesia, constipation, tolerance development, and respiratory depression.63 Thus there is a 
need to develop analgesics devoid of the current side effects. Since MOP agonists are currently 
the “gold-standard” for moderate to severe pain relief,91 attention should be turned to the design 
and synthesis of small molecule DMLs that consist of MOP agonism and NPFF antagonism, as 
these ligands would block hyperalgesia and tolerance development, and in turn maintain low 
dosages that would prevent constipation and respiratory depression.314 When an MOP agonist 
and NPFF antagonist are administered together, they provide powerful analgesic effects while 
blocking opioid-induced side effects, specifically tolerance and hyperalgesia.198, 314, 315 There 
have been cases where NPFF agonists show similar results to NPFF antagonists based on the 
route of administration; for example, intrathecal (i.t.) administration of NPFF produces 
antinociceptive effects and potentiates morphine analgesia, whereas intracerebroventricular 
(i.c.v.) administration of NPFF reduces the analgesic effects of systemic morphine.316 
The one of first designed DMLs was BN-9 (84) an opioid-NPFF pharmacophore-
containing chimeric peptide; it was developed to combine the analgesic properties of opioid 
receptors and the opioid-modulating properties of NPFF into a single chimerically fused 
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ligand.317 BN-9 (84), which has a designed sequence of Tyr-D.Ala-Gly-Phe-Gln-Pro-Gln-Arg-
Phe-NH2, was designed with half of the opioid agonist biphalin (Tyr-D.Ala-Gly-Phe-NH-) and 
the sequence of NPFF with an overlapping of the phenylalanine residue.317 In vitro assays 
showed BN-9 (84) to be a nonselective opioid agonist with nonselective NPFFR agonist activity; 
animal studies concurred the findings of the in vitro data.317 BN-9 (84) produced antinociceptive 
effects that are thought to be MOP and KOP-mediated mechanisms.317, 318 BN-9 (84) also 
provided consistent analgesia without the loss of potency, which suggests that the opioid and 
NPFF receptor coactivation may play a role.318 BN-9 (84) did produce conditioned place 
preference (CPP) in animal models, which suggests that the reward pathway is still activated 
through the opioid receptors.317 
An analog of BN-9 (84), DN-9 (85) was designed to further understand the structural and 
conformational requirements necessary for opioid and NPFF receptor interactions, while 
providing balanced receptor effect.319 The sequence of DN-9 (85) is Tyr-D.Ala-Gly-NMe.Phe-
Gly-Pro-Gln-Arg-Phe-NH2, which was identified as a mixed opioid-NPFF agonist that provided 
potent analgesia devoid of tolerance and had 33-fold increased potency compared to BN-9 (84) 
in the tail-flick assays.319 The -NMe.Phe-Gly- substitution of DN-9 (85) provided an improved 
metabolic stability profile in mice and produced dramatic antinociceptive effect in the formalin-
induced pain assay while also displaying anti-allodynic effects in the chronic inflammatory test, 
thus strengthening the concept of MOP-NPFF DML therapeutics.319  
DMLs provide better PK and PD profiles with improved intrinsic clearance, simple and 
predictable ADME properties (absorption, distribution, metabolism, excretion), lower risk for 
drug-drug interactions, and potential for active compounds to consist of a high, local 
concentration compared to multiple drugs given together.320 Although chimeric peptides tend to 
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show more receptor selectivity in many cases, optimized small molecules display even more 
improved profiles and tend to provide better metabolic stability and have improved 
bioavailability.321 
2.4: Design Strategy 
The original design scaffold of the MOP agonist-NPFF antagonist began with the design of 
VBJ192, a nonselective opioid agonist, and CM695, a selective MOP agonist. These ligands 
were designed to be nonpeptidic KOP ligands constructed from the SAR results of BW373U86 
(86) and 5’-guanidinonaltrindole (GNTI, 87). BW373U86 (86) was designed to consist of 
common pharmacophoric features of the mixed agonist-antagonist opioid ligand R-(-)-MT45 
(88) and NTI (89), which resulted in a DOP IC50 = 0.31 ± 0.02 nM and MOP IC50 = 46.3 ± 4.42 
nM and lack of respiratory depression in mice, however, it resulted in proconvulsant activity and 
subpar analgesic efficacy and potency.322, 323 The potent KOP antagonist ligand, GNTI (87), was 
designed in a similar manner to that of BW373U86 (86), by the superimposition of the common 
pharmacophoric moieties of NTI (89) and KOP antagonist, norBNI (90).324, 325 GNTI (87) 
resulted in preferential KOP antagonism with a KOP Ki = 0.18 ± 0.05 nM, a DOP Ki = 46.3 ± 
5.1 nM, and a MOP Ki = 22.5 ± 3.9 nM.324 Based on their 3D overlay rendering, features from 
both BW373U86 (86) and GNTI (87) were made into the diphenylmethylenepiperidine scaffold 
(91) and consisted of various hydroxy and guanidine substitution patterns as shown in figure 14. 
The diphenylmethylenepiperidine scaffold was employed to improve oral bioavailability and PK 
profiles compared to previously reported ligands.  
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Figure 13: Structures leading to the design of VBJ192 and CM695. 
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Figure 14: Diphenylmethylenepiperidine Scaffold with Substitution Patterns. 
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pharmacophores necessary for NPFF binding. EC50 results demonstrated opioid agonist activity 
with moderate potency, while also suggesting NPFFR antagonistic activity. This paved the way 
for the design and synthesis of dual-acting opioid agonist/NPFF antagonist ligands. 
A question that has been asked is why the quantitative structure activity relationship 
(QSAR) approach has not been implemented in the design of these molecules. QSAR is a ligand-
based computational learning method of drug design used to predict protein-ligand interactions 
through the comparison of new ligands verses known ligands.326, 327 Although QSAR has shown 
great success in the capability to select the most favorable compounds, if there are limited known 
ligands, selective or non-selective, QSAR is much less effective. QSAR also utilizes the 3-
dimensional structure of the target proteins, to predict the protein-ligand interactions and if the 
3D structure is unknown, QSAR cannot be applied.328, 329 In addition, it has been found 
challenging to implement QSAR methods for membrane proteins such as ion channels and 
GPCRs, because of the intricacy of defining their 3-dimensional configuration.245 This is the case 
for the NPFF system; not only does the system have few known ligands, but its two GPCR 
receptors do not have a 3-dimensional configurations available to predict protein interactions. 
Thus in our case, it is necessary to utilize the knowledge-based approach to the design and 
synthesis of our compounds. 	  
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CHAPTER 3 
PREVIOUS IN-HOUSE WORK 
 
 Previous in-house work towards the development of novel dual-acting small molecule 
MOP agonist/NPFF antagonist ligands includes the CM-, VBJ-, MC- and CNK-series. SAR 
studies indicated that a minimum of two lipophilic phenyl rings A and B (Figure 15) and a 
guanidine group were required for binding. It was determined that the rigidity of the 
diphenylmethylenepiperidine scaffold was well tolerated at opioid and NPFF binding sites. In its 
3-dimensional form, the methylenepiperidine moiety mimics the structure of the 4-anilido 
piperidine found in the MOP agonist fentanyl. An N-benzyl moiety on the piperidine nitrogen 
fulfilled the hydrophobic substitution of ring B, whereas the diphenyl rings A and C allowed for 
various substitutions at the 3- and 4-positions (i.e. guanidine moiety). 
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Figure 15. Common Pharmacophores for Opioid and NPFF Activity. 
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3.1: VBJ and CM Series 
Figure 16. Simplified analogs VBJ192 and CM695. 
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polypharmacology utilizing opioid receptors while simultaneously blocking NPFF receptors and 
their associated tolerance development. 
 The simplified analogs of the diphenylmethylenepiperidine scaffold, VBJ192 and 
CM695 were synthesized with a guanidine substituted at the 4- and 3-positions, respectively. 
The ligands were subjected to binding and functional studies; however, opioid in vitro data for 
VBJ192 (Table 9) and CM695 (Table 10) was continuously inconsistent. The first set of data for 
both VBJ192 and CM695 was recorded and obtained from the laboratory of Dr. Catherine 
Mollereau at the Institut de Pharmacologie et Biologie Structurale in Toulouse, France, but when 
the same compounds were tested in-house, by COBRE Core C, the data was inconstant with Dr. 
Mollereau’s results, thus making both sets of data unreliable. It was thought that the results of 
VBJ192 were due to its salt form; VBJ192 was then resynthesized into a dihydrochloride salt. In 
vitro data compared the TFA and HCl salt forms of VBJ192, which showed insignificant 
differences in affinity, but moderate differences in KOP and MOP potencies. In regards to 
CM695, it was thought that the original compound had degraded, thus it was resynthesized and 
together retested; both sets of data fell within the error margin citing insignificant changes in 
affinity. NPFF receptors were also not fully reliable due to the use of differing conditions (i.e. 
CHOhNPFF receptors labeled with radioligand vs. radioligand displacement) (Table 11). Due to 
the continuous inconclusive results it was determined that in vitro data could not be fully 
dependable.  
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Table 9. In vitro binding and functional data for VBJ192 at DOP, KOP, and MOP 
receptors 
 DOP* KOP† MOP‡ 
Cmpd. 
Code 
Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type 
VBJ192a 31 ± 6 N.T. N.T. 
67 ± 
24 
N.T. N.T. 
322 ± 
113 
N.T. N.T. 
VBJ192b 
322 ± 
45 
938 ± 
85 
Full 
354 ± 
56 
1250 ± 
181 
Partial 
487 ± 
49 
N.T. N.T. 
VBJ192c 
8.5 ± 
0.7 
539 ± 
93 
Full+ 
30 ± 
4 
2711 ± 
398 
Partial 
651 ± 
76 
576 ± 
311 
Partial 
VBJ192d 
6.3 ± 
0.6 
631 ± 2 Full+ 
59 ± 
10 
58 ± 9 Partial 
797 ± 
70 
34 ± 
6 
Partial 
aResults reported in the thesis of Journigan 330, data obtained from Dr. Catherine Mollereau, 
Institut de Pharmacologie et Biologie Structurale, Toulouse, France 
bResults reported by COBRE Core C, December 2014 
cResults of TFA salt reported by COBRE Core C, November 2016 
dResults of HCl salt reported by COBRE Core C, November 2016 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.T., Not tested, awaiting testing 
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Table 10. In vitro binding and functional data for CM695 at DOP, KOP, and MOP 
receptors 
 DOP* KOP† MOP‡ 
Cmpd. 
Code 
Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type 
CM695a 23 ± 75 N.T. N.T. 8 ± 3 25.47 N.T. 36 ± 7 N.T. N.T. 
CM695b 83 ± 15 
256 ± 
25 
Full 
8.7 ± 
1.1 
25 ± 
58 
Partial 
2.97 ± 
0.31 
102 ± 21 Partial 
CM695c 92.34 
124 ± 
20 
Full 43.26 
412 ± 
52 
Full 6.58 24 ± 3 Full 
CM695d 70 ± 11 N.T. N.T. 
34 ± 
4 
N.T. N.T. 
8.3 ± 
1.0 
N.T. N.T. 
aResults reported in the thesis of Journigan 330, data obtained from Dr. Catherine Mollereau, 
Institut de Pharmacologie et Biologie Structurale, Toulouse, France 
bResults reported by COBRE Core C, December 2014 
cResults of original compound reported by COBRE Core C, November 2016 
dResults of resynthesized ligand reported by COBRE Core C, November 2016 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.T., Not tested, awaiting testing 
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Table 11. In vitro activity of VBJ192 and CM695 at NPFF1 and NPFF2 receptors. 
Cmpd. Code NPFF1R  Ki (nM) NPFF2R  Ki (nM) 
VBJ192a 976c 106d 
VBJ192 (TFA salt)b * 863.3 ± 29.0e 
VBJ192 (HCl salt)b * 763.0 ± 41.1e 
CM695a 314c 534d 
CM695b * 1820 ± 95e 
aResults reported in the thesis of Journigan 330, data obtained from Dr. 
Catherine Mollereau, Institut de Pharmacologie et Biologie Structurale, 
Toulouse, France. 
bResults reported by COBRE Core C, November 2016 
cCHOhNPFF1 receptor labeled with [3H]NPVF. 
dCHOhNPFF2 receptor labeled with [3H]EYF. 
eReflects displacement of hNPFF2R radioligand [3H]-EYW 
*Not tested, awaiting testing 
 
In order to determine the activity of VBJ192, animal studies that focused on 
antinociception and receptor selectivity were performed (Figure 17). Results showed VBJ192 
provided significant antinociception compared to the vehicle (Figure 17A), which was mediated 
through MOP receptors (Figure 17B). In order to establish the ability of VBJ192 to block 
tolerance activity, mice were subjected to a 55 ºC warm-water tail-withdrawal assay and 
administered morphine (white open circles) or VBJ192 (blue open squares) at 0 hours and the 
percent antinociception was calculated; after 8 hours, mice were administered a second dosage of 
morphine (solid black circles) or VBJ192 (solid blue squares) (Figure 18). Mice that had been 
administered morphine displayed a significant increase and right shift in acute tolerance 
development, whereas VBJ192 had limited tolerance development as shown by the less 
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pronounced right shift of the second dose. VBJ192 in vivo displays analgesia-mediated MOP 
agonism, while it also blocks acute tolerance development in mice. 
Figure 17. Antinociception and opioid receptor selectivity of VBJ192 in the 55 ºC warm-
water tail-withdrawal assay. 
A) 
 
 
B) 
 
 
Figure 18. Significant acute antinociceptive tolerance develops to morphine, but not 
VBJ192. 
 
 
 Substituted hydroxy analogs of CM695 and VBJ192 were designed to follow the original 
diphenylmethylenepiperidine scaffold and consisted of either a 3- or 4-positioned hydroxy 
substituent on the A ring (Figure 19). VBJ193, contained a 3-hydroxy moiety, which displayed 
highly potent and full agonism at DOP and MOP, while providing partial agonism at KOP (Table 
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12); it also showed moderate to low affinity for NPFF1 and NPFF2 (Table 13). The adjustment of 
the hydroxy to the 4-position of VBJ197 decreased potency at all opioid and NPFF receptors, but 
retained full agonism at DOP. VBJ214 consisted of a p-guanidine paired with an m-hydroxy 
moiety and potent agonism at DOP, partial agonism at KOP and MOP, and nonselective affinity 
for NPFF receptor subtypes. The adjustment of the hydroxy substituent to the p-position, to yield 
VBJ215, caused an increase in KOP and MOP affinity and a 4-fold decrease in DOP affinity, 
while it displayed a slight increase in affinity for NPFF1 and slight decrease in affinity for 
NPFF2, compared to VBJ214. 
 
Figure 19. Analogs of VBJ192 and CM695 
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Table 12. In vitro opioid binding and functional data for VBJ193, VBJ197, VBJ214, and 
VBJ215.** 
 DOP* KOP† MOP‡ 
Cmpd. 
Code 
Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type Ki 
(nM) 
EC50 
(nM) 
Type 
VBJ193 
7.8 ± 
1.0 
21 ± 3 Full 
2.3 ± 
0.2 
42 ± 5 Partial 
2.1 ± 
0.1 
28 ± 3 Full 
VBJ197 53 ± 5 
455 ± 
62 
Full 
18 ± 
2 
482 ± 
82 
Partial 22 ± 2 420 ± 54 Partial 
VBJ214 
3.6 ± 
0.6 
9.6 ± 
1.3 
Full 
8.9 ± 
1.2 
268 ± 
32 
Partial 57 ± 9 
1442 ± 
226 
Partial 
VBJ215 15 ± 3 
227 ± 
13 
Full 
5.6 ± 
0.7 
136 ± 
24 
Partial 
3.0 ± 
0.3 
N.T. N.T. 
**Data obtained in-house from COBRE Core C. 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.T., Not tested, awaiting testing 
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Table 13. In vitro binding data and inhibition of forskolin-induced cAMP accumulation for 
VBJ193, VBJ197, VBJ214, and VBJ215 at NPFF1 and NPFF2 receptors.* 
 NPFF1R NPFF2R 
Cmpd. Code Ki (nM)a EC50 (nM) Ki (nM)b EC50 (nM) 
VBJ193 311 ± 13 >10 µM 909 ±73 >10 µM 
VBJ197 570 ± 161 >10 µM 4134 ± 392 >10 µM 
VBJ214 1061 ± 94 >10 µM 707 ± 6 >10 µM 
VBJ215 935 ± 46 >10 µM 1251 ± 110 >10 µM 
*Results reported in the thesis of Journigan 330, data obtained from Dr. 
Catherine Mollereau, Institut de Pharmacologie et Biologie Structurale, 
Toulouse, France. 
aCHOhNPFF1 receptor labeled with [3H]-NPVF. 
bCHOhNPFF2 receptor labeled with [3H]-EYF. 
cEC50 values is the concentration of agonist that inhibits 50% of 
intracellular cAMP production induced by 2 mM forskolin in 
recombinant CHO cells expressing hNPFF1 and hNPFF2, respectively. 
*Ki values for NPFF1 and NPFF2 represent the average of double runs. 
 
3.2: CNK and MC Series 
 Although it was established that a guanidine moiety was required for NPFFR activity, a 
proposition to address the basicity of the guanidine (pKa 13.6) through the use of a 2,2-
difluororethyl chain attached to the guanidine or through a slightly less basic amidine moiety was 
employed. The intention behind the design of the 2,2-difluoroethyl derivatives was to pull the 
basicity of the guanidine and distribute the electronics of the conjugated system. The amidine 
moiety would mimic and act as a replacement of the guanidine on the 
diphenylmethylenepiperidine scaffold, thus yielding the CNK and MC series.331  
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3.2.1: 2,2-Difluoroethyl Derivatives 
 The 2,2-difluoroethyl derivatives CNK401, CNK402, and CNK409 were the first 
compounds to be synthesized. CNK401 and CNK402 consisted of a 2,2-difluoroethyl chain 
added to the terminal nitrogen of the guanidine. The 2,2-difluoroethyl substitution of CNK401 
caused an overall loss in opioid (DOP = 10-fold, KOP and MOP = 3.7-fold) and NPFF2R activity 
compared to VBJ192. The repositioning of the guanidine-difluoroethyl to the p-position in 
CNK402 increased affinity at opioid receptors compared to CNK401, but further decreased 
activity at NPFF2R compared to both CM695 and CNK401; CNK402 was still less active at 
opioid receptors that its guanidine counterpart CM695. Due to the loss at both opioid and NPFF 
receptors, it was suggested that either the 2,2-difluoroethyl linker was extending beyond of the 
active site and was not able to properly bind or the basicity of the guanidine was still playing a 
role. Thus, CNK409, an amidine derivative with the 2,2-difluoroethyl extension was 
synthesized. CNK409 binding studies showed a 5-fold loss in MOP activity, a mild decrease in 
KOP activity, and overall moderate DOP affinity (Ki = 73 ± 8 nM). It should be noted that the 
amidine modification appeared to cause a significant increase in NPFF activity, however, due to 
conflicting radioligands used in the binding assays ([3H]-EYW vs. [125I]-EYW) between 
CNK401, CNK402 and CNK409, a concise deduction of activity cannot be properly established 
until CNK409 has repeated with the radioligand [3H]-EYW for NPFF2. Functional assays 
showed all 2,2-difluoroethyl derivatives to be full DOP agonists, with CNK401 being the most 
potent  (EC50 = 71 ± 18 nM). CNK401 showed low potency with full agonism at KOP, whereas 
CNK409 showed weak potency (EC50 = 4215 ± 1153 nM) and only partial agonism for KOP. 
Currently, the synthesis of the 2,2-difluoroethyl derivatives has been suspended until a 
more well-defined method to couple the 2,2-difluoroethyl to the guanidine is established. The 
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current method, employs the Mitsunobu reaction, which uses the reagents 2,2-difluoroethanol, 
1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, triphenylphosophine, and diethyl 
azodicarboxylate at an initial temperature of 0 ºC (upon addition of the diethyl 
azodicarboxylate); the reaction is allowed to warm to room temperature, where it is left to stir for 
24 hours. The reaction is then concentrated in vacuo and purified via flash column 
chromatography, which provides low yields. The product of this reaction is used in the 
guanidinylation of the Suzuki intermediates, thus the yields must be optimized in order to resume 
these derivatives. Consequently, focus was placed upon the synthesis of the amidine derivatives 
minus the 2,2-difluoroethyl chain. 
Figure 20. CNK series: 2,2-difluoroethyl derivatives. 
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Table 14. In vitro binding data for CNK series: 2,2-diflouroethyl derivatives.** 
Cmpd 
DOP Ki 
(nM)a 
KOP Ki 
(nM)b 
MOP Ki 
(nM)c 
NPFF1 Ki 
(nM)d 
NPFF2 Ki 
(nM)e 
CNK401 86 ± 7 111 ± 19 2,459 ± 965 * 2982 ± 210 
CNK402 363 ± 45 148 ± 18 196 ± 31 * 5742 ± 629 
CNK409 73 ± 8 317 ± 39 957 ± 165 * 163 ± 44f 
**Data obtained in-house from COBRE Core C 
aReflects displacement of [3H]-DPDPE. 
bReflects displacement of [3H]-U69,593. 
cReflects displacement of [3H]-DAMGO. 
dReflects displacement hNPFF1R radioligand [3H]-NPVF 
eReflects displacement hNPFF2R radioligand [3H]-EYW 
fReflects displacement hNPFF2R radioligand [125I]-EYW 
N.A., No affinity as determined by a primary screen 
*Not tested, awaiting testing. 
 
Table 15. In vitro [35S]GTPγS functional data for CNK series: 2,2-diflouroethyl 
derivatives.** 
 DOP* KOP† MOP‡ 
Cmpd EC50 (nM) Type EC50 (nM) Type EC50 (nM) Type 
CNK401 71 ± 18 Full 521 ± 136 Full N.A.  
CNK402 403 ± 53 Full N.T.  N.T. Antagonist 
CNK409 971 ± 240 Full 4215 ± 1153 Partial N.A.  
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested, awaiting testing 
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3.2.2: Amidine Derivatives 
 CNK404 was the first unsubstituted amidine derivative to be synthesized in the form of a 
dihydrochloride salt. CNK404 displayed less affinity for DOP and KOP, but demonstrated 
greater affinity for MOP receptors compared to VBJ192. CNK404 displayed full agonism for 
DOP and MOP receptors (EC50 = 398 ± 51 and EC50 = 1954 ± 323 nM, respectively). NPFF 
binding studies showed CNK404 had weak affinity for both receptors, but had 5.5-fold more 
affinity for NPFF1 over NPFF2. Its m-positioned counterpart, CNK415, was designed to compare 
affinity differences between CNK404 and guanidine compound, CM 695. CNK415 a full and 
potent agonist at all three opioid receptors, displayed a drastic increase in affinity at all three 
opioid receptors, some results similar or better than those for CM695. The activity of CNK415 
at NPFF1 increased almost 4-fold, whereas CNK415 appears to have gained NPFF2 activity, but 
cannot be accurately compared due to conflicting radioligands used in the binding assays ([3H]-
EYW vs. [125I]-EYW). Electron withdrawing and electron donating substituents were substituted 
on the aromatic rings to begin SAR development. The first electron withdrawing ligand, MC88, 
a 3-chloro-4-amidine dihydrochloride salt presented a decrease in DOP and MOP activity and 
weak affinity at both NPFF subtypes, while acting as a full agonist at KOP (EC50 = 559 ± 152 
nM).  The 3-F of CNK412 was not well tolerated at any opioid receptors and had weak affinity 
for both NPFF subtypes. The electron donating effects of CNK406 and CNK413 had similar 
effects on opioid receptors; the effects of the methoxy substituent were tolerated at both 
NPFFRs, but CNK406 displayed over a 12-fold preference for NPFF1 over NPFF2. Due to the 
increase in NPFF1 activity from the electron donating methoxy, amidoxime derivatives (Section 
3.2.3.), which contain a hydroxy and are precursors to the amidine derivatives, would also be 
submitted for testing. 
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Figure 21. CNK and MC series: amidine derivatives. 
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Table 16. In vitro binding data for CNK and MC series: amidine derivatives.** 
Cmpd 
DOP Ki 
(nM)a 
KOP Ki 
(nM)b 
MOP Ki 
(nM)c 
NPFF1 Ki 
(nM)d 
NPFF2 Ki 
(nM)f 
MC88 1137 ± 146 170 ± 23 436 ± 100 2711 ± 895 9497 ± 940e 
CNK404 150 ± 15 498 ± 79 94 ± 20 4325 ± 1178 24030 ± 10850 
CNK406 244 ± 14 313 ± 98 135 ± 16 156 ± 28 1939 ± 114e 
CNK412 903 ± 135 996 ± 134 471 ± 68 3939 ± 1442 2299 ± 446 
CNK413 64 ± 15 262 ± 36 298 ± 44 754 ± 160 3217 ± 884 
CNK415 17 ± 2 5.9 ± 0.7 3.52 ± 0.41 1178 ± 319 3509 ± 230e 
**Data obtained in-house from COBRE Core C 
aReflects displacement of [3H]-DPDPE. 
bReflects displacement of [3H]-U69,593. 
cReflects displacement of [3H]-DAMGO. 
dReflects displacement hNPFF1R radioligand [125I]-NPVF 
eReflects displacement hNPFF2R radioligand [3H]-EYW 
fReflects displacement hNPFF2R radioligand [125I]-EYW 
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Table 17. In vitro [35S]GTPγS functional data for CNK and MC series: amidine 
derivatives.** 
 DOP* KOP† MOP‡ 
Cmpd EC50 (nM) Type EC50 (nM) Type EC50 (nM) Type 
MC88 N.A.  559 ± 152 Full N.A.  
CNK404 398 ± 51 Full N.A.  1954 ± 323 Full 
CNK406 944 ± 356 Full 1120 ± 254 Partial 1034 ± 1677 Partial 
CNK412 N.A.  N.A.  N.A.  
CNK413 933 ± 206 Full 3069 ± 870 Partial 887 ± 565 Partial 
CNK415 27 ± 4 Full 62 ± 20 Full 11.1 ± 3.7 Full 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested, awaiting testing 
 
 
3.2.3: Amidoxime Derivatives 
 CNK403, the precursor to CNK404, displayed full DOP agonism (EC50 = 107 ± 18 nM) 
but had weak affinity at KOP, MOP and NPFF1. The change of the 4-amidoxime in CNK403 to 
a 3-amidoxime yielded CNK414, which displayed high affinity and potent agonist activity at all 
opioid receptors (DOP EC50 = 60 ± 13 nM, KOP EC50 = 158 ± 33 nM, MOP EC50 = 62 ± 8 nM) 
and moderate affinity for NPFF1 (Ki = 328 ± 100 nM). To better explore the electronics of the 
system, CNK410 investigated the electron withdrawing effects of the 3-F with the electron 
donating effects of the 4-amidoxime; results indicated that the 3-F was still not tolerated well in 
the binding of CNK410. The replacement of the 3-F with an electron donating 3-OH, provided 
 81 
CNK408, which displayed extremely high affinity and potency for DOP receptors (Ki = 0.670 ± 
0.036 nM, EC50 = 1.48 ± 0.35 nM). CNK408 had only moderate affinity with weak partial 
agonism for KOP and MOP, while it displayed low NPFF1 affinity (Ki = 3767 ± 700 nM). O-
demethylation of CNK408 provided MC44, which held moderate affinity and potency for DOP 
(Ki = 85 ± 9 nM, EC50 = 644 ± 97 nM) and almost a 16-fold affinity preference for NPFF1 over 
NPFF2. 
 
Figure 22. CNK and MC series: amidoxime derivatives. 
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Table 18. In vitro binding data for CNK and MC series: amidoxime derivatives.** 
Cmpd 
DOP Ki 
(nM)a 
KOP Ki 
(nM)b 
MOP Ki 
(nM)c 
NPFF1 Ki 
(nM)d 
NPFF2 Ki 
(nM)e 
MC44 85 ± 9 N.A. N.A. 245 ± 137 3829 ± 1971 
CNK403 53 ± 3 856 ± 147 1603 ± 512 19320 ± 9723 * 
CNK408 0.670 ± 0.036 106 ± 22 119 ± 22 3767 ± 700 * 
CNK410 422 ± 55 N.A. 1090 ± 112 2790 ± 712 8425 ± 1640 
CNK414 7.8 ± 0.4 15 ± 2 7.8 ± 0.4 328 ± 100 * 
**Data obtained in-house from COBRE Core C 
aReflects displacement of [3H]-DPDPE. 
bReflects displacement of [3H]-U69,593. 
cReflects displacement of [3H]-DAMGO. 
dReflects displacement hNPFF1R radioligand [125I]-NPVF 
eReflects displacement hNPFF2R radioligand [125I]-EYW 
N.A., No affinity as determined by a primary screen 
*Not tested, awaiting testing. 
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Table 19. In vitro [35S]GTPγS functional data for CNK and MC series: amidoxime 
derivatives.** 
 DOP* KOP† MOP‡ 
Cmpd EC50 (nM) Type EC50 (nM) Type EC50 (nM) Type 
MC44 644 ± 97 Full N.A.  N.A.  
CNK403 107 ± 18 Full N.A.  N.A.  
CNK408 1.48 ± 0.35 Full 947 ± 216 Partial 337 ± 202 Partial 
CNK410 N.A.  N.A.  N.A.  
CNK414 60 ± 13 Full 158 ± 33 Full 62 ± 8 Full 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 	  
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CHAPTER 4 
CURRENT WORK (KL and KGM Series) 
 
4.1: Synthetic Schemes of KL and KGM Series 
The diphenylmethylenepiperidine scaffold SAR was further explored through the 
extension of the N-benzyl linker in VBJ192 to an N-phenethyl. Derivatives compared meta and 
para guanidine with its amidine counterparts along with various substitutions which mostly 
followed the Topliss approach on the diphenyl ring system.332 The chemistry that was applied to 
synthesize these derivatives is presented in Figures 23-69. 
4.1.1: KL13, KL15, KGM01087, and KGM01095 
Figure 23. Synthesis of Suzuki Coupling Intermediate 5 used for KL13, KL15, KGM01087, 
and KGM01095. 
 
(a) Triphenylphosphine, benzyl bromide, toluene, 110 ºC, o/n, 99%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 45%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 59%. 
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 The phosphonium salt of 1 was prepared (99%) and subjected to Wittig olefination with 
1-phenethylpiperidin-4-one to yield the alkene intermediate 3 (45%). Dibromination of 3 was 
carried out by careful addition of a bromine solution in DCM to the reaction mixture at -78 ºC to 
afford the unstable intermediate 4, which was converted into the monobrominated form through 
in situ elimination by drop-wise addition of NaOH in MeOH to provide intermediate 5 (59%). 
Figure 24. Synthesis of KL13. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 8%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 72 h, 12%; (c) 4N HCl in 1,4-dioxane, DCM, o/n, 65%. 
 Suzuki coupling of 5 with 3-aminophenylboronic acid yielded intermediate 6 in low yield 
(8%) depending on the quality of degassed solvent, followed by conversion to the BOC-
protected guanidine 7 (12%). Final deprotection with 4N HCl in 1,4-dioxane yielded final 
dihydrochloride compound 8 (KL13, 65%). 
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Figure 25. Synthesis of KL15. 
 
(a) 4-Nitrophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 
ºC, o/n, 89%; (b) 10% Pd/C, MeOH, H2, 40 psi, 4 h, 98%; (c) HgCl2, 1,3-Bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DCM, rt, 72 h, 34%; (d) 2N HCl in diethyl 
ether, DCM, o/n, 98%. 
 Suzuki coupling of 5 with 4-nitrophenylbornic acid yielded intermediate 9 (89%), which 
was then reduced to the free amine to yield intermediate 10 (98%). Guanidinylation of 10 
provided the BOC-protected guanidine (34%), followed by deprotection using 2N HCl in diethyl 
ether to yield the final dihydrochloride compound 12 (KL15, 98%). 
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Figure 26. Synthesis of KGM01087. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 89%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 77%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, 25 psi, rt, 84 h, 2N HCl in diethyl ether, 95%. 
Attention was then turned to amidine derivatives of KL13 and KL15 to make the 
comparison between both 3- and 4- substituted amidine and guanidine. Similar chemistry was 
used to couple 5 with 4-cyanophenylboronic acid to provide intermediate 13 (96%). Intermediate 
13 was treated with hydroxylamine HCl to yield the amidine intermediate 14 (77%), followed by 
acetylation to give the intermediate 15, which was reduced in situ to yield the amidine final 
compound 16 (KGM01087, 95%). 
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Figure 27. Synthesis of KGM01095. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 69%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 97%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, 25 psi, rt, 60 h, 2N HCl in diethyl ether, 93% 
 Similar chemistry as in the synthesis of KGM01087 was employed to obtain KGM01095 
(93%).  
4.1.2: KGM01080, KGM01082, KGM02001, and KGM02004 
The naphthalene was chosen as an aromatic substitution due to the NPFF2R preference 
results of other naphthalene-containing peptidomimetic ligands.241  
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Figure 28. Synthesis of Suzuki Coupling Intermediate 25 used for KGM01080, KGM01082, 
KGM02001, and KGM02004. 
 
(a) Triphenylphosphine, 2-(bromomethyl)naphthalene, toluene, 110 ºC, o/n, 94%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 48%; (c) Br2, DCM, -10 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 63%. 
Analogous chemical reactions as in the synthesis of KGM01087 and KGM01095 were 
employed to obtain compounds 29 (KGM01080, 60%) and 33 (KGM01082, 74%). 
Figure 29. Synthesis of KGM01080. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 76%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 77%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, 25 psi, rt, 36 h, 2N HCl in diethyl ether, 60% 
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Figure 30. Synthesis of KGM01082. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 66%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 80%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, 25 psi, rt, 60 h, 2N HCl in diethyl ether, 23%. 
 The same conditions used in the synthesis of KL13 were employed to yield compound 36 
(KGM02001, +99.9%), starting from the phosphonium salt of 2-(bromomethyl)naphthalene. 
Figure 31. Synthesis of KGM02001. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 68%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 72 h, 33%; (c) 2N HCl in diethyl ether, MeOH, 72 h, +99.9%. 
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The same conditions used in the synthesis of KL15 were employed to yield compound 40 
(KGM02004, 99%). 
Figure 32. Synthesis of KGM02004. 
 
(a) 4-Nitrophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 
ºC, o/n, 67%; (b) 10% Pd/C, MeOH, H2, 40 psi, 4 h, 96%; (c) HgCl2, 1,3-Bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DCM, rt, 72 h, 19%; (d) 2N HCl in diethyl 
ether, DCM, 48 h, 99%. 
4.1.3: KGM01098, KGM02002, KGM02008, and KGM02009 
In order to better explore the SAR of the (diphenylmethylene)phenethylpiperidine, 
substitution patterns were employed, to loosely follow the Topliss approach in order to find the 
most potent compound and collect additional binding site information. According to this 
approach, subsequent to the synthesis of the unsubstituted phenyl ring, the first substitution is a 
4-chloro. 
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Figure 33. Synthesis of Suzuki Coupling Intermediate 45 used for KGM01098, KGM02002, 
KGM02008, and KGM02009. 
 
(a) Triphenylphosphine, 4-chlorobenzyl bromide, toluene, 110 ºC, o/n, 97%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 55%; (c) Br2, DCM, -10 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 63%. 
Comparable to the aforementioned syntheses, the synthesis of the 4-chlorophenyl 
derivatives followed in an iterative manner that began with the phosphonium salt 41, which was 
subjected to Wittig olefination to provide 43 in 57% yield. Intermediate 43 was dibrominated 
and in situ elimination provided the Suzuki intermediate 45, which was used to synthesize the 4-
chloro-3-amidine substituted compound 49 (KGM01098, +99.9%), the 4-chloro-3-guanidine 
substituted compound 52 (KGM02002, 47%), the 4-chloro-4-amidine substituted compound 56 
(KGM02008, +99.9%), and the 4-chloro-4-guanidine substituted compound 59 (KGM02009, 
84%).  
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Figure 34. Synthesis of KGM01098. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 97%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 74%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, 25 psi, rt, 36 h, 2N HCl in diethyl ether, +99.9%. 
Figure 35. Synthesis of KGM02002. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 89%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 72 h, 58%; (c) 2N HCl in diethyl ether, MeOH, 48 h, 47%. 
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Figure 36. Synthesis of KGM02008. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 94%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 86%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 2N HCl in diethyl ether, 18%. 
Suzuki coupling of 45 with 4-aminophenylboronic acid provided an opportunity to 
bypass the nitro-reduction, which was previously used in the synthesis of KL15 and 
KGM02004, to provide the free amine 57. Guanidinylation of 57 provided the BOC-protected 
guanidine 58 in moderate yield, followed by BOC cleavage with 2N HCl in diethyl ether to yield 
the final dihydrochloride compound 59 (KGM02009, 84%). 
 
 
 
 
 
N
Ph
N
Ph
N
Ph
53 54
KGM02005
55
a b c45
N
Ph
56
KGM02008
d
HCl
HCl
55
Cl Cl Cl
Cl
CN NH2
N OH
NH2
N
O
O
NH
NH2
 95 
Figure 37. Synthesis of KGM02009. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 80%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 24 h, 71%; (c) 2N HCl in diethyl ether, diethyl ether, 48 h, 84%. 
4.1.4: KGM02018, KGM02022, KGM02023, and KGM02024. 
According to the Topliss pathway, if results of the 4-chloro derivatives are equi-active to 
that of the unsubstituted phenyl derivatives, the 4-methylphenyl derivatives subsequently follow. 
However, binding studies had yet to be performed thus the second tier analogs, which include the 
4-methyl derivatives, were synthesized; analogous chemistry as paralleled to that of the 4-chloro 
derivatives was employed. 
Figure 38. Synthesis of Suzuki Coupling Intermediate 64 used for KGM02018, KGM02022, 
KGM02023, and KGM02024. 
 
(a) Triphenylphosphine, 4-methylbenzyl bromide, toluene, 110 ºC, o/n, 98%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 26%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 57%. 
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Figure 39. Synthesis of KGM02018. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 81%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 88%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 2N HCl in diethyl ether, 88%. 
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Figure 40. Synthesis of KGM02022. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 74%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 65%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 1.25N HCl in ethanol, 85%. 
Figure 41. Synthesis of KGM02023. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 46%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 24 h, 99%; (c) 4N HCl in 1,4-dioxane, 48 h, 63%. 
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Figure 42. Synthesis of KGM02024. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 94%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 72 h, 47%; (c) 4N HCl in 1,4-dioxane, 48 h, 68%. 
4.1.5: KGM02034, KGM02035, KGM02036, and KGM02037 
The 3,4-dichloro derivatives also fell into the second tier of the Topliss pathway, 
however, a 3,4-dichloro substitution is used if the p-chloro is more active than that of the 
unsubstituted phenyl.  
Figure 43. Synthesis of Suzuki Coupling Intermediate 83 used for KGM02034, KGM02035, 
KGM02036, and KGM02037. 
 
(a) Triphenylphosphine, 3,4-dichlorobenzyl bromide, toluene, 110 ºC, o/n, 98%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 50%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 71%. 
 3,4-dichlorobenzyl bromide was prepared with triphenylphosphine to give the 
phosphonium salt 80, which was subjected to Wittig olefination with 1-phenethylpiperidin-4-one 
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to provide 81. Dibromination of 81 followed by in situ elimination yielded the Suzuki coupling 
intermediate 83 in moderate yield (71%). 
Figure 44. Synthesis of KGM02034. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 77%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 96%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 2N HCl in diethyl ether, 61%. 
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Figure 45. Synthesis of KGM02035. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 39%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 65%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 48 h, 4N HCl in 1,4-dioxane, 77%. 
Figure 46. Synthesis of KGM02036. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 85%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 24 h, 75%; (c) 4N HCl in 1,4-dioxane, 48 h, 55%. 
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Figure 47. Synthesis of KGM02037. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 78%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 24 h, 88%; (c) 4N HCl in 1,4-dioxane, 48 h, 99.9%. 
4.1.6: KGM02089, KGM03001, KGM03002, and KGM03003 
 The next tier of the Topliss substitution pathway is a 3-chloro. This is synthesized if the 
4-methyl derivatives are equi- or less active than the 4-chloro, however, not all in vitro data had 
been fully evaluated. In order to compare the substitution changes, the 3-chloro was synthesized 
to provide the 3-chloro-4-guanidine KGM02089, the 3-chloro-3-guanidine KGM03001, the 3-
chloro-4-amidine KGM03002, and the 3-chloro-3-amidine KGM03003. 
Figure 48. Synthesis of Suzuki Coupling Intermediate 102 used for KGM02089, 
KGM03001, KGM03002, and KGM03003. 
 
(a) Triphenylphosphine, 3-chlorobenzyl bromide, toluene, 110 ºC, 3h, 93%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 30%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 71%. 
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 The phosphonium salt of 98 was prepared (93%) and subjected to Wittig olefination with 
N-phenethylpiperidone to yield the alkene intermediate 100 (30%). Dibromination of 100 was 
carried out by careful addition of a bromine solution to the reaction mixture at -78 ºC to afford 
the unstable intermediate 101, which was converted into the monobrominated form via in situ 
elimination to provide intermediate 102 (71%).  
 Following the consistent chemistry, the Suzuki intermediate 102 was coupled with 4-
aminophenylboronic acid to yield 103 in moderate yield (78%) and was subsequently 
guanidinylated to the BOC-guanidine intermediate 104. 104 was cleaved with 4N HCl in 1,4-
dioxane to yield final compound 105 (KGM02089, +99.9%). 
Figure 49. Synthesis of KGM02089. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 78%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 60 h, 64%; (c) 4N HCl in 1,4-dioxane, 24 h, +99.9%. 
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Figure 50: Reaction Issues for Intermediate 106 for the Synthesis of KGM03001. 
 
 
Reaction 1: 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 
toluene/ethanol, 80 ºC, o/n, 13%; Reaction 2: 3-Aminophenylboronic acid hydrochloride, 
tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 49%; Reaction 3: 3-
Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1:1 toluene/ethanol/H2O, 
80 ºC, o/n, 48%. 
 The Suzuki coupling to yield intermediate 106 was an overall low yielding reaction and 
brought to light many questions. Under normal reaction conditions, reaction 1 produced 106 in 
13% yield and it was thought that the tetrakis had decomposed. In reaction 2, a fresh bottle of 
tetrakis was used while all conditions remained the same and was monitored closely. Thin-layer 
chromatography (TLC) showed the reaction rate to be slow. After extraction and purification, the 
yield increased to 49%. Although the reaction moved forward, it is unusual for a Suzuki coupling 
reaction to have such low yields, thus reaction 3 was utilized to determine the issue. The results 
from the previous reaction suggested a possible solubility issue, thus a 3:1:1 (toluene, ethanol, 
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H2O) solvent ratio was applied, which yielded 106 in 48%. This suggested the solubility is not to 
blame, whereas the tetrakis is only a part of the issue. It is thought that the weak electron-
withdrawing effect of the 3-chloro plays a role in the electronics of the system and its reactivity. 
It is possible that the m-chloro is destabilizing the intermediate cation in an inductive manner, 
which decreases the reaction rate, while still contributing to the resonance in the p-system. 
Figure 51. Synthesis of KGM03001. 
 
(a) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DCM, rt, 60 h, 87%; 
(b) 4N HCl in 1,4-dioxane, 24 h, 36%. 
 The 106 intermediate acquired in reactions 2 and 3 were combined and the BOC-
guanidine was installed via guanidinylation to yield 107 (87%). The BOC was subsequently 
cleaved with 4N HCl in 1,4-dioxane to provide 108 (KGM03001, 36%) 
 Similar amidine chemistry was employed in the synthesis of final derivatives 112 
(KGM03002, 43%) and 116 (KGM03003, 33%). 
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Figure 52. Synthesis of KGM03002. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 72%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 29%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 4N HCl in 1,4-dioxane, 43%. 
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Figure 53. Synthesis of KGM03003. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 70%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 91%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 72 h, 4N HCl in 1,4-dioxane, 33%. 
4.1.7: KGM02092, KGM02093, KGM02096, and KGM02097 
 Following the synthesis of the 3-chloro derivatives, the 3-methyl derivatives are 
congruently synthesized. These derivatives follow the substitution pattern subsequent to the 3-
chloro motifs. 
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Figure 54. Synthesis of Suzuki Coupling Intermediate 121 used for KGM02092, 
KGM02093, KGM02096, and KGM02097. 
 
(a) Triphenylphosphine, 3-methylbenzyl bromide, toluene, 110 ºC, 3h, 93%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 30%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 52%. 
 As in the preceding syntheses, the phosphonium salt 118 is subjected to Wittig 
olefination with 1-phenethylpiperidin-4-one to give the alkene intermediate 119. 119, had to be 
synthesized twice to have a sufficient amount of intermediate, which was dibrominated then in 
situ eliminated to give the monobrominated Suzuki intermediate 121 (52%). 
Figure 55. Synthesis of KGM02092. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 94%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 60 h, 64%; (c) 4N HCl in 1,4-dioxane, 24 h, 51%. 
 Intermediate 125 in the synthesis of KGM02093, showed low yield (44%), similar to that 
of the 3-chloro intermediate 106 in figure 50. Although further reactions were not synthesized, it 
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is possible the Suzuki’s yield was low due to the system’s electronics. In the case of the m-
methyl, the carbon is already electron poor and lacks a resonance contributor, which makes it 
unstable and a weak activator of the conjugated p-system. Additional reactions were not 
synthesized since there was an adequate amount of 125 to be guanylated into the BOC-protected 
intermediate 126, which was then swiftly cleaved with 4N HCl in 1,4-dioxane to yield 127 
(KGM02093, 99%). 
Figure 56. Synthesis of KGM02093. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 44%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 24 h, 35%; (c) 4N HCl in 1,4-dioxane, 48 h, 99%. 
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Figure 57. Synthesis of KGM02096. 
 
(a) 3-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 72%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 58%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 4N HCl in 1,4-dioxane, 37%. 
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Figure 58. Synthesis of KGM02097. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 88%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 42%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 4N HCl in 1,4-dioxane, 31%. 
4.1.8: KGM02090, KGM02091, KGM03010, and KGM03011 
 The synthesis of the 3-methoxy derivatives followed suit to that of the 3-methyl, to 
provide 3-methoxy-3-guanidine 143 (KGM02090, 93%), 3-methoxy-4-guanidine 146 
(KGM02091, 98%), 3-methoxy-4-amidine 150 (KGM03010, 40%), and 3-methoxy-3-guanidine 
154 (KGM03011, 53%). 
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Figure 59. Synthesis of Suzuki Coupling Intermediate 140 used for KGM02090, 
KGM02091, KGM03010, and KGM03011. 
 
(a) Triphenylphosphine, 3-methoxybenzyl bromide, toluene, 110 ºC, o/n, 99%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 49%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 39%. 
Figure 60. Synthesis of KGM02090. 
 
(a) 3-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 69%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, 
DCM, rt, 60 h, 68%; (c) 4N HCl in 1,4-dioxane, 24 h, 93%. 
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Figure 61. Synthesis of KGM02091. 
 
(a) 4-Aminophenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 
toluene/ethanol/H2O, 80 ºC, o/n, 71%; (b) HgCl2, 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, TEA, DCM, rt, 60 h, 64%; (c) 4N HCl in 1,4-dioxane, 24 h, 98%. 
Figure 62. Synthesis of KGM03010. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 97%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 84%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 4N HCl in 1,4-dioxane, 40%. 
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Figure 63. Synthesis of KGM03011. 
 
(a) 4-Cyanophenylboronic acid, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 80 ºC, o/n, 68%; 
(b) NH2OH•HCl, Na2CO3, 10:1 ethanol/H2O, 80 ºC, 3 h, 34%; (c) acetic anhydride, acetic acid, 
rt, 3 h; (d) 10% Pd/C, H2, rt, 84 h, 4N HCl in 1,4-dioxane, 53%. 
4.1.9: KGM03012 and KGM03013 
 In order to compare data, the syntheses of 4-methoxy and 4-hydroxy derivatives were 
designed. Problems developed in the synthesis execution and only one of each derivative were be 
finalized. Details of the unsuccessful synthesis schemes can be found in 4.2. 
Figure 64. Synthesis of Suzuki Coupling Intermediate 159 used for KGM03012 and 
KGM03013. 
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(a) Triphenylphosphine, 3-nitrobenzyl bromide, toluene, 110 ºC, o/n, 94%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 36%; (c) Br2, DCM, -78 ºC à rt, 2 h; (d) 
NaOH, MeOH, 70 ºC, 2 h, 28%. 
 3-Nitrobenzyl bromide (155) was prepared with triphenylphosphine to attain the 
phosphonium salt 156 in high yield (94%), which was subjected to Wittig olefination and yielded 
157 (36%). Dibromination followed by in situ elimination achieved the monobrominated Suzuki 
intermediate 159 (28%). 
Figure 65. Synthesis of KGM03012. 
 
(a) 4-Methoxyphenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 70%; (b) 10% Pd/C CatCart®, MeOH, H2, 29 psi, 40 ºC, 30 min, 84%; (c) HgCl2, 1,3-
Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DCM, rt, 72 h, 77%; (d) 4N HCl in 
1,4-dioxane, DCM, o/n, +99.9%. 
 Suzuki coupling of 159 with 4-methoxyphenylboronic acid yielded intermediate 160 
(70%), then 3-nitro was reduced to the free amine via flow hydrogenation using conditions 
established by Cossar et al. to yield intermediate 161 (98%).333 Guanidinylation of 161 provided 
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the BOC-protected guanidine 162 (34%), followed by deprotection using 4N HCl in 1,4-dioxane 
to yield the final dihydrochloride compound 163 (KGM03012, +99.9%). 
Figure 66. Synthesis of KGM03013. 
 
(a) 4-Hydroxyphenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 toluene/ethanol, 
80 ºC, o/n, 49%; (b) 10% Pd/C CatCart®, MeOH, H2, 29 psi, 30 ºC, 30 min, 52%; (c) HgCl2, 1,3-
Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DCM, rt, 72 h, 82%; (d) 4N HCl in 
1,4-dioxane, DCM, o/n, +99.9%. 
 Suzuki coupling of 159 with 4-hydroxyphenylboronic acid yielded intermediate 164 
(49%), subsequently the 3-nitro was reduced to the free amine via flow hydrogenation using 
conditions established by Cossar et al. to yield intermediate 165 (98%).333 Guanidinylation of 
165 provided the BOC-protected guanidine 166 (34%), followed by deprotection using 4N HCl 
in 1,4-dioxane to yield the final dihydrochloride compound 167 (KGM03013, +99.9%). 
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4.2: Unsuccessful (diphenylmethylene)phenethylpiperidines 
Synthesis of the 4-methoxy-4-guanidine and 4-methoxy-4-amidine derivatives were 
unsuccessful. Two routes were employed to synthesize these compounds but all, which would 
contain a 4-guanidine, or a 4-amidine failed.  
Figure 67. Synthetic Attempt 1. 
 
(a) Triphenylphosphine, 3-methoxybenzyl chloride, toluene, 110 ºC, o/n, 60%; (b) LDA, 1-
phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 61%; (c) Br2, DCM, -78 ºC à rt, 2 h. 
The same synthetic process as previously used was employed because it would allow the 
compounds to be easily split into four reactions (two guanidine and two amidine). 4-
methoxybenzyl chloride 168 was prepared with triphenylphosphine to give the phosphonium salt 
169 in moderate yield (60.0%). The phosphonium salt was subjected to Wittig olefination with 1-
phenethylpiperidin-4-one to yield 170. Dibromination of 170 was met with failure and the target 
compound 172 was not synthesized. 
The next logical approach was to work backwards by synthesizing the compounds as 4-
nitrophenyl derivatives first, then utilize the Suzuki reaction to couple the compounds into their 
corresponding 4-methoxy and 4-hydroxy forms. However, these alterations made it more 
difficult to synthesize the amidine derivatives, thus the amidine derivatives were omitted from 
this series. 
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Figure 68. Synthetic Attempt 2. 
 
(a) LDA, 1-phenethylpiperidin-4-one, THF (ah), -78 ºC à rt, o/n, 12%; (b) Br2, DCM, -78 ºC à 
rt, 2 h; (c) NaOH, MeOH, 70 ºC, 2 h, 15%. 
A previously made phosphonium salt 173 was subjected to Wittig olefination to yield 174 
in low yield (12%) as a red oil. It was later determined via NMR analysis, that 174 still contained 
starting material, 1-phenethylpiperidin-4-one. This was not originally caught due to the massive 
overlap in the aromatic and aliphatic regions. However, it was determined through the 1H NMR, 
that the 1-phenethylpiperidin-4-one was in excess and had an approximate 2:1 ratio over 174. 
This was not discovered until after the synthesis of 176. Dibromination of 174 followed by in 
situ elimination provided the monobrominated intermediate 176 in a low yield of 15%. 
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Figure 69. Reaction Adjustments for Intermediate 177. 
 
Reaction 1: 4-Hydroxyphenylboronic acid hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:1 
toluene/ethanol and 4 drops of H2O, 80 ºC, o/n, 18%; Reaction 2: 4-hydroxyphenylboronic acid 
hydrochloride, tetrakis Pd(PPh3)4, K2CO3, 3:2:2 toluene/ethanol/H2O, 80 ºC, o/n, 0%. 
The Suzuki coupling to yield 177 was low yielding in reaction 1 (18%) and was thought 
to be a solubility issue. However, the amount produced in reaction 1 was not enough to move 
forward in the reaction scheme. 75 mg of starting material (176) was recovered and used for 
reaction 2. In reaction 2, a 3:2:2 ratio of toluene, ethanol, and H2O was employed; the reaction 
moved forward according to TLC, however, it was not until after purification where it was 
determined that 177 was not present and had somehow reverted back to its Wittig form (174). 
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4.3: Presentation and Discussion of Preliminary In-House Results 
Table 20. In vitro opioid binding and [35S]GTPγS functional data for phenyl derivatives 
KL13, KL15, KGM01086, KGM01087, KGM01092, and KGM01095.** 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
8, KL13 127 ± 14 59 ± 6 774 ± 99 N.A. 2.88 ± 0.31 34 ± 4 
12, KL15 1,627 ± 128 N.A. 3,198 ± 609 N.A. 52 ± 6 468 ± 145 
14, KGM01086 N.A. N.A. N.A. N.A. 1,833 ± 288 N.A. 
16, KGM01087 129 ± 16 148 ± 15 582 ± 76 N.A. 2.99 ± 0.62 4.1 ± 1.0 
18, KGM01092 234 ± 29 N.T. 977 ± 153 N.A. 3.33 ± 0.29 71 ± 4 
20, KGM01095 174 ± 8 118 ± 16 97 ± 10 167 ± 12 1.62 ± 0.18 7.0 ± 1.6 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested; awaiting testing 
 
 Compound 8 yielded high affinity for MOP (Ki = 2.88 ± 0.31 nM) and consisted of a 44-
fold preference for MOP vs. DOP and a 269-fold preference for MOP vs. KOP. [35S]GTPγS 
functional assays showed 8 to have moderate potency and full agonism for both DOP (EC50 = 59 
± 6 nM) and MOP (EC50 = 34 ± 4 nM); whereas 12, showed moderate affinity for MOP (Ki = 52 
± 6 nM) and 31-fold preference for MOP/DOP and 61-fold preference for MOP/KOP. 12 was 
not as potent (EC50 = 468 ± 145) as 8, but consisted of partial agonism (37%) at MOP. 
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 The amidine and the amidoxime phenyl derivatives were also tested under the same 
considerations. Although 14 provided minor displacement (Ki = 1,833 ± 288 nM) at MOP, it did 
not move on to functional testing. However, its subsequent amidine not only regained high 
affinity and preference for MOP (Ki = 2.99 ± 0.62 nM) over both DOP and KOP, it was a full 
agonist with a 113-fold increase in potency (EC50 = 4.14 ± 1.00 nM) compared to that of 12. This 
indicates that the smaller amidine in the para position is better tolerated in the MOP binding 
pocket. The m-amidoxime 18 had an affinity for MOP, similar to that of 13; the m-amidoxime 
increased selectivity for MOP (70-fold MOP/DOP; 293-fold MOP/KOP), but dropped slightly in 
MOP potency (EC50 = 71 ± 4 nM) and displayed antagonistic functionality in the [35S]GTPγS 
assay. The corresponding amidine 20 increased slightly in MOP and DOP affinity, but had a 10-
fold increase affinity for KOP (Ki = 97 ± 10 nM). 20 was still over 15-fold more potent at MOP 
compared to DOP and KOP, but was classified as a full agonist at DOP, KOP, and MOP. When 
20 is compared to 8, it has slightly more affinity and potency for MOP, but does not consist of as 
much receptor preference as its guanidine counterpart 8. This indicates that the m-amidine 
although well tolerated at MOP and retains potency, is also more tolerated in the DOP and KOP 
binding sites. 
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Figure 70. Binding and [35S]GTPγS functional curves for KL13. 
A) 
 
B) 
 
C) 
 
D) 
 
E) 
 
 
Figure 71. Binding and [35S]GTPγS functional curves for KL15. 
A) 
 
B) 
 
C) 
 
D) 
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Figure 72. MOP binding curve for KGM01086. 
 
 
Figure 73. Binding and [35S]GTPγS functional curves for KGM01087. 
A) 
 
B) 
 
C) 
 
D) 
 
E) 
 
 
 
 
 
 
 
 
Binding Assay - Mu
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Mu
Ki
KGM01086
1.833e-006
Naloxone - Mu
1.690e-009
IC50
KGM01086
3.666e-006
Naloxone - Mu
3.379e-009
KGM01086
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Delta
-12 -10 -8 -6 -4 -2
0
50
100
150
Naloxone - Delta
Ki
KGM01087
1.294e-007
Naloxone - Delta
4.118e-008
IC50
KGM01087
2.587e-007
Naloxone - Delta
8.235e-008
KGM01087
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Kappa
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Kappa
Ki
KGM01087
5.823e-007
Naloxone - Kappa
5.271e-009
IC50
KGM01087
1.165e-006
Naloxone - Kappa
1.054e-008
KGM01087
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Mu
-10 -8 -6 -4
-50
0
50
100
150
Naloxone - Mu
Ki
KGM01087
2.991e-009
Naloxone - Mu
2.406e-009
IC50
KGM01087
5.982e-009
Naloxone - Mu
4.811e-009
KGM01087
LOG(M)
%
 o
f C
on
tr
ol
GTPγS Delta Agonist Functional Assay
-12 -10 -8 -6 -4 -2
-50
0
50
100
150
200
KGM01087
DPDPE
EC50
KGM01087
1.475e-007
DPDPE
7.816e-010
Log(M)
%
 o
ve
r 
ba
sa
l
GTPγS Mu Agonist Functional Assay
-12 -10 -8 -6 -4
-50
0
50
100
150
KGM01087
DAMGO
EC50
KGM01087
4.141e-009
DAMGO
2.943e-008
Log(M)
%
 o
ve
r 
ba
sa
l
 123 
Figure 74. Binding and [35S]GTPγS functional curves for KGM01092. 
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Figure 75. Binding and [35S]GTPγS functional curves for KGM01095. 
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Table 21. In vitro opioid binding and [35S]GTPγS functional data for naphthyl derivatives 
KGM01080, KGM01082, KGM02001, and KGM02004.** 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
29, KGM01080 644 ± 66 N.A. 595 ± 88 N.A. 16 ± 1 13 ± 8 
33, KGM01082 N.A N.A. N.A. N.A. 46 ± 4 363 ± 69 
36, KGM02001 N.A. N.A. N.A. N.A. 273 ± 44 445 ± 67 
40, KGM02004 1,451 ± 260 N.A. 1,138 ± 208 N.A. 76 ± 14 N.T. 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested, awaiting testing 
 
 The naphthyl derivatives showed a massive overall decrease in opioid receptor affinity 
compared to the phenyl derivatives. Compound 29 had a 3.7-fold decrease in DOP, a 6-fold 
decrease in KOP, and a 9.9-fold decrease in MOP affinities compared to its phenyl counterpart, 
20. However, 29 did show preferential binding for MOP over DOP (40-fold) and KOP (37-fold) 
and displayed full agonism with a relatively high potency (EC50 = 13 ±8 nM) for MOP. Full 
agonist 33 did not show affinity for DOP or KOP as determined by a primary screen, which is a 
drastic decrease compared to that of 16. Although it lost 15-fold affinity for MOP, it exhibited 
more MOP receptor preference compared to 16, 29, 36, and 40. Compound 36, like 33, did not 
display affinity for DOP or KOP, and consisted of almost a 95-fold decrease in MOP affinity; 36 
is a full agonist, but does not show much potency at MOP (EC50 = 445 ± 67 nM). Compound 40 
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followed suit and lacked modest affinity for DOP (Ki = 1,451 ± 260 nM) and KOP (Ki = 1,138 ± 
208 nM). It had a moderate affinity for MOP, but its [35S]GTPγS functional assay showed 
antagonist activity, thus 40 is awaiting an antagonism assay. Although the naphthyl derivatives 
displayed extensive preferential binding for MOP, their affinities were not to that of the phenyl 
derivatives, which could indicate that the rigidity of the naphthyl substitution is not as well 
tolerated in the opioid receptor binding sites. Based on these results, poor MOP, KOP and DOP 
as well as NPFF2 (Table 25), it is to be assumed that the naphthyl in this position is unfavorable 
and should be ruled out of any further SAR. 
 
Figure 76. Binding and [35S]GTPγS functional curves for KGM01080. 
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Figure 77. MOP binding and [35S]GTPγS functional curves for KGM01082. 
A) 
 
B) 
 
 
Figure 78. MOP binding and [35S]GTPγS functional curves for KGM02001. 
A) 
 
B) 
 
 
Figure 79. Binding and [35S]GTPγS functional curves for KGM02004. 
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Table 22. In vitro opioid binding and [35S]GTPγS functional data for 4-chlorophenyl 
derivatives KGM01096, KGM01098, KGM02002, KGM02005, KGM02008, and 
KGM02009.** 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
47, KGM01096 754 ± 175 N.A. 1,588 ± 522 N.A. 28 ± 2 519 ± 47 
49, KGM01098 163 ± 16 433 ± 53 152 ± 18 605 ± 73 9.6 ± 0.9 12.0 ± 1.6 
52, KGM02002 891 ± 152 N.A. N.A. N.A. 177 ± 13 439 ± 45 
54, KGM02005 N.A. N.A. N.A. N.A. N.A. N.A. 
56, KGM02008 N.A. N.A. N.A. N.A. 57 ± 5 N.T. 
59, KGM02009 435 ± 99 N.A. N.A. N.A. 918 ± 171 N.A. 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested, awaiting testing 
 
 The 4-chlorophenyl derivatives consisted of the first substitution that followed the 
Topliss potency pathway. The compounds and their Topliss comparisons will be described in 
further detail later in this section. This discussion will speak on the differences within the 4-
chlorophenyl derivatives themselves. 
Of all ligands in this derivative family, the m-amidoxime and m- and p-amidine 
derivatives displayed the most affinity at MOP. Compound 47, a 4-chloro-3-amidoxime 
derivative, showed a high affinity for MOP (Ki = 28 ± 2) and displayed an elevated receptor 
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preference for MOP over DOP (30-fold) and KOP (56.7-fold). 47 is described as a full agonist 
with a moderately-low potency (EC50 = 519 ± 47 nM). The reduction to its amidine successor, 49 
retained full agonism and allowed for an almost 3-fold increase in MOP affinity, while 
significantly increasing its MOP potency 43-fold. However, the amidoxime reduction also lead 
to moderate DOP and KOP affinity, while also acting as a full agonist at both receptors (EC50 = 
433 ± 53 nM and EC50 = 605 ± 73 nM, respectively). The positioning of the neutral amidoxime, 
basic amidine, or basic guanidine played a key role in ligand success.334 The p-amidoxime 
derivative 54 lost all activity at opioid receptors, while its reduction to the corresponding 
amidine 56, allowed for only MOP affinity (Ki = 57 ± 5 nM). Whereas the m-guanidine 52 was a 
full MOP agonist (EC50 = 439 ± 45 nM) with moderate MOP affinity (Ki = 177 ± 13 nM), but 
had low affinity for DOP (Ki = 891 ± 152 nM) and no affinity for KOP. Interestingly, 52 not 
only has an 18-fold decrease in affinity, but also a 36-fold decrease in potency compared to that 
of 49; this could indicate that the MOP binding pocket has better interactions with the m-amidine 
vs. the m-guanidine. Compound 59 was synthesized to have the p-guanidine, which in turn 
caused more affinity for DOP (Ki = 435 ± 99 nM) and less for MOP (Ki = 918 ± 171 nM). These 
results could indicate that the 4-chloro substituent provides more MOP preference, but the 
position of the amidoxime, amidine, or guanidine in the m-position is key to provide MOP 
affinity. 
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Figure 80. Binding and [35S]GTPγS functional curves for KGM01096. 
A) 
 
B) 
 
C) 
 
D) 
 
 
Figure 81. Binding and [35S]GTPγS functional curves for KGM01098. 
A) 
 
B) 
 
C) 
 
D) 
 
E) 
 
F) 
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Figure 82. Binding and [35S]GTPγS functional curves for KGM02002. 
A) 
 
B) 
 
C) 
 
 
Figure 83. MOP binding curve for KGM02008. 
 
 
Figure 84. DOP and MOP binding curves for KGM02009. 
A) 
 
B) 
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Table 23. In vitro opioid binding data for 4-methylphenyl derivatives KGM02013, 
KGM02018, KGM02019, KGM02022, KGM02023, and KGM02024.** 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) Ki (nM) Ki (nM) 
66, KGM02013 1,097 ± 301 504 ± 102 21 ± 3 
68, KGM02018 N.A. N.A. 76 ± 8 
70, KGM02019 N.A. N.A. N.A. 
72, KGM02022 3,386 ± 1871 1,462 ± 239 61 ± 9 
75, KGM02023 N.A. N.A. 1,194 ± 266 
78, KGM02024 N.A. N.A. N.A. 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
 
 Derivatives consisting of a 4-methylphenyl did not show affinities as high as those 
mentioned above. Most compounds, however, consisted of MOP receptor preference. 
Interestingly, 66 displayed the lowest affinity (Ki = 21± 3 nM) for the 4-methyl derivatives, 
while consisting of a 52-fold preference for MOP/DOP and a 24-fold preference for MOP/KOP. 
The reduction of the amidoxime 66, to its corresponding amidine 68, removed DOP and KOP 
activity while only slightly decreasing MOP affinity (Ki = 76 ± 8 nM). However, the 
repositioning of the amidoxime to the p-position in compound 70 removed all opioid activity, but 
its reduction to the subsequent amidine 72 regained opioid activity with relatively high affinity at 
MOP (Ki = 69 ± 9 nM). 72 also presented MOP receptor preference with 55-fold over DOP and 
24-fold over KOP. The guanidine derivatives were not as successful in opioid binding, which 
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could be due to being slightly larger. 75, which consists of a m-guanidine, had no activity at DOP 
or KOP and low affinity for MOP (Ki = 1,194 ± 266 nM), while the repositioning of the 
guanidine to the p-position in compound 78 lost all opioid activity. Overall, these derivatives 
displayed MOP preference, but it was indicated that positioning as well as the size of the basic 
substitution (i.e. amidine with 2 nitrogens vs. guanidine with 3 nitrogens), allow for better 
opioid, specifically MOP, binding. 
 
Figure 85. Binding curves for KGM02013. 
A) 
 
B) 
 
C) 
 
 
Figure 86. MOP binding curve for KGM02018. 
 
 
 
 
 
Binding Assay - Delta
-12 -10 -8 -6 -4
0
50
100
150
Naloxone - Delta
Ki
KGM02013
1.097e-006
Naloxone - Delta
2.082e-008
IC50
KGM02013
2.195e-006
Naloxone - Delta
4.164e-008
KGM02013
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Kappa
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Kappa
Ki
KGM02013
5.035e-007
Naloxone - Kappa
2.486e-009
IC50
KGM02013
1.007e-006
Naloxone - Kappa
4.973e-009
KGM02013
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Mu
-12 -10 -8 -6 -4
0
50
100
150
Naloxone - Mu
Ki
KGM02013
2.133e-008
Naloxone - Mu
1.700e-009
IC50
KGM02013
4.267e-008
Naloxone - Mu
3.400e-009
KGM02013
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Mu
-12 -10 -8 -6 -4
0
50
100
150
Naloxone - Mu
Ki
KGM02018
7.549e-008
Naloxone - Mu
1.846e-009
IC50
KGM02018
1.510e-007
Naloxone - Mu
3.691e-009
KGM02018
LOG(M)
%
 o
f C
on
tr
ol
 133 
Figure 87. Binding curves for KGM02022. 
A) 
 
B) 
 
C) 
 
 
Figure 88. MOP binding curve for KGM02023. 
 
 
 
 
 
 
 
 
 
 
 
 
Binding Assay - Delta
-12 -10 -8 -6 -4
0
50
100
150
Naloxone - Delta
Ki
KGM02022
3.386e-006
Naloxone - Delta
1.769e-008
IC50
KGM02022
6.773e-006
Naloxone - Delta
3.538e-008
KGM02022
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Kappa
-10 -8 -6 -4 -2
-50
0
50
100
150
Naloxone - Kappa
Ki
KGM02022
1.462e-006
Naloxone - Kappa
2.810e-009
IC50
KGM02022
2.924e-006
Naloxone - Kappa
5.620e-009
KGM02022
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Mu
-10 -8 -6 -4
-50
0
50
100
150
Naloxone - Mu
Ki
KGM02022
6.062e-008
Naloxone - Mu
2.132e-009
IC50
KGM02022
1.212e-007
Naloxone - Mu
4.264e-009
KGM02022
LOG(M)
%
 o
f C
on
tr
ol
Binding Assay - Mu
-10 -8 -6 -4
-50
0
50
100
150
Naloxone - Mu
Ki
KGM02023
1.194e-006
Naloxone - Mu
1.623e-009
IC50
KGM02023
2.387e-006
Naloxone - Mu
3.247e-009
KGM02023
LOG(M)
%
 o
f C
on
tr
ol
 134 
Table 24. In vitro opioid binding data for 3,4-dichlorophenyl derivatives KGM02031, 
KGM02034, KGM02033, KGM02035, KGM02036, and KGM02037.** 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) Ki (nM) Ki (nM) 
85, KGM02031 651 ± 135 1174 ± 287 102 ± 9 
87, KGM02034 189 ± 13 397 ± 74 389 ± 64 
89, KGM02033 N.A. N.A. N.A. 
91, KGM02035 N.A. 3059 ± 635 73 ± 10 
94, KGM02036 230 ± 22 985 ± 163 115 ± 10 
97, KGM02037 422 ± 35 516 ± 59 583 ± 48 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
 
 Compounds with a 3,4-dichlorophenyl substitution presented various affinity at all opioid 
receptors. 85 had a moderate affinity for MOP (Ki = 102 ± 9 nM) and showed moderate 
preference for MOP over DOP (6-fold) and KOP (11.5-fold), whereas its amidine counterpart, 87 
displayed a 4-fold decrease in MOP affinity while gaining DOP and KOP activity (Ki = 189 ± 13 
nM and Ki = 397 ± 74 nM, respectively). The p-amidoxime, 89 was not tolerated at any of the 
opioid receptors, but when reduced to its amidine form 91 showed a sufficient affinity for MOP 
(Ki = 73 ± 10 nM). 91 gained MOP preference with no activity at DOP and a 42-fold preference 
for MOP/KOP. M-positioning of the guanidine, 94 displayed moderate non-preferential binding 
between DOP and MOP (Ki = 230 ± 22 nM and Ki = 115 ± 10 nM, respectively), but also weak 
KOP affinity (Ki = 985 ± 163 nM). The repositioning of the guanidine to the p-position, 97 
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exhibited non-preferential, moderate-low affinity at all opioid receptors. These results could 
indicate that although the 4-chlorophenyl derivatives showed MOP preference, the additional 3-
chloro substitution in the 3,4-dichlorophenyl derivatives could remove much of the preference, 
which in turn could suggest that the subsequent 3-chlorophenyl derivatives will show less opioid 
receptor preference with non-selectivity at DOP, KOP and MOP. 
 
Figure 89. Binding curves for KGM02031. 
A) 
 
B) 
 
C) 
 
 
Figure 90. Binding curves for KGM02034. 
A) 
 
B) 
 
C) 
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Figure 91. KOP and MOP binding curves for KGM02035. 
A) 
 
B) 
 
 
Figure 92. Binding curves for KGM02036. 
A) 
 
B) 
 
C) 
 
 
Figure 93. Binding curves for KGM02037. 
A) 
 
B) 
 
C) 
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Table 25. In vitro NPFF1R and NPFF2R binding data for all KL and KGM derivatives.** 
Cmpd Code Ki hNPFF1 (nM) Ki hNPFF2 (nM) 
8, KL13 * 3255 ± 163 
12, KL15 * 1846 ± 119 
14, KGM01086 N.A. N.A. 
16, KGM01087 * 4548 ± 230 
18, KGM01092 * N.A. 
20, KGM01095 * 816 ± 24 
29, KGM01080 * N.A. 
33, KGM01082 N.A. N.A. 
36, KGM02001 N.A. N.A. 
40, KGM02004 * N.A. 
47, KGM01096 * N.A. 
49, KGM01098 * * 
52, KGM02002 * N.A. 
54, KGM02005 N.A. N.A. 
56, KGM02008 N.A. N.A. 
59, KGM02009 * * 
66, KGM02013 * N.A. 
68, KGM02018 N.A. N.A. 
70, KGM02019 N.A. N.A. 
72, KGM02022 * * 
75, KGM02023 N.A. N.A. 
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78, KGM02024 N.A. N.A. 
85, KGM02031 * N.A. 
87, KGM02034 * * 
89, KGM02033 N.A. N.A. 
91, KGM02035 * N.A. 
94, KGM02036 * * 
97, KGM02037 * * 
**Data obtained in-house from COBRE Core C 
hNPFF1R radioligand [3H]-NPVF 
hNPFF2R radioligand [3H]-EYW 
N.A., no affinity as determined by a primary screen. 
*Not tested, awaiting testing. 
 
Figure 94. NPFF2R binding curve for KL13. Figure 95. NPFF2R binding curve for KL15. 
  
Figure 96. NPFF2R binding curve for 
KGM01080 
Figure 97. NPFF2R binding curve for 
KGM01087 
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Figure 98. NPFF2R binding curve for 
KGM01095 
Figure 99. NPFF2R binding curve for 
KGM01098 
  
Figure 100. NPFF2R binding curve for 
KGM02004. 
Figure 101. NPFF2R binding curve for 
KGM02009. 
  
 
4.3.1: Topliss Approach and Ligand Discussion 
 As earlier mentioned, the first analog in the Topliss approach was to synthesize 4-
chlorophenyl derivatives and compare them to the unsubstituted phenyl ligands. This was then 
broken down into four separate comparisons: MOP, KOP, DOP, and NPFF2. This breakdown 
allowed for a better look into each of the receptors, the specific binding changes, and the effects 
of the substitutions. 
 When the unsubstituted phenyl derivatives were compared to their respective 4-
chlorophenyl derivatives, it demonstrated that all unsubstituted phenyl compounds contained a 
higher affinity for MOP. Since the results had not been reported prior to the subsequent 
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which in turn showed the m- and p-guanidines to be less active, the m- and p-amidoximes equi-
active (the p-amidoxime like its 4-chlorophenyl counterpart had no MOP affinity), the m-
amidine 20 was 6-fold less active, and the p-amidine 16 was equi-active in comparison. When 
the following derivatives were designed with a 3,4-dichlorophenyl substitution, which is 
typically synthesized when the 4-chlorophenyl compounds are more active than the unsubstituted 
phenyl, some interesting results developed. Not only were both 3,4-dichloro guanidine 
derivatives more active than their 4-chloro counterparts, but also the p-amidoximes were both 
inactive and the m- and p-amidines were equi-active and slightly less active. 
 The 4-chlorophenyl guanidines displayed less activity at KOP than the unsubstituted 
phenyl, but the 3,4-dichloro derivatives were more active over the 4-chloro. This does not match 
the Topliss pathway because the pathway suggests that 3,4-dichloro derivatives should be 
synthesized if the 4-chlorophenyl derivatives are more active than the unsubstituted phenyl. 
However, it could suggest that the 3-chloro is more tolerated in the KOP binding site. The 
amidoximes showed that a 3-positioning of the amidoxime within a 4-chloro, 4-methyl, or 3,4-
dichloro provided an increase in overall KOP affinity, whereas the p-amidoximes exhibited little 
to no KOP affinity, which indicates the amidoxime positioning is key. The amidines all had low 
to no affinity for KOP, with the exception of 87. It has a m-amidine and is a 3,4-dichlorophenyl 
derivative; the 4-chloro derivative 49 had little affinity at KOP, but once the 3-chloro was added, 
it had a 4-fold increase at KOP, thus strengthening the indication that the 3-chlorophenyl 
derivatives may have non-selective properties and high binding affinities at opioid receptors. 
 All guanidine derivatives had low to no activity at DOP, with the exception of 94, which 
is a m-guanidine, 3,4-dichlorophenyl derivative. The structure is slightly more confined together 
which in turn may allow it to fit better into the binding pocket. The amidoximes and most of the 
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amidines also had less affinity for DOP, but 4-chloro derivative 49 and 3,4-dichloro derivative 
87 had under a 200 nM affinity for DOP. Both of these ligands contained the chlorine 
substituents, while consisting of an m-amidine. The 4-chloro was slightly more active at DOP, 
which suggests that the 3-chloro addition decreases DOP activity, and proposes that the 3-
chlorophenyl derivatives will have less affinity for DOP. 
 Since, most of the NPFF ligands have yet to be tested they cannot be extensively 
compared, however, compounds that displayed promising results in the preliminary screening 
suggest some sort of activity at either NPFF1 or NPFF2. The unsubstituted phenyl derivatives are 
currently the only results listed for NPFF2, which showed moderately low affinity for NPFF2R, 
which is not enough information to assemble an accurate SAR. 
 Overall thoughts surrounding these results are that the 4-position substitutions (Cl/CH3) 
with m-guanidines are more tolerated at MOP, KOP, and DOP receptors compared to their 
corresponding p-guanidines with the exception of 59. Results also indicate that the 3,4-
dichlorophenyl guanidine derivatives consist of more activity at MOP, KOP, and DOP, which 
could indicate that the 3-chloro addition adds more receptor tolerability. This in turn could 
suggest that the subsequent 3-chlorophenyl derivatives will have better activity than the 4-
chlorophenyl and the 3,4-dichlorophenyl equivalents. The 4-amidoxime derivatives are not 
highly tolerated at MOP, KOP, DOP or NPFF2, which could be due to bulkiness, extending too 
far into the binding pocket, or there is no need/location for hydrogen bonding to stabilize the 
ligand and activate the receptor. The amidine derivatives typically display a lower affinity for all 
tested receptors, when compared to the 4-chlorophenyl derivatives and especially the 
unsubstituted phenyl derivatives. The biggest surprise is the 3,4-dichlorophenyl derivatives 
displaying greater affinity at opioid receptors in the presence of the guanidines, however it also 
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lost receptor preference. It would have been thought that if the 4-chloro compounds were less 
active than the unsubstituted phenyl derivatives, then the 3,4-dichlorophenyl derivatives should 
have not been active. It is thought that the 3-chloro addition provided more activity, which in 
turn could indicate the 3-chlorophenyl derivatives will be more active as well. The compounds 
did not follow the Topliss pathway as closely as one would have thought. The Topliss approach 
provides a general guideline for the initial design and synthesis of ligands. However, it can 
bypass probable compounds if followed perfectly. As an example, the 3,4-dichlorophenyl 
derivatives would not have been synthesized based off of the in vitro data of the 4-chlorophenyl 
derivatives in comparison to the unsubstituted phenyl. Although, the deduction based off the 
activity of the 3,4-dichlorophenyl derivatives suggests potential activity of the 3-chlorophenyl 
derivatives, this conclusion could have potentially been determined by methodical execution of 
the Topliss approach, as well. Though the Topliss pathway has loopholes, it does allow for 
compounds to be methodically synthesized based off of electronics. The pathway, due to these 
loopholes, should be utilized as a guideline rather than mindlessly followed.  
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4.3.2: Suggested Lead Compounds 
Table 26. Suggested Lead Compounds 
 DOP* KOP† MOP‡ 
Cmpd Code Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
Ki (nM) EC50 
(nM) 
8, KL13 127 ± 14 59 ± 6 774 ± 99 N.A. 2.88 ± 0.31 34 ± 4 
18, KGM01092 234 ± 29 N.T. 977 ± 153 N.A. 3.33 ± 0.29 71 ± 4 
20, KGM01095 174 ± 8 118 ± 16 97 ± 10 167 ± 12 1.62 ± 0.18 7.0 ± 1.6 
47, KGM01096 754 ± 175 N.A. 1,588 ± 522 N.A. 28 ± 2 519 ± 47 
49, KGM01098 163 ± 16 433 ± 53 152 ± 18 605 ± 73 9.6 ± 0.9 12.0 ± 1.6 
72, KGM02022 3,386 ± 1871 N.A. 1,462 ± 239 N.A. 61 ± 9 N.T. 
91, KGM02035 N.A. N.A. 3059 ± 635 N.A. 73 ± 10 N.T. 
94, KGM02036 230 ± 22 N.T. 985 ± 163 N.A. 115 ± 10 N.T. 
**Data obtained in-house from COBRE Core C 
*Reflects displacement of [3H]-DPDPE. 
†Reflects displacement of [3H]-U69,593. 
‡Reflects displacement of [3H]-DAMGO. 
N.A., No affinity as determined by a primary screen 
N.T., Not tested, awaiting testing 
 
 The table above (Table 26) suggests the lead compounds to move into in vivo animal 
studies for further SAR development. Compound 8, was chosen for its high affinity and 
moderately high potency at MOP, while it is nonselective for MOP and DOP, it does contain 
MOP preference. Although it has a relatively low affinity for NPFF2, it is still pending for NPFF1 
activity. Compound 18 has a high affinity and potency for MOP and although it does not show 
NPFF2 activity, it has potential for NPFF1, but also has DOP antagonism. Reportedly, DOP 
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antagonism can display anti-opioid-like activity, which is why this ligand should be studied in 
further detail. Compound 20 is the amidine form of 18 and was chosen as a lead ligand for not 
only its very high affinity and potency at MOP, while holding MOP preference, but also for its 
minor NPFF2 affinity and possible NPFF1 activity. Currently, 18 provides the best NPFF2 
activity (Ki = 816 ± 24 nM) of the reported data. Compound 47 was chosen for its MOP 
preference and moderately high affinity for MOP, although it was not active at NPFF2, its NPFF1 
binding results are still pending. Compound 49, which also has high affinity, high potency, and 
preference for MOP, is still pending on both NPFF1 and NPFF2 binding outcomes. NPFF1 and 
NPFF2 binding is still pending for 72, but 72 does have high MOP preference and low affinity 
for both DOP and KOP. Amidine compound 91, although not active at NPFF2, is pending its 
binding results at NPFF1 and displays MOP preference including moderate MOP affinity. The 
final ligand that is suggested to move on to animal assays is 94. Although this compound does 
not consist of high affinity or receptor preference, it is still awaiting NPFF results and could 
possess high NPFF activity. 
4.4: Presentation and Discussion of External Results  
 Animal study experimentation data was obtained through our co-investigator and external 
collaborator, Dr. Jay McLaughlin at the University of Florida, Gainesville, FL, as facilities were 
in order to evaluate compounds and their activities in vivo. Currently, compounds 8 (KL13), 12 
(KL15), 20 (KGM01095), 29 (KGM01080), 33 (KGM01082), 36 (KGM02001), 47 
(KGM01096), and 56 (KGM02008) have moved on to in vivo studies. Several of the 
compounds proceeded on to in vivo studies is to gather additional insight into their SAR. All 
reported antinociceptive and hyperalgesic in vivo data was generated and obtained from Dr. Jay 
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McLaughlin of the University of Florida, Gainesville, FL. Each time point is equal to 8 mice 
with the exception of compound 29 at a dosage of 30 nmol. 
Antinociception: 55 ºC warm-water tail-withdrawal assay. 
Compounds 8, 12, 20, 29, 33, 36, 47, and 56 were screened for antinociception through 
the utilization of a 55 ºC warm-water tail-withdrawal assay. Prior to i.c.v. administration of the 
compound, mice were tested for their baseline tail-withdrawal latency with a maximum response 
time at each testing of 15 seconds, to prevent tissue damage. Compounds 8, 29, 33, and 36 had 
the initial dose at 10 nmol with two more corresponding dosages (30 nmol and 100 nmol), 
whereas 12, 20, 47, and 56 had a single dosage of 30 nmol. Compound 8 provided modest 
analgesic activity in the antinociception assay (Figure 102A) whereas 12 showed mild activity 
for the first 20 minutes after initial injection (Figure 103A). Both 8 and 12 showed decent 
correlation to the in vitro activity with the moderate MOP potency of 8 (EC50 = 34 ± 4 nM) and 
12 with low potency (EC50 = 468 ± 145 nM). Interestingly, 20, 29, and 33 showed poor 
correlation between in vitro and in vivo activities. 20, which consisted of the highest affinity and 
potency at MOP, with some activity at KOP and DOP in vitro, exhibited no significant 
antinociceptive activity in the 55 ºC warm-water tail-withdrawal assay (Figure 104A). 29 
provided modest analgesia and 33 high antinociception, however at doses of 100 nmol i.c.v., 
induced seizures (Figure 105A and 106A, respectively). In vitro, 29 had low affinity for DOP 
receptors, whose agonism induces seizures, whereas 33 did not meet the initial screening 
requirement for either DOP or KOP receptors to proceed onto receptor binding. Compound 36 
provided mild analgesic activities at 10 and 30 nmol doses, while at 100 nmol provided modest 
antinociceptive activity for 50-60 minutes after the initial injection (Figure 107A). Both 47 and 
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56 provided mild antinociception in the 55 ºC warm-water tail-withdrawal assay for the first 20-
30 minutes after injection (Figure 108A and 109A, respectively). 
Although 33 induced seizures, it did contain the highest antinociceptive properties over 
the course of 210 minutes. In order to determine which receptor it elicited its action through, a 
100 nmol dose of 33 was administered i.c.v. into wild-type mice, KOP gene knock-out (KO) 
mice, and MOP KO mice. A baseline response was taken prior to administration of 33. Alone, 33 
in the wild-type mice showed a significant difference in baseline response with the latency to 
withdrawal around 12 seconds. When 33 was administered to KOP KO mice, it also produced a 
significant antinociceptive effect, similar to that of the wild-type mice. Although the MOP KO 
mice showed a significant baseline difference, the latency response was lessened compared to the 
wild type and KOP KO mice. Wild-type mice were administered 33 and the DOP antagonist 
naltrindole; results showed a further decrease in latency response and a significant difference 
from 33 response. These data suggests that 33 is a DOP agonist and may also consist of some 
MOP agonism as well. These results confirm that the seizures that transpired in mice at 100 nmol 
doses of 33 were DOP-induced (Figure 106C).  
Anti-hyperalgesia: 48 ºC warm-water tail-withdrawal assay. 
 Compounds 8, 12, 20, 29, 33, 36, 47, and 56 were screened for hyperalgesic activity 
through the utilization of a 48 ºC warm-water tail-withdrawal assay. Mice were tested for their 
baseline tail-withdrawal latency with a maximum response time at each testing of 30 seconds, to 
prevent tissue damage. Following the control latencies, mice received a single dose of compound 
or vehicle via i.c.v. administration 90 minutes prior to administration of NPFF to eliminate any 
possibility for the analgesic effects. A compound that induces a decrease in tail-withdrawal 
latency indicates hyperalgesic effects. At a 10 nmol i.c.v. dose, compound 8 exhibits 
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hyperalgesic effects and follows a similar response compared to 30 nmol i.c.v., whereas at 30 
nmol and 100 nmol i.c.v. compound 8 displays mild anti-hyperalgesic effects (Figure 102B). 
Compound 12, at a dosage of 30 nmol, displayed approximately 35 minutes of anti-hyperalgesic 
effects before it hyperalgesia development occurred at t = 40 (Figure 103B). Out of the 
compounds tested, 20 showed the some of the best and most consistent anti-hyperalgesic 
activity. 20 remained similar to the vehicle and from 30-50 minutes displayed a significant 
difference from NPFF (Figure 104B). Compound 29 appeared to display agonist activities when 
dosed at 10 nmol i.c.v., but when administered a 30 nmol dosage 29 appeared to have anti-
hyperalgesic effects for the first 30 minutes before a sharp increase in hyperalgesic activity 
(Figure 105B). It should be noted that 30 nmol dosages of 29, contained error bars that were 
quite large, which would suggest significant differences in anti-hyperalgesic activity, mouse to 
mouse. Due to seizure development at 100 nmol, mice were not administered 100 nmol dosages 
of 29 or 33. Compound 33, which in the antinociception assay provided the best analgesic 
effects, showed a significant baseline response and indicated NPFF agonist-like effects for both 
the 10 nmol and 30 nmol dosages (Figure 106B). Both dosages of 33 displayed significantly 
prolonged hyperalgesic activity, even compared to that of NPFF. Compound 36 at dosages of 10 
and 30 nmol i.c.v. displayed agonist-like hyperalgesic activity, however, 100 nmol dosages 
provided anti-hyperalgesic effects for the first 50 minutes and showed a significant difference 
from NPFF from the 40-50 minute mark (Figure 107B). Compound 47, displayed approximately 
30 minutes of anti-hyperalgesic activity before succumbing to hyperalgesic activity (Figure 
108B). Compound 56 provided mild anti-hyperalgesic activity (Figure 109B).  
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Figure 102. Antinociception and anti-hyperalgesia screening for KL13. 
A) 
 
B) 
 
 
Figure 103. Antinociception and anti-hyperalgesia screening for KL15. 
A) 
 
B) 
 
 
Figure 104. Antinociception and anti-hyperalgesia screening for KGM01095. 
A) 
 
B) 
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Figure 105. Antinociception and anti-hyperalgesia screening for KGM01080. 
A) 
 
B) 
 
 
 
Figure 106. Antinociception, anti-hyperalgesia, and receptor selectivity screening for 
KGM01082. 
A) 
 
B) 
 
C) 
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Figure 107. Antinociception and anti-hyperalgesia screening for KGM02001. 
A) 
 
B) 
 
 
Figure 108. Antinociception and anti-hyperalgesia screening for KGM01096. 
A) 
 
B) 
 
 
Figure 109. Antinociception and anti-hyperalgesia screening for KGM02008.  
A) 
 
B) 
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CHAPTER 5 
CONCLUSIONS 
 The population of people that experience moderate to severe pain continues to 
exponentially increase, while the most commonly prescribed form of analgesics is opioids. 
Opioid analgesics, although effective, contain adverse side effects such as constipation, 
addiction, respiratory depression, opioid-induced hyperalgesia, and tolerance development. To 
combat these undesirable side effects, ligands were designed using a merged scaffold approach 
with pharmacophores that would in theory bind as agonists to opioid receptors and antagonists at 
NPFF receptors. Original lead molecules that consisted of a diphenylmethylenepiperidine 
scaffold displayed prolonged analgesia and reduced NPFF-induced hyperalgesia. 
In order to continue research on dual-acting small molecule ligands, a knowledge-based 
drug design strategy provided analogs that utilized the diphenylmethylenepiperidine scaffold, but 
replaced the N-benzyl with an N-phenethyl substitution on the piperidine nitrogen. The N-
phenethyl substitution was added to drive ligand preference for MOP, while decreasing DOP and 
KOP activity. In addition to the diphenylmethylenepiperidine scaffold, a loosely followed 
Topliss Pathway approach provided analogs with various substitutions in order to distinguish 
optimum binding affinity at target receptors, but even the slightest changes in structure lead to 
drastic alterations in receptor affinity and activity.  
Currently, the binding and functional profiles of the analogs at DOP, KOP, MOP and 
both NPFF receptor subtypes are still pending full completion. However, preliminary in vitro 
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results indicate that the Topliss Pathway approach does consist of possible loopholes, which may 
overlook feasible ligands. It should be noted that in the VBJ and CM series, ligands with 
substitutions in the 3-position including 3-guanidine provided opioid affinity and potency, which 
could suggest that the remaining compounds (all of which contain 3-R substitution) will have 
similar activities. However, preliminary data between in vitro and in vivo data demonstrates 
some significant inconsistencies. Data from the binding and functional studies, showed several 
ligands presented high affinities and potencies at MOP receptors with low activities at other 
tested receptors. In the tail-withdrawal assays, analogs 8, 20, and 47, which had the highest 
affinities and potencies at MOP, showed minor to no antinociceptive effects. 20 provided 
moderate anti-hyperalgesic activity at a dose of 30 nmol, whereas mice administered 47 
developed hyperalgesia similar to that of NPFF. Other ligands, 29 and 33, displayed in vitro 
MOP preference with little to no DOP affinity, but in vivo presented DOP-mediated analgesia. 
These results were unanticipated and unfounded based off of the employed knowledge-based 
drug design approach. 
It is clear that in order to develop a better understanding of these derivatives, in vitro 
results cannot be the only source of data. It needs to be mentioned that in vitro and in vivo studies 
do not always correlate, which shows why in vivo studies are pertinent for the advancement of 
drug design. Although the aforementioned results do not give a clear indication of optimal 
structural modifications, it has been established that the various ring substitutions at the 
piperidine nitrogen (i.e. benzyl, phenethyl) and amidine modifications provide better opioid 
receptor activities and potencies, but remain unclear at the NPFF receptor subtypes. After the 
remaining in vitro and in vivo data has been recorded and optimal substitutions of the currently 
designed ligands have been determined, substitutions that continue to follow the Topliss pathway 
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should be carried out. However, additional analogs designed to follow the Topliss approach, 
should heed pathway perfection and utilize the approach as a general guideline to optimize 
phenyl ring substitutions. 
Although the structure of the designed compounds are intended to bind to opioid and 
NPFF receptors, the established pharmacophores have potential to promiscuously bind at other 
off target receptors that are intertwined with the opioid system or consist of peptide sequences 
similar to NPFF receptors such as neuropeptide Y1 or imidazoline-2 (I2) receptors. Neuropeptide 
Y (NPY), an endogenous peptide for Y1 and Y2 receptors, is located throughout the CNS and 
PNS and has been associated in both pro- and antinociceptive effects.335 NPY and its receptors 
are highly expressed in the superficial laminae of the dorsal horn of the spinal cord, which is 
believed to be the site of its antinociception mediation.335 Since both Y receptor subtypes are Gi/o 
protein coupled, their activation leads to several downstream molecular pathways similar to 
NPFF receptors.336 NPY and NPFF systems have shown an overlap in pathways; the NPY Y1 
receptor antagonist, BIBP3226, has been found to inhibit NPFF agonism through animal studies, 
which suggests that NPY and NPFF receptors share similar binding pockets.337 NPY and its 
receptors, like the NPFF system are involved in appetite, stress, anxiety, and pain.336, 338, 339 It has 
been suggested that I2 receptors are also involved in the potentiation of morphine- and 
oxycodone-induced antinociception when agonists such as agmatine, an endogenous 
nonselective agonist that is metabolically produced in plants, are present.340-343 Although success 
has been shown in animal models through antagonist binding, I2 receptors have yet to be cloned 
which leaves many in the scientific community uncertain of the true existence of these receptors. 
However, the NPY Y subtypes and I2 receptors show parallels in activity between themselves 
 154 
and NPFF, which begs the question of how closely related are these systems and are assays, both 
in vitro and in vivo truly binding to the intended receptors?  
Not only could off-target activity promote false positive or negative results, but single 
nucleotide polymorphisms (SNPs) could as well. Several groups have supported research that 
suggests SNPs are present within the opioid system. From these inferences, it adds to the 
question of the clinical interpersonal variability of treated populations. Research in the field of 
enzymes recently discovered that cytochrome P450 (CYP) 2C9 consists of SNPs that differ 
between populations based off of continental ancestry.344 This discovery emphasized genetic 
variations and discovered that several populations were more susceptible to stroke or 
cardiovascular events just based from the CYP2C9 SNPs and therapeutic effectiveness.344 This 
makes one deliberate, if analogous incidences could be effect therapeutic treatments that involve 
the opioid system. Hypothetically, there could be populations of people that have SNP variations 
within the opioid system and treatments that utilize opioid pharmacology may be more or less 
effective based off of a person’s ancestry. Data surrounding ethnic variations on the basis of 
genetic variants and opioid dependence have been reported with similar inferences; however, the 
field of SNPs with relation to the opioid system has not been well characterized.345, 346 This goes 
to show that when ligands are designed, there is numerous possibilities involved that may cause 
changes in therapeutic efficacy.  
In conclusion, although ligands did not display the intended opioid activity or potency as 
designed, they did exhibit modest opioid agonism and mild anti-hyperalgesic activity. While the 
ratio between opioid and NPFF receptors needs to be improved, results suggest that the dual-
acting small molecule approach is plausible for a future non-tolerance forming, opioid-like 
analgesic. 
 155 
 
 
 
CHAPTER 6 
EXPERIMENTAL DATA 
 
Synthesis. Unless otherwise stated, reagents and starting materials were obtained from 
commercial suppliers and used without further purification. Pre-coated silica gel GF Uniplates 
(Analtech; Newark, DE, U.S.A.) were used for thin-layer chromatography (TLC). 
Chromatography was performed with silica gel 60 (Sorbent Technologies; Norcross, GA, 
U.S.A.), an Isolera One Biotage system, or a Combiflash RF+ Teledyne ISCO system. Mass 
Spectra (MS) were recorded on a Waters Acquity Ultra Performance LC with a Waters ZQ mass 
detector in ESI(+) mode and photodiode array detector,  or on a Waters Acquity UPLC H-Class 
System with a Waters QDa mass detector in ESI(+) mode, and photodiode array detector, both 
equipped with an Acquity UPLC™ BEH column (C-18, 2.1 mm x 50 mm) with 90% of a 0.1% 
HCOOH solution in H2O/10% ACN as the mobile phase. NMR spectra were recorded on a 
Bruker Avance DRX 400 spectrometer, a Bruker Ascend™ 500 spectrometer with CryoProbe, a 
Varian Mercury+ 400 spectrometer, or a Bruker Avance III spectrometer with a FBBO-Z probe. 
Purity analysis was performed on either a Waters Acquity UPLC H-Class system with 
OpenLynx software (LCMS method) 90% H2O with 0.1% formic acid and 10% ACN with 0.1% 
formic acid as the eluent in gradient conditions at a flow rate of 0.6 mL/min; or HPLC analysis 
on a Waters Alliance 2695 HPLC system coupled with a Waters 996 UV detector, eluted peaks 
were monitored at 254 nm; both on a reverse phase XBridge™ C18 (4.6 mm x 150 mm) column, 
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using either: (HPLC method 1) 25% ACN/30% MeOH/45% of 0.1% TFA (aq) as the eluent in 
gradient conditions at a flow rate of 2.0 mL/min; (HPLC method 2) 20% of a 1.0% HCOOH 
solution in H2O/80% MeOH as the eluent in isocratic conditions at a flow rate of 2.0 mL/min; 
(HPLC method 3) 15% of a 1.0% HCOOH solution in H2O/85% MeOH as the eluent in isocratic 
conditions at a flow rate of 2.0 mL/min. Nitro reductions were implemented using a ThalesNano 
H-Cube Mini+ Flow Hydrogenator with a 10% Pd/C CatCart®, 29 psi (2 bar), at a flow rate of 1.0 
mL/min with a temperature of either: (temperature 1) 40 ºC or (temperature 2) 30 ºC. 
6.1: Experimental Data for KL13, KL15, KGM01087, and KGM01095. 
6.1.1: Experimental Data for compounds in Figure 23. 
Benzyltriphenylphosphonium bromide (2, KL[1]). 
Triphenylphosphine (11.50 g, 43.85 mmol) was dissolved in toluene (60 mL) and benzyl 
bromide 1 (5.20 mL, 43.85 mmol) was added drop wise and set to reflux at 110 ˚C overnight. 
The precipitate was filtered and washed with toluene and diethyl ether. The salt was further dried 
in vacuo, to provide 2 as a fine white powder (18.75 g, 43.26 mmol, 98.7%). 1H NMR (500 
MHz, CDCl3) δ 7.73 – 7.67 (m, 3H), 7.65 – 7.59 (m, 6H), 7.58 – 7.53 (m, 6H), 7.17 – 7.11 (m, 
1H), 7.06 – 6.98 (m, 4H), 5.21 (d, JH, P = 14.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 135.06, 
135.03 (2C), 134.31 (3C), 134.24 (3C), 131.41, 131.37, 130.21 (3C), 130.12 (3C), 128.82, 
128.79, 128.43, 128.40, 127.05, 126.98, 117.92, 117.24, 30.82 (d, JC, P = 47.1 Hz). MS(ESI) m/z 
calcd. for C25H22P+ 353.15, found 354.23 [M]+, 355.11 [M+1]+, 356.12 [M+2]+. 
4-Benzylidene-1-phenethylpiperidine (3, KL[2]). 
Compound 2 (18.74 g, 43.24 mmol) was suspended in anhydrous THF (46 mL) under argon at -
78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (25.93 mL, 51.89 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min, then allowed to warm to room temperature 
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until a color change to dark orange. A solution of 1-phenethylpiperidin-4-one (8.80 g, 43.24 
mmol) in anhydrous THF (23 mL) was added via syringe and the reaction was allowed to stir at 
room temperature overnight. The reaction was quenched with H2O, extracted using DCM, 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified via flash column chromatography (7:3, hexane: ethyl acetate). Fractions were collected 
and concentrated in vacuo to provide 3 as a light yellow oil (5.43 g, 19.57 mmol, 45.2 %). 1H 
NMR (500 MHz, CDCl3) δ 7.25 – 7.17 (m, 4H), 7.15 – 7.08 (m, 6H), 6.22 (s, 1H), 2.78 – 2.73 
(m, 2H), 2.58 – 2.52 (m, 4H), 2.51 – 2.47 (m, 2H), 2.46 – 2.41 (m, 2H), 2.39 – 2.34 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 140.39, 139.31, 137.82, 129.01 (2C), 128.79 (2C), 128.49 (2C), 
128.19 (2C), 126.22, 126.15, 123.48, 60.56, 55.23, 54.58, 36.40, 33.77, 29.10. MS(ESI) m/z 
calcd. for C20H23N 277.18, found 277.72 [M], 279.23 [M+1]+, 280.17 [M+2]+. 
4-(Bromo(phenyl)methylene)-1-phenethylpiperidine (5, KL[3]). 
Compound 3 (5.40 g, 19.46 mmol) was dissolved in DCM (240 mL) under argon at -78˚C. Br2 
(1.50 mL, 29.19 mmol) was diluted in DCM (82 mL) and the solution was added drop wise using 
an addition funnel. The mixture was stirred at room temperature for 2 h, until the complete 
conversion to the dibromo intermediate 4, which was determined by TLC. NaOH (4.67 g, 116.75 
mmol) was dissolved in MeOH (194 mL) and the solution was added drop wise using an addition 
funnel. The mixture was heated to reflux (70 ºC) for 4 hr until the full conversion to the 
monobromo, then cooled to rt. The reaction was quenched using H2O, extracted with DCM, 
dried over Na2SO4, and concentrated in vacuo. The crude material was purified via flash column 
chromatography (7:3, hexane: ethyl acetate). Fractions were collected and concentrated in vacuo 
to provide 5 as an orange oil (4.07 g, 11.43 mmol, 58.7%). 1H NMR (500 MHz, CDCl3) δ 7.27 
– 7.23 (m, 2H), 7.22 – 7.16 (m, 5H), 7.13 – 7.09 (m, 3H), 2.80 – 2.73 (m, 2H), 2.71 – 2.66 (m, 
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2H), 2.64 – 2.55 (m, 4H), 2.44 – 2.38 (m, 2H), 2.29 – 2.24 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 140.25, 139.99, 136.91, 129.39 (2C), 128.76 (2C), 128.53 (2C), 128.32 (2C), 128.09, 
126.25, 116.05, 60.07, 54.23, 53.89, 34.27, 33.57, 31.57. MS(ESI) m/z calcd. for C20H22BrN 
355.09, found 355.99 [M], 358.88 [M+2]+, 360.02 [M+4]+. 
6.1.2: Experimental Data for compounds in Figure 24. 
3-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)aniline (6, KL[11]). 
Argon (g) was bubbled into a mixture of compound 5 (1.00 g, 3.09 mmol), 3-
aminophenylboronic acid hydrochloride (0.64 g, 3.71 mmol) and K2CO3 (2.14 g, 15.46 mmol) in 
toluene (15 mL)/ethanol (5 mL) (3:1 ratio). The mixture was degassed prior to the addition of 
Pd(PPh3)4 (74.09 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, quenched with H2O, extracted with ethyl acetate, washed 
with brine, dried over Na2SO4 and concentrated in vacuo. The crude material was purified via 
flash column chromatography (3:7, hexane: ethyl acetate). Fractions were collected and 
concentrated in vacuo to provide 6 as a dark yellow, sticky oil (92.9 mg, 0.25 mmol, 8.2%). 1H 
NMR (400 MHz, CDCl3) δ 7.28 – 7.16 (m, 4H), 7.16 – 7.08 (m, 4H), 7.09 – 7.03 (m, 2H), 7.03 
– 6.92 (m, 1H), 6.52 – 6.40 (m, 2H), 6.40 – 6.29 (m, 1H), 3.64 – 3.04 (m, 2H), 2.83 – 2.69 (m, 
2H), 2.69 – 2.44 (m, 6H), 2.46 – 2.30 (m, 4H).  
(Z)-1,3-bis(tert-butoxycarbonyl)-3-(4-((1-phenethylpiperidin-4-
ylidene)(phenyl)methyl)phenyl)guanidine (7, KL[12]). 
Triethylamine (TEA) (0.86 mL, 6.18 mmol) was added drop wise to a suspension of compound 6 
(0.76 g, 2.06 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.66 g, 2.27 mmol), 
HgCl2 (0.62 g, 2.27 mmol) in DCM. The mixture was stirred for 72 hours at rt then filtered 
through a silica plug to remove the HgCl2. The crude material was concentrated in vacuo and 
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was purified using flash column chromatography (7:3, hexane: ethyl acetate). Fractions were 
collected and concentrated in vacuo to provide 7 (153.2 mg, 0.25 mmol, 12.2%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 11.53 (s, 1H), 10.18 (s, 1H), 7.53 – 7.49 (m, 1H), 7.32 – 7.28 (m, 
1H), 7.18 – 7.13 (m, 8H), 7.05 – 7.01 (m, 3H), 6.80 – 6.76 (m, 1H), 3.04 – 2.98 (m, 2H), 2.91 – 
2.80 (m, 4H), 2.71 – 2.54 (m, 6H), 1.44 (s, 9H), 1.44 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
163.60, 153.70 (3C), 153.41, 148.86, 136.73 (2C), 129.60 (2C), 128.95, 128.87 (2C), 128.82 
(3C), 128.38 (2C), 127.04, 126.16, 123.42, 121.21, 119.21, 83.95, 79.75, 67.26 (2C), 65.99, 
45.74, 44.90, 29.84, 28.12 (6C). MS(ESI) m/z calcd. for C37H46N4O4 610.35, found 611.30 [M]+, 
612.25 [M+1]+, 613.32 [M+2]+, 511.20 [M-Boc]+, 411.13 [M-2Boc]+. 
1-(3-((1-phenethylpiperidin-4-ylidene)(phenyl)methyl)phenyl)guanidine dihydrochloride (8, 
KL[13]). 
Compound 7 (0.15 g, 0.25 mmol) was dissolved in DCM (1.5 mL). 4N HCl in 1,4-dioxane (1.5 
mL) was added to the reaction vessel and left to stir for 72 hr at room temperature. The reaction 
was concentrated in vacuo to provide 8 as an off white powder (79.4 mg, 0.164 mmol, 65.4%). 
1H NMR (500 MHz, DMSO) δ 11.15 (s, 1H), 10.01 (s, 1H), 7.54 (s, 3H), 7.38 – 7.35 (m, 3H), 
7.33 (s, 1H), 7.29 – 7.26 (m, 4H), 7.20 – 7.19 (m, 1H), 7.06 – 7.04 (m, 1H), 7.00 (s, 1H), 3.64 – 
3.58 (m, 4H), 3.31 – 3.26 (m, 2H), 3.12 – 3.07 (m, 3H), 2.67 – 2.62 (m, 3H). 13C NMR (126 
MHz, DMSO) δ 156.06, 142.72, 140.84, 137.15, 135.50, 130.30, 129.38 (2C), 128.85 (4C), 
128.59 (2C), 127.50, 127.32, 127.02, 125.23, 123.19, 66.49, 56.42, 52.42, 52.31, 29.68, 28.08, 
27.99. MS(ESI) m/z calcd. for C27H30N4 410.25, found 411.13 [M]+, 412.14 [M+1]+. HPLC 
Method 1: 97.80%, tR = 3.72 min. 
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6.1.3: Experimental Data for compounds in Figure 25. 
4-((4-Nitrophenyl)(phenyl)methylene)-1-phenethylpiperidine (9, KL[4]). 
Compound 5 (0.39 g, 1.10 mmol), 4-nitrophenylboronic acid hydrochloride (0.22 g, 1.32 mmol) 
and K2CO3 (0.38 g, 2.76 mmol) were dissolved in toluene (15 mL)/ethanol (5 mL) (3:1 ratio). 
The mixture was degassed prior to the addition of Pd(PPh3)4 (39.3 mg). The reaction was 
wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The mixture was cooled, 
filtered through Celite®, quenched with H2O, extracted with ethyl acetate, washed with brine, 
dried over Na2SO4, and concentrated in vacuo. The crude material was purified via flash column 
chromatography (6:4, hexane: ethyl acetate). Fractions were collected and concentrated in vacuo 
to provide 9 as a light orange oil (0.39 g, 0.98 mmol, 89.0%). 1H NMR (400 MHz, CDCl3) δ 
8.12 – 8.02 (m, 2H), 7.29 – 7.17 (m, 7H), 7.17 – 7.07 (m, 3H), 7.07 – 6.97 (m, 2H), 2.84 – 2.70 
(m, 2H), 2.70 – 2.49 (m, 6H), 2.47 – 2.31 (m, 4H).  
4-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)aniline (10, KL[5]). 
Compound 9 (0.38 g, 0.96 mmol) was dissolved in MeOH (40 mL) and 10% Pd/C (38.4 mg) was 
added to the reaction vessel. The mixture was hydrogenated at 40 psi for 4 hours, filtered through 
Celite®, and concentrated in vacuo to provide 10 as a light yellow, sticky oil (0.35 g, 0.95 mmol, 
98.2 %). 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 6.6 Hz, 4H), 7.13 (d, J = 6.7 Hz, 4H), 7.03 
(d, J = 7.2 Hz, 2H), 6.82 (d, J = 8.1 Hz, 2H), 6.53 (d, J = 8.1 Hz, 2H), 3.72 – 3.34 (m, 2H), 2.87 
– 2.78 (m, 2H), 2.68 – 2.55 (m, 6H), 2.48 (s, 2H), 2.44 – 2.37 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 148.87, 146.59, 145.08, 142.73, 142.68, 140.74, 130.88 (2C), 129.84 (2C), 128.83 
(3C), 128.70 (2C), 128.11 (2C), 126.52, 114.77 (2C), 60.12, 55.20, 55.13, 31.83, 30.88, 30.84. 
MS(ESI) m/z calcd. for C26H28N2 368.23, found 369.14 [M]+, 370.15 [M+1]+, 371.16 [M+2]+. 
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(Z)-1,3-bis(tert-butoxycarbonyl)-4-(4-((1-phenethylpiperidin-4-
ylidene)(phenyl)methyl)phenyl)guanidine (11, KL[14]). 
Triethylamine (0.41 mL, 2.90 mmol) was added drop wise to a suspension of compound 10 (0.36 
g, 0.97 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.31 g, 1.06 mmol), HgCl2 
(0.29 g, 1.06 mmol) in DCM (30 mL). The mixture was stirred for 72 hours at room temperature 
then filtered through Celite® and the filtrate was concentrated in vacuo. The crude material was 
purified using flash column chromatography (3:7, hexane:diethyl ether). Fractions were collected 
and concentrated in vacuo followed by crystallization in MeOH to provide 11 as white crystals 
(0.20 g, 0.32 mmol, 33.5%). 1H NMR (400 MHz, CDCl3) δ 11.55 (s, 1H), 10.24 (s, 1H), 7.49 – 
7.44 (m, 2H), 7.25 – 7.20 (m, 3H), 7.17 – 7.11 (m, 5H), 7.04 – 6.97 (m, 4H), 2.93 – 2.83 (m, 
2H), 2.77 – 2.59 (m, 6H), 2.56 – 2.44 (m, 4H), 1.46 (s, 9H), 1.43 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 162.5, 152.4, 152.2, 141.3, 139.2 (2C), 137.8, 134.5, 134.1, 129.3, 128.9, 127.7, 127.4, 
126.9, 125.4, 125.0, 120.6, 82.7, 78.6, 59.4, 54.3, 54.2, 32.6, 30.5, 30.5, 27.2, 27.1. MS(ESI) m/z 
calcd. for C37H46N4O4 610.35, found 611.30 [M]+, 612.30 [M+1]+, 613.38 [M+2]+, 511.20 [M-
Boc]+, 411.13 [M-2Boc]+. 
1-(4-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)phenyl)guanidine dihydrochloride 
(12, KL[15]). 
Compound 11 (0.18 g, 0.30 mmol) was dissolved in DCM (3.5 mL). 2N HCl in diethyl ether (3.5 
mL) was added to the reaction vessel and left to stir for 72 hr at room temperature. The reaction 
was concentrated in vacuo to provide 12 as an off white powder (140 mg, 0.29 mmol, 97.5%). 
1H NMR (400 MHz, DMSO) δ 11.37 (s, 1H), 10.17 (s, 1H), 7.58 (s, 4H), 7.39 – 7.32 (m, 4H), 
7.31 – 7.24 (m, 4H), 7.24 – 7.16 (m, 6H), 3.63 – 3.56 (m, 2H), 3.30 – 3.23 (m, 2H), 3.13 – 3.02 
(m, 4H), 2.71 – 2.52 (m, 4H). 13C NMR (101 MHz, DMSO) δ 156.00, 140.95, 138.96, 137.16, 
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137.02, 134.06, 130.37 (2C), 130.10, 129.15 (2C), 128.66 (3C), 128.64, 128.40 (2C), 127.02, 
126.78, 123.98 (2C), 56.17, 52.11, 52.04, 29.42, 27.83, 27.73. MS(ESI) m/z calcd. for C27H30N4 
410.25, found 411.07 [M]+, 412.08 [M+1]+, 413.21 [M+2]+. HPLC Method 1: 97.05%, tR = 
3.77 min. 
6.1.4: Experimental Data for compounds in Figure 26.  
4-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)benzonitrile (13, KGM01085). 
Under Argon (g), a mixture of 5 (2.13 g, 5.98 mmol), 4-cyanophenylboronic acid (1.06 g, 7.18 
mmol) and K2CO3 (2.07 g, 14.95 mmol) in toluene (90 mL)/ethanol (30 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (214 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using an Isolera One Biotagé system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 13 as a yellow-
orange oil (2.16 g, 5.71 mmol, 95.5%). 1H NMR (500 MHz, Chloroform-d) δ 7.61 – 7.55 (m, 
2H), 7.37 – 7.25 (m, 7H), 7.25 – 7.21 (m, 3H), 7.14 – 7.08 (m, 2H), 2.92 – 2.84 (m, 2H), 2.74 – 
2.62 (m, 6H), 2.53 – 2.43 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 147.18, 141.13, 139.97, 
137.26, 134.90, 131.95 (2C), 130.63 (2C), 129.84 (2C), 128.72 (2C), 128.52 (2C), 128.39 (2C), 
127.06, 126.24, 119.01, 110.19, 60.25, 55.03, 54.99, 33.53, 31.50, 31.43. MS(ESI) m/z calcd. for 
C27H26N2 378.21, found 378.71 [M], 380.35 [M+1]+, 381.10 [M+2]+. 
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(Z)-N'-hydroxy-4-((1-phenethylpiperidin-4-ylidene)(phenyl)methyl)benzimidamide (14, 
KGM01086). 
A mixture of 13 (2.14 g, 5.65 mmol), hydroxylamine hydrochloride (1.45 g, 20.89 mmol), and 
sodium carbonate (1.02 g, 9.60 mmol) in ethanol (17.3 mL)/H20 (1.73 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was the 
further dried in vacuo to provide 14 as a fine white powder (1.80 g, 4.37 mmol, 77.3%). 1H 
NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 7.66 – 7.59 (m, 2H), 7.35 – 7.29 (m, 2H), 7.29 – 7.14 
(m, 7H), 7.14 – 7.10 (m, 3H), 5.78 (s, 2H), 2.79 – 2.72 (m, 2H), 2.63 – 2.51 (m, 6H), 2.33 – 2.26 
(m, 4H). 13C NMR (126 MHz, DMSO) δ 150.69 (2C), 142.57, 141.86, 140.30, 134.85, 131.52, 
129.41 (2C), 129.16 (2C), 128.62 (2C), 128.23 (2C), 128.16 (2C), 126.48, 125.85, 125.24 (2C), 
59.46, 54.42 (2C), 32.75, 31.10 (2C). MS(ESI) m/z calcd. for C27H29N3O 411.23, found 412.08 
[M]+, 413.08 [M+1]+, 414.22 [M+2]+. HPLC Method 1: 96.47%, tR = 3.26 min. 
4-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)benzimidamide dihydrochloride (16, 
KGM01087) 
To a solution of 14 (1.66 g, 4.03 mmol), in acetic acid (20.4 mL), acetic anhydride (0.53 mL, 
5.64 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 15 was determined by LC/MS. 10% Pd/C (166 mg) was introduced to the 
mixture and the reaction was hydrogenated at 25 psi for 84 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a tan oil. MeOH and ethyl acetate were 
used to remove excess acetic acid and provide a residue. The residue was treated with excess 2N 
HCl in diethyl ether. The HCl was evaporated in vacuo to provide 16 as a white-orange powder 
(1.78 g, 3.80 mmol, 94.5%). 1H NMR (400 MHz, CDCl3) δ 7.84 – 7.77 (m, 2H), 7.49 – 7.40 (m, 
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2H), 7.36 – 7.26 (m, 8H), 7.23 – 7.17 (m, 2H), 3.78 – 3.67 (m, 2H), 3.45 – 3.36 (m, 2H), 3.23 – 
3.09 (m, 4H), 2.83 – 2.64 (m, 4H). 13C NMR (101 MHz, MeOD) δ 168.00, 148.52, 141.57, 
139.63, 137.63, 131.56 (2C), 131.50, 130.54 (2C), 129.94 (2C), 129.93 (2C), 129.71 (2C), 
129.20 (2C), 128.69, 128.24, 128.12, 59.04, 54.59, 54.56, 49.64, 31.53, 29.59, 29.54. MS(ESI) 
m/z calcd. for C27H29N3 395.24, found 396.09 [M]+, 397.16 [M+1]+, 399.17 [M+3]+. HPLC 
Method 2: 97.41%, tR = 2.42 min. 
6.1.5: Experimental Data for compounds in Figure 27. 
3-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)benzonitrile (17, KGM01091). 
Under Argon (g), a mixture of 5 (1.94 g, 5.45 mmol), 3-cyanophenylboronic acid (0.96 g, 6.54 
mmol) and K2CO3 (1.88 g, 13.62 mmol) in toluene (81 mL)/ethanol (27 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (194 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using an Isolera One Biotagé system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 17 as an orange 
oil (1.43 g, 3.78 mmol, 69.4%). 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.40 (m, 1H), 7.36 (s, 
1H), 7.35 – 7.29 (m, 2H), 7.27 – 7.17 (m, 5H), 7.17 – 7.11 (m, 3H), 7.05 – 7.01 (m, 2H), 2.81 – 
2.75 (m, 2H), 2.61 – 2.52 (m, 6H), 2.38 (t, J = 5.3 Hz, 2H), 2.34 (t, J = 5.3 Hz, 2H). 13C NMR 
(126 MHz, CDCl3) δ 143.67, 141.33, 140.31, 137.58, 134.41, 134.14, 133.42, 130.16, 129.88 
(2C), 129.02, 128.80 (2C), 128.54 (2C), 128.43 (2C), 127.06, 126.21, 118.98, 112.37, 60.43, 
55.20, 55.17, 33.81, 31.72, 31.66. MS(ESI) m/z calcd. for C27H26N2 378.21, found 379.09 [M]+, 
380.03 [M+1]+. 
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(Z)-N'-hydroxy-3-((1-phenethylpiperidin-4-ylidene)(phenyl)methyl)benzimidamide (18, 
KGM01092). 
A mixture of 17 (1.38 g, 3.65 mmol), hydroxylamine hydrochloride (0.94 g, 13.49 mmol), and 
sodium carbonate (0.66 g, 6.20 mmol) in ethanol (11.2 mL)/H20 (1.12 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was the 
further dried in vacuo to provide 18 as a fine white powder (1.46 g, 3.55 mmol, 97.4%). 1H 
NMR (500 MHz, DMSO) δ 9.63 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.45 (s, 1H), 7.35 – 7.30 (m, 
3H), 7.30 – 7.26 (m, 2H), 7.25 – 7.21 (m, 3H), 7.21 – 7.16 (m, 1H), 7.13 (d, J = 7.4 Hz, 3H), 
5.79 (s, 2H), 2.82 – 2.74 (m, 2H), 2.69 – 2.48 (m, 6H), 2.36 – 2.24 (m, 4H). 13C NMR (126 
MHz, DMSO) δ 150.67, 141.80, 141.75, 135.14, 133.23, 129.84, 129.33 (2C), 128.61 (3C), 
128.24 (3C), 128.16 (2C), 127.92, 126.48, 126.35, 125.90, 123.54, 59.53, 54.43, 54.28, 32.64, 
31.02, 30.96. MS(ESI) m/z calcd. for C27H29N3O 411.23, found 412.14 [M]+, 413.08 [M+1]+, 
414.22 [M+2]+. HPLC Method 2: 98.17%, tR = 2.47 min. 
3-((1-Phenethylpiperidin-4-ylidene)(phenyl)methyl)benzimidamide dihydrochloride (20, 
KGM01095) 
To a solution of 18 (1.22 g, 2.97 mmol), in acetic acid (15.0 mL), acetic anhydride (0.39 mL, 
4.16 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 19 was determined by LC/MS. 10% Pd/C (123 mg) was introduced to the 
mixture and the reaction was hydrogenated at 25 psi for 60 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a tan oil. MeOH was used to remove 
excess acetic acid and provide a residue. The residue was treated with excess 2N HCl in diethyl 
ether. The HCl was evaporated in vacuo to provide 20 as a beige powder (1.30 g, 2.76 mmol, 
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93.1%). 1H NMR (500 MHz, DMSO) δ 11.71 (s, 1H), 9.59 (s, 2H), 9.41 (s, 2H), 7.79 (s, 1H), 
7.57 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.38 – 7.31 (m, 4H), 7.30 – 7.25 (m, 4H), 7.25 
– 7.19 (m, 3H), 3.71 – 3.53 (m, 4H), 3.30 – 3.18 (m, 3H), 3.15 – 3.06 (m, 3H), 2.78 – 2.67 (m, 
2H). 13C NMR (126 MHz, DMSO) δ 165.41, 141.99, 140.40, 137.15, 136.28, 134.29, 131.07, 
129.14 (3C), 128.60 (6C), 128.43 (2C), 128.34, 127.13, 126.71, 56.12, 51.95, 51.90, 29.35, 
27.75, 27.64. MS(ESI) m/z calcd. for C27H29N3 395.24, found 396.09 [M]+, 397.09 [M+1]+, 
398.10 [M+2]+, 399.11 [M+3]+. HPLC Method 2: 99.34%, tR = 2.31 min. 
6.2: Experimental Data for KGM01080, KGM01082, KGM02001, and KGM02004. 
6.2.1: Experimental Data for compounds in Figure 28. 
Naphthyltriphenylphosphonium bromide (22, KL[16]). 
Triphenylphosphine (23 g, 87.7 mmol) was dissolved in toluene (120 mL) and 2-
(bromomethyl)naphthalene 21 (19.4 g, 87.7 mmol) was added drop wise and set to reflux at 110 
˚C overnight. The precipitate was filtered and washed with toluene, and diethyl ether. The salt 
was further dried in vacuo, to provide 22 as a fine white powder (40.0 g, 82.8 mmol, 94.4%). 1H 
NMR (500 MHz, CDCl3) δ 7.67 – 7.59 (m, 10H), 7.53 – 7.47 (m, 6H), 7.44 – 7.40 (m, 3H), 
7.35 – 7.25 (m, 2H), 7.07 – 7.02 (m, 1H), 5.36 (d, JH, P = 14.5 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 134.85, 134.83 (2C), 134.16 (3C), 134.08 (3C), 132.65 (d, JC, P = 3.5 Hz), 132.38 (d, 
JC, P = 2.8 Hz), 130.96, 130.90, 130.01 (3C), 129.91 (3C), 128.30, 128.26, 128.19, 128.17, 
127.59, 127.58, 127.35, 127.33, 126.40, 126.39, 126.21, 124.26, 124.19, 117.74, 117.06, 30.75 
(d, JC, P = 46.9 Hz). MS(ESI) m/z calcd. for C29H24P+ 403.16, found 404.27 [M]+, 405.09 
[M+1]+, 406.22 [M+2]+. 
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4-(Naphthalen-2-ylmethylene)-1-phenethylpiperidine (23, KL[20]). 
Compound 22 (16.74 g, 34.62 mmol) was suspended in anhydrous THF (35 mL) under argon at -
78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (20.77 mL, 41.54 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (7.04 g, 34.62 mmol) in anhydrous THF (17 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H20, extracted with ethyl acetate, washed with brine, 
dried over Na2SO4, and concentrated in vacuo. The crude material was purified via flash column 
chromatography (7:3, hexane: ethyl acetate). Fractions were collected and concentrated in vacuo 
to provide 23 as a light yellow oil (5.45 g, 16.63 mmol, 48.0%). 1H NMR (500 MHz, CDCl3) δ 
7.85 – 7.80 (m, 3H), 7.67 (s, 1H), 7.51 – 7.44 (m, 2H), 7.39 – 7.35 (m, 1H), 7.35 – 7.29 (m, 2H), 
7.27 – 7.20 (m, 3H), 6.51 (s, 1H), 2.98 – 2.91 (m, 2H), 2.82 – 2.71 (m, 6H), 2.71 – 2.63 (m, 2H), 
2.61 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 135.14, 133.48 (2C), 132.15 (2C), 128.85 (2C), 
128.65 (2C), 127.89, 127.77, 127.73, 127.59, 127.49, 126.40, 126.22, 125.76, 60.33, 55.11, 
54.43, 35.96, 33.32, 28.79. MS(ESI) m/z calcd. for C24H25N 327.20, found 328.17 [M]+, 329.12 
[M+1]+, 330.19 [M+2]+, 331.26 [M+3]+. 
4-(Bromo(naphthalen-2-yl)methylene)-1-phenethylpiperidine (25, KL[21]). 
Compound 23 (3.22 g, 9.85 mmol) was dissolved in DCM (123 mL) under argon at-10 ˚C. Br2 
(0.76 mL, 14.77 mmol) diluted in DCM (40 mL) was added to the solution drop wise using an 
addition funnel and stirred -10 ˚C until the solution was fully added. The mixture was allowed to 
warm to room temperature until the complete conversion to the dibromo intermediate 24, which 
was determined by TLC. NaOH (2.36 g, 59.09 mmol) was dissolved in MeOH (98 mL) and was 
added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) until the full 
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conversion to the monobromo, determined via TLC. The reaction was quenched with H2O, 
extracted with DCM, washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
crude material was purified via flash column chromatography (7:3, hexane: ethyl acetate). 
Fractions were collected and concentrated in vacuo to provide 25 as a yellow oil that solidified 
upon standing (2.52 g, 6.20 mmol, 62.9%). 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.81 (m, 3H), 
7.76 (s, 1H), 7.54 – 7.48 (m, 2H), 7.48 – 7.43 (m, 1H), 7.34 – 7.28 (m, 2H), 7.27 – 7.18 (m, 3H), 
2.90 – 2.79 (m, 4H), 2.75 – 2.64 (m, 4H), 2.54 – 2.46 (m, 2H), 2.44 – 2.37 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 140.3, 137.7, 137.7, 133.0, 132.9, 128.8 (2C), 128.5 (2C), 128.4, 128.3, 
128.1, 127.8, 127.4, 126.7, 126.5, 126.2, 116.0, 60.2, 54.4, 54.1, 34.6, 33.8, 32.0. MS(ESI) m/z 
calcd. for C24H24BrN 405.11, found 405.97 [M], 407.92 [M+1]+, 408.93 [M+2]+, 410.06 [M+4]+. 
6.2.2: Experimental Data for compounds in Figure 29. 
3-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzonitrile (26, KGM01075) 
Under argon (g), a mixture of 25 (0.40 g, 0.98 mmol), 3-cyanophenylboronic acid (0.17 g, 1.18 
mmol) and K2CO3 (0.34 g, 2.46 mmol) in toluene (15 mL)/ethanol (5 mL) (3:1 ratio) were added 
to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (40 mg). The 
reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The reaction was 
cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, washed with 
brine, dried over Na2SO4 and concentrated in vacuo. The crude material was purified using an 
Isolera One Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. 
Fractions were collected and concentrated in vacuo to provide 26 as a light orange oil (0.32 g, 
0.75 mmol, 76.2%). 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 3H), 7.61 (s, 1H), 7.54 – 
7.47 (m, 4H), 7.46 – 7.38 (m, 2H), 7.34 – 7.29 (m, 2H), 7.26 – 7.20 (m, 4H), 2.91 – 2.85 (m, 
2H), 2.73 – 2.63 (m, 6H), 2.56 – 2.47 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 143.4, 140.1, 
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138.6, 137.8, 134.4, 134.1, 133.4, 133.2, 132.3, 130.2, 129.0, 128.7 (2C), 128.5, 128.5 (2C), 
128.0, 127.9, 127.9, 127.7, 126.3, 126.1, 126.1, 118.8, 112.3, 60.3, 55.0 (2C), 33.6, 31.7, 31.5. 
MS(ESI) m/z calcd. for C31H28N2 428.23, found 428.70 [M], 430.21 [M+1]+, 431.15 [M+2]+, 
432.22 [M+3]+. 
(Z)-N'-hydroxy-3-((1-phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzimidamide (27, 
KGM01077). 
A mixture of 26 (0.27 g, 0.64 mmol), hydroxylamine hydrochloride (0.19 g, 2.69 mmol), and 
sodium carbonate (1.02 g, 9.60 mmol) in ethanol (2.23 mL)/H20 (0.22 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was the 
further dried in vacuo to provide 27 as a white precipitate (0.24 g, 0.52 mmol, 80.3%). 1H NMR 
(500 MHz, MeOD) δ 7.84 – 7.76 (m, 3H), 7.67 (s, 1H), 7.58 – 7.51 (m, 2H), 7.48 – 7.43 (m, 
2H), 7.40 – 7.35 (m, 1H), 7.33 – 7.29 (m, 2H), 7.28 – 7.18 (m, 5H), 3.20 – 3.07 (m, 6H), 3.03 – 
2.96 (m, 2H), 2.67 – 2.58 (m, 4H). 13C NMR (126 MHz, MeOD) δ 155.37, 143.06, 139.89, 
139.62, 138.80, 134.69, 134.39, 133.85, 132.53, 132.01, 129.83 (2C), 129.76 (2C), 129.63, 
129.24, 129.00, 128.94, 128.64 (2C), 128.40, 127.93, 127.36, 127.17, 126.05, 59.79, 55.17, 
55.14, 32.40, 30.49 (2C). MS(ESI) m/z calcd. for C31H31N3O 461.25, found 461.76 [M], 463.08 
[M+1]+, 464.15 [M+2]+. 
3-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzimidamide dihydrochloride (13b, 
KGM01080) 
To a solution of 27 (0.24 g, 0.52 mmol), in acetic acid (2.93 mL), acetic anhydride (0.08 mL, 
0.81 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 28 was determined by LC/MS. 10% Pd/C (23.9 mg) was introduced to 
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the mixture and the reaction was hydrogenated at 25 psi for 36 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a tan oil. MeOH and ethyl acetate were 
used to remove excess acetic acid and provide a residue. The residue was treated with excess 2N 
HCl in diethyl ether. The HCl was evaporated in vacuo to provide 29 as a grayish-white solid 
(181.3 mg, 0.35 mmol, 67.6%). H NMR (500 MHz, DMSO) δ 11.67 (s, 1H), 9.56 (s, 2H), 9.36 
(s, 2H), 7.95 – 7.89 (m, 4H), 7.81 (d, J = 9.5 Hz, 3H), 7.36 – 7.31 (m, 4H), 7.30 – 7.23 (m, 5H), 
3.62 (d, J = 9.6 Hz, 3H), 3.32 – 3.26 (m, 3H), 3.23 – 3.08 (m, 6H). 13C NMR (126 MHz, 
DMSO) δ 165.43, 141.90, 137.87, 137.16, 136.27, 134.52, 132.78, 131.91, 131.59, 129.23, 
128.65 (2C), 128.53, 128.24, 127.97, 127.87 (2C), 127.53, 127.46, 126.76 (2C), 126.41, 126.25, 
56.17, 52.03, 51.96, 29.40, 27.87, 27.82. MS(ESI) m/z calcd. for C31H31N3 445.25, found 446.01 
[M]+, 447.02 [M+1]+, 448.16 [M+2]+. HPLC Method 2: 98.22%, tR = 2.48 min. 
6.2.3: Experimental Data for compounds in Figure 30. 
4-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzonitrile (30, KGM01073) 
Under argon (g), a mixture of 25 (0.41 g, 1.00 mmol), 4-cyanophenylboronic acid (0.18 g, 1.20 
mmol) and K2CO3 (0.35 g, 2.50 mmol) in toluene (15 mL)/ethanol (5 mL) (3:1 ratio) were added 
to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (40.7 mg). 
The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The reaction 
was cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, washed 
with brine, dried over Na2SO4 and concentrated in vacuo. The crude material was purified using 
an Isolera One Biotagé system under gradient conditions with hexane and ethyl acetate as 
eluents. Fractions were collected and concentrated in vacuo to provide 30 as a yellow wax (0.28 
g, 0.66 mmol, 66.3%). 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.67 (m, 3H), 7.51 – 7.47 (m, 3H), 
7.42 – 7.34 (m, 2H), 7.23 – 7.17 (m, 4H), 7.14 – 7.06 (m, 4H), 2.77 (dd, J = 10.0, 6.2 Hz, 2H), 
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2.62 – 2.53 (m, 6H), 2.42 (dt, J = 10.7, 5.6 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 147.1, 
140.0, 138.6, 137.9, 134.7, 133.2, 132.3, 131.9 (2C), 130.7 (2C), 128.7 (2C), 128.6, 128.5 (2C), 
128.0 (2C), 127.9, 127.7, 126.3, 126.2, 126.1, 119.0, 110.2, 60.2, 55.0 (2C), 33.6, 31.7, 31.5. 
MS(ESI) m/z calcd. for C31H28N2 428.23, found 428.70 [M], 430.40 [M+1]+, 431.15 [M+2]+, 
432.22 [M+3]+. 
(Z)-N'-hydroxy-4-((1-phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzimidamide (31, 
KGM01076). 
A mixture of 30 (0.24 g, 0.55 mmol), hydroxylamine hydrochloride (0.16 g, 2.31 mmol), and 
sodium carbonate (0.11 g, 1.06 mmol) in ethanol (1.91 mL)/H20 (0.19 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was the 
further dried in vacuo to provide 31 as a white precipitate (0.19 g, 0.41 mmol, 75.0%). 1H NMR 
(400 MHz, DMSO) δ 9.79 (s, 1H), 7.89 (d, J = 8.2 Hz, 3H), 7.73 (s, 1H), 7.68 (d, J = 8.2 Hz, 
2H), 7.54 – 7.49 (m, 2H), 7.36 – 7.30 (m, 2H), 7.30 – 7.19 (m, 6H), 6.08 (s, 2H), 3.31 – 3.23 (m, 
4H), 3.17 – 3.05 (m, 4H), 2.74 – 2.58 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 143.11, 143.09, 
143.07, 143.05, 138.76, 138.01, 136.33, 133.15, 132.43, 129.88, 129.03 (3C), 128.85 (3C), 
128.28, 128.18, 128.04, 127.79, 127.46, 127.30, 126.62, 126.45, 126.33, 77.41, 58.27, 58.26, 
34.26, 30.50, 30.49, 29.82. MS(ESI) m/z calcd. for C31H31N3O 461.25, found 462.07 [M]+, 
463.08 [M+1]+, 464.15 [M+2]+.  
4-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)benzimidamide dihydrochloride (33, 
KGM01082) 
To a solution of 31 (0.15 g, 0.37 mmol), in acetic acid (1.85 mL), acetic anhydride (0.05 mL, 
0.51 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
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acetylated intermediate 32 was determined by LC/MS. 10% Pd/C (15.1 mg) was introduced to 
the mixture and the reaction was hydrogenated at 25 psi for 60 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a brown oil. MeOH and ethyl acetate 
were used to remove excess acetic acid and provide a residue. The residue was treated with 
excess 2N HCl in diethyl ether. The HCl was evaporated in vacuo to provide the crude. Further 
purification utilized a Combiflash RF system with a basic alumina column with DCM and 2M 
ammonia in MeOH as eluents. Fractions were collected, concentrated in vacuo, treated with 4N 
HCl in 1,4-dioxane, and re-concentrated in vacuo to provide 33 as a light tan solid (43.3 mg, 0.08 
mmol, 22.6%). 1H NMR (500 MHz, MeOD) δ 7.86 – 7.80 (m, 5H), 7.72 (s, 1H), 7.50 (t, J = 7.9 
Hz, 4H), 7.35 – 7.30 (m, 4H), 7.27 (d, J = 7.7 Hz, 2H), 3.74 (t, J = 11.8 Hz, 2H), 3.43 – 3.38 (m, 
2H), 3.24 (q, J = 11.6 Hz, 2H), 3.16 – 3.10 (m, 2H), 2.90 – 2.66 (m, 4H). 13C NMR (126 MHz, 
MeOD) δ 168.07, 148.46, 139.64, 138.95, 137.60, 134.70, 134.02, 131.89, 131.63 (2C), 129.98 
(2C), 129.85 (2C), 129.47, 129.39, 129.24 (2C), 128.97, 128.70, 128.29 (2C), 128.25, 127.62, 
127.52, 58.94, 54.46 (2C), 31.48, 29.71, 29.58. MS(ESI) m/z calcd. for C31H31N3 445.25, found 
446.01 [M]+, 447.09 [M+1]+, 448.16 [M+2]+. HPLC Method 2: 96.99%, tR = 2.58 min. 
6.2.4: Experimental Data for compounds in Figure 31. 
3-(Naphthalen-2-yl(1-phenethylpiperidin-4-ylidene)methyl)aniline (34, KL[22]). 
Under argon (g), a mixture of compound 25 (0.68 g, 1.67 mmol), 3-aminophenylboronic acid 
hydrochloride (0.35 g, 2.00 mmol) and K2CO3 (0.58 g, 4.17 mmol) in toluene (24 mL)/ethanol (8 
mL) (3:1 ratio) were added to the reaction vessel. The mixture was degassed prior to the addition 
of Pd(PPh3)4 (67.8 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, extracted with 
ethyl acetate, washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude 
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material was purified via flash column chromatography (3:7, ethyl acetate:diethyl ether). 
Fractions were collected and concentrated in vacuo to provide 34 as a dark orange solid (0.48 g, 
1.14 mmol, 68.0%). 1H NMR (500 MHz, CDCl3) δ 7.88 – 7.73 (m, 3H), 7.66 (s, 1H), 7.48 (s, 
2H), 7.40 – 7.18 (m, 6H), 7.18 – 7.08 (m, 1H), 6.66 (d, J = 6.8 Hz, 1H), 6.58 (d, J = 6.8 Hz, 1H), 
6.52 (s, 1H), 3.96 – 3.55 (m, 2H), 2.98 – 2.82 (m, 2H), 2.69 (d, J = 14.1 Hz, 6H), 2.63 – 2.57 (m, 
2H), 2.57 – 2.46 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 146.21, 143.40, 140.22, 139.91, 
136.31, 135.19, 133.29, 132.19, 128.98, 128.80 (2C), 128.53 (2C), 128.42, 128.21, 127.98, 
127.68, 127.58, 126.21, 126.05, 125.73, 120.50, 116.76, 113.50, 60.43, 55.34, 55.25, 33.59, 
31.60, 31.52. MS(ESI) m/z calcd. for C30H30N2 418.24, found 419.29 [M]+, 420.66 [M+1]+. 
(Z)-1,3-bis(tert-butoxycarbonyl)-3-(4-(naphthalen-2-yl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (35, KL[23]). 
Triethylamine (0.20 mL, 1.46 mmol) was added drop wise to a suspension of compound 34 (0.20 
g, 0.49 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.16 g, 0.54 mmol), HgCl2 
(0.15 g, 0.54 mmol) in DCM (15 mL). The mixture was stirred for 72 hours at room temperature 
then filtered through Celite® and the filtrate was concentrated in vacuo. The crude material was 
purified using flash column chromatography (3:7, hexane:diethyl ether). Fractions were collected 
and concentrated in vacuo to provide 35 as a white solid (0.11 g, 0.16 mmol, 32.7%). 1H NMR 
(400 MHz, CDCl3) δ 11.53 (s, 1H), 10.16 (s, 1H), 7.74 – 7.66 (m, 3H), 7.56 – 7.51 (m, 2H), 
7.38 (td, J = 6.7, 6.0, 3.6 Hz, 2H), 7.24 – 7.18 (m, 4H), 7.12 (d, J = 7.6 Hz, 4H), 6.85 (d, J = 7.7 
Hz, 1H), 2.86 – 2.80 (m, 2H), 2.69 – 2.56 (m, 6H), 2.56 – 2.45 (m, 4H), 1.44 (s, 9H), 1.42 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 152.5, 141.6, 138.7, 138.7, 138.4, 138.4, 138.4, 135.5, 
132.2, 131.1, 127.7, 127.5, 127.3, 127.2, 126.9, 126.6, 125.5, 125.2, 125.0, 124.7, 122.7, 119.9, 
82.7, 78.5, 59.1, 53.9, 32.3, 30.2, 27.2, 27.1. MS(ESI) m/z calcd. for C41H48N4O4 660.37, found 
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661.21 [M]+, 662.15 [M+1]+, 663.29 [M+2]+, 664.29 [M+3]+, 561.15 [M-Boc]+, 461.07 [M-
2Boc]+. 
1-(3-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)phenyl)guanidine dihydrochloride 
(36, KGM02001). 
Compound 35 (0.15 g, 0.23 mmol) was dissolved in MeOH (3.5 mL). 2N HCl in diethyl ether (5 
mL) was added to the reaction vessel and the reaction was left to stir for 72 hr at room 
temperature. The reaction was concentrated in vacuo to provide 36 as a light yellow solid (0.20 
g, 0.37 mmol, +99.9%). 1H NMR (500 MHz, DMSO) δ 11.65 (s, 1H), 10.46 (s, 2H), 7.90 – 7.79 
(m, 2H), 7.76 – 7.63 (m, 3H), 7.62 – 7.54 (m, 2H), 7.52 – 7.44 (m, 2H), 7.41 – 7.32 (m, 1H), 
7.32 – 7.14 (m, 4H), 7.14 – 7.05 (m, 1H), 7.05 – 6.91 (m, 1H), 3.30 – 2.97 (m, 6H), 2.77 – 2.60 
(m, 2H), 2.59 – 2.40 (m, 4H). 13C NMR (126 MHz, DMSO) δ 156.23, 142.34, 138.12, 137.13, 
136.59, 135.27, 132.62, 131.71, 130.83, 129.70, 128.64 (2C), 128.60 (2C), 127.83 (2C), 127.72, 
127.52, 127.49, 127.18, 126.70, 126.33, 126.14, 124.55, 123.67, 122.46, 56.15, 52.05, 51.96, 
29.30, 27.90, 27.76. MS(ESI) m/z calcd. for C31H32N4 460.26, found 461.13 [M]+, 462.14 
[M+1]+, 463.21 [M+2]+. HPLC Method 2: 96.96%, tR = 2.44 min. 
6.2.5: Experimental Data for compounds in Figure 32. 
4-(Naphthalen-2-yl(4-nitrophenyl)methylene)-1-phenethylpiperidine (37, KL[27]). 
Under argon (g), a mixture of compound 25 (0.43 g, 1.07 mmol), 4-nitrophenylboronic acid 
(0.21 g, 1.28 mmol) and K2CO3 (0.37 g, 2.67 mmol) in toluene (15 mL)/ethanol (5 mL) (3:1 
ratio) were added to the reaction vessel. The mixture was degassed prior to the addition of 
Pd(PPh3)4 (43.4 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, extracted with 
ethyl acetate, washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude 
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material was purified via flash column chromatography (7:3; hexane: ethyl acetate). Fractions 
were collected and concentrated in vacuo to provide 37 as a dark orange oil (0.32 g, 0.71 mmol, 
66.5%). 1H NMR (400 MHz, CDCl3) δ 8.10 – 8.07 (m, 2H), 7.77 – 7.66 (m, 3H), 7.51 (s, 1H), 
7.44 – 7.38 (m, 2H), 7.31 – 7.26 (m, 2H), 7.24 – 7.19 (m, 2H), 7.15 – 7.08 (m, 4H), 2.89 – 2.81 
(m, 2H), 2.74 – 2.63 (m, 6H), 2.57 – 2.46 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 148.8, 146.5 
(2C), 145.8, 138.2, 133.2 (2C), 132.3, 130.7 (2C), 128.7, 128.6 (2C), 128.6 (2C), 128.1, 127.9, 
127.7, 127.7, 126.4, 126.4, 126.2, 123.5 (2C), 59.9 (2C), 54.7 (2C), 33.0, 31.0.  
4-(Naphthalen-2-yl(1-phenethylpiperidin-4-ylidene)methyl)aniline (38, KL[28]). 
Compound 37 (0.32 g, 0.71 mmol), was dissolved in MeOH (30 mL). 10% Pd/C (31.9 mg) was 
added to the reaction vessel and the reaction was hydrogenated at 40 psi for 4 hours. The reaction 
was filtered through Celite® and the filtrate was concentrated in vacuo, to provide 38 as a 
yellow-orange solid (0.29 g, 0.68, 96.0%). 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.65 (m, 3H), 
7.51 (s, 1H), 7.40 – 7.34 (m, 2H), 7.24 – 7.17 (m, 3H), 7.16 – 7.06 (m, 5H), 6.86 (d, J = 8.3 Hz, 
1H), 6.53 (d, J = 8.3 Hz, 1H), 2.88 – 2.75 (m, 2H), 2.69 – 2.56 (m, 6H), 2.51 – 2.32 (m, 4H). 13C 
NMR (101 MHz, CDCl3) δ 145.11, 140.81, 140.27, 133.29, 132.37, 132.25, 132.22, 131.09, 
128.83 (3C), 128.65 (3C), 128.29, 127.99 (2C), 127.71 (2C), 126.09, 125.76, 123.56, 114.76, 
112.79, 60.32, 60.12, 55.07, 33.05, 31.16, 29.83. MS(ESI) m/z calcd. for C30H30N2 418.24, 
found 419.13 [M]+, 420.14 [M+1]+. 
(Z)-1,3-bis(tert-butoxycarbonyl)-4-(4-(naphthalen-2-yl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (39, KL[29]). 
Triethylamine (0.27 mL, 1.94 mmol) was added drop wise to a suspension of compound 38 (0.27 
g, 0.65 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.21 g, 0.71 mmol), HgCl2 
(0.19 g, 0.71 mmol) in DCM (20 mL). The mixture was stirred for 72 hours at room temperature 
 176 
then filtered through Celite® and the filtrate was concentrated in vacuo. The crude material was 
purified using flash column chromatography (3:7, ethyl acetate:methylene chloride) and with an 
Isolera One Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. 
Fractions were collected and concentrated in vacuo to provide 39 as a light orange solid (80 mg, 
0.12 mmol, 18.7%). 1H NMR (500 MHz, CDCl3) δ 11.65 (s, 1H), 10.35 (s, 1H), 7.84 – 7.77 (m, 
3H), 7.61 (s, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.50 – 7.47 (m, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.28 (s, 
1H), 7.25 (d, J = 7.3 Hz, 3H), 7.13 (d, J = 8.3 Hz, 2H), 3.09 – 3.02 (m, 2H), 2.95 – 2.82 (m, 5H), 
2.80 – 2.67 (m, 5H), 1.55 (s, 9H), 1.52 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.61, 153.56 
(3C), 153.40 (2C), 135.67 (2C), 133.27 (3C), 132.36 (2C), 130.47 (2C), 128.84 (2C), 128.80 
(2C), 128.47, 128.24, 128.06, 127.84, 127.74, 126.72, 126.28, 126.03, 121.92 (2C), 83.92 (2C), 
79.83, 59.78, 54.85 (2C), 28.31 (9C), 28.20 (9C). MS(ESI) m/z calcd. for C41H48N4O4 660.37, 
found 661.21 [M]+, 662.28 [M+1]+, 663.29 [M+2]+, 561.15 [M-Boc]+, 461.07 [M-2Boc]+. 
1-(4-((1-Phenethylpiperidin-4-ylidene)(naphthyl)methyl)phenyl)guanidine dihydrochloride 
(40, KGM02004). 
Compound 39 (75.4 mg, 0.11 mmol) was dissolved in diethyl ether (1 mL) and DCM (1 mL). 2N 
HCl in diethyl ether (7 mL) was added to the reaction vessel and the reaction was left to stir for 
48 hr at room temperature. The reaction was concentrated in vacuo to provide 40 as a orange-
beige solid (60 mg, 0.11 mmol, 98.6%). 1H NMR (400 MHz, DMSO) δ 11.50 (s, 1H), 10.26 (s, 
1H), 7.99 – 7.93 (m, 3H), 7.80 (s, 1H), 7.69 – 7.63 (m, 3H), 7.60 – 7.55 (m, 2H), 7.43 – 7.38 (m, 
2H), 7.37 – 7.25 (m, 9H), 3.74 – 3.65 (m, 2H), 3.54 – 3.44 (m, 4H), 3.23 – 3.12 (m, 4H), 2.81 – 
2.74 (m, 2H). 13C NMR (101 MHz, DMSO) δ 155.91, 138.76, 138.35, 137.08, 136.85, 134.05, 
132.70 (2C), 131.77, 130.48, 128.59 (2C), 128.58 (2C), 127.81, 127.75, 127.64, 127.47, 127.45, 
126.71, 126.31, 126.10, 123.92 (2C), 56.13, 52.09, 52.00, 29.36, 27.93, 27.75. MS(ESI) m/z 
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calcd. for C31H32N4 460.26, found 461.07 [M]+, 462.07 [M+1]+, 463.27 [M+2]+. HPLC Method 
2: 99.24%, tR = 2.47 min. 
6.3: Experimental Data for KGM01098, KGM02002, KGM02008, and KGM02009. 
6.3.1: Experimental Data for compounds in Figure 33. 
(4-Chlorobenzyl)triphenylphosphonium bromide (42, KGM01088). 
Triphenylphosphine (3.19 g, 12.17 mmol) was dissolved in toluene (17 mL) and 4-chlorobenzyl 
bromide 41 (2.50 g, 12.17 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 42 as a fine white powder (5.52 g, 11.80 mmol, 97.0%). 1H NMR 
(500 MHz, CDCl3) δ 7.73 – 7.66 (m, 9H), 7.57 – 7.51 (m, 6H), 7.08 – 7.03 (m, 2H), 6.99 – 6.94 
(m, 2H), 5.49 (d, JH, P = 14.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 135.06, 135.03 (2C), 
134.62 (3C), 134.54 (3C), 134.47, 133.16, 133.12, 130.27 (3C), 130.17 (3C), 128.90, 128.87, 
126.12, 126.05, 118.08, 117.39, 29.92 (d, JC, P = 47.1 Hz). MS(ESI) m/z calcd. for C25H21ClP+ 
387.11, found 388.91 [M]+, 389.92 [M+1]+, 391.05 [M+3]+.  
4-(4-Chlorobenzylidene)-1-phenethylpiperidine (43, KGM01089). 
Compound 42 (5.41 g, 11.57 mmol) was suspended in anhydrous THF (12 mL) under argon at -
78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (6.95 mL, 13.88 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (2.35 g, 11.57 mmol) in anhydrous THF (6 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified via flash column chromatography (5:5, 
hexane: ethyl acetate). Fractions were collected and concentrated in vacuo to provide 43 as a 
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light yellow-orange oil that solidified upon standing (1.97 g, 6.32 mmol, 54.6%). 1H NMR (500 
MHz, CDCl3) δ 7.23 – 7.17 (m, 4H), 7.15 – 7.10 (m, 3H), 7.06 – 7.03 (m, 2H), 6.16 (s, 1H), 
2.80 – 2.75 (m, 2H), 2.60 – 2.54 (m, 4H), 2.46 (s, 4H), 2.40 – 2.35 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 140.29, 136.22, 131.97, 130.33 (2C), 128.81 (2C), 128.54 (2C), 128.38 (2C), 
126.22, 122.42, 110.09, 60.50, 55.14, 54.46, 36.33, 33.74, 29.06. MS(ESI) m/z calcd. for 
C20H22ClN 311.14, found 312.00 [M]+, 313.95 [M+1]+, 315.02 [M+2]+, 316.16 [M+3]+. 
4-(Bromo(4-chlorophenyl)methylene)-1-phenethylpiperidine (45, KGM01090). 
Compound 43 (1.91 g, 6.11 mmol) was dissolved in DCM (76 mL) under argon at -10 ˚C. Br2 
(0.47 mL, 9.16 mmol) diluted in DCM (25 mL) was added to the solution drop wise using an 
addition funnel and stirred -10 ˚C until the solution was fully added. The mixture was allowed to 
warm to room temperature until the complete conversion to the dibromo intermediate 44, which 
was determined by TLC. NaOH (1.47 g, 36.65 mmol) was dissolved in MeOH (61 mL) and was 
added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) until the full 
conversion to the monobromo, determined via TLC. The reaction was quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified via flash column chromatography (7:3, hexane: ethyl acetate). Fractions were collected 
and concentrated in vacuo to provide 45 as a light-orange oil that solidified upon standing (1.51 
g, 3.84 mmol, 63.3%) and was used directly in the next reaction without full characterization. 
MS(ESI) m/z calcd. for C20H21BrClN 389.05, found 389.48 [M], 390.86 [M]+, 393.82 [M+3]+, 
394.89 [M+4]+, 395.96 [M+5]+. 
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6.3.2: Experimental Data for compounds in Figure 34. 
3-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (49, KGM01094). 
Under argon (g), a mixture of 45 (0.40 g, 1.02 mmol), 3-cyanophenylboronic acid (0.18 g, 1.23 
mmol) and K2CO3 (0.35 g, 2.56 mmol) in toluene (15 mL)/ethanol (5 mL) (3:1 ratio) were added 
to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (40 mg). The 
reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The reaction was 
cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, washed with 
brine, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using an 
Isolera One Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. 
Fractions were collected and concentrated in vacuo to provide 46 as a yellow wax (0.41 g, 0.99 
mmol, 97.1%). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.7 Hz, 1H), 7.36 – 7.31 (m, 2H), 
7.27 (d, J = 7.8 Hz, 1H), 7.24 – 7.19 (m, 4H), 7.16 – 7.11 (m, 3H), 6.97 – 6.93 (m, 2H), 2.82 – 
2.76 (m, 2H), 2.64 – 2.51 (m, 6H), 2.41 – 2.36 (m, 2H), 2.36 – 2.30 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 143.16, 139.64, 134.37, 133.37, 133.13, 131.24 (2C), 130.45, 129.22, 128.81 
(3C), 128.73 (3C), 128.61 (3C), 126.34, 118.85, 112.58, 60.31, 55.11, 55.04, 33.65, 31.61, 31.58. 
MS(ESI) m/z calcd. for C27H25ClN2 412.17, found 412.64 [M], 414.97 [M+1]+, 415.98 [M+2]+. 
(Z)-3-((4-chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-hydroxybenzimidamide 
(47, KGM01096). 
A mixture of 46 (0.39 g, 0.96 mmol), hydroxylamine hydrochloride (0.25 g, 3.53 mmol), and 
sodium carbonate (0.17 g, 1.62 mmol) in ethanol (3 mL)/H20 (0.3 mL) (10:1 ratio) were refluxed 
at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo leaving 
a residue. The residue was triturated in H2O and filtered again. The precipitate was further dried 
in vacuo to provide 47 as a white powder (0.31 g, 0.70 mmol, 73.5%). 1H NMR (500 MHz, 
 180 
DMSO) δ 9.63 (s, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.43 (s, 1H), 7.38 (d, J = 8.2 Hz, 2H), 7.33 (t, J 
= 7.7 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.22 (d, J = 7.2 Hz, 2H), 7.18 (d, J = 7.2 Hz, 1H), 7.12 (t, J = 
8.2 Hz, 3H), 2.77 – 2.72 (m, 2H), 2.58 – 2.49 (m, 6H), 2.28 (s, 4H). 13C NMR (126 MHz, 
DMSO) δ 150.63, 141.42, 140.68, 133.32, 131.24 (2C), 131.16, 129.89, 128.60 (3C), 128.20 
(4C), 128.17 (2C), 128.01, 126.40, 125.80, 123.67, 59.54, 59.49, 54.40, 32.84, 31.27, 31.16. 
MS(ESI) m/z calcd. for C27H28ClN3O 445.19, found 446.01 [M]+, 447.90 [M+1]+, 449.10 
[M+3]+, 450.17 [M+4]+. HPLC Method 2: 98.87%, tR = 2.48 min. 
3-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (49, KGM01098) 
To a solution of 47 (0.21 g, 0.47 mmol), in acetic acid (2.35 mL), acetic anhydride (0.06 mL, 
0.65 mmol) was added drop wise and the reaction was left to stir at room temperature for 3 
hours, until the acetylated intermediate 48 was determined by LC/MS. 10% Pd/C (21 mg) was 
introduced to the mixture and the reaction was hydrogenated at 25 psi for 36 hours. The mixture 
was filtered through Celite® and the filtrate was evaporated to give a tan oil. MeOH was used to 
remove excess acetic acid and provide a residue, which was treated with excess 2N HCl in 
diethyl ether. The HCl was evaporated in vacuo to provide 49 as a pale-yellow solid (0.26 g, 0.52 
mmol, +99.9%). 1H NMR (500 MHz, DMSO) δ 11.74 (s, 1H), 9.63 (s, 2H), 9.43 (s, 2H), 7.81 
(s, 2H), 7.59 – 7.55 (m, 1H), 7.47 – 7.39 (m, 3H), 7.35 – 7.29 (m, 3H), 7.27 – 7.23 (m, 4H), 3.62 
– 3.52 (m, 3H), 3.50 – 3.39 (m, 5H), 3.28 – 3.23 (m, 2H), 2.75 – 2.67 (m, 2H). 13C NMR (126 
MHz, DMSO) δ 165.31, 141.52, 139.16, 137.11, 134.97, 134.30, 131.87, 131.82, 131.07 (2C), 
129.20, 129.11, 128.58 (4C), 128.42 (2C), 128.04, 126.68 (2C), 56.09, 51.80, 48.50, 29.31, 
27.75, 27.60. MS(ESI) m/z calcd. for C27H28ClN3 429.20, found 430.02 [M]+, 431.97 [M+1]+, 
433.04 [M+3]+, 433.99 [M+3]+. HPLC Method 2: 98.06%, tR = 2.35 min. 
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6.3.3: Experimental Data for compounds in Figure 35. 
3-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (50, KGM01093). 
Under argon (g), a mixture of 45 (0.42 g, 1.06 mmol), 3-cyanophenylboronic acid (0.22 g, 1.28 
mmol) and K2CO3 (0.37 g, 2.66 mmol) in toluene (15 mL)/ethanol (5 mL) (3:1 ratio) were added 
to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (42 mg). The 
reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The reaction was 
cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, washed with 
brine, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using an 
Isolera One Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. 
Fractions were collected and concentrated in vacuo to provide 50 as an orange wax (0.38 g, 0.95 
mmol, 88.9%). 1H NMR (500 MHz, CDCl3) δ 7.24 – 7.17 (m, 3H), 7.17 (s, 1H), 7.15 – 7.11 (m, 
3H), 7.03 – 6.96 (m, 3H), 6.50 – 6.46 (m, 1H), 6.46 – 6.42 (m, 1H), 6.32 (s, 1H), 3.53 (s, 2H), 
2.86 – 2.78 (m, 2H), 2.68 – 2.53 (m, 6H), 2.43 (s, 2H), 2.39 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 146.33, 143.04, 140.72, 132.40, 131.14 (2C), 129.16, 128.83 (3C), 128.63 (3C), 
128.34 (3C), 126.37, 120.27, 116.48, 113.69, 60.53, 60.33, 55.22, 55.14, 21.19, 14.34. MS(ESI) 
m/z calcd. for C26H27ClN2 402.19, found 403.01 [M]+, 404.90 [M+1]+, 406.10 [M+3]+, 407.10 
[M+4]+. 
(Z)-1,3-bis(tert-butoxycarbonyl)-3-((4-chloro(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (51, KGM01097). 
Triethylamine (0.25 mL, 1.82 mmol) was added drop wise to a suspension of compound 50 (0.37 
g, 0.91 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.29 g, 1.00 mmol), HgCl2 
(0.27 g, 1.00 mmol) in DCM (12.9 mL).The mixture was stirred for 72 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
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material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 51 as 
a white solid (0.34 g, 0.53 mmol, 57.9%). 1H NMR (500 MHz, CDCl3) δ 11.53 (s, 1H), 10.16 
(s, 1H), 7.52 – 7.48 (m, 1H), 7.22 – 7.20 (m, 1H), 7.20 – 7.17 (m, 4H), 7.15 (s, 1H), 7.13 (d, J = 
7.4 Hz, 3H), 7.00 – 6.97 (m, 2H), 6.77 (d, J = 7.6 Hz, 1H), 2.82 – 2.76 (m, 2H), 2.63 – 2.51 (m, 
6H), 2.44 – 2.39 (m, 2H), 2.38 – 2.34 (m, 2H), 1.45 (s, 9H), 1.43 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 163.65, 153.67, 153.43, 142.50, 140.59, 136.70, 134.61, 132.48, 131.27 (2C), 128.83 
(4C), 128.57 (3C), 128.39 (3C), 126.43, 126.26, 123.72, 120.98, 83.88, 79.69, 60.46, 55.32, 
55.16, 33.70, 33.64, 31.53, 28.37 (3C), 28.22 (3C). MS(ESI) m/z calcd. for C37H45ClN4O2 
644.31, found 645.14 [M]+, 647.09 [M+2]+, 545.09 [M-Boc]+, 445.01 [M-2Boc]+. 
1-(3-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (52, KGM02002). 
Compound 51 (0.32 g, 0.49 mmol) was dissolved in MeOH (8 mL). 2N HCl in diethyl ether (8 
mL) was added to the reaction vessel and the reaction was left to stir for 48 hr at room 
temperature. The reaction was concentrated in vacuo. Extraction was performed with DCM and 
H2O and the aqueous layer was concentrated in vacuo to provide 52 as a pale yellow-white solid 
(0.12 g, 0.23 mmol, 47.1%). 1H NMR (500 MHz, DMSO) δ 11.70 (s, 1H), 10.40 (s, 1H), 7.69 
(s, 2H), 7.33 – 7.29 (m, 3H), 7.24 – 7.20 (m, 2H), 7.18 – 7.10 (m, 5H), 7.06 – 7.03 (m, 1H), 6.93 
– 6.89 (m, 2H), 3.50 – 3.43 (m, 2H), 3.17 – 3.12 (m, 2H), 3.06 – 2.98 (m, 4H), 2.66 – 2.46 (m, 
4H). 13C NMR (126 MHz, DMSO) δ 156.41, 142.21, 139.61, 137.27, 135.54, 135.49, 131.76, 
131.34, 131.20 (2C), 129.78, 128.65 (4C), 128.41 (2C), 127.10, 126.74, 124.66, 122.74, 56.13, 
51.92, 51.85, 29.38, 27.80, 27.74. MS(ESI) m/z calcd. for C27H29ClN4 444.21, found 445.01 
[M]+, 447.02 [M+2]+, 448.09 [M+3]+. HPLC Method 2: 96.91%, tR = 2.45 min. 
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6.3.4: Experimental Data for compounds in Figure 36. 
4-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (53, KGM01100). 
Under argon (g), a mixture of 45 (0.43 g, 1.11 mmol), 4-cyanophenylboronic acid (0.20 g, 1.33 
mmol) and K2CO3 (0.38 g, 2.78 mmol) in toluene (16.5 mL)/ethanol (5.5 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (44 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 53 as a light-orange wax (0.43 g, 1.04 
mmol, 93.8%). 1H NMR (500 MHz, CDCl3) δ 7.50 – 7.46 (m, 2H), 7.21 – 7.17 (m, 4H), 7.14 – 
7.08 (m, 5H), 6.95 – 6.91 (m, 2H), 2.77 – 2.72 (m, 2H), 2.59 – 2.54 (m, 2H), 2.54 – 2.49 (m, 
4H), 2.36 – 2.30 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 146.76, 140.16, 139.60, 138.49, 
133.51, 132.97, 132.03 (2C), 131.25 (2C), 130.65 (2C), 128.72 (2C), 128.59 (2C), 128.48 (2C), 
126.18, 118.90, 110.42, 60.29, 55.01 (2C), 33.72, 31.73, 31.68. MS(ESI) m/z calcd. for 
C27H25ClN2 412.17, found 412.64 [M], 415.98 [M+2]+, 417.11 [M+4]+, 418.18 [M+5]+. 
(Z)-4-((4-chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-hydroxybenzimidamide 
(54, KGM02005). 
A mixture of 53 (0.32 g, 0.78 mmol), hydroxylamine hydrochloride (0.20 g, 2.87 mmol), and 
sodium carbonate (0.14 g, 1.32 mmol) in ethanol (2.4 mL)/H20 (0.24 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 54 as a pale yellow solid (0.30 g, 0.67 mmol, 86.1%). 1H NMR 
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(500 MHz, CDCl3) δ 7.46 (d, J = 7.8 Hz, 2H), 7.20 – 7.14 (m, 4H), 7.14 – 7.08 (m, 3H), 7.02 (d, 
J = 7.9 Hz, 2H), 6.97 – 6.91 (m, 2H), 4.81 (s, 2H), 2.86 – 2.76 (m, 2H), 2.64 – 2.51 (m, 6H), 
2.45 – 2.35 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 152.18, 143.48, 140.33, 139.90, 136.23, 
134.62, 132.58, 131.24 (2C), 131.04, 130.09 (2C), 128.78 (2C), 128.54 (2C), 128.40 (2C), 
126.27, 125.67 (2C), 60.22, 54.98 (2C), 33.30, 31.20 (2C). MS(ESI) m/z calcd. for C27H28ClN3O 
445.19, found 446.01 [M]+, 447.97 [M+1]+, 449.10 [M+3]+. HPLC Method 2: 97.24%, tR = 
2.38 min. 
4-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (56, KGM02008) 
To a solution of 54 (0.22 g, 0.50 mmol), in acetic acid (2.5 mL), acetic anhydride (0.07 mL, 0.70 
mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 55 was determined by LC/MS. 10% Pd/C (22.3 mg) was introduced to 
the mixture and the reaction was stirred under hydrogen for 84 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a brown oil. The residue was dissolved in 
MeOH and treated with excess 2N HCl in diethyl ether. The excess solvent was evaporated in 
vacuo to provide the crude. Extraction was performed using DCM and H2O; the aqueous layer 
was concentrated in vacuo and purification using a Combiflash RF with a basic alumina column 
with DCM and 2M ammonia in MeOH eluents was utilized. Fractions were collected, 
concentrated in vacuo, treated with 4N HCl in 1,4-dioxane, and re-concentrated in vacuo to 
provide 56 as a light beige solid (44.2 mg, 0.09 mmol, 17.7%). 1H NMR (500 MHz, MeOD) δ 
7.97 – 7.95 (m, 1H), 7.82 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 
7.33 – 7.32 (m, 3H), 7.27 – 7.24 (m, 1H), 7.20 (d, J = 8.2 Hz, 2H), 3.75 – 3.69 (m, 2H), 3.40 (dd, 
J = 10.3, 6.6 Hz, 2H), 3.26 – 3.18 (m, 2H), 3.15 (dd, J = 10.3, 6.6 Hz, 2H), 2.80 – 2.67 (m, 4H). 
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13C NMR (126 MHz, MeOD) δ 168.01, 148.12, 138.35, 137.67, 134.63, 132.73, 132.39, 
132.18, 131.52, 131.29, 130.05, 129.94 (2C), 129.86 (2C), 129.82 (2C), 129.35, 129.29, 128.33, 
128.24, 58.91, 54.30, 54.28, 31.46, 29.54, 29.51. MS(ESI) m/z calcd. for C27H28ClN3 429.20, 
found 430.02 [M]+, 431.97 [M+1]+, 433.11 [M+3]+. HPLC Method 3: 99.38%, tR = 2.37 min. 
6.3.5: Experimental Data for compounds in Figure 37. 
4-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (57, KGM01099). 
Under argon (g), a mixture of compound 45 (0.45 g, 1.15 mmol), 4-aminophenylboronic acid 
(0.24 g, 1.38 mmol) and K2CO3 (0.40 g, 2.88 mmol) in toluene (3 mL)/ethanol (2 mL)/H2O 
(2mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (45 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using an Isolera One Biotagé system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 57 as a dark 
brown wax (0.37 g, 0.92 mmol, 79.8%). 1H NMR (500 MHz, CDCl3) δ 7.23 – 7.19 (m, 2H), 
7.18 – 7.15 (m, 2H), 7.14 – 7.11 (m, 3H), 6.98 – 6.95 (m, 2H), 6.81 – 6.77 (m, 2H), 6.54 – 6.51 
(m, 2H), 3.57 (s, 2H), 2.84 – 2.79 (m, 2H), 2.64 – 2.55 (m, 6H), 2.45 (t, J = 5.4 Hz, 2H), 2.37 (t, 
J = 5.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 145.16 (2C), 141.35 (2C), 132.23 (2C), 132.19, 
131.30 (2C), 130.94 (2C), 128.81 (2C), 128.61 (2C), 128.24 (2C), 126.34, 114.77 (2C), 60.38, 
55.23 (2C), 33.43, 31.37 (2C). MS(ESI) m/z calcd. for C26H27ClN2 402.19, found 403.07 [M]+, 
404.96 [M+1]+, 406.03 [M+3]+, 407.10 [M+4]+. 
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(Z)-1,3-bis(tert-butoxycarbonyl)-4-((4-Chloro(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (58, KGM02003). 
Triethylamine (0.25 mL, 1.80 mmol) was added drop wise to a suspension of compound 57 (0.36 
g, 0.90 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.29 g, 0.99 mmol), HgCl2 
(0.27 g, 0.99 mmol) in DCM (12.7 mL).The mixture was stirred for 24 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 58 as 
an off-white solid (0.41 g, 0.64 mmol, 70.5%). 1H NMR (600 MHz, CDCl3) δ 11.56 (s, 1H), 
10.25 (s, 1H), 7.48 – 7.45 (m, 2H), 7.23 – 7.17 (m, 4H), 7.15 – 7.12 (m, 3H), 6.99 – 6.96 (m, 
4H), 2.80 – 2.76 (m, 2H), 2.60 – 2.51 (m, 6H), 2.43 – 2.39 (m, 2H), 2.36 (s, 2H), 1.46 (s, 9H), 
1.43 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 163.64, 153.54, 153.42, 153.34, 140.83, 140.32, 
138.40, 135.48, 134.55, 132.41, 131.43 (2C), 130.49 (2C), 128.83 (2C), 128.55 (2C), 128.30 
(2C), 126.23, 121.84 (2C), 83.88, 79.80, 60.51, 55.32, 55.27, 33.74, 31.72, 31.69, 28.32 (3C), 
28.21 (3C). MS(ESI) m/z calcd. for C37H45ClN4O2 644.31, found 645.14 [M]+, 647.09 [M+2]+, 
648.23 [M+3]+, 649.30 [M+4]+, 545.09 [M-Boc]+, 445.01 [M-2Boc]+. 
1-(4-((4-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (10c, KGM02009). 
Compound 58 (73 mg, 0.11 mmol) was dissolved in diethyl ether (1 mL). 2N HCl in diethyl 
ether (4 mL) was added to the reaction vessel and the reaction was left to stir for 48 hr at room 
temperature. The reaction was concentrated in vacuo to provide 59 as a light-yellow solid (49.4 
mg, 0.10 mmol, 84.4%). 1H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 10.17 (s, 1H), 7.61 – 
7.53 (m, 4H), 7.43 – 7.38 (m, 3H), 7.35 – 7.28 (m, 3H), 7.27 – 7.23 (m, 3H), 3.62 – 3.51 (m, 
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3H), 3.14 – 2.98 (m, 6H), 2.69 – 2.56 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.97, 139.69, 
138.47, 137.09, 135.65, 134.11, 131.66, 131.05 (2C), 130.85, 130.38 (2C), 128.59 (4C), 128.36 
(2C), 126.71, 123.94 (2C), 56.14, 51.95, 51.89, 29.36, 27.76, 27.72. MS(ESI) m/z calcd. for 
C27H29ClN4 444.21, found 445.01 [M]+, 446.90 [M+1]+, 448.09 [M+3]+. HPLC Method 2: 
97.96%, tR = 2.42 min. 
6.4 Experimental Data for KGM02018, KGM02022, KGM02023, and KGM02024. 
6.4.1: Experimental Data for compounds in Figure 38. 
(4-Methylbenzyl)triphenylphosphonium bromide (61, KGM02006). 
Triphenylphosphine (3.41 g, 13 mmol) was dissolved in toluene (18.2 mL) and 4-methylbenzyl 
bromide 60 (2.41 g, 13 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 61 as a fine white powder (5.7 g, 12.74 mmol, 98.0%). 1H NMR (500 
MHz, CDCl3) δ 7.80 – 7.75 (m, 3H), 7.73 – 7.67 (m, 6H), 7.66 – 7.61 (m, 6H), 6.95 – 6.90 (m, 
4H), 5.22 (d, JH, P = 14.1 Hz, 2H), 2.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 138.43 (d, JC, P = 
4.1 Hz), 135.09, 135.07 (2C), 134.47 (3C), 134.39 (3C), 131.40, 131.36, 130.30 (3C), 130.20 
(3C), 129.63, 129.61, 123.74, 123.68, 118.23, 117.55, 77.41, 30.67 (d, JC, P = 46.9 Hz), 21.22. 
MS(ESI) m/z calcd. for C26H24P+ 367.16, found 367.13 [M], 368.01 [M]+, 369.08 [M+1]+, 
370.21 [M+2]+. 
4-(4-Methylbenzylidene)-1-phenethylpiperidine (62, KGM02007). 
Compound 61 (5.52 g, 12.33 mmol) was suspended in anhydrous THF (13 mL) under argon at -
78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (7.41 mL, 14.79 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (2.51 g, 12.33 mmol) in anhydrous THF (6.4 mL) 
 188 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified via flash column chromatography (6:4, 
hexane: ethyl acetate). Fractions were collected and concentrated in vacuo to provide 62 as a pale 
yellow oil (0.93 g, 3.19 mmol, 25.9%). 1H NMR (600 MHz, CDCl3) δ 7.22 – 7.19 (m, 2H), 7.14 
– 7.10 (m, 3H), 7.06 – 7.01 (m, 4H), 6.20 (s, 1H), 2.80 – 2.76 (m, 2H), 2.59 – 2.55 (m, 4H), 2.52 
– 2.49 (m, 2H), 2.48 – 2.44 (m, 2H), 2.39 – 2.35 (m, 2H), 2.26 (s, 3H). 13C NMR (151 MHz, 
CDCl3) δ 140.38, 138.58, 135.89, 134.91, 128.94 (4C), 128.83 (2C), 128.53 (2C), 126.20, 
123.43, 60.58, 55.28, 54.59, 36.36, 33.75, 29.09, 21.27. MS(ESI) m/z calcd. for C21H25N 291.20, 
found 292.19 [M]+, 293.13 [M+1]+, 294.20 [M+2]+, 295.27 [M+3]+. 
4-(Bromo(p-tolyl)methylene)-1-phenethylpiperidine (64, KGM02010). 
Compound 62 (0.83 g, 2.85 mmol) was dissolved in DCM (15 mL) under argon at -78 ˚C. Br2 
(0.22 mL, 4.27 mmol) diluted in DCM (32 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 63, 
which was determined by LC/MS. NaOH (0.68 g, 17.09 mmol) was dissolved in MeOH (28.4 
mL) and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) 
until the full conversion to the monobromo, determined via LC/MS. The reaction was quenched 
with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 64 as 
a yellow oil (0.6 g, 1.62 mmol, 56.8%). 1H NMR (500 MHz, MeOD) δ 7.32 – 7.29 (m, 2H), 
7.27 – 7.24 (m, 2H), 7.24 – 7.21 (m, 1H), 7.19 – 7.16 (m, 4H), 3.14 – 3.09 (m, 2H), 3.06 – 3.02 
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(m, 2H), 3.00 – 2.96 (m, 2H), 2.96 – 2.92 (m, 2H), 2.90 – 2.86 (m, 2H), 2.47 – 2.44 (m, 2H), 
2.35 (s, 3H). 13C NMR (126 MHz, MeOD) δ 139.12, 138.91, 138.12, 130.09 (2C), 130.08 (2C), 
129.78 (2C), 129.74 (2C), 129.60, 127.83, 119.46, 54.36 (2C), 54.15, 33.50, 32.68 (2C), 21.25. 
MS(ESI) m/z calcd. for C21H24BrN 369.11, found 370.09 [M]+, 372.98 [M+2]+, 374.12 [M+4]+. 
6.4.2: Experimental Data for compounds in Figure 39. 
3-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzonitrile (65, KGM02011). 
Under argon (g), a mixture of 64 (0.14 g, 0.38 mmol), 3-cyanophenylboronic acid (0.07 g, 0.45 
mmol) and K2CO3 (0.13 g, 0.94 mmol) in toluene (5.5 mL)/ethanol (1.84 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (14 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 65 as a yellow wax (0.12 g, 0.31 mmol, 
81.3%). 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 7.7 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.31 
(s, 1H), 7.29 – 7.22 (m, 3H), 7.18 – 7.15 (m, 3H), 7.07 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 
2H), 3.19 – 3.04 (m, 3H), 3.04 – 2.90 (m, 3H), 2.90 – 2.46 (m, 6H), 2.27 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 142.82, 137.64, 134.00, 132.98, 130.76, 129.47 (3C), 129.40 (2C), 129.38 (2C), 
129.06 (3C), 128.82 (3C), 127.24, 118.73, 112.74, 59.12, 54.15 (2C), 29.08, 21.30 (2C). 
MS(ESI) m/z calcd. for C28H28N2 392.23, found 392.87 [M], 394.32 [M+1]+, 395.20 [M+2]+, 
396.21 [M+3]+. 
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(Z)-N'-hydroxy-3-((1-phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzimidamide (66, 
KGM02013). 
A mixture of 65 (0.10 g, 0.26 mmol), hydroxylamine hydrochloride (0.07 g, 0.94 mmol), and 
sodium carbonate (0.05 g, 0.43 mmol) in ethanol (0.79 mL)/H20 (0.08 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 66 as a beige-white powder (96 mg, 0.225 mmol, 88.1%). 1H 
NMR (400 MHz, CDCl3) δ 7.42 – 7.29 (m, 2H), 7.21 – 7.13 (m, 3H), 7.10 – 7.04 (m, 2H), 7.04 
– 6.91 (m, 4H), 6.90 – 6.82 (m, 2H), 4.93 (s, 2H), 2.99 – 2.90 (m, 2H), 2.90 – 2.74 (m, 6H), 2.61 
– 2.44 (m, 4H), 2.21 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.51, 142.28, 138.31, 138.05, 
137.35, 136.68, 132.47, 131.85, 131.12, 129.49 (2C), 129.02 (2C), 128.79 (2C), 128.75 (2C), 
128.64, 126.94, 126.74, 124.21, 77.48, 59.19, 54.33 (2C), 31.78, 29.67 (2C), 21.22. MS(ESI) 
m/z calcd. for C28H31N3O 425.25, found 426.05 [M]+, 427.12 [M+1]+, 428.26 [M+2]+. HPLC 
Method 2: 96.88%, tR = 2.33 min. 
3-((1-phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzimidamide dihydrochloride (68, 
KGM02018) 
To a solution of 66 (47 mg, 0.11 mmol), in acetic acid (0.55 mL), acetic anhydride (0.02 mL, 
0.15 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 67 was determined by LC/MS. 10% Pd/C (5 mg) was introduced to the 
mixture and the reaction was stirred under hydrogen for 84 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a tan oil. MeOH was used to remove 
excess acetic acid and provide a residue, which was treated with excess 2N HCl in diethyl ether. 
The HCl was evaporated in vacuo to provide the crude. Extraction was performed using DCM 
 191 
and H2O; the aqueous layer was concentrated in vacuo to provide 68 as a pale-green-white solid 
(20 mg, 0.04 mmol, 88.2%). 1H NMR (500 MHz, MeOD) δ 7.63 – 7.61 (m, 1H), 7.56 (s, 1H), 
7.51 – 7.45 (m, 2H), 7.23 – 7.19 (m, 4H), 7.14 – 7.12 (m, 1H), 7.06 (d, J = 7.8 Hz, 2H), 7.00 (d, 
J = 7.9 Hz, 2H), 3.34 – 3.26 (m, 4H), 3.10 – 2.99 (m, 3H), 2.71 – 2.51 (m, 5H), 2.20 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 165.19, 141.96, 137.58, 137.35, 137.00, 136.13, 135.95, 128.99, 
128.97 (2C), 128.85 (2C), 128.51 (2C), 128.47 (3C), 128.23, 127.62, 126.56, 126.43, 56.05, 
51.87 (2C), 29.21, 27.65, 27.56, 20.64. MS(ESI) m/z calcd. for C28H31N3 409.25, found 410.00 
[M]+, 411.07 [M+1]+, 412.14 [M+2]+. HPLC Method 2: 98.32%, tR = 2.01 min. 
6.4.3: Experimental Data for compounds in Figure 40. 
4-((1-phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzonitrile (69, KGM02015). 
Under argon (g), a mixture of 64 (0.14 g, 0.38 mmol), 4-cyanophenylboronic acid (0.07 g, 0.46 
mmol) and K2CO3 (0.13 g, 0.95 mmol) in toluene (5.7 mL)/ethanol (1.9 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (15 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with ethyl acetate, 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using an Isolera One Biotagé system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 69 as a bright 
yellow oil (0.11 g, 0.28 mmol, 73.6%). 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.44 (m, 2H), 7.23 
– 7.17 (m, 2H), 7.17 – 7.15 (m, 1H), 7.14 – 7.09 (m, 4H), 7.05 – 7.01 (m, 2H), 6.91 – 6.87 (m, 
2H), 2.80 – 2.73 (m, 2H), 2.59 – 2.50 (m, 6H), 2.41 – 2.36 (m, 2H), 2.36 – 2.31 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 147.51, 140.17, 138.30, 137.22, 136.78, 134.68, 131.95 (2C), 
130.67 (2C), 129.80 (2C), 129.09 (2C), 128.76 (2C), 128.53 (2C), 126.22, 119.11, 110.09, 60.40, 
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55.15, 55.12, 33.71, 31.69, 31.63, 21.25. MS(ESI) m/z calcd. for C28H28N2 392.23, found 393.06 
[M]+, 394.01 [M+1]+, 395.14 [M+2]+, 396.15 [M+3]+. 
(Z)-N'-hydroxy-4-((1-phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzimidamide (70, 
KGM02019). 
A mixture of 69 (0.09 g, 0.23 mmol), hydroxylamine hydrochloride (0.06 g, 0.85 mmol), and 
sodium carbonate (0.04 g, 0.39 mmol) in ethanol (0.71 mL)/H20 (0.07 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 70 as a pale yellow-white solid (0.06 g, 0.15 mmol, 64.7%). 1H 
NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.5 Hz, 1H), 7.24 – 7.17 (m, 2H), 7.16 – 6.95 (m, 7H), 
6.90 (d, J = 7.4 Hz, 2H), 4.80 (s, 2H), 2.96 – 2.84 (m, 2H), 2.79 – 2.60 (m, 6H), 2.56 – 2.42 (m, 
4H), 2.25 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.41, 152.35, 143.95, 143.91, 138.68, 
136.62, 136.55, 130.85, 130.03 (2C), 129.68 (2C), 129.01 (2C), 128.82 (2C), 128.71 (2C), 
126.56, 125.68 (2C), 59.88, 54.83 (2C), 32.65, 30.52 (2C), 21.28. MS(ESI) m/z calcd. for 
C28H31N3O 425.25, found 426.12 [M]+, 427.12 [M+1]+, 428.26 [M+2]+. HPLC Method 2: 
99.50%, tR = 2.06 min. 
4-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)benzimidamide dihydrochloride (72, 
KGM02022) 
To a solution of 70 (0.05 g, 0.12 mmol), in acetic acid (0.61 mL), acetic anhydride (0.02 mL, 
0.17 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 71 was determined by LC/MS. 10% Pd/C (5.2 mg) was introduced to the 
mixture and the reaction was stirred under hydrogen for 84 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a brown oil. The residue was treated with 
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excess 1.25M HCl in ethanol. The excess solvent was evaporated in vacuo, extraction was 
performed using DCM and H2O, and the aqueous layer was concentrated in vacuo to provide 72 
as an orange solid (50 mg, 0.10 mmol, 84.9%). MS(ESI) m/z calcd. for C28H31N3 409.25, found 
410.00 [M]+, 411.13 [M+1]+. HPLC Method 2: 99.28%, tR = 1.98 min. 
6.4.4: Experimental Data for compounds in Figure 41. 
3-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)aniline (73, KGM02012). 
Under argon (g), a mixture of 64 (0.15 g, 0.40 mmol), 3-cyanophenylboronic acid (0.08 g, 0.47 
mmol) and K2CO3 (0.14 g, 0.99 mmol) in toluene (5.6 mL)/ethanol (1.85 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (15 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 73 as an orange wax (0.07 g, 0.18 mmol, 
46.1%). 1H NMR (400 MHz, CDCl3) δ 7.26 – 7.20 (m, 2H), 7.18 – 7.05 (m, 4H), 7.04 – 6.98 
(m, 2H), 6.95 – 6.88 (m, 2H), 6.83 – 6.75 (m, 1H), 6.50 – 6.42 (m, 1H), 6.36 – 6.32 (m, 1H), 
3.01 – 2.91 (m, 2H), 2.91 – 2.62 (m, 6H), 2.62 – 2.44 (m, 4H), 2.25 (s, 2H), 1.18 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 146.33 (2C), 129.46 (2C), 129.17, 129.05, 128.97 (3C), 128.84 
(6C), 126.85, 120.02, 116.31 (2C), 113.71, 54.79, 54.70, 32.07, 29.85, 22.84, 21.30. MS(ESI) 
m/z calcd. for C27H30N2 382.24, found 383.18 [M]+, 384.12 [M+1]+, 385.26 [M+2]+, 386.27 
[M+3]+. 
 
 194 
(Z)-1,3-bis(tert-butoxycarbonyl)-3-(((p-tolyl)methyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (74, KGM02014). 
Triethylamine (0.04 mL, 0.26 mmol) was added drop wise to a suspension of compound 73 (0.05 
g, 0.13 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.04 g, 0.14 mmol), HgCl2 
(0.04 g, 0.14 mmol) in DCM (1.83 mL). The mixture was stirred for 24 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 74 as 
a white solid (0.08 g, 0.13 mmol, 98.5%). 1H NMR (400 MHz, CDCl3) δ 11.61 (s, 1H), 10.26 
(s, 1H), 7.63 – 7.59 (m, 1H), 7.34 – 7.28 (m, 2H), 7.26 – 7.20 (m, 5H), 7.11 (d, J = 7.9 Hz, 2H), 
6.99 (d, J = 8.0 Hz, 2H), 6.86 – 6.83 (m, 1H), 3.17 – 2.65 (m, 12H), 1.54 (s, 9H), 1.51 (s, 11H), 
1.50 (s, 8H). 13C NMR (126 MHz, CDCl3) δ 163.61, 153.70 (2C), 153.42, 136.85, 136.75 (2C), 
129.46 (3C), 129.12 (3C), 128.98 (2C), 128.95 (2C), 128.84 (3C), 127.04, 126.12, 123.32 (2C), 
121.22, 83.96, 79.76 (2C), 59.16, 54.39 (2C), 28.40 (3C), 28.22 (3C), 21.30. MS(ESI) m/z calcd. 
for C38H48N4O4 624.37, found 625.23 [M]+, 626.17 [M+1]+, 627.31 [M+2]+, 628.44 [M+3]+, 
525.12 [M-Boc]+, 425.05 [M-2Boc]+. 
1-(3-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)phenyl)guanidine dihydrochloride 
(75, KGM02023). 
Compound 74 (60 mg, 0.10 mmol) was treated with 4N HCl in 1,4-dioxane (5 mL) and the 
reaction was left to stir for 48 hr at room temperature. The reaction was concentrated in vacuo to 
remove the remaining solvent. Extraction was performed with DCM and H2O; the aqueous layer 
was concentrated in vacuo to provide 75 as an orange solid (30 mg, 0.06 mmol, 62.8%). 
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MS(ESI) m/z calcd. for C28H32N4 424.26, found 425.05 [M]+, 426.12 [M+1]+. HPLC Method 2: 
98.55%, tR = 1.84 min. 
6.3.5: Experimental Data for compounds in Figure 42. 
4-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)aniline (76, KGM02016). 
Under Argon (g), a mixture of compound 64 (0.15 g, 0.39 mmol), 4-aminophenylboronic acid 
(0.08 g, 0.47 mmol) and K2CO3 (0.14 g, 0.98 mmol) in toluene (1.02 mL)/ethanol (0.68 
mL)/H2O (0.68 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed 
prior to the addition of Pd(PPh3)4 (15 mg). The reaction was wrapped in aluminum foil and 
heated to reflux (80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched 
with H2O, extracted with ethyl acetate, washed with brine, dried over Na2SO4, and concentrated 
in vacuo. The crude material was purified using an Isolera One Biotagé system under gradient 
conditions with hexane and ethyl acetate as eluents. Fractions were collected and concentrated in 
vacuo to provide 76 as a dark orange wax (0.14 g, 0.37 mmol, 93.6%). 1H NMR (400 MHz, 
CDCl3) δ 7.24 – 7.19 (m, 2H), 7.15 – 7.11 (m, 3H), 7.02 – 6.98 (m, 2H), 6.93 – 6.90 (m, 2H), 
6.84 – 6.78 (m, 2H), 6.55 – 6.48 (m, 2H), 4.08 – 3.31 (m, 2H), 2.86 – 2.79 (m, 2H), 2.67 – 2.56 
(m, 6H), 2.50 – 2.45 (m, 1H), 2.45 – 2.40 (m, 2H), 2.25 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
144.91 (2C), 139.92, 139.84, 136.01, 135.98, 132.84, 130.92 (2C), 129.81 (2C), 128.83 (2C), 
128.76 (2C), 128.62 (2C), 126.36, 114.73 (2C), 60.27, 55.20, 55.17, 33.21, 31.17, 29.84, 21.28. 
MS(ESI) m/z calcd. for C27H30N2 382.24, found 383.24 [M]+, 384.19 [M+1]+, 385.19 [M+2]+. 
 (Z)-1,3-bis(tert-butoxycarbonyl)-4-(((p-tolyl)methyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (77, KGM02020). 
Triethylamine (0.09 mL, 0.68 mmol) was added drop wise to a suspension of compound 76 (0.13 
g, 0.34 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.11 g, 0.37 mmol), HgCl2 
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(0.10 g, 0.37 mmol) in DCM (4.78 mL). The mixture was stirred for 72 hours at room 
temperature, filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 77 as 
a white solid (0.1 g, 0.16 mmol, 47.1%). 1H NMR (400 MHz, CDCl3) δ 11.56 (s, 1H), 10.24 (s, 
1H), 7.46 – 7.43 (m, 2H), 7.24 – 7.19 (m, 2H), 7.15 – 7.12 (m, 2H), 7.03 – 6.96 (m, 5H), 6.93 – 
6.90 (m, 2H), 2.86 – 2.80 (m, 2H), 2.66 – 2.56 (m, 6H), 2.47 – 2.41 (m, 4H), 1.45 (s, 9H), 1.43 
(s, 9H), 1.43 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 163.65, 153.53 (2C), 153.39, 139.34, 
138.97, 138.93, 136.22, 135.22, 130.45 (2C), 129.92 (2C), 128.84 (3C), 128.81 (2C), 128.59 
(2C), 126.31, 121.77 (2C), 83.82, 83.79, 79.75, 60.46, 55.37, 55.27, 33.45, 33.41, 31.36, 28.31 
(3C), 28.20 (3C), 21.28. MS(ESI) m/z calcd. for C38H48N4O4 624.37, found 625.16 [M]+, 626.11 
[M+1]+, 627.31 [M+2]+, 628.25 [M+3]+, 525.12 [M-Boc]+, 425.05 [M-2Boc]+. 
1-(4-((1-Phenethylpiperidin-4-ylidene)(p-tolyl)methyl)phenyl)guanidine dihydrochloride 
(78, KGM02024). 
Compound 77 (80 mg, 0.13 mmol) was treated with excess 4N HCl in 1,4-dioxane (10 mL) and 
the reaction was left to stir for 48 hr at room temperature. The reaction was concentrated in 
vacuo to remove the remaining solvent. Extraction was performed with DCM and H2O; the 
aqueous layer was concentrated in vacuo providing 78 as a pale yellow-orange solid (43.2 mg, 
0.09 mmol, 67.8%). MS(ESI) m/z calcd. for C28H32N4 424.26, found 425.05 [M]+, 426.12 
[M+1]+. HPLC Method 2: 99.37%, tR = 2.05 min. 
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6.5: Experimental Data for KGM02034, KGM02035, KGM02036, and KGM02037. 
6.5.1: Experimental Data for compounds in Figure 43. 
(3,4-Dichlorobenzyl)triphenylphosphonium bromide (80, KGM02017). 
Triphenylphosphine (3.41 g, 13.0 mmol) was dissolved in toluene (18.2 mL) and 3,4-
dichlorobenzyl bromide 79 (1.89 g, 13.0 mmol) was added drop wise and set to reflux at 110 ˚C 
overnight. The precipitate was filtered and washed with toluene and diethyl ether. The precipitate 
was further dried in vacuo, to provide 80 as a fine white powder (6.41 g, 12.77 mmol, 98.2%). 
1H NMR (400 MHz, DMSO) δ 7.96 – 7.88 (m, 3H), 7.80 – 7.72 (m, 12H), 7.58 – 7.50 (m, 1H), 
7.15 – 7.10 (m, 1H), 7.10 – 7.01 (m, 1H), 5.43 – 5.31 (m, 2H). 13C NMR (101 MHz, DMSO) δ 
135.71 (3C), 134.60 (3C), 134.50 (3C), 133.19 (d, JCP = 21.5 Hz), 131.66, 131.64, 131.36 (2C), 
130.71 (3C), 130.58 (3C), 129.70, 129.62, 118.17, 117.32, 27.60 (d, JCP = 188.12 Hz). MS(ESI) 
m/z calcd. for C25H20Cl2P+ 421.07, found 422.97 [M]+, 423.98 [M+1]+, 424.92 [M+2]+, 425.99 
[M+3]+, 427.06 [M+5]+. 
4-(3,4-Dichlorobenzylidene)-1-phenethylpiperidine (81, KGM02021). 
Compound 80 (5.98 g, 11.91 mmol) was suspended in anhydrous THF (12.6 mL) under argon at 
-78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (7.16 mL, 14.29 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (2.42 g, 11.91 mmol) in anhydrous THF (6.2 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified via flash column chromatography (3:7, 
hexane: ethyl acetate). Fractions were collected and concentrated in vacuo to provide 81 as a 
yellow oil (2.06 g, 5.95 mmol, 49.9%). 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.20 (m, 1H), 7.17 
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– 7.14 (m, 3H), 7.10 – 7.07 (m, 3H), 6.91 – 6.87 (m, 1H), 6.05 (s, 1H), 2.74 – 2.67 (m, 3H), 2.53 
– 2.46 (m, 6H), 2.32 – 2.28 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 141.59, 140.27, 137.78, 
132.04, 130.63, 129.98, 129.88, 128.68 (2C), 128.39 (2C), 128.32, 126.05, 121.10, 60.37, 54.98, 
54.26, 36.36, 33.76, 29.11. MS(ESI) m/z calcd. for C20H21Cl2N 345.11, found 346.05 [M]+, 
348.06 [M+2]+, 249.07 [M+3]+, 350.01 [M+4]+, 351.08 [M+5]+. 
4-(Bromo(3,4-dichlorophenyl)methylene)-1-phenethylpiperidine (83, KGM02025). 
Compound 81 (1.99 g, 5.75 mmol) was dissolved in DCM (15 mL) under argon at -78 ˚C. Br2 
(0.44 mL, 8.62 mmol) diluted in DCM (80 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 82, 
which was determined by LC/MS. NaOH (1.38 g, 34.48 mmol) was dissolved in MeOH (57 mL) 
and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) until the 
full conversion to the monobromo, determined via LC/MS. The reaction was quenched with 
H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material 
was purified using an Isolera One Biotagé system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 83 as a 
yellow-green oil (1.73 g, 4.07 mmol, 70.8%). 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.24 (m, 
2H), 7.21 – 7.14 (m, 2H), 7.12 – 7.05 (m, 3H), 7.03 – 6.99 (m, 1H), 2.75 – 2.67 (m, 2H), 2.64 – 
2.57 (m, 2H), 2.56 – 2.48 (m, 4H), 2.38 – 2.31 (m, 2H), 2.22 – 2.15 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 140.17, 140.11, 139.21, 132.33, 132.15, 131.33, 130.27, 128.83, 128.70 (2C), 
128.46 (2C), 126.15, 112.68, 60.02, 54.08, 53.80, 34.46, 33.79, 31.88. MS(ESI) m/z calcd. for 
C20H20BrCl2N 423.02, found 424.04 [M]+, 427.88 [M+3]+, 429.77 [M+5]+. 
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6.5.2: Experimental Data for compounds in Figure 44. 
3-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (84, 
KGM02027). 
Under argon (g), a mixture of 83 (0.41 g, 0.96 mmol), 3-cyanophenylboronic acid (0.17 g, 1.16 
mmol) and K2CO3 (0.33 g, 2.41 mmol) in toluene (14.1 mL)/ethanol (4.7 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (41 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 84 as a dark orange wax (0.33 g, 0.74 mmol, 
76.6%). 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.42 (m, 1H), 7.37 – 7.28 (m, 3H), 7.28 – 7.24 
(m, 1H), 7.23 – 7.18 (m, 2H), 7.15 – 7.08 (m, 4H), 6.88 – 6.83 (m, 1H), 2.81 – 2.73 (m, 2H), 
2.63 – 2.50 (m, 6H), 2.40 – 2.29 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 142.52, 141.13, 
139.99, 139.10, 134.29, 133.28, 132.63, 132.09, 131.62, 131.36, 130.66, 130.47, 129.35, 129.27, 
128.77 (2C), 128.57 (2C), 126.30, 118.70, 112.70, 60.18, 54.90, 54.86, 33.59, 31.58, 31.50. 
MS(ESI) m/z calcd. for C27H24Cl2N2 446.13, found 446.77 [M], 448.03 [M+1]+, 449.04 [M+2]+, 
450.04 [M+3]+, 450.99 [M+3]+, 452.00 [M+5]+, 453.13 [M+6]+. 
(Z)-3-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-
hydroxybenzimidamide (85, KGM02031). 
A mixture of 84 (0.30 g, 0.67 mmol), hydroxylamine hydrochloride (0.17 g, 2.48 mmol), and 
sodium carbonate (0.12 g, 1.14 mmol) in ethanol (2.07 mL)/H2O (0.21 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
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leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 85 as a white powder (0.31 g, 0.64 mmol, 95.6%). 1H NMR 
(400 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 1H), 7.34 – 7.31 (m, 1H), 7.24 (s, 1H), 7.22 – 7.17 (m, 
3H), 7.15 – 7.08 (m, 5H), 7.03 (d, J = 7.6 Hz, 1H), 6.87 – 6.83 (m, 1H), 4.88 (s, 2H), 2.94 – 2.87 
(m, 2H), 2.79 – 2.69 (m, 6H), 2.52 – 2.45 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 152.31 (2C), 
141.47, 141.33, 132.83 (2C), 132.41, 131.46, 131.17, 131.09, 130.36, 129.21, 128.89, 128.81 
(2C), 128.74 (2C), 127.08, 126.66, 124.57, 121.02, 59.64, 54.49, 54.45, 32.46, 30.34, 30.31. 
MS(ESI) m/z calcd. for C27H27Cl2N3O 479.15, found 480.02 [M]+, 482.04 [M+2]+, 483.11 
[M+3]+, 484.05 [M+4]+, 485.06 [M+5]+. HPLC Method 2: 99.76%, tR = 2.19 min. 
3-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (87, KGM02034) 
To a solution of 85 (0.21 g, 0.44 mmol), in acetic acid (2.18 mL), acetic anhydride (0.06 mL, 
0.61 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 86 was determined by LC/MS. 10% Pd/C (21 mg) was introduced to the 
mixture and the reaction was stirred under hydrogen for 48 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a tan oil. MeOH was used to remove 
excess acetic acid and provide a residue, which was treated with excess 2N HCl in diethyl ether. 
The excess solvent was evaporated in vacuo to provide the crude. Extraction was performed 
using DCM and H2O; the aqueous layer was concentrated in vacuo to provide 87 as a light 
yellow solid (0.14 g, 0.27 mmol, 61.3%). 1H NMR (500 MHz, DMSO) δ 11.61 (s, 1H), 9.51 (s, 
2H), 9.33 (s, 2H), 7.77 – 7.73 (m, 2H), 7.60 – 7.54 (m, 2H), 7.47 – 7.43 (m, 2H), 7.31 – 7.27 (m, 
2H), 7.25 – 7.19 (m, 4H), 3.58 – 3.50 (m, 2H), 3.25 – 3.20 (m, 2H), 3.17 – 3.03 (m, 5H), 2.71 – 
2.63 (m, 2H), 2.41 – 2.35 (m, 1H). 13C NMR (126 MHz, DMSO) δ 165.35, 141.04, 140.98, 
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137.13, 134.31, 133.86, 132.93, 131.11, 130.96, 130.69, 129.97, 129.66, 129.29, 128.62 (5C), 
128.30, 126.95, 126.73, 56.10, 51.75, 51.70, 29.36, 27.74, 27.62. MS(ESI) m/z calcd. for 
C27H27Cl2N3 463.16, found 464.03 [M]+, 466.04 [M+2]+, 467.05 [M+3]+, 469.06 [M+5]+. HPLC 
Method 2: 99.45%, tR = 2.13 min. 
6.5.3: Experimental Data for compounds in Figure 45. 
4-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (88, 
KGM02030). 
Under argon (g), a mixture of 83 (0.41 g, 0.97 mmol), 4-cyanophenylboronic acid (0.17 g, 1.16 
mmol) and K2CO3 (0.33 g, 2.42 mmol) in toluene (14.4 mL)/ethanol (4.8 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (42 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 88 as a yellow wax (0.17 g, 0.38 mmol, 
39.3%). 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.2 Hz, 1H), 7.21 – 
7.16 (m, 2H), 7.13 – 7.07 (m, 6H), 6.87 – 6.83 (m, 1H), 2.78 – 2.72 (m, 2H), 2.60 – 2.55 (m, 
2H), 2.55 – 2.50 (m, 4H), 2.37 – 2.29 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 146.09, 141.12, 
140.10, 139.47, 132.51, 132.47, 132.17 (2C), 131.64, 131.25, 130.61 (2C), 130.38, 129.32, 
128.72 (2C), 128.49 (2C), 126.19, 118.78, 110.74, 60.15, 54.88, 54.83, 33.65, 31.71, 31.63. 
MS(ESI) m/z calcd. for C27H24Cl2N2 446.13, found 446.77 [M], 448.03 [M+1]+, 449.04 [M+2]+, 
450.04 [M+3]+, 450.99 [M+3]+, 452.06 [M+5]+, 453.19 [M+6]+. 
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(Z)-4-((3,4-Dichorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N’-
hydroxybenzimidamide (89, KGM02033). 
A mixture of 88 (0.17 g, 0.37 mmol), hydroxylamine hydrochloride (0.10 g, 1.37 mmol), and 
sodium carbonate (0.07 g, 0.63 mmol) in ethanol (1.14 mL)/H20 (0.11 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 89 as a pale yellow solid (38 mg, 0.08 mmol, 21.5%). 1H NMR 
(500 MHz, CDCl3) δ 7.47 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 1H), 7.23 – 7.20 (m, 2H), 
7.19 (s, 1H), 7.14 – 7.12 (m, 2H), 7.08 (d, J = 1.9 Hz, 1H), 7.00 (d, J = 8.2 Hz, 2H), 6.85 (dd, J = 
8.2, 1.9 Hz, 1H), 4.92 (s, 2H), 3.04 – 2.99 (m, 2H), 2.95 – 2.84 (m, 6H), 2.64 – 2.55 (m, 4H). 13C 
NMR (126 MHz, CDCl3) δ 152.27 (2C), 142.25, 141.10, 141.09, 132.57 (2C), 131.43, 131.39, 
130.49, 129.89 (2C), 129.11, 128.90 (2C), 128.82 (2C), 126.98, 126.08 (2C), 110.11, 59.21, 
54.18, 54.09, 29.82, 29.59, 25.19. MS(ESI) m/z calcd. for C27H27Cl2N3O 479.15, found 479.96 
[M], 481.91 [M+1]+, 483.11 [M+3]+, 484.93 [M+4]+. HPLC Method 2: 96.02%, tR = 2.20 min. 
4-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (91, KGM02035) 
To a solution of 89 (30.4 mg, 0.06 mmol), in acetic acid (0.32 mL), acetic anhydride (0.01 mL, 
0.09 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 90 was determined by LC/MS. 10% Pd/C (3.1 mg) was introduced to the 
mixture and the reaction was stirred under hydrogen for 48 hours. The mixture was filtered 
through Celite® and the filtrate was evaporated to give a brown oil. The residue was treated with 
excess 4N HCl in 1,4-dioxane. The excess solvent was evaporated in vacuo, extraction was 
performed using DCM and H2O, and the aqueous layer was concentrated in vacuo to provide 91 
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as an light yellow solid (26 mg, 0.05 mmol, 76.8%). 1H NMR (500 MHz, MeOD) δ 8.01 – 7.97 
(m, 1H), 7.86 (s, 1H), 7.58 – 7.50 (m, 3H), 7.38 – 7.33 (m, 5H), 7.27 (s, 2H), 3.84 – 3.53 (m, 
4H), 3.49 – 3.43 (m, 2H), 3.19 (s, 2H), 2.76 (s, 4H). 13C NMR (126 MHz, MeOD) δ 167.99, 
147.49, 141.94, 137.60, 137.10, 133.51, 133.28, 132.60, 132.52, 131.87, 131.68, 130.70, 130.00 
(2C), 129.91 (3C), 129.44 (2C), 128.50, 128.19, 59.12, 54.49, 54.35, 31.58, 29.59 (2C). 
MS(ESI) m/z calcd. for C27H27Cl2N3 463.16, found 464.09 [M]+, 466.04 [M+2]+, 467.11 
[M+3]+.  
6.5.4: Experimental Data for compounds in Figure 46. 
3-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (92, KGM02026). 
Under argon (g), a mixture of 83 (0.39 g, 0.92 mmol), 3-aminophenylboronic acid (0.19 g, 1.10 
mmol) and K2CO3 (0.32 g, 2.25 mmol) in toluene (13 mL)/ethanol (4.3 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (40 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using an Isolera One 
Biotagé system under gradient conditions with hexane and ethyl acetate as eluents. Fractions 
were collected and concentrated in vacuo to provide 92 as an orange wax (0.34 g, 0.78 mmol, 
84.7%). 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.2 Hz, 1H), 7.23 – 7.17 (m, 2H), 7.15 – 
7.09 (m, 4H), 7.00 (t, J = 7.8 Hz, 1H), 6.89 (dd, J = 8.2, 1.8 Hz, 1H), 6.47 (dd, J = 7.9, 2.3 Hz, 
1H), 6.44 – 6.39 (m, 1H), 6.33 – 6.26 (m, 1H), 3.55 (s, 2H), 2.80 – 2.72 (m, 2H), 2.62 – 2.55 (m, 
2H), 2.55 – 2.48 (m, 4H), 2.39 – 2.30 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 146.39, 142.49, 
142.40, 140.17, 136.46, 134.21, 132.10, 131.53, 130.47, 130.04, 129.26, 129.24, 128.79 (2C), 
128.54 (2C), 126.24, 120.18, 116.38, 113.80, 60.37, 55.21, 55.08, 33.64, 31.59, 31.45. MS(ESI) 
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m/z calcd. for C26H26Cl2N2 436.15, found 436.76 [M], 438.08 [M+1]+, 439.09 [M+2]+, 440.10 
[M+3]+, 440.98 [M+3]+, 442.05 [M+5]+, 443.18 [M+6]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-3-((3,4-dichlorophenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (93, KGM02028). 
Triethylamine (0.19 mL, 1.33 mmol) was added drop wise to a suspension of compound 92 (0.29 
g, 0.66 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.21 g, 0.73 mmol), HgCl2 
(0.20 g, 0.73 mmol) in DCM (9.32 mL). The mixture was stirred for 24 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrate in vacuo to provide 93 as a 
yellow-white solid (0.34 g, 0.50 mmol, 74.8%). 1H NMR (400 MHz, CDCl3) δ 11.54 (s, 1H), 
10.17 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 7.21 – 7.15 (m, 4H), 7.13 – 7.08 
(m, 4H), 6.90 – 6.86 (m, 1H), 6.77 – 6.73 (m, 1H), 2.77 – 2.71 (m, 2H), 2.58 – 2.49 (m, 6H), 
2.40 – 2.35 (m, 2H), 2.34 – 2.29 (m, 2H), 1.42 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 163.50, 
153.55, 153.29, 142.15, 141.85, 140.26, 137.58, 136.69, 133.28, 132.10, 131.61, 130.54, 130.04, 
129.32, 128.82, 128.71 (2C), 128.41 (2C), 126.29, 126.08, 123.61, 121.01, 83.77, 79.56, 60.38, 
55.17, 55.06, 53.47, 33.77, 31.65, 28.24 (3C), 28.12 (3C). MS(ESI) m/z calcd. for 
C37H44Cl2N4O4 678.27, found 679.23 [M]+, 681.24 [M+2]+, 682.19 [M+3]+, 683.20 [M+4]+, 
684.21 [M+5]+, 685.34 [M+6]+, 579.17 [M-Boc]+, 479.08 [M-2Boc]+. 
1-(3-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (94, KGM02036). 
Compound 93 (0.23 g, 0.34 mmol) was treated with 4N HCl in 1,4-dioxane (5 mL) and the 
reaction was left to stir for 48 hr at room temperature. The reaction was concentrated in vacuo to 
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provide 94 as a beige-white solid (0.10 g, 0.19 mmol, 55.4%). 1H NMR (500 MHz, MeOD) δ 
7.56 (d, J = 8.1 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.42 (s, 1H), 7.38 – 7.34 (m, 4H), 7.29 (d, J = 
7.3 Hz, 2H), 7.24 (t, J = 8.4 Hz, 2H), 7.18 (s, 1H), 3.79 – 3.75 (m, 2H), 3.49 – 3.42 (m, 2H), 3.33 
– 3.25 (m, 2H), 3.24 – 3.19 (m, 2H), 2.88 – 2.83 (m, 1H), 2.79 – 2.72 (m, 3H). 13C NMR (126 
MHz, MeOD) δ 157.90, 143.38, 142.33, 137.65, 137.38, 136.43, 133.36, 132.50, 132.39, 
132.33, 131.68, 131.33, 130.55, 129.88 (4C), 129.59, 128.17, 127.29, 125.38, 58.86, 54.30, 
54.18, 31.43, 29.52, 29.44. MS(ESI) m/z calcd. for C27H28N4 478.17, found 479.08 [M]+, 481.03 
[M+2]+, 482.10 [M+3]+, 484.05 [M+5]+. HPLC Method 2: 96.29%, tR = 2.07 min. 
6.5.5: Experimental Data for compounds in Figure 47. 
4-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (95, KGM02029). 
Under argon (g), a mixture of compound 83 (0.41 g, 0.97 mmol), 4-aminophenylboronic acid 
(0.20 g, 1.16 mmol) and K2CO3 (0.33 g, 2.42 mmol) in toluene (2.53 mL)/ethanol (1.68 
mL)/H2O (1.68 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed 
prior to the addition of Pd(PPh3)4 (42 mg). The reaction was wrapped in aluminum foil and 
heated to reflux (80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched 
with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 95 as 
an orange wax (0.33 g, 0.75 mmol, 77.9%). 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.16 (m, 3H), 
7.12 – 7.07 (m, 4H), 6.88 – 6.84 (m, 1H), 6.77 (d, J = 8.0 Hz, 2H), 6.50 (d, J = 8.0 Hz, 2H), 3.65 
(s, 2H), 2.74 (dd, J = 10.0, 6.3 Hz, 2H), 2.55 (dd, J = 10.1, 6.3 Hz, 2H), 2.52 – 2.46 (m, 4H), 
2.40 – 2.35 (m, 2H), 2.32 – 2.28 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 145.26, 143.08, 
140.29, 135.87, 133.84, 131.96, 131.68, 131.58, 130.90 (2C), 130.23, 129.91, 129.42, 128.75 
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(2C), 128.48 (2C), 126.14, 114.74 (2C), 60.40, 55.20, 55.14, 33.69, 31.71, 31.65. MS(ESI) m/z 
calcd. for C26H26Cl2N2 436.15, found 437.14 [M]+, 439.09 [M+2]+, 440.03 [M+3]+, 440.98 
[M+3]+, 442.05 [M+5]+, 443.12 [M+6]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-4-((3,4-dichlorophenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (96, KGM02032). 
Triethylamine (0.19 mL, 1.37 mmol) was added drop wise to a suspension of compound 95 (0.3 
g, 0.69 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.22 g, 0.75 mmol), HgCl2 
(0.21 g, 0.75 mmol) in DCM (9.64 mL). The mixture was stirred for 24 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using an Isolera One Biotagé system under gradient conditions with hexane 
and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 96 as 
a beige-white solid (0.41 g, 0.60 mmol, 87.9%). 1H NMR (600 MHz, CDCl3) δ 11.56 (s, 1H), 
10.27 (s, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.29 – 7.26 (m, 1H), 7.23 – 7.18 (m, 3H), 7.14 – 7.11 (m, 
3H), 6.97 (d, J = 8.3 Hz, 2H), 6.89 – 6.86 (m, 1H), 2.82 – 2.78 (m, 2H), 2.63 – 2.53 (m, 6H), 
2.44 – 2.40 (m, 2H), 2.39 – 2.36 (m, 2H), 1.46 (s, 9H), 1.43 (s, 9H). 13C NMR (151 MHz, 
CDCl3) δ 163.62, 153.56, 153.43, 153.25, 142.36, 137.69, 135.76, 132.23, 131.80, 130.67, 
130.45 (2C), 130.11, 129.51, 128.84 (2C), 128.59 (2C), 126.30, 121.95 (2C), 83.94, 79.86, 
60.41, 55.18, 48.93, 41.80, 33.66, 31.61, 28.32 (3C), 28.22 (3C). MS(ESI) m/z calcd. for 
C37H44Cl2N4O4 678.27, found 679.23 [M]+, 681.24 [M+2]+, 682.25 [M+3]+, 683.20 [M+4]+, 
684.21 [M+5]+, 579.17 [M-Boc]+, 479.08 [M-2Boc]+. 
 
 
 207 
1-(4-((3,4-Dichlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (97, KGM02037). 
Compound 96 (0.32 g, 0.47 mmol) was treated with 4N HCl in 1,4-dioxane (5 mL) and the 
reaction was left to stir for 48 hr at room temperature. The reaction was concentrated in vacuo to 
provide 97 as a beige-white solid (0.26 g, 0.47 mmol, 99.9%). 1H NMR (500 MHz, DMSO) δ 
11.31 (s, 1H), 10.06 (s, 1H), 7.41 (d, J = 8.3 Hz, 3H), 7.21 (s, 1H), 7.12 – 7.08 (m, 2H), 7.06 – 
7.01 (m, 3H), 6.99 (s, 2H), 6.95 (d, J = 8.1 Hz, 1H), 3.23 – 3.18 (m, 2H), 3.07 – 3.01 (m, 2H), 
2.91 – 2.86 (m, 3H), 2.50 – 2.42 (m, 2H), 2.37 – 2.31 (m, 1H), 2.28 – 2.23 (m, 2H). 13C NMR 
(126 MHz, DMSO) δ 156.06, 141.66, 137.97, 137.17, 134.52, 134.38, 131.99, 131.06, 130.93, 
130.65, 130.44 (2C), 129.81, 129.64, 128.64 (4C), 126.76, 124.06 (2C), 56.16, 51.86, 51.77, 
29.40, 27.82, 27.73. MS(ESI) m/z calcd. for C27H28Cl2N4 478.17, found 479.08 [M]+, 481.03 
[M+2]+, 482.10 [M+3]+, 484.12 [M+5]+. HPLC Method 2: 95.49%, tR = 2.15 min. 
6.6 Experimental Data for KGM02089, KGM03001, KGM03002, and KGM03003. 
6.6.1: Experimental Data for compounds in Figure 48. 
(3-Chlorobenzyl)triphenylphosphonium bromide (99, KGM02042). 
Triphenylphosphine (3.41 g, 13.0 mmol) was dissolved in toluene (18.2 mL) and 3,4-
dichlorobenzyl bromide 98 (1.7 g, 13.0 mmol) was added drop wise and set to reflux at 110 ˚C 
overnight. The precipitate was filtered and washed with toluene and diethyl ether. The precipitate 
was further dried in vacuo, to provide 99 as a fine white powder (5.65 g, 12.08 mmol, 92.9%). 
1H NMR (500 MHz, CDCl3) δ 7.74 – 7.68 (m, 9H), 7.59 – 7.53 (m, 6H), 7.16 (d, J = 7.6 Hz, 
1H), 7.09 (d, J = 7.9 Hz, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.82 – 6.79 (m, 1H), 5.48 (d, JHP = 14.7 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 135.16 (2C), 135.13 (2C), 134.54 (3C), 134.46 (3C), 
134.30 (d, JCP = 4.0 Hz), 131.22 (d, JCP = 5.4 Hz), 130.32 (3C), 130.22, 129.56, 129.49, 128.55 
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(d, JCP = 3.9 Hz), 117.98, 117.30, 30.39 (d, JCP = 47.1 Hz). MS(ESI) m/z calcd. for C25H21ClP+ 
387.11, found 387.90 [M], 388.91 [M]+, 390.04 [M+2]+, 391.11 [M+3]+. 
4-(3-Chlorobenzylidene)-1-phenethylpiperidine (100, KGM02046). 
Compound 99 (5.45 g, 11.65 mmol) was suspended in anhydrous THF (12.3 mL) under argon at 
-78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (7.0 mL, 13.98 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (2.37 g, 11.65 mmol) in anhydrous THF (6.1 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using an Isolera One Biotagé system 
under gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 100 as a yellow oil (1.09 g, 3.50 mmol, 30.0%). 1H NMR (500 
MHz, CDCl3) δ 7.21 (t, J = 7.5 Hz, 2H), 7.16 – 7.08 (m, 6H), 6.99 (d, J = 7.5 Hz, 1H), 6.15 (s, 
1H), 2.79 – 2.74 (m, 2H), 2.58 – 2.54 (m, 4H), 2.46 (s, 4H), 2.38 – 2.34 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 140.92, 140.40, 139.69, 134.06, 129.45, 128.99, 128.82 (2C), 128.53 (2C), 
127.23, 126.33, 126.20, 122.24, 60.51, 55.18, 54.50, 36.42, 33.82, 29.18. MS(ESI) m/z calcd. for 
C20H22ClN 311.14, found 312.00 [M]+, 313.01 [M+1]+, 315.02 [M+3]+, 316.16 [M+4]+. 
4-(Bromo(3-chlorophenyl)methylene)-1-phenethylpiperidine (102, KGM02048). 
Compound 100 (1.05 g, 3.36 mmol) was dissolved in DCM (13.5 mL) under Argon at -78 ˚C. 
Br2 (0.26 mL, 5.04 mmol) diluted in DCM (42 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 101, 
which was determined by LC/MS. NaOH (0.81 g, 20.14 mmol) was dissolved in MeOH (33.3 
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mL) and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) 
until the full conversion to the monobromo, determined via LC/MS. The reaction was quenched 
with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 102 as a 
yellow wax (0.67 g, 1.71 mmol, 51.0%). 1H NMR (600 MHz, CDCl3) δ 7.23 – 7.17 (m, 5H), 
7.14 – 7.11 (m, 3H), 7.10 – 7.07 (m, 1H), 2.77 – 2.72 (m, 2H), 2.67 – 2.63 (m, 2H), 2.59 – 2.54 
(m, 4H), 2.41 – 2.37 (m, 2H), 2.25 – 2.21 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 140.88, 
139.16, 137.46, 132.97, 128.48, 128.43, 127.65 (2C), 127.39 (2C), 127.11, 126.54, 125.08, 
112.72, 59.03, 53.12, 52.81, 33.35, 32.72, 30.78. MS(ESI) m/z calcd. for C20H21BrClN 389.05, 
found 390.15 [M]+, 392.12 [M+2]+, 394.40 [M+4]+. 
6.6.2: Experimental Data for compounds in Figure 49. 
4-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (103, KGM02065). 
Under argon (g), a mixture of compound 102 (0.19 g, 0.48 mmol), 4-aminophenylboronic acid 
(0.10 g, 0.57 mmol) and K2CO3 (0.17 g, 1.19 mmol) in toluene (1.24 mL)/ethanol (0.82 
mL)/H2O (0.82 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed 
prior to the addition of Pd(PPh3)4 (19 mg). The reaction was wrapped in aluminum foil and 
heated to reflux (80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched 
with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 103 as an 
orange wax (0.15 g, 0.37 mmol, 78.2%). 1H NMR (500 MHz, CDCl3) δ 7.21 – 7.18 (m, 2H), 
7.13 – 7.06 (m, 5H), 7.01 (s, 1H), 6.94 – 6.90 (m, 1H), 6.79 (d, J = 8.4 Hz, 2H), 6.52 (d, J = 8.4 
 210 
Hz, 2H), 3.55 (s, 2H), 2.79 – 2.74 (m, 2H), 2.59 – 2.49 (m, 6H), 2.41 (d, J = 5.0 Hz, 2H), 2.32 (d, 
J = 5.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 145.14, 144.90, 140.32, 134.96, 133.88, 
132.10, 130.95 (2C), 129.90, 129.29, 128.83 (3C), 128.57 (2C), 128.18, 126.51, 126.24, 114.81 
(2C), 60.52, 55.33, 55.31, 33.72, 31.68, 31.60. MS(ESI) m/z calcd. for C26H27ClN2 402.19, 
found 403.48 [M]+, 404.44 [M+2]+, 406.46 [M+4]+, 406.47 [M+4]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-4-((3-chlorophenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (104, KGM02069). 
Triethylamine (0.08 mL, 0.60 mmol) was added drop wise to a suspension of compound 103 
(0.12 g, 0.30 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.10 g, 0.33 mmol), 
HgCl2 (0.09 g, 0.33 mmol) in DCM (4.21 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate, then with DCM and MeOH as eluents. Fractions were collected and concentrated 
in vacuo to provide 104 as a white solid (0.12 g, 0.19 mmol, 63.6%). 1H NMR (500 MHz, 
CDCl3) δ 11.56 (s, 1H), 10.25 (s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.23 – 7.18 (m, 2H), 7.16 – 7.10 
(m, 5H), 7.03 (s, 1H), 6.99 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 7.1 Hz, 1H), 2.81 – 2.75 (m, 2H), 
2.62 – 2.50 (m, 6H), 2.43 – 2.38 (m, 2H), 2.38 – 2.33 (m, 2H), 1.46 (s, 9H), 1.43 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 163.64, 153.54, 153.42, 144.24, 140.34, 138.16, 135.53, 134.44, 
133.98 (2C), 130.46, 129.98, 129.38, 128.84 (3C), 128.55 (3C), 128.27, 126.71, 126.22, 121.86, 
83.88, 79.81, 60.53, 55.32, 55.29, 33.78, 31.74, 31.67, 28.32 (3C), 28.22 (3C). MS(ESI) m/z 
calcd. for C37H45ClN4O4 644.31, found 645.75 [M]
+, 545.56 [M-Boc]+, 445.42 [M-2Boc]+, 
447.45 [(M+2)-2Boc]+. 
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1-(4-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (105, KGM02089). 
Compound 104 (90 mg, 0.14 mmol) was dissolved in DCM (0.3 mL), treated with 4N HCl in 
1,4-dioxane (0.7 mL, 2.29 mmol) and left to stir for 24 hr at room temperature. The reaction was 
concentrated in vacuo to provide 105 as an off-white solid (76.3 mg, 0.15 mmol, +99.9%). 1H 
NMR (500 MHz, DMSO) δ 11.40 (s, 1H), 10.16 (s, 1H), 7.55 (s, 2H), 7.37 – 7.32 (m, 1H), 7.30 
– 7.26 (m, 3H), 7.21 (d, J = 7.3 Hz, 3H), 7.16 (s, 5H), 7.10 (d, J = 7.4 Hz, 1H), 3.56 – 3.51 (m, 
2H), 3.22 – 3.18 (m, 2H), 3.10 – 2.96 (m, 5H), 2.63 – 2.56 (m, 2H), 2.53 – 2.48 (m, 1H).. 13C 
NMR (126 MHz, DMSO) δ 156.02, 143.10, 138.29, 137.16, 135.54, 134.28, 133.04, 131.33, 
130.36 (3C), 128.74, 128.65 (4C), 127.90, 127.04, 126.77, 124.05 (2C), 56.16, 51.96, 51.83, 
29.40, 27.81, 27.68. MS(ESI) m/z calcd. for C27H29ClN4 444.21, found 445.37 [M]+, 446.38 
[M+1]+, 447.40 [M+2]+, 448.42 [M+3]+. LCMS Method: 98.10%. 
6.6.3: Experimental Data for compounds in Figure 50. 
3-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (106). 
Reaction 1 (KGM02063) 
Under argon (g), a mixture of 102 (0.18 g, 0.46 mmol), 3-aminophenylboronic acid (0.10 g, 0.55 
mmol) and K2CO3 (0.16 g, 1.15 mmol) in toluene (6.53 mL)/ethanol (2.16 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (18 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
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collected and concentrated in vacuo to provide 106 as an orange wax (24 mg, 0.06 mmol, 
12.9%). 
Reaction 2 (KGM02081) 
Under argon (g), a mixture of 102 (0.36 g, 0.92 mmol), 3-aminophenylboronic acid (0.19 g, 1.10 
mmol) and K2CO3 (0.32 g, 2.30 mmol) in toluene (13 mL)/ethanol (4.3 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of freshly opened 
Pd(PPh3)4 (36 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, extracted with 
DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using a 
Combiflash RF system under isocratic conditions with hexane (35%) and ethyl acetate (65%) as 
eluents. Fractions were collected and concentrated in vacuo to provide 106 as a brown wax (0.18 
g, 0.45 mmol, 49.4%). 
Reaction 3 
Under argon (g), a mixture of 102 (0.13 g, 0.32 mmol), 3-aminophenylboronic acid (0.07 g, 0.39 
mmol) and K2CO3 (0.11 g, 0.81 mmol) in toluene (4.6 mL)/ethanol (1.5 mL)/H2O (1.5 mL) 
(3:1:1 ratio) were added to the reaction vessel. The mixture was degassed prior to the addition of 
Pd(PPh3)4 (13 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, extracted with 
DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using a 
Combiflash RF system under isocratic conditions with hexane (35%) and ethyl acetate (65%) as 
eluents. Fractions were collected and concentrated in vacuo to provide 106 as a yellow wax (62.1 
mg, 0.15 mmol, 47.6%). Final products from Reaction 2 and Reaction 3 were combined and 
further purified using a Combiflash RF system with a shallow gradient with DCM and MeOH 
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(MeOH starting at 0% à 2%). Fractions were collected and concentrated in vacuo to provide 
pure 106 as an orange wax (0.20 g, 0.51 mmol). 1H NMR (500 MHz, CDCl3) δ 7.21 (t, J = 7.4 
Hz, 2H), 7.14 – 7.08 (m, 5H), 7.05 (s, 1H), 7.01 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 7.2 Hz, 1H), 
6.47 (t, J = 7.9 Hz, 2H), 6.34 (s, 1H), 3.53 (s, 2H), 2.80 – 2.75 (m, 2H), 2.61 – 2.50 (m, 6H), 2.40 
– 2.36 (m, 2H), 2.36 – 2.32 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 146.30, 144.22, 142.86, 
140.25, 135.91, 135.13, 133.92, 129.72, 129.36, 129.15, 128.82 (2C), 128.56 (2C), 128.01, 
126.62, 126.24, 120.28, 116.47, 113.68, 60.47, 55.30, 55.20, 33.68, 31.58, 31.44. MS(ESI) m/z 
calcd. for C26H27ClN2 402.19, found 403.42 [M]+, 404.44 [M+1]+, 405.40 [M+2]+, 406.42 
[M+3]+. 
6.6.4: Experimental Data for compounds in Figure 51. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-3-((3-chlorophenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (107, KGM02088). 
Triethylamine (0.12 mL, 0.84 mmol) was added drop wise to a suspension of compound 106 
(0.17 g, 0.42 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.14 g, 0.46 mmol), 
HgCl2 (0.13 g, 0.46 mmol) in DCM (5.95 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 107 as a 
white solid (0.24 g, 0.37 mmol, 87.3%). 1H NMR (500 MHz, CDCl3) δ 11.54 (s, 1H), 10.17 (s, 
1H), 7.54 – 7.51 (m, 1H), 7.23 – 7.19 (m, 3H), 7.15 – 7.12 (m, 6H), 7.04 – 7.03 (m, 1H), 6.95 – 
6.93 (m, 1H), 6.80 – 6.77 (m, 1H), 2.83 – 2.77 (m, 2H), 2.65 – 2.52 (m, 6H), 2.46 – 2.36 (m, 
4H), 1.46 (s, 9H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.65, 153.67, 153.42, 143.90, 
142.17, 136.72, 134.03, 129.82, 129.47, 128.89, 128.82 (4C), 128.59 (3C), 128.10, 126.84, 
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126.38, 126.31, 123.62, 121.10, 83.89, 79.70, 60.29, 55.22, 55.05, 31.40, 31.31, 28.37 (3C), 
28.22 (3C), 14.64. MS(ESI) m/z calcd. for C37H45ClN4O4 644.31, found 645.114 [M]+, 646.19 
[M+1]+, 647.04 [M+2]+, 648.10 [M+3]+, 445.05 [M-2Boc]+. 
1-(3-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (108, KGM03001). 
Compound 107 (100.2 mg, 0.16 mmol) was dissolved in DCM (0.34 mL), treated with 4N HCl 
in 1,4-dioxane (0.78 mL, 3.11 mmol) and left to stir for 24 hr at room temperature. The reaction 
was concentrated in vacuo. The crude material was purified using a Combiflash RF system with 
a basic alumina column under gradient conditions with DCM and 2M ammonia in MeOH. 
Fractions were collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane (0.23 mL), 
and re-concentrated in vacuo to provide 108 as a white solid (28.7 mg, 0.06 mmol, 35.8%). 1H 
NMR (500 MHz, MeOD) δ 7.50 – 7.45 (m, 1H), 7.37 – 7.29 (m, 6H), 7.25 (t, J = 7.3 Hz, 2H), 
7.21 (s, 1H), 7.18 (d, J = 7.3 Hz, 2H), 7.11 (s, 1H), 3.75 – 3.69 (m, 2H), 3.43 – 3.35 (m, 2H), 
3.24 – 3.11 (m, 4H), 2.86 – 2.78 (m, 1H), 2.76 – 2.63 (m, 3H). 13C NMR (126 MHz, MeOD) δ 
158.01, 143.97, 143.75, 138.55, 137.63, 136.49, 135.44, 131.80, 131.29, 131.19, 130.36, 129.96 
(2C), 129.85 (2C), 129.60, 128.96, 128.59, 128.26, 127.32, 125.34, 58.91, 54.47, 54.32, 31.47, 
29.55, 29.44. MS(ESI) m/z calcd. for C27H29ClN4 444.21, found 445.48 [M]+, 446.44 [M+1]+, 
447.51 [M+2]+, 449.43 [M+4]+. LCMS Method: 96.88%. 
6.6.5: Experimental Data for compounds in Figure 52. 
4-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (109, KGM02066). 
Under argon (g), a mixture of 102 (0.15 g, 0.37 mmol), 4-cyanophenylboronic acid (0.07 g, 0.45 
mmol) and K2CO3 (0.13 g, 0.93 mmol) in toluene (5.42 mL)/ethanol (1.81 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (15 
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mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 109 as a yellow wax (0.11 g, 0.27 mmol, 71.6%). 
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.50 (m, 2H), 7.24 – 7.17 (m, 3H), 7.16 (s, 2H), 7.15 – 
7.11 (m, 4H), 7.01 (s, 1H), 6.93 – 6.90 (m, 1H), 2.80 – 2.74 (m, 1H), 2.61 – 2.49 (m, 6H), 2.38 – 
2.30 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 146.58, 143.05, 140.28, 139.00, 134.35, 133.48, 
132.17 (2C), 130.69 (2C), 129.91, 129.74, 128.80 (2C), 128.57 (2C), 128.17, 127.31, 126.26, 
60.37 (2C), 55.09 (2C), 33.83, 31.83. MS(ESI) m/z calcd. for C27H25ClN2 412.17, found 413.15 
[M]+, 415.40 [M+2]+, 416.43 [M+3]+. 
(Z)-4-((3-Chorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N’-hydroxybenzimidamide 
(110, KGM02073). 
A mixture of 109 (0.09 g, 0.22 mmol), hydroxylamine hydrochloride (0.06 g, 0.83 mmol), and 
sodium carbonate (0.04 g, 0.38 mmol) in ethanol (0.69 mL)/H20 (0.07 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 110 as a beige-gray solid (29 mg, 0.07 mmol, 29.3%). 1H NMR 
(500 MHz, MeOD) δ 7.55 – 7.52 (m, 1H), 7.26 – 7.13 (m, 8H), 7.13 – 7.07 (m, 2H), 7.07 – 7.01 
(m, 2H), 4.77 (s, 2H), 3.28 – 3.19 (m, 6H), 3.02 – 2.95 (m, 2H), 2.60 – 2.52 (m, 4H). 13C NMR 
(126 MHz, MeOD) δ 155.36, 144.22, 143.51, 138.91, 137.87, 135.37, 132.97, 131.74, 131.10, 
130.58, 130.34, 129.94 (3C), 129.81 (3C), 128.92, 128.45, 128.20, 127.54, 59.10, 54.57, 54.53, 
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31.70, 29.74, 29.72. MS(ESI) m/z calcd. for C27H28ClN3O 445.19, found 446.38 [M]+, 447.45 
[M+1]+, 448.41 [M+2]+.  
4-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (112, KGM03002) 
To a solution of 110 (22.3 mg, 0.05 mmol), in acetic acid (0.25 mL), acetic anhydride (0.01 mL, 
0.07 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 111 was determined by LC/MS. 10% Pd/C (2.2 mg) was introduced to 
the mixture and the reaction was stirred under hydrogen for 84 hours. The mixture was filtered 
through a 0.2 µm polyethersulfone membrane syringe filter and and the filtrate was evaporated to 
give a brown oil. The oil was dissolved in MeOH (0.06 mL) and treated with 4N HCl in 1,4-
dioxane (0.25 mL,1.01 mmol). The excess solvent was evaporated in vacuo. The crude material 
was purified using a Combiflash RF system with a basic alumina column under gradient 
conditions with DCM and 2M ammonia in MeOH. Fractions were collected, concentrated in 
vacuo, treated with 4N HCl in 1,4-dioxane (0.1 mL), and re-concentrated in vacuo to provide 
112 as a light tan solid (10.8 mg, 0.02 mmol, 43.0%. 1H NMR (500 MHz, MeOD) δ 7.97 (s, 
1H), 7.85 – 7.78 (m, 3H), 7.73 – 7.69 (m, 1H), 7.67 – 7.63 (m, 1H), 7.61 – 7.54 (m, 1H), 7.50 – 
7.46 (m, 1H), 7.35 – 7.30 (m, 5H), 3.82 – 3.70 (m, 2H), 3.70 – 3.63 (m, 2H), 3.63 – 3.52 (m, 
2H), 3.26 – 3.04 (m, 4H), 2.82 – 2.67 (m, 2H). 13C NMR (126 MHz, MeOD) δ 168.02, 147.82, 
137.65, 135.54, 134.22, 131.45, 131.36, 130.63, 129.95 (3C), 129.94 (3C), 129.89, 129.85, 
129.48, 129.39, 129.36, 128.25, 128.23, 62.14, 62.11, 58.98, 35.00, 31.40, 30.73. MS(ESI) m/z 
calcd. for C27H28ClN3 429.20, found 430.45 [M]+, 432.48 [M+2]+, 433.48 [M+3]+.  
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6.6.6: Experimental Data for compounds in Figure 53. 
3-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (113, KGM02064). 
Under argon (g), a mixture of 102 (0.16 g, 0.41 mmol), 3-cyanophenylboronic acid (0.07 g, 0.50 
mmol) and K2CO3 (0.14 g, 1.03 mmol) in toluene (6.0 mL)/ethanol (2.0 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (16 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 113 as a yellow wax (0.12 g, 0.29 mmol, 70.2%). 
1H NMR (500 MHz, CDCl3) δ 7.47 – 7.43 (m, 1H), 7.36 – 7.32 (m, 2H), 7.30 – 7.27 (m, 1H), 
7.24 – 7.19 (m, 2H), 7.18 (d, J = 1.8 Hz, 1H), 7.17 (d, J = 1.9 Hz, 1H), 7.16 – 7.11 (m, 3H), 7.02 
– 7.00 (m, 1H), 6.94 – 6.90 (m, 1H), 2.81 – 2.74 (m, 2H), 2.63 – 2.48 (m, 6H), 2.39 – 2.28 (m, 
4H). 13C NMR (126 MHz, CDCl3) δ 143.07, 142.96, 140.23, 138.84, 134.38, 134.36, 133.38, 
132.93, 130.49, 129.86, 129.78, 129.25, 128.82 (2C), 128.59 (2C), 128.11, 127.33, 126.29, 
118.87, 112.61, 60.36 (2C), 55.08 (2C), 33.78, 31.65. MS(ESI) m/z calcd. for C27H25ClN2 
412.17, found 413.19 [M]+, 416.43 [M+3]+. 
(Z)-3-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-
hydroxybenzimidamide (114, KGM02072). 
A mixture of 113 (0.09 g, 0.22 mmol), hydroxylamine hydrochloride (0.06 g, 0.83 mmol), and 
sodium carbonate (0.04 g, 0.38 mmol) in ethanol (0.69 mL)/H2O (0.07 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
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further dried in vacuo to provide 114 as a white solid (90.4 mg, 0.20 mmol, 90.9%). 1H NMR 
(500 MHz, DMSO) δ 11.76 (s, 1H), 10.07 (s, 1H), 8.02 – 7.98 (m, 1H), 7.89 (s, 1H), 7.82 – 7.78 
(m, 2H), 7.76 – 7.71 (m, 4H), 7.69 – 7.65 (m, 3H), 7.59 – 7.55 (m, 2H), 6.25 (s, 2H), 3.93 – 3.26 
(m, 12H). 13C NMR (126 MHz, CDCl3) δ 153.21, 142.58, 141.01, 137.01, 134.23, 132.77, 
130.87, 129.70, 129.26, 128.83 (4C), 128.62 (3C), 127.56, 127.34, 126.99, 126.87, 124.88, 
58.79, 53.93 (2C), 31.10, 28.92 (2C). MS(ESI) m/z calcd. for C27H28ClN3O 445.19, found 
446.38 [M]+, 447.45 [M+1]+, 448.36 [M+2]+. 
3-((3-Chlorophenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (116, KGM03003) 
To a solution of 114 (40.1 mg, 0.09 mmol), in acetic acid (0.46 mL), acetic anhydride (0.01 mL, 
0.13 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 115 was determined by LC/MS. 10% Pd/C (4 mg) was introduced to the 
mixture and the reaction was stirred under hydrogen for 72 hours. The mixture was filtered 
through a 0.2 µm polyethersulfone membrane syringe filter and and the filtrate was evaporated to 
give a tan oil. The oil was dissolved in MeOH (0.14 mL) treated with 4N HCl in 1,4-dioxane (0.6 
mL, 2.39 mmol). The excess solvent was evaporated in vacuo to provide the crude. The crude 
material was purified using a Combiflash RF system with a basic alumina column under gradient 
conditions with DCM and 2M ammonia in MeOH. Fractions were collected, concentrated in 
vacuo, treated with 4N HCl in 1,4-dioxane (0.12 mL), and re-concentrated in vacuo to provide 
116 as a light yellow solid (14.9 mg, 0.03 mmol, 32.9%). 1H NMR (500 MHz, MeOD) δ 7.81 
(s, 1H), 7.76 – 7.68 (m, 3H), 7.67 – 7.62 (m, 2H), 7.60 – 7.55 (m, 2H), 7.33 – 7.32 (m, 3H), 7.26 
– 7.25 (m, 1H), 7.22 – 7.20 (m, 1H), 3.74 – 3.69 (m, 2H), 3.40 (dd, J = 10.3, 6.6 Hz, 2H), 3.27 – 
3.19 (m, 2H), 3.14 (dd, J = 10.2, 6.7 Hz, 2H), 2.79 – 2.73 (m, 1H), 2.72 – 2.64 (m, 3H). 13C 
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NMR (126 MHz, MeOD) δ 168.24, 143.58, 143.24, 137.59, 136.00, 135.57, 134.11, 132.93, 
131.43, 131.31, 130.82, 130.03, 129.98 (2C), 129.84 (2C), 129.46, 128.94, 128.77, 128.29, 
128.01, 58.91, 54.35, 54.24, 31.48, 29.43 (2C). MS(ESI) m/z calcd. for C27H28ClN3 429.20, 
found 430.41 [M]+, 431.42 [M+1]+, 432.44 [M+2]+, 433.40 [M+3]+.  
6.7: Experimental Data for KGM02092, KGM02093, KGM02096, and KGM02097. 
6.7.1: Experimental Data for compounds in Figure 54. 
(3-Methylbenzyl)triphenylphosphonium bromide (118, KGM02043, KGM02061). 
Triphenylphosphine (4.20 g, 16.0 mmol) was dissolved in toluene (22.4 mL) and 3-methylbenzyl 
bromide 117 (2.16 g, 16.0 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 118 as a fine white powder (6.63 g, 14.82 mmol, 92.6%). 1H NMR 
(500 MHz, CDCl3) δ 7.72 – 7.68 (m, 3H), 7.65 – 7.60 (m, 6H), 7.59 – 7.54 (m, 6H), 6.96 – 6.91 
(m, 2H), 6.83 – 6.79 (m, 1H), 6.66 (s, 1H), 5.13 (d, J = 14.2 Hz, 2H), 2.01 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 138.49 (d, J = 3.2 Hz), 135.04 (2C), 135.02 (2C), 134.36 (3C), 134.28 
(3C), 132.09 (d, J = 5.5 Hz), 130.19 (3C), 130.09 (4C), 129.16 (d, J = 3.7 Hz), 128.44, 128.39, 
126.74, 126.67, 118.07, 117.38, 30.96 (d, J = 46.9 Hz), 21.15. MS(ESI) m/z calcd. for C26H24P+ 
367.16, found 367.13 [M], 368.07 [M]+, 369.14 [M+1]+, 370.21 [M+2]+. 
4-(3-Methylbenzylidene)-1-phenethylpiperidine (119, KGM02047, KGM02062). 
Compound 118 (6.51 g, 14.54 mmol) was suspended in anhydrous THF (15.4 mL) under Argon 
at -78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (8.8 mL, 17.45 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (2.96 g, 14.54 mmol) in anhydrous THF (7.57 
mL) was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
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overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using a Combiflash RF system under 
gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 119 as a yellow oil (1.28 g, 4.39 mmol, 30.2%). 1H NMR (600 
MHz, CDCl3) δ 7.22 – 7.18 (m, 2H), 7.14 – 7.09 (m, 4H), 6.95 – 6.92 (m, 3H), 6.19 (s, 1H), 
2.78 – 2.73 (m, 2H), 2.56 – 2.52 (m, 4H), 2.50 – 2.47 (m, 2H), 2.45 – 2.41 (m, 2H), 2.37 – 2.34 
(m, 2H), 2.26 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 140.60, 139.41, 137.87, 137.77, 129.79, 
128.85 (2C), 128.53 (2C), 128.14, 127.01, 126.16, 126.14, 123.48, 60.69, 55.38, 54.70, 36.60, 
33.94, 29.32, 21.62. MS(ESI) m/z calcd. for C21H25N 291.20, found 292.06 [M]+, 293.00 
[M+1]+, 294.20 [M+2]+. 
4-(Bromo(3-methylphenyl)methylene)-1-phenethylpiperidine (121, KGM02049). 
Compound 119 (2.12g, 7.27 mmol) was dissolved in DCM (30 mL) under argon at -78 ˚C. Br2 
(0.56 mL, 10.91 mmol) diluted in DCM (90 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 120, 
which was determined by LC/MS. NaOH (1.75 g, 43.65 mmol) was dissolved in MeOH (72 mL) 
and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) until the 
full conversion to the monobromo, determined via LC/MS. The reaction was quenched with 
H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material 
was purified using a Combiflash RF system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 121 as an 
orange wax (1.41 g, 3.81 mmol, 52.4%). 1H NMR (500 MHz, CDCl3) δ 7.23 – 7.19 (m, 2H), 
7.17 – 7.11 (m, 4H), 7.04 – 6.99 (m, 3H), 2.79 – 2.74 (m, 2H), 2.70 – 2.65 (m, 2H), 2.62 – 2.55 
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(m, 4H), 2.43 – 2.37 (m, 2H), 2.28 – 2.25 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 140.29, 
140.21, 138.08, 136.92, 130.03, 128.91, 128.81 (2C), 128.57 (2C), 128.23, 126.48, 126.26, 
116.15, 60.22, 54.37, 54.03, 34.42, 33.75, 31.78, 21.52. MS(ESI) m/z calcd. for C21H24BrN 
369.11, found 370.21 [M]+, 372.25 [M+2]+. 
6.7.2: Experimental Data for compounds in Figure 55. 
4-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (122, KGM02070). 
Under argon (g), a mixture of compound 121 (0.36 g, 0.98 mmol), 4-aminophenylboronic acid 
(0.20 g, 1.18 mmol) and K2CO3 (0.34 g, 2.45 mmol) in toluene (2.6 mL)/ethanol (1.7 mL)/H2O 
(1.7 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (36 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using a Combiflash RF system under gradient conditions with hexane and ethyl acetate 
as eluents. Fractions were collected and concentrated in vacuo to provide 122 as an orange wax 
(0.35 g, 0.92 mmol, 93.5%). 1H NMR (500 MHz, CDCl3) δ 7.20 (t, J = 7.5 Hz, 2H), 7.13 – 7.06 
(m, 4H), 6.92 (d, J = 7.5 Hz, 1H), 6.84 (t, J = 8.7 Hz, 4H), 6.52 (d, J = 8.4 Hz, 2H), 3.52 (s, 2H), 
2.78 – 2.74 (m, 2H), 2.57 – 2.53 (m, 2H), 2.52 – 2.48 (m, 4H), 2.42 – 2.39 (m, 2H), 2.35 – 2.31 
(m, 2H), 2.22 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 144.80, 143.04, 140.52, 137.48, 136.04, 
134.10, 133.01, 130.93 (2C), 130.58, 128.82 (2C), 128.51 (2C), 127.83, 127.04 (2C), 126.15, 
114.72 (2C), 60.67, 55.50 (2C), 33.83, 31.83, 31.71, 21.59. MS(ESI) m/z calcd. for C27H30N2 
382.24, found 383.32 [M]+, 384.51 [M+1]+. 
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(Z)-1,3-Bis(tert-butoxycarbonyl)-4-((3-methylphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (123, KGM02077). 
Triethylamine (0.23 mL, 1.62 mmol) was added drop wise to a suspension of compound 122 
(0.31 g, 0.81 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.26 g, 0.89 mmol), 
HgCl2 (0.24 g, 0.89 mmol) in DCM (11.4 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate, then with DCM and MeOH as eluents. Fractions were collected and concentrated 
in vacuo to provide 123 as a white solid (0.32 g, 0.52 mmol, 63.8%). 1H NMR (600 MHz, 
CDCl3) δ 11.56 (s, 1H), 10.23 (s, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.22 – 7.18 (m, 2H), 7.15 – 7.08 
(m, 4H), 7.00 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.83 (s, 1H), 
2.80 – 2.75 (m, 2H), 2.60 – 2.55 (m, 2H), 2.55 – 2.49 (m, 4H), 2.42 – 2.38 (m, 2H), 2.39 – 2.34 
(m, 2H), 2.23 (s, 3H), 1.45 (s, 9H), 1.43 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 163.68, 153.54, 
153.41, 142.39, 140.45, 139.05, 137.64, 135.67, 135.18, 130.72, 130.47, 128.84 (3C), 128.53 
(3C), 127.90, 127.27, 127.11, 126.17, 121.75, 110.11, 83.81, 79.74, 60.63, 55.49, 55.41, 33.81, 
31.80, 31.69, 28.33 (3C), 28.22 (3C), 21.58. MS(ESI) m/z calcd. for C38H48N4O4 624.37, found 
625.31 [M]+, 525.23 [M-BOC]+, 425.27 [M-2BOC]+, 426.30 [(M-2BOC)+1]+, 427.39 [(M-
2BOC)+2]+. 
1-(4-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (124, KGM02092). 
Compound 123 (150 mg, 0.24 mmol) was dissolved in DCM (0.6 mL), treated with 4N HCl in 
1,4-dioxane (1.2 mL, 4.80 mmol) and left to stir for 24 hr at room temperature. The reaction was 
concentrated in vacuo to provide 124 as an off-white solid (60.8 mg, 0.12 mmol, 50.9%). 1H 
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NMR (500 MHz, DMSO) δ 11.48 (s, 1H), 10.24 (s, 1H), 7.61 (s, 2H), 7.34 (t, J = 7.5 Hz, 2H), 
7.29 – 7.24 (m, 4H), 7.20 (s, 4H), 7.09 (d, J = 7.5 Hz, 1H), 6.98 – 6.95 (m, 2H), 3.62 – 3.57 (m, 
2H), 3.29 – 3.24 (m, 2H), 3.13 – 3.04 (m, 4H), 2.69 – 2.52 (m, 4H), 2.28 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 156.03, 140.93, 138.96, 137.53, 137.17, 137.07, 134.00, 130.30, 129.93, 
129.55, 128.64 (3C), 128.62 (3C), 128.29, 127.66, 126.75, 126.22, 123.92, 56.16, 52.12, 52.02, 
29.40, 27.85, 27.67, 21.00. MS(ESI) m/z calcd. for C28H32N4 424.26, found 425.44 [M]+, 426.46 
[M+1]+, 427.58 [M+2]+. LCMS Method: 99.21%. 
6.7.3: Experimental Data for compounds in Figure 56. 
3-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (125, KGM02067). 
Under argon (g), a mixture of 121 (0.36 g, 0.98 mmol), 3-aminophenylboronic acid (0.20 g, 1.18 
mmol) and K2CO3 (0.34 g, 2.45 mmol) in toluene (13.9 mL)/ethanol (4.6 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (37 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 125 as an orange wax (0.17 g, 0.43 mmol, 
44.2%). 1H NMR (500 MHz, CDCl3) δ 7.22 – 7.18 (m, 2H), 7.14 – 7.09 (m, 5H), 6.99 (t, J = 7.7 
Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 6.81 – 6.77 (m, 1H), 6.50 – 6.43 (m, 2H), 6.38 – 6.34 (m, 1H), 
3.49 (s, 2H), 2.76 (dd, J = 10.1, 6.4 Hz, 2H), 2.56 (dd, J = 10.0, 6.5 Hz, 2H), 2.53 – 2.47 (m, 
4H), 2.39 – 2.36 (m, 2H), 2.36 – 2.32 (m, 2H), 2.22 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
146.13, 143.68, 142.73, 142.39, 140.40, 136.37, 134.72, 130.40, 128.94, 128.82 (2C), 128.53 
(2C), 127.90, 127.20, 126.86, 126.19, 120.40, 116.61, 113.40, 60.57, 55.44, 55.39, 33.74, 31.63, 
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31.55, 21.59. MS(ESI) m/z calcd. for C27H30N2 382.24, found 383.29 [M]+, 384.45 [M+1]+, 
385.57 [M+2]+. 
 (Z)-1,3-Bis(tert-butoxycarbonyl)-3-((3-methylphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (126, KGM02076). 
Triethylamine (0.09 mL, 0.70 mmol) was added drop wise to a suspension of compound 125 
(0.13 g, 0.35 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.11 g, 0.38 mmol), 
HgCl2 (0.10 g, 0.38 mmol) in DCM (4.91 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate, then with DCM and MeOH as eluents. Fractions were collected and concentrated 
in vacuo to provide 126 as a white solid (77 mg, 0.12 mmol, 35.4%). 1H NMR (500 MHz, 
CDCl3) δ 11.54 (s, 1H), 10.14 (s, 1H), 7.56 – 7.53 (m, 1H), 7.23 – 7.18 (m, 3H), 7.15 – 7.10 (m, 
5H), 6.95 – 6.93 (m, 1H), 6.87 (d, J = 7.6 Hz, 1H), 6.83 (s, 1H), 6.80 (d, J = 7.7 Hz, 1H), 2.80 – 
2.76 (m, 2H), 2.60 – 2.52 (m, 6H), 2.42 – 2.39 (m, 2H), 2.38 – 2.35 (m, 2H), 2.23 (s, 3H), 1.45 
(s, 9H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.70, 153.67, 153.41, 143.06, 142.10, 
137.68, 136.51, 130.53, 128.82 (4C), 128.71, 128.54 (3C), 127.98, 127.35, 126.95, 126.52, 
126.21, 123.62, 120.85, 83.80, 79.64, 60.51, 55.43, 55.24, 33.72, 31.56, 31.53, 28.37 (3C), 28.23 
(3C), 21.59. MS(ESI) m/z calcd. for C38H48N4O4 624.37, found 625.38 [M]+, 626.69 [M+1]+, 
525.42 [M-BOC]+, 425.30 [M-2BOC]+, 426.56 [(M-2BOC)+1]+. 
1-(3-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (127, KGM02093). 
Compound 126 (50.2 mg, 0.08 mmol) was dissolved in DCM (0.17 mL), treated with 4N HCl in 
1,4-dioxane (0.40 mL, 1.61 mmol) and left to stir for 24 hr at room temperature. The reaction 
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was concentrated in vacuo. The crude material was purified using a Combiflash RF system with 
a basic alumina column under gradient conditions with DCM and 2M ammonia in MeOH. 
Fractions were collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane, and re-
concentrated in vacuo to provide 127 as a beige solid (39.7 mg, 0.08 mmol, 99.3%). 1H NMR 
(500 MHz, DMSO) δ 11.43 (s, 1H), 10.16 (s, 1H), 7.61 (s, 2H), 7.41 (t, J = 7.8 Hz, 1H), 7.34 (t, 
J = 7.4 Hz, 2H), 7.28 – 7.23 (m, 4H), 7.15 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 7.5 Hz, 1H), 7.04 (d, 
J = 7.5 Hz, 1H), 6.98 (d, J = 7.5 Hz, 3H), 3.61 – 3.56 (m, 2H), 3.29 – 3.23 (m, 2H), 3.12 – 3.03 
(m, 4H), 2.68 – 2.52 (m, 4H), 2.28 (s, 3H). 13C NMR (126 MHz, DMSO) δ 156.14, 142.58, 
140.71, 137.53, 137.16, 136.92, 135.37, 130.23, 129.62, 128.63 (5C), 128.27, 127.74, 127.12, 
126.75, 126.30, 124.83, 122.75, 56.14, 52.13, 52.00, 29.41, 27.85, 27.71, 20.99. MS(ESI) m/z 
calcd. for C28H32N4 424.26, found 425.61 [M]+, 426.57 [M+1]+, 427.64 [M+2]+. LCMS 
Method: 99.17%. 
6.7.4: Experimental Data for compounds in Figure 57. 
3-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (128, 
KGM02068). 
Under argon (g), a mixture of 121 (0.35 g, 0.94 mmol), 3-cyanophenylboronic acid (0.17 g, 1.13 
mmol) and K2CO3 (0.32 g, 2.34 mmol) in toluene (13.7 mL)/ethanol (4.6 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (35 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 128 as an orange wax (0.27 g, 0.68 mmol, 
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72.3%). 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.39 (m, 1H), 7.35 (s, 1H), 7.33 – 7.28 (m, 2H), 
7.20 (q, J = 7.8 Hz, 2H), 7.15 – 7.10 (m, 4H), 6.98 (d, J = 7.6 Hz, 1H), 6.84 – 6.80 (m, 2H), 2.75 
(dd, J = 10.0, 6.4 Hz, 2H), 2.56 (dd, J = 10.0, 6.5 Hz, 2H), 2.54 – 2.48 (m, 4H), 2.38 – 2.33 (m, 
2H), 2.33 – 2.28 (m, 2H), 2.24 (s, 3H). 3C NMR (126 MHz, CDCl3) δ 143.76, 141.30, 140.40, 
138.05, 137.47, 134.36, 134.15, 133.39, 130.46, 130.09, 128.99, 128.80 (2C), 128.52 (2C), 
128.28, 127.80, 126.94, 126.18, 119.04, 112.33, 60.48, 55.22 (2C), 33.87, 31.80, 31.67, 21.56. 
MS(ESI) m/z calcd. for C28H28N2 392.23, found 393.24 [M]+, 394.42 [M+1]+. 
(Z)-3-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-
hydroxybenzimidamide (129, KGM02074). 
A mixture of 128 (0.21 g, 0.54 mmol), hydroxylamine hydrochloride (0.14 g, 1.98 mmol), and 
sodium carbonate (0.10 g, 0.91 mmol) in ethanol (1.65 mL)/H2O (0.17 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 129 as a white solid (0.13 g, 0.31 mmol, 58.4%). 1H NMR (500 
MHz, CDCl3) δ 7.41 – 7.36 (m, 2H), 7.20 – 7.15 (m, 3H), 7.14 – 7.10 (m, 3H), 7.06 (t, J = 7.5 
Hz, 1H), 7.00 (d, J = 7.5 Hz, 1H), 6.98 – 6.93 (m, 1H), 6.82 – 6.74 (m, 2H), 4.99 (s, 1H), 3.16 – 
2.92 (m, 8H), 2.74 – 2.60 (m, 4H), 2.18 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.62, 141.74, 
140.76, 138.80, 138.16, 132.54, 131.00, 130.03, 128.97 (3C), 128.83 (4C), 128.36, 128.08, 
127.16, 126.86, 126.47, 124.49, 58.59, 53.97, 53.93, 30.86, 28.71, 28.67, 21.51. MS(ESI) m/z 
calcd. for C28H31N3O 425.25, found 426.57 [M]+, 427.53 [M+1]+. 
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3-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (131, KGM02096) 
To a solution of 129 (100 mg, 0.24 mmol), in acetic acid (1.19 mL), acetic anhydride (0.03 mL, 
0.33 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 130 was determined by LC/MS. The intermediate was purified on a 
Combiflash RF under isocratic conditions with DCM (96%) and MeOH (4%). Fractions were 
collected and concentrated in vacuo leaving 43.9 mg of 130, which was then dissolved in MeOH 
(1.5 mL), 10% Pd/C (4.4 mg) was introduced to the mixture and the reaction was stirred under 
hydrogen for 72 hours. The mixture was filtered through a 0.2 µm polyethersulfone membrane 
syringe filter and the filtrate was evaporated to give a tan oil. The oil was dissolved in MeOH 
(0.09 mL) and treated with 4N HCl in 1,4-dioxane (0.4 mL, 1.61 mmol). The excess solvent was 
evaporated in vacuo to provide the crude. The crude material was purified using a Combiflash 
RF system with a basic alumina column under gradient conditions with DCM and 2M ammonia 
in MeOH. Fractions were collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane 
(0.4 mL), and re-concentrated in vacuo to provide 131 as a white solid (41.7 mg, 0.09 mmol, 
36.8%). 1H NMR (500 MHz, MeOD) δ 7.83 (s, 1H), 7.65 – 7.61 (m, 1H), 7.59 – 7.54 (m, 1H), 
7.35 – 7.27 (m, 5H), 7.26 – 7.16 (m, 4H), 7.04 – 7.00 (m, 1H), 3.75 – 3.71 (m, 1H), 3.64 – 3.54 
(m, 2H), 3.16 – 3.04 (m, 4H), 2.74 – 2.66 (m, 1H), 2.31 (s, 3H), 1.89 – 1.70 (m, 2H), 1.69 – 1.50 
(m, 2H). 13C NMR (126 MHz, MeOD) δ 168.41, 146.21, 143.18, 139.84, 137.71, 134.83, 
130.92, 129.95 (3C), 129.87 (2C), 129.80 (3C), 128.69, 128.65, 128.27, 128.23, 127.15, 126.02, 
59.17, 58.93, 53.97, 37.83, 31.37, 29.92, 21.49. MS(ESI) m/z calcd. for C28H31N3 409.25, found 
410.53 [M]+, 412.52 [M+2]+, 413.54 [M+3]+, 414.57 [M+5]+.  
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6.7.5: Experimental Data for compounds in Figure 58. 
4-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (132, 
KGM02071). 
Under argon (g), a mixture of 121 (0.33 g, 0.90 mmol), 4-cyanophenylboronic acid (0.16 g, 1.08 
mmol) and K2CO3 (0.31 g, 2.25 mmol) in toluene (13.1 mL)/ethanol (4.4 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (33 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 132 as a yellow wax (0.31 g, 0.79 mmol, 87.8%). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 2H), 7.23 – 7.18 (m, 2H), 7.18 – 7.14 (m, 2H), 
7.14 – 7.10 (m, 4H), 7.00 – 6.95 (m, 1H), 6.85 – 6.79 (m, 2H), 2.75 (dd, J = 10.0, 6.4 Hz, 2H), 
2.56 (dd, J = 10.0, 6.5 Hz, 2H), 2.54 – 2.48 (m, 4H), 2.35 (t, J = 5.6 Hz, 2H), 2.32 (t, J = 5.6 Hz, 
2H), 2.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 147.44, 141.25, 140.37, 138.03, 137.61, 
134.77, 131.97 (2C), 130.66 (2C), 130.51, 128.78 (2C), 128.52 (2C), 128.26, 127.81, 126.99, 
126.19, 119.12, 110.15, 60.46, 55.21 (2C), 33.85, 31.85, 31.72, 21.54. MS(ESI) m/z calcd. for 
C28H28N2 392.23, found 393.32 [M]+, 394.27 [M+1]+, 395.50 [M+2]+. 
(Z)-4-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N’-
hydroxybenzimidamide (133, KGM02075). 
A mixture of 132 (0.26 g, 0.65 mmol), hydroxylamine hydrochloride (0.17 g, 2.40 mmol), and 
sodium carbonate (0.12 g, 1.10 mmol) in ethanol (2 mL)/H20 (0.2 mL) (10:1 ratio) were refluxed 
at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo leaving 
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a residue. The residue was triturated in H2O and filtered again. The precipitate was further dried 
in vacuo to provide 133 as a beige-gray solid (0.12 g, 0.27 mmol, 42.2%). 1H NMR (500 MHz, 
CDCl3) δ 7.46 – 7.43 (m, 1H), 7.20 – 7.16 (m, 2H), 7.15 – 7.06 (m, 5H), 7.01 – 6.94 (m, 3H), 
6.77 (s, 2H), 4.93 (s, 1H), 3.11 – 2.89 (m, 8H), 2.71 – 2.58 (m, 4H), 2.19 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 152.48, 143.04, 140.85, 138.14, 137.07, 132.19, 131.10, 130.07, 129.72 (2C), 
128.96 (3C), 128.82 (3C), 128.36, 128.07, 127.12, 126.51, 125.91, 58.78, 54.09 (2C), 31.06, 
28.86 (2C), 21.53. MS(ESI) m/z calcd. for C28H31N3O 425.25, found 426.51 [M]+, 427.47 
[M+1]+, 428.71 [M+2]+. 
4-((3-Methylphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (135, KGM02097) 
To a solution of 133 (22.3 mg, 0.05 mmol), in acetic acid (0.25 mL), acetic anhydride (0.01 mL, 
0.07 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 134 was determined by LC/MS. The intermediate was purified on a 
Combiflash RF under isocratic conditions with DCM (96%) and MeOH (4%). Fractions were 
collected and concentrated in vacuo leaving 35 mg of 134, which was then dissolved in MeOH, 
10% Pd/C (3.5 mg) was introduced to the mixture and the reaction was stirred under hydrogen 
for 72 hours. The mixture was filtered through a 0.2 µm polyethersulfone membrane syringe 
filter and the filtrate was evaporated to give a tan oil. The oil was dissolved in MeOH (0.10 mL) 
and treated with 4N HCl in 1,4-dioxane (0.41 mL, 1.62 mmol). The excess solvent was 
evaporated in vacuo to provide the crude. The crude material was purified using a Combiflash 
RF system with a basic alumina column under gradient conditions with DCM and 2M ammonia 
in MeOH. Fractions were collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane 
(0.3 mL), and re-concentrated in vacuo to provide 135 as a light beige solid (31.2 mg, 0.07 
 230 
mmol, 30.6%. 1H NMR (500 MHz, MeOD) δ 7.80 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 7.8 Hz, 2H), 
7.67 (d, J = 7.9 Hz, 2H), 7.44 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 10.2 Hz, 5H), 7.01 (d, J = 10.1 Hz, 
2H), 3.73 (s, 1H), 3.64 – 3.58 (m, 2H), 3.13 – 3.05 (m, 4H), 2.72 – 2.67 (m, 2H), 2.30 (s, 3H), 
1.84 – 1.74 (m, 2H), 1.66 – 1.55 (m, 2H). 13C NMR (126 MHz, MeOD) δ 166.81, 150.08, 
147.32, 141.73, 140.28, 138.53, 138.31, 136.44, 136.37, 130.17, 128.91, 128.65 (2C), 128.53 
(2C), 128.32, 128.14, 127.87, 127.42, 126.93, 124.78, 57.68, 53.17, 52.65, 36.50, 30.07, 28.50, 
20.19. MS(ESI) m/z calcd. for C28H31N3 409.25, found 410.50 [M]+, 411.51 [M+1]+, 412.53 
[M+2]+, 413.53 [M+3]+, 414.58 [M+4]+.  
6.8: Experimental Data for KGM02090, KGM02091, KGM03010, and KGM03011. 
6.8.1: Experimental Data for compounds in Figure 59. 
(3-Methoxybenzyl)triphenylphosphonium bromide (137, KGM02039). 
Triphenylphosphine (7.88 g, 30.0 mmol) was dissolved in toluene (42 mL) and 3-methoxybenzyl 
bromide 136 (4.2 g, 30.0 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 137 as a fine white powder (13.79 g, 29.76 mmol, 99.2%). 1H NMR 
(500 MHz, CDCl3) δ 7.70 – 7.66 (m, 4H), 7.66 – 7.62 (m, 5H), 7.58 – 7.53 (m, 6H), 6.93 (t, J = 
7.8 Hz, 1H), 6.69 – 6.65 (m, 2H), 6.57 (d, J = 7.5 Hz, 1H), 5.20 (d, JHP = 14.4 Hz, 2H), 3.44 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 159.55 (d, JCP = 3.4 Hz), 135.00 (2C), 134.40 (4C), 134.32 
(3C), 130.16 (4C), 130.06 (3C), 128.42, 128.35, 116.15 (d, JCP = 5.4 Hz), 115.18 (d, JCP = 3.9 
Hz), 55.40, 30.81 (d, JCP = 47.0 Hz). MS(ESI) m/z calcd. for C26H24OP+ 383.16, found 383.12 
[M], 384.06 [M]+, 385.13 [M+1]+, 386.14 [M+2]+. 
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4-(3-Methoxybenzylidene)-1-phenethylpiperidine (138, KGM02041). 
Compound 137 (13.56 g, 29.27 mmol) was suspended in anhydrous THF (31 mL) under argon at 
-78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (17.6 mL, 35.12 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (5.95 g, 29.27 mmol) in anhydrous THF (15.2 
mL) was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using an Isolera One Biotagé system 
under gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 138 as a yellow oil (4.36 g, 14.20 mmol, 48.5%). 1H NMR 
(500 MHz, CDCl3) δ 7.18 – 7.14 (m, 2H), 7.11 – 7.09 (m, 2H), 7.09 – 7.05 (m, 2H), 6.71 – 6.68 
(m, 1H), 6.66 – 6.61 (m, 2H), 6.16 (s, 1H), 3.65 (s, 3H), 2.75 – 2.68 (m, 2H), 2.52 – 2.45 (m, 
6H), 2.39 (t, J = 5.6 Hz, 2H), 2.31 (t, J = 5.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 159.39, 
140.39, 139.70, 139.16, 129.04, 128.69 (2C), 128.37, 126.01, 123.18, 121.46, 114.58, 111.54, 
60.47, 55.15, 55.09, 54.48, 36.40, 33.77, 29.22. MS(ESI) m/z calcd. for C21H25NO 307.19, found 
308.04 [M]+, 309.11 [M+1]+, 310.18 [M+2]+. 
4-(Bromo(3-Methoxyphenyl)methylene)-1-phenethylpiperidine (140, KGM02045). 
Compound 138 (4.24 g, 13.80 mmol) was dissolved in DCM (168 mL) under Argon at -78 ˚C. 
Br2 (1.06 mL, 20.71 mmol) diluted in DCM (60 mL) was added to the solution drop wise using 
an addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was 
allowed to warm to room temperature until the complete conversion to the dibromo intermediate 
139, which was determined by LC/MS. NaOH (3.31 g, 82.83 mmol) was dissolved in MeOH 
(137 mL) and added drop wise using an addition funnel. The mixture was heated to reflux (70 
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˚C) until the full conversion to the monobromo, determined via LC/MS. The reaction was 
quenched with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The 
crude material was purified using an Isolera One Biotagé system under gradient conditions with 
hexane and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to 
provide 140 as a yellow oil (2.08 g, 5.38 mmol, 39.0%). 1H NMR (500 MHz, CDCl3) δ 7.22 – 
7.16 (m, 3H), 7.14 – 7.10 (m, 3H), 6.80 – 6.77 (m, 1H), 6.76 – 6.73 (m, 2H), 3.72 (s, 3H), 2.79 – 
2.74 (m, 2H), 2.70 – 2.65 (m, 2H), 2.61 – 2.55 (m, 4H), 2.43 – 2.39 (m, 2H), 2.30 – 2.26 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 159.40, 141.56, 140.12, 137.14, 129.36, 128.78 (2C), 
128.55 (2C), 126.25, 121.77, 115.65, 114.97, 113.80, 60.13, 55.39, 54.30, 53.94, 34.31, 33.67, 
31.75. MS(ESI) m/z calcd. for C21H24BrNO 385.10, found 385.95 [M], 387.90 [M+1]+, 389.04 
[M+3]+, 390.11 [M+4]+. 
6.8.2: Experimental Data for compounds in Figure 60. 
3-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (141, KGM02053). 
Under argon (g), a mixture of 140 (0.52 g, 1.34 mmol), 3-aminophenylboronic acid (0.28 g, 1.61 
mmol) and K2CO3 (0.46 g, 3.36 mmol) in toluene (19 mL)/ethanol (6.3 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (52 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 141 as a light-orange wax (0.37 g, 0.93 mmol, 
69.3%). 1H NMR (500 MHz, CDCl3) δ 7.19 (t, J = 7.4 Hz, 2H), 7.13 – 7.08 (m, 4H), 6.98 (t, J = 
7.7 Hz, 1H), 6.66 (d, J = 7.8 Hz, 2H), 6.61 (s, 1H), 6.48 (d, J = 7.5 Hz, 1H), 6.45 – 6.41 (m, 1H), 
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6.36 (s, 1H), 3.67 (s, 3H), 3.48 (s, 2H), 2.77 – 2.72 (m, 2H), 2.56 – 2.51 (m, 2H), 2.50 – 2.45 (m, 
4H), 2.37 – 2.31 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 159.30, 146.15, 143.92, 143.38, 
140.47, 135.96, 135.16, 128.98, 128.92, 128.78, 128.47, 126.11, 122.31, 120.27, 116.50, 115.62, 
113.40, 111.55, 60.58, 55.41, 55.38, 55.23, 33.81, 31.69, 31.66. MS(ESI) m/z calcd. for 
C27H30N2O 398.24, found 399.33 [M]+, 400.35 [M+1]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-3-((3-Methoxyphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (142, KGM02055). 
Triethylamine (0.21 mL, 1.51 mmol) was added drop wise to a suspension of compound 141 
(0.30 g, 0.75 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.24 g, 0.83 mmol), 
HgCl2 (0.23 g, 0.83 mmol) in DCM (10.6 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate, then with DCM and MeOH as eluents. Fractions were collected and concentrated 
in vacuo to provide 142 as a white solid (0.33 g, 0.51 mmol, 68.2%). 1H NMR (500 MHz, 
CDCl3) δ 11.54 (s, 1H), 10.14 (s, 1H), 7.56 – 7.51 (m, 1H), 7.23 – 7.15 (m, 3H), 7.15 – 7.09 (m, 
5H), 6.83 – 6.80 (m, 1H), 6.70 – 6.63 (m, 2H), 6.59 (s, 1H), 3.69 (s, 3H), 2.79 – 2.72 (m, 2H), 
2.59 – 2.47 (m, 6H), 2.42 – 2.37 (m, 2H), 2.37 – 2.32 (m, 2H), 1.45 (s, 9H), 1.43 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 163.68, 159.39, 153.66, 153.40, 143.69, 142.81, 140.53, 136.51, 
136.07, 135.30, 129.09, 128.81 (2C), 128.70, 128.50 (2C), 126.47, 126.14, 123.61, 122.44, 
120.84, 115.67, 111.82, 83.79, 79.62, 60.59, 55.49, 55.28 (2C), 33.90, 31.81, 31.69, 28.36 (3C), 
28.22 (3C). MS(ESI) m/z calcd. for C38H48N4O5 640.36, found 641.23 [M]+, 642.71 [M+1]+, 
441.31 [M-2BOC]+, 442.56 [(M-2BOC)+1]+. 
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1-(3-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (143, KGM02090). 
Compound 142 (100 mg, 0.16 mmol) was dissolved in DCM (0.5 mL), treated with 4N HCl in 
1,4-dioxane (0.6 mL, 2.34 mmol) and left to stir for 24 hr at room temperature. The reaction was 
concentrated in vacuo to provide 143 as an off-white, beige solid (74.8 mg, 0.15 mmol, 93.3%). 
1H NMR (500 MHz, DMSO) δ 11.46 (s, 1H), 10.17 (s, 1H), 7.62 (s, 2H), 7.41 (t, J = 7.8 Hz, 
1H), 7.36 – 7.32 (m, 2H), 7.30 – 7.25 (m, 4H), 7.17 – 7.14 (m, 1H), 7.06 (d, J = 7.7 Hz, 1H), 
7.01 (s, 1H), 6.88 – 6.85 (m, 1H), 6.76 – 6.73 (m, 2H), 3.74 (s, 3H), 3.62 – 3.56 (m, 2H), 3.29 – 
3.24 (m, 2H), 3.13 – 3.04 (m, 4H), 2.72 – 2.54 (m, 4H). 13C NMR (126 MHz, DMSO) δ 159.13, 
156.17, 142.37, 142.15, 137.18, 136.65, 135.38, 130.47, 129.64, 129.52, 128.64 (2C), 128.63 
(2C), 127.07, 126.76, 124.79, 122.80, 121.42, 115.03, 112.20, 56.14, 55.06, 52.08, 51.95, 30.68, 
29.41, 27.88. MS(ESI) m/z calcd. for C28H32N4O 440.26, found 441.47 [M]+, 442.54 [M+1]+, 
443.33 [M+2]+. LCMS Method: 98.62%. 
6.8.3: Experimental Data for compounds in Figure 61. 
4-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)aniline (144, KGM02057). 
Under argon (g), a mixture of compound 140 (0.56 g, 1.45 mmol), 4-aminophenylboronic acid 
(0.30 g, 1.74 mmol) and K2CO3 (0.50 g, 3.61 mmol) in toluene (3.9 mL)/ethanol (2.5 mL)/H2O 
(2.5 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (56 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using a Combiflash RF system under gradient conditions with hexane and ethyl acetate 
as eluents. Fractions were collected and concentrated in vacuo to provide 144 as a dark orange 
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wax that solidified upon standing (0.41 g, 1.03 mmol, 70.9%). 1H NMR (500 MHz, CDCl3) δ 
7.22 – 7.18 (m, 2H), 7.14 – 7.09 (m, 4H), 6.83 (d, J = 8.3 Hz, 2H), 6.68 – 6.62 (m, 2H), 6.59 (s, 
1H), 6.52 (d, J = 8.3 Hz, 2H), 3.68 (s, 3H), 3.53 (s, 2H), 2.80 – 2.74 (m, 2H), 2.58 – 2.54 (m, 
2H), 2.54 – 2.48 (m, 4H), 2.41 (t, J = 5.2 Hz, 2H), 2.35 (t, J = 5.3 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 159.30, 144.89, 144.53, 140.38, 135.90, 134.16, 132.62, 130.86 (2C), 128.94, 128.81 
(2C), 128.52 (2C), 126.18, 122.49, 115.73, 114.72 (2C), 111.53, 60.60, 55.45, 55.40, 55.25, 
33.74, 31.77, 31.61. MS(ESI) m/z calcd. for C27H30N2O 398.24, found 399.34 [M]+, 400.54 
[M+1]+, 401.45 [M+2]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-4-((3-methoxyphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (145, KGM02060). 
Triethylamine (0.23 mL, 1.66 mmol) was added drop wise to a suspension of compound 144 
(0.33 g, 0.83 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.27 g, 0.91 mmol), 
HgCl2 (0.25 g, 0.91 mmol) in DCM (11.7 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate, then with DCM and MeOH as eluents. Fractions were collected and concentrated 
in vacuo to provide 145 as a light beige solid (0.34 g, 0.53 mmol, 63.6%). 1H NMR (500 MHz, 
CDCl3) δ 11.56 (s, 1H), 10.23 (s, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.23 – 7.18 (m, 2H), 7.15 – 7.09 
(m, 4H), 7.01 (d, J = 8.5 Hz, 2H), 6.70 – 6.66 (m, 1H), 6.65 – 6.62 (m, 1H), 6.60 – 6.57 (m, 1H), 
3.69 (s, 3H), 2.79 – 2.73 (m, 2H), 2.59 – 2.48 (m, 6H), 2.41 – 2.38 (m, 2H), 2.38 – 2.33 (m, 2H), 
1.45 (s, 9H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.66, 159.38, 153.51, 153.41, 
143.92, 140.51, 138.72, 135.72, 135.38, 135.25, 130.41, 129.03, 128.82 (3C), 128.51 (3C), 
126.14, 122.58, 121.71, 115.69, 111.88, 83.81, 79.73, 60.62, 55.47, 55.36, 55.28, 33.86, 31.90, 
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31.72, 28.31 (3C), 28.21 (3C). MS(ESI) m/z calcd. for C38H48N4O5 640.36, found 641.39 [M]
+, 
541.33 [M-BOC]+, 441.30 [M-2BOC]+, 442.49 [(M-2BOC)+1]+. 
1-(4-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (146, KGM02091). 
Compound 145 (100 mg, 0.16 mmol) was dissolved in DCM (0.5 mL), treated with 4N HCl in 
1,4-dioxane (0.6 mL, 2.34 mmol) and left to stir for 24 hr at room temperature. The reaction was 
concentrated in vacuo to provide 146 as an off-white beige solid (78.3 mg, 0.15 mmol, 97.7%). 
1H NMR (500 MHz, DMSO) δ 11.46 (s, 1H), 10.22 (s, 1H), 7.61 (s, 2H), 7.36 – 7.32 (m, 2H), 
7.30 – 7.25 (m, 4H), 7.21 (s, 4H), 6.88 – 6.84 (m, 1H), 6.75 – 6.71 (m, 2H), 3.74 (s, 3H), 3.59 (s, 
2H), 3.29 – 3.24 (m, 2H), 3.13 – 3.04 (m, 4H), 2.72 – 2.52 (m, 4H). 13C NMR (126 MHz, 
DMSO) δ 159.14, 156.03, 142.36, 138.74, 137.18, 136.79, 134.05, 130.25, 130.16, 129.54, 
128.64 (3C), 128.62 (3C), 126.76, 123.92, 121.35, 114.95, 112.14, 56.16, 55.06, 52.08, 51.98, 
30.68, 29.41, 27.88. MS(ESI) m/z calcd. for C28H32N4O 440.26, found 441.41 [M]+, 442.43 
[M+1]+. LCMS Method: 97.95%. 
6.8.4: Experimental Data for compounds in Figure 62. 
4-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (147, 
KGM02058). 
Under argon (g), a mixture of 140 (0.48 g, 1.24 mmol), 4-cyanophenylboronic acid (0.22 g, 1.49 
mmol) and K2CO3 (0.43 g, 3.10 mmol) in toluene (18.1 mL)/ethanol (6.0 mL) (3:1 ratio) were 
added to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (48 
mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The 
reaction was cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried 
over Na2SO4, and concentrated in vacuo. The crude material was purified using a Combiflash RF 
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system under gradient conditions with hexane and ethyl acetate as eluents. Fractions were 
collected and concentrated in vacuo to provide 147 as a yellow oil (0.49 g, 1.20 mmol, 96.7%). 
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.48 (m, 2H), 7.22 – 7.15 (m, 5H), 7.12 (d, J = 7.7 Hz, 
3H), 6.73 – 6.70 (m, 1H), 6.61 (d, J = 7.6 Hz, 1H), 6.55 (s, 1H), 3.69 (s, 3H), 2.79 – 2.74 (m, 
2H), 2.60 – 2.55 (m, 2H), 2.53 (s, 4H), 2.40 – 2.37 (m, 2H), 2.36 – 2.32 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 159.57, 147.08, 142.64, 140.21, 137.70, 134.60, 132.01, 130.61, 129.43, 
128.78, 128.54, 126.24, 122.35, 119.08, 115.91, 112.07, 110.25, 60.39, 55.31, 55.16, 55.12, 
33.74, 31.79, 31.60. MS(ESI) m/z calcd. for C28H28N2O 408.22, found 409.32 [M]+, 410.39 
[M+1]+, 411.45 [M+2]+. 
(Z)-4-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N’-
hydroxybenzimidamide (148, KGM02059). 
A mixture of 147 (0.44 g, 1.08 mmol), hydroxylamine hydrochloride (0.28 g, 3.98 mmol), and 
sodium carbonate (0.19 g, 1.83 mmol) in ethanol (3 mL)/H20 (0.3 mL) (10:1 ratio) were refluxed 
at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo leaving 
a residue. The residue was triturated in H2O and filtered again. The precipitate was further dried 
in vacuo to provide 148 as a gray-white solid (0.40 g, 0.90 mmol, 83.7%). 1H NMR (500 MHz, 
DMSO) δ 9.68 (s, 1H), 7.65 (d, J = 7.5 Hz, 2H), 7.28 – 7.24 (m, 4H), 7.16 (d, J = 7.5 Hz, 2H), 
6.89 – 6.83 (m, 2H), 6.73 – 6.70 (m, 3H), 5.87 (s, 2H), 3.73 (s, 3H), 3.39 – 3.35 (m, 2H), 3.25 – 
3.18 (m, 4H), 3.10 – 3.07 (m, 2H), 2.62 – 2.56 (m, 4H). 13C NMR (126 MHz, DMSO) δ 159.13, 
150.74, 142.48, 142.23, 141.60, 137.39, 137.01, 131.81, 129.53, 128.89, 128.65 (5C), 127.58, 
126.72, 125.43, 121.43, 114.93, 112.18, 56.41, 56.36, 55.06, 52.20, 29.63, 28.11, 27.94. 
MS(ESI) m/z calcd. for C28H31N3O2 441.24, found 442.49 [M]+, 443.50 [M+1]+, 444.52 [M+2]+. 
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4-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (150, KGM03010) 
To a solution of 148 (112.3 mg, 0.25 mmol), in acetic acid (1.27 mL), acetic anhydride (0.03 
mL, 0.36 mmol) was added drop wise and the reaction was left to stir at room temperature, until 
the acetylated intermediate 149 was determined by LC/MS. 10% Pd/C (3.5 mg) was introduced 
to the mixture and the reaction was stirred under hydrogen for 72 hours. The mixture was filtered 
through a 0.2 µm polyethersulfone membrane syringe filter and the filtrate was evaporated to 
give a brown oil. The oil was dissolved in MeOH (0.3 mL) and treated with 4N HCl in 1,4-
dioxane (1.28 mL, 5.13 mmol). The excess solvent was evaporated in vacuo; extraction was 
performed with DCM and H2O and the aqueous layer was concentrated in vacuo to provide the 
crude. The crude material was purified using a Combiflash RF system with a basic alumina 
column under gradient conditions with DCM and 2M ammonia in MeOH. Fractions were 
collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane (0.44 mL), and re-
concentrated in vacuo to provide 150 as an off-white solid (50.9 mg, 0.10 mmol, 40.2%). 1H 
NMR (500 MHz, MeOD) δ 7.81 (d, J = 7.8 Hz, 2H), 7.46 (d, J = 7.8 Hz, 2H), 7.33 – 7.31 (m, 
4H), 7.28 – 7.24 (m, 2H), 6.88 – 6.85 (m, 1H), 6.79 – 6.76 (m, 1H), 6.73 (s, 1H), 3.74 – 3.70 (m, 
2H), 3.65 (s, 3H), 3.41 – 3.37 (m, 2H), 3.22 – 3.12 (m, 4H), 2.83 – 2.78 (m, 1H), 2.73 – 2.63 (m, 
3H). 13C NMR (126 MHz, MeOD) δ 168.05, 161.33, 148.36, 142.90, 139.46, 137.66, 131.57, 
131.40 (2C), 130.81, 129.95 (2C), 129.86 (2C), 129.17 (2C), 128.24, 128.17, 122.68, 116.26, 
113.88, 68.13, 58.91, 55.76, 54.40, 31.47, 29.63, 29.43. MS(ESI) m/z calcd. for C28H31N3O 
425.25, found 426.46 [M]+, 427.53 [M+1]+.  
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6.8.5: Experimental Data for compounds in Figure 63. 
3-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzonitrile (151, 
KGM02054). 
Under argon (g), a mixture of 140 (0.47 g, 1.23 mmol), 3-cyanophenylboronic acid (0.22 g, 1.47 
mmol) and K2CO3 (0.43 g, 3.07 mmol) in toluene (18 mL)/ethanol (6 mL) (3:1 ratio) were added 
to the reaction vessel. The mixture was degassed prior to the addition of Pd(PPh3)4 (48 mg). The 
reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) overnight. The reaction was 
cooled, filtered through Celite®, quenched with H2O, extracted with DCM, dried over Na2SO4 
and concentrated in vacuo. The crude material was purified using a Combiflash RF system under 
gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 151 as a yellow-orange wax (0.34 g, 0.83 mmol, 67.7%). 1H 
NMR (500 MHz, CDCl3) δ 7.44 – 7.40 (m, 1H), 7.35 (s, 1H), 7.32 – 7.29 (m, 2H), 7.21 (t, J = 
7.5 Hz, 2H), 7.19 – 7.16 (m, 1H), 7.16 – 7.12 (m, 3H), 6.74 – 6.70 (m, 1H), 6.61 (d, J = 7.5 Hz, 
1H), 6.55 (s, 1H), 3.70 (s, 3H), 2.80 – 2.75 (m, 2H), 2.60 – 2.56 (m, 2H), 2.54 (s, 4H), 2.41 – 
2.36 (m, 2H), 2.35 – 2.30 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 159.58, 143.41, 142.69, 
140.22, 137.53, 134.31, 134.00, 133.33, 130.20, 129.46, 129.04, 128.80 (2C), 128.55 (2C), 
126.24, 122.31, 118.99, 115.88, 112.36, 112.06, 60.40, 55.32, 55.16, 55.12, 33.74, 31.73, 31.54. 
MS(ESI) m/z calcd. for C28H28N2O 408.22, found 409.31 [M]+, 410.50 [M+1]+, 411.56 [M+2]+. 
(Z)-3-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)-N'-
hydroxybenzimidamide (152, KGM02056). 
A mixture of 151 (0.28 g, 0.69 mmol), hydroxylamine hydrochloride (0.18 g, 2.54 mmol), and 
sodium carbonate (0.12 g, 1.17 mmol) in ethanol (2.12 mL)/H2O (0.2 mL) (10:1 ratio) were 
refluxed at 80 °C for 3 hours. The reaction was filtered and the filtrate was concentrated in vacuo 
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leaving a residue. The residue was triturated in H2O and filtered again. The precipitate was 
further dried in vacuo to provide 152 as a light green solid (0.10 g, 0.24 mmol, 34.4%). 1H NMR 
(600 MHz, CDCl3) δ 7.38 (s, 2H), 7.21 – 7.17 (m, 4H), 7.14 – 7.11 (m, 3H), 7.04 – 7.01 (m, 
1H), 6.71 – 6.68 (m, 1H), 6.58 – 6.56 (m, 1H), 6.53 (s, 1H), 4.97 (s, 2H), 3.10 – 3.06 (m, 3H), 
3.05 – 3.02 (m, 3H), 2.77 – 2.62 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 159.62, 152.63, 
142.21, 141.46, 138.56, 136.78, 132.58, 130.95, 129.60, 129.00 (2C), 128.94, 128.89, 128.83 
(2C), 127.21, 126.83, 124.58, 121.82, 115.40, 112.42, 58.60, 55.37, 53.94, 53.92, 30.85, 28.74, 
28.63. MS(ESI) m/z calcd. for C28H31N3O2 441.24, found 442.24 [M]+, 443.48 [M+1]+, 444.56 
[M+2]+. 
3-((3-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)benzimidamide 
dihydrochloride (154, KGM03011) 
To a solution of 152 (82.7 mg, 0.19 mmol), in acetic acid (0.94 mL), acetic anhydride (0.03 mL, 
0.26 mmol) was added drop wise and the reaction was left to stir at room temperature, until the 
acetylated intermediate 153 was determined by LC/MS. 10% Pd/C (8.3 mg) was introduced to 
the mixture and the reaction was stirred under hydrogen for 72 hours. The mixture was filtered 
through a 0.2 µm polyethersulfone membrane syringe filter and the filtrate was evaporated to 
give a brown oil. The oil was dissolved in MeOH (0.03 mL) and treated with 4N HCl in 1,4-
dioxane (1.16 mL, 4.65 mmol). The excess solvent was evaporated in vacuo; extraction was 
performed with DCM and H2O and the aqueous layer was concentrated in vacuo to provide the 
crude. The crude material was purified using a Combiflash RF system with a basic alumina 
column under gradient conditions with DCM and 2M ammonia in MeOH. Fractions were 
collected, concentrated in vacuo, treated with 4N HCl in 1,4-dioxane (0.42 mL), and re-
concentrated in vacuo to provide 154 as a tan solid (49.1 mg, 0.10 mmol, 52.7%). 1H NMR (500 
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MHz, MeOD) δ 7.74 – 7.70 (m, 1H), 7.66 (s, 1H), 7.63 – 7.57 (m, 2H), 7.33 – 7.31 (m, 4H), 
7.29 – 7.24 (m, 2H), 6.89 – 6.85 (m, 1H), 6.83 – 6.79 (m, 1H), 6.77 (s, 1H), 3.73 – 3.68 (m, 2H), 
3.65 (s, 3H), 3.42 – 3.37 (m, 2H), 3.25 – 3.11 (m, 4H), 2.83 – 2.77 (m, 1H), 2.72 – 2.62 (m, 3H). 
13C NMR (126 MHz, MeOD) δ 161.32, 143.75, 142.99, 139.25, 137.67, 136.01, 131.43, 
130.80, 130.69, 129.95 (3C), 129.86 (3C), 129.50, 128.24, 127.74, 122.67, 116.28, 113.82, 
68.13, 58.92, 55.79, 54.46, 31.47, 29.55, 29.40. MS(ESI) m/z calcd. for C28H31N3O 425.25, 
found 426.51 [M]+, 427.52 [M+1]+, 428.71 [M+2]+.  
6.9: Experimental Data for KGM03012 and KGM03013. 
6.9.1: Experimental Data for compounds in Figure 64. 
(3-Nitrobenzyl)triphenylphosphonium bromide (156, KGM02086). 
Triphenylphosphine (5.25 g, 20.0 mmol) was dissolved in toluene (28 mL) and 3-nitrobenzyl 
bromide 155 (4.32 g, 20.0 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 156 as a fine white powder (9.01 g, 18.84 mmol, 94.2%). 1H NMR 
(500 MHz, CDCl3) δ 7.94 (d, J = 7.5 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.81 – 7.75 (m, 6H), 7.70 (t, 
J = 7.4 Hz, 3H), 7.59 – 7.53 (m, 7H), 7.25 – 7.21 (m, 1H), 5.85 (d, JHP = 15.1 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 147.66, 138.74 (d, JCP = 5.4 Hz), 135.31 (2C), 134.52 (2C), 134.44 
(3C), 130.42 (2C), 130.32 (3C), 130.16 (d, JCP = 8.3 Hz), 125.69 (d, JCP = 5.0 Hz), 123.07, 
117.67, 116.98, 29.93 (d, JCP = 47.6 Hz). MS(ESI) m/z calcd. for C25H21NO2P+ 398.13, found 
398.34 [M], 399.42 [M]+, 400.49 [M+1]+. 
4-(3-Nitrobenzylidene)-1-phenethylpiperidine (157, KGM02087). 
Compound 156 (8.84 g, 18.48 mmol) was suspended in anhydrous THF (19.5mL) under argon at 
-78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (11.11 mL, 22.18 mmol) was added drop 
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wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (3.76 g, 18.48 mmol) in anhydrous THF (9.7 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using a Combiflash RF system under 
gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 157 as an orange oil (2.12 g, 6.57 mmol, 35.7%). 1H NMR 
(500 MHz, CDCl3) δ 7.98 (s, 1H), 7.41 – 7.37 (m, 1H), 7.23 – 7.19 (m, 3H), 7.15 – 7.12 (m, 
4H), 6.25 (s, 1H), 2.79 – 2.74 (m, 5H), 2.60 – 2.57 (m, 3H), 2.42 – 2.39 (m, 4H). 13C NMR (126 
MHz, CDCl3) δ 148.28, 142.56, 140.29, 139.42, 135.05, 129.08, 128.76 (2C), 128.49 (2C), 
126.17, 123.69, 121.32, 121.11, 60.38, 55.02, 54.30, 36.39, 34.21, 33.77. MS(ESI) m/z calcd. for 
C20H22N2O2 322.17, found 323.20 [M]+, 323.66 [M]+, 324.48 [M+1]+. 
4-(Bromo(3-Nitrophenyl)methylene)-1-phenethylpiperidine (159, KGM02094). 
Compound 157 (2.05 g, 6.37 mmol) was dissolved in DCM (26.3 mL) under argon at -78 ˚C. Br2 
(0.13 mL, 7.65 mmol) diluted in DCM (79 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 158, 
which was determined by LC/MS. NaOH (1.53 g, 38.24 mmol) was dissolved in MeOH (63.2 
mL) and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) 
until the full conversion to the monobromo, determined via LC/MS. The reaction was quenched 
with H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 159 as an 
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orange wax (0.72 g, 1.78 mmol, 28.0%). 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 7.6 Hz, 
2H), 7.54 (d, J = 7.7 Hz, 1H), 7.48 – 7.44 (m, 1H), 7.21 (t, J = 7.5 Hz, 2H), 7.13 (d, J = 7.7 Hz, 
3H), 2.79 – 2.75 (m, 2H), 2.72 – 2.69 (m, 2H), 2.64 – 2.57 (m, 4H), 2.46 – 2.42 (m, 2H), 2.28 – 
2.24 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 148.17, 141.84, 140.04, 139.70, 135.59, 129.48, 
128.79 (2C), 128.58 (2C), 126.31, 124.56, 123.01, 112.66, 60.03, 54.06, 53.81, 34.40, 33.71, 
31.79. MS(ESI) m/z calcd. for C29H21BrN2O2 400.08, found 401.34 [M]+, 402.37 [M+1]+, 
403.33 [M+2]+, 404.33 [M+3]+, 405.36 [M+4]+. 
6.9.2: Experimental Data for compounds in Figure 65. 
4-((4-Methoxyphenyl)(3-nitrophenyl)methylene-1-phenethylpiperidine (160, KGM02098). 
Under argon (g), a mixture of compound 159 (0.34 g, 0.84 mmol), 4-methoxyphenylboronic acid 
(0.15 g, 1.01 mmol) and K2CO3 (0.29 g, 2.11 mmol) in toluene (2.2 mL)/ethanol (1.5 mL)/H2O 
(1.5 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (34 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using a Combiflash RF system under gradient conditions with hexane and ethyl acetate 
as eluents. Fractions were collected and concentrated in vacuo to provide 160 as an orange wax 
(0.25 g, 0.59 mmol, 69.5%). 1H NMR (500 MHz, CDCl3) δ 8.01 – 7.97 (m, 1H), 7.91 (s, 1H), 
7.40 – 7.36 (m, 2H), 7.21 (t, J = 7.5 Hz, 2H), 7.13 (d, J = 7.3 Hz, 3H), 6.95 (d, J = 8.4 Hz, 2H), 
6.77 (d, J = 8.4 Hz, 4H), 3.72 (s, 3H), 2.80 – 2.75 (m, 2H), 2.61 – 2.52 (m, 6H), 2.44 – 2.40 (m, 
2H), 2.36 – 2.30 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 158.64, 148.24, 144.45, 140.25, 
137.28, 136.12, 133.65, 133.58, 131.08 (2C), 129.05, 128.80 (2C), 128.55 (2C), 126.24, 124.67, 
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121.53, 113.85 (2C), 60.43, 55.36, 55.21, 55.11, 33.76, 31.71 (2C). MS(ESI) m/z calcd. for 
C27H28N2O3 428.21, found 429.50 [M]+, 430.46 [M+1]+, 431.48 [M+2]+. 
3-((4-methoxyphenyl)(1-Phenethylpiperidin-4-ylidene)methyl)aniline (161, KGM03004, 
KGM3005). 
Compound 160 (0.15 g, 0.35 mmol) was dissolved in MeOH (7 mL) and subjected to reduction 
by flow hydrogenation under the established conditions with temperature 1. Fractions were 
collected and concentrated in vacuo leaving the crude. The crude material was purified using a 
Combiflash RF system under isocratic conditions using hexane (10%) and ethyl acetate (90%). 
Fractions were collected and concentrated in vacuo to provide 161 as a yellow wax (0.12 g, 0.30 
mmol, 84.4%). 1H NMR (500 MHz, CDCl3) δ 7.21 (t, J = 7.5 Hz, 2H), 7.13 (d, J = 7.3 Hz, 3H), 
7.03 – 6.92 (m, 3H), 6.77 – 6.69 (m, 2H), 6.51 – 6.40 (m, 2H), 6.35 (s, 1H), 3.71 (s, 3H), 2.83 – 
2.75 (m, 2H), 2.64 – 2.51 (m, 6H), 2.43 – 2.35 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 158.20, 
146.17, 143.90, 140.22, 135.98, 134.86, 130.90 (2C), 128.95, 128.82 (3C), 128.56 (2C), 126.24, 
120.40, 116.62, 113.46 (2C), 113.39, 60.51, 60.47, 55.32, 33.59, 31.58, 31.39, 21.17. MS(ESI) 
m/z calcd. for C27H30N2O 398.24, found 399.46 [M]+, 400.49 [M+1]+, 401.51 [M+2]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-3-((4-Methoxyphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (162, KGM03006). 
Triethylamine (0.08 mL, 0.59 mmol) was added drop wise to a suspension of compound 161 
(0.12 g, 0.30 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.09 g, 0.33 mmol), 
HgCl2 (0.09 g, 0.33 mmol) in DCM (4.16 mL). The mixture was stirred for 60 hours at room 
temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The crude 
material was purified using a Combiflash RF system under gradient conditions with hexane and 
ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to provide 162 as a 
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white solid (0.15 g, 0.23 mmol, 76.8%). 1H NMR (500 MHz, CDCl3) δ 11.53 (s, 1H), 10.14 (s, 
1H), 7.53 (d, J = 8.1 Hz, 1H), 7.23 – 7.19 (m, 3H), 7.15 – 7.11 (m, 4H), 6.96 (d, J = 8.4 Hz, 2H), 
6.79 (d, J = 7.6 Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H), 3.72 (s, 3H), 2.85 – 2.79 (m, 2H), 2.69 – 2.54 
(m, 6H), 2.47 – 2.40 (m, 4H), 1.45 (s, 9H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.67, 
158.33, 153.68, 153.42, 143.20, 136.56, 134.51, 130.99 (2C), 128.84 (4C), 128.72, 128.60 (3C), 
126.49, 126.32, 123.66, 120.85, 113.57 (2C), 83.83, 79.65, 60.38, 55.33 (2C), 55.18, 31.39, 
28.38 (3C), 28.23 (3C), 28.14 (2C). MS(ESI) m/z calcd. for C38H48N4O5 640.36, found 641.70 
[M]+, 642.70 [M+1]+, 643.70 [M+2]+, 541.9 [M-BOC]+, 441.46 [M-2BOC]+, 442.48 [(M+1)-
2BOC]+, 443.51 [(M+2)-2BOC]+. 
1-(3-((4-Methoxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (163, KGM03012). 
Compound 162 (0.13 mg, 0.20 mmol) was dissolved in DCM (0.43 mL), treated with 4N HCl in 
1,4-dioxane (1.0 mL, 3.95 mmol) and the reaction was left to stir for 24 hr at room temperature. 
The reaction was concentrated in vacuo to provide 163 as an off-white beige solid (107.9 mg, 
0.21 mmol, +99.9%). 1H NMR (500 MHz, DMSO) δ 11.44 (s, 1H), 10.20 (s, 1H), 7.62 (s, 2H), 
7.41 (t, J = 7.8 Hz, 1H), 7.35 – 7.32 (m, 2H), 7.29 – 7.25 (m, 3H), 7.16 – 7.13 (m, 1H), 7.08 (d, J 
= 8.5 Hz, 2H), 7.02 (d, J = 7.7 Hz, 1H), 6.97 (s, 1H), 6.91 (d, J = 8.5 Hz, 2H), 3.75 (s, 3H), 3.64 
– 3.58 (m, 2H), 3.30 – 3.24 (m, 2H), 3.13 – 3.04 (m, 4H), 2.70 – 2.58 (m, 4H). 13C NMR (126 
MHz, DMSO) δ 158.19, 156.18, 142.94, 137.19, 136.49, 135.34, 132.95, 130.52 (2C), 129.83, 
129.59, 128.64 (4C), 127.23, 126.75, 124.93, 122.69, 113.75 (2C), 66.34, 56.16, 55.06, 52.14, 
52.03, 29.42, 27.87. MS(ESI) m/z calcd. for C28H32N4O 440.26, found 441.47 [M]+, 442.54 
[M+1]+, 443.62 [M+2]+. LCMS Method: 98.67%. 
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6.9.3: Experimental Data for compounds in Figure 66. 
4-((3-Nitrophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenol (164, KGM02099). 
Under argon (g), a mixture of compound 159 (0.37 g, 0.92 mmol), 4-hydroxyphenylboronic acid 
(0.15 g, 1.10 mmol) and K2CO3 (0.32 g, 2.29 mmol) in toluene (2.4 mL)/ethanol (1.6 mL)/H2O 
(1.6 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (37 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using a Combiflash RF system under gradient conditions with hexane and ethyl acetate 
as eluents. Fractions were collected and concentrated in vacuo to provide 164 as a yellow-orange 
wax (0.19 g, 0.45 mmol, 48.9%). 1H NMR (500 MHz, CDCl3) δ 8.02 – 7.97 (m, 1H), 7.89 (s, 
1H), 7.39 – 7.34 (m, 2H), 7.21 – 7.17 (m, 2H), 7.14 – 7.09 (m, 3H), 6.87 (d, J = 8.4 Hz, 2H), 
6.70 (d, J = 8.4 Hz, 2H), 2.83 – 2.78 (m, 2H), 2.66 – 2.59 (m, 6H), 2.48 – 2.43 (m, 2H), 2.40 – 
2.35 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 155.54, 148.24, 144.34, 139.75, 136.09, 134.19, 
132.91, 131.22 (2C), 129.11, 128.79 (2C), 128.63 (2C), 126.40, 124.61, 121.61, 115.54 (2C), 
60.61, 60.30, 55.06, 54.93, 33.29, 31.22, 21.20. MS(ESI) m/z calcd. for C26H26N2O3 414.19, 
found 415.46 [M]+, 416.45 [M+1]+, 417.47 [M+2]+. 
4-((3-Aminophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenol (165, KGM03007, 
KGM03008). 
Compound 164 (0.12 g, 0.29 mmol) was dissolved in MeOH (4.35 mL) and DCM (1.47 mL) and 
subjected to reduction by flow hydrogenation under the established conditions with temperature 
2. Fractions were collected and concentrated in vacuo leaving the crude. The crude material was 
purified using a Combiflash RF system under isocratic conditions using hexane (10%) and ethyl 
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acetate (90%). Fractions were collected and concentrated in vacuo to provide 165 as a lightly 
tinted purple solid (57.9 mg, 0.15 mmol, 51.7%). 1H NMR (500 MHz, CDCl3) δ 7.22 – 7.19 (m, 
3H), 7.13 (t, J = 7.4 Hz, 3H), 6.99 (t, J = 7.7 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 8.4 
Hz, 2H), 6.50 – 6.43 (m, 2H), 6.34 (s, 1H), 2.88 – 2.81 (m, 2H), 2.72 – 2.56 (m, 6H), 2.48 – 2.39 
(m, 4H). 13C NMR (126 MHz, CDCl3) δ 155.19, 146.01, 133.84, 130.91 (2C), 129.00, 128.80 
(5C), 128.68 (3C), 126.49, 120.41, 116.63 (2C), 113.60, 55.05, 50.22, 50.05, 49.88, 49.71, 49.54. 
MS(ESI) m/z calcd. for C26H28N2O 384.22, found 385.46 [M]+, 386.48 [M+1]+, 387.47 [M+2]+. 
(Z)-1,3-Bis(tert-butoxycarbonyl)-3-((4-Hydroxyphenyl(1-phenethylpiperidin-4-
ylidene)methyl)phenyl)guanidine (166, KGM03009). 
Triethylamine (0.04 mL, 0.30 mmol) was added drop wise to a suspension of compound 165 
(57.9 mg, 0.15 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (48 mg, 0.17 
mmol), HgCl2 (45 mg, 0.17 mmol) in DCM (2.12 mL). The mixture was stirred for 60 hours at 
room temperature then filtered through Celite® and the filtrate was concentrated in vacuo. The 
crude material was purified using a Combiflash RF system under gradient conditions with 
hexane and ethyl acetate as eluents. Fractions were collected and concentrated in vacuo to 
provide 166 as a white solid (77.3 mg, 0.12 mmol, 81.7%). 1H NMR (500 MHz, CDCl3) δ 11.53 
(s, 1H), 10.15 (s, 1H), 7.53 – 7.50 (m, 1H), 7.21 – 7.18 (m, 3H), 7.13 – 7.10 (m, 4H), 6.87 (d, J = 
8.0 Hz, 2H), 6.77 – 6.75 (m, 1H), 6.67 (d, J = 8.0 Hz, 2H), 2.86 – 2.81 (m, 2H), 2.67 – 2.57 (m, 
6H), 2.47 – 2.42 (m, 4H), 1.45 (s, 9H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 163.69, 
155.02, 153.76, 153.40, 146.94, 143.12, 136.50, 133.95, 131.08 (2C), 128.83 (5C), 128.66 (3C), 
126.52, 123.68, 121.01, 115.26 (2C), 83.87, 79.73, 55.22, 55.02, 53.88, 43.58, 31.06, 29.40, 
28.37 (2C), 28.24 (2C). MS(ESI) m/z calcd. for C37H46N4O5 626.35, found 627.72 [M]
+, 628.69 
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[M+1]+, 629.74 [M+2]+, 527.55 [M-BOC]+, 427.49 [M-2BOC]+, 428.50 [(M+1)-2BOC]+ , 
429.56 [(M+2)-2BOC]+. 
1-(3-((4-Hydroxyphenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenyl)guanidine 
dihydrochloride (167, KGM03013). 
Compound 166 (64.2 mg, 0.10 mmol) was dissolved in DCM (0.37 mL), treated with 4N HCl in 
1,4-dioxane (0.5 mL, 2.05 mmol) and left to stir for 24 hr at room temperature. The reaction was 
concentrated in vacuo to provide 167 as a beige solid (51.8 mg, 0.10 mmol, +99.9%). 1H NMR 
(500 MHz, DMSO) δ 11.35 (s, 1H), 10.14 (s, 1H), 7.59 (s, 2H), 7.40 (t, J = 7.8 Hz, 1H), 7.34 (t, 
J = 7.4 Hz, 2H), 7.29 – 7.24 (m, 3H), 7.14 (d, J = 7.9 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.96 – 
6.93 (m, 3H), 6.77 – 6.73 (m, 2H), 3.54 – 3.36 (m, 2H), 3.29 – 3.23 (m, 2H), 3.13 – 3.02 (m, 
4H), 2.66 – 2.57 (m, 4H). 13C NMR (126 MHz, DMSO) δ 156.50, 156.15, 143.16, 137.17, 
136.87, 135.29, 131.22, 130.48 (2C), 129.54, 129.26, 128.64 (4C), 127.26, 126.76, 124.96, 
122.64, 115.08 (2C), 66.33, 56.16, 52.20, 52.11, 29.42, 27.89 (2C). MS(ESI) m/z calcd. for 
C27H30N4O 426.24, found 427.53 [M]+, 428.52 [M+1]+, 429.54 [M+2]+. LCMS Method: 
95.66%. 
6.10:	Experimental	Data	for	Unsuccessful	(Diphenylmethylene)phenethylpiperidines	
6.10.1: Experimental Data for compounds in Figure 67. 
(4-Methoxybenzyl)triphenylphosphonium chloride (169, KGM02038). 
Triphenylphosphine (7.88 g, 30.0 mmol) was dissolved in toluene (42 mL) and 4-methoxybenzyl 
chloride 168 (4.07 g, 30.0 mmol) was added drop wise and set to reflux at 110 ˚C overnight. The 
precipitate was filtered and washed with toluene and diethyl ether. The precipitate was further 
dried in vacuo, to provide 169 as a fine white powder (7.54 g, 17.99 mmol, 60.0%). 1H NMR 
(500 MHz, CDCl3) δ 7.72 – 7.67 (m, 3H), 7.64 (s, 1H), 7.63 – 7.61 (m, 3H), 7.60 (s, 2H), 7.58 – 
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7.54 (m, 6H), 6.91 (d, J = 2.5 Hz, 1H), 6.89 (d, J = 2.5 Hz, 1H), 6.58 – 6.53 (m, 1H), 5.16 (d, JHP 
= 13.8 Hz, 1H), 3.63 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.51 (d, JCP = 3.6 Hz), 134.91, 
134.88 (2C), 134.24 (3C), 134.16 (3C), 132.49 (d, JCP = 5.4 Hz), 130.12 (4C), 130.02 (4C), 
118.54, 118.47, 118.09, 117.41, 114.15 (d, JCP = 3.1 Hz), 55.17, 29.85 (d, JCP = 46.9 Hz). 
MS(ESI) m/z calcd. for C26H24OP+ 383.16, found 383.12 [M], 384.06 [M]+, 385.13 [M+1]+, 
386.20 [M+2]+. 
4-(4-Methoxybenzylidene)-1-phenethylpiperidine (170, KGM02040). 
Compound 169 (7.32 g, 17.47 mmol) was suspended in anhydrous THF (18.5 mL) under argon 
at -78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (10.5 mL, 20.96 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (3.55 g, 17.47 mmol) in anhydrous THF (9.1 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using an Isolera One Biotagé system 
under gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 170 as a white solid (3.25 g, 10.57 mmol, 60.5%). 1H NMR 
(600 MHz, CDCl3) δ 7.22 – 7.19 (m, 2H), 7.14 – 7.11 (m, 3H), 7.06 (d, J = 8.6 Hz, 2H), 6.78 (d, 
J = 8.6 Hz, 2H), 6.16 (s, 1H), 3.72 (s, 3H), 2.79 – 2.74 (m, 2H), 2.57 – 2.53 (m, 4H), 2.48 (d, J = 
5.5 Hz, 2H), 2.45 (d, J = 5.3 Hz, 2H), 2.37 – 2.34 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 
158.06, 140.52, 138.15, 130.44, 130.15 (2C), 128.83 (2C), 128.52 (2C), 126.16, 122.89, 113.67 
(2C), 60.67, 55.38, 55.33, 54.64, 36.44, 33.86, 29.15. MS(ESI) m/z calcd. for C21H25NO 307.19, 
found 308.17 [M]+, 309.17 [M+1]+, 310.18 [M+2]+. 
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4-(Bromo(3-Nitrophenyl)methylene)-1-phenethylpiperidine (172, KGM02044). 
Compound 170 (3.18 g, 10.34 mmol) was dissolved in DCM (120 mL) under argon at -78 ˚C. 
Br2 (0.8 mL, 15.52 mmol) diluted in DCM (51 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 171, 
which was determined by LC/MS. Dibromo intermediate 171 was not able to be determined via 
LC/MS. MS(ESI) m/z calcd. for C21H25Br2NO 465.03, found 406.03, 413.97, 418.12, 420.01, 
421.08, 422.15, 432.04, 435.06. 
6.10.2: Experimental Data for compounds in Figure 68. 
4-(4-Nitrobenzylidene)-1-phenethylpiperidine (174, KGM02083). 
Compound 173 (10.0 g, 20.91 mmol) was suspended in anhydrous THF (22 mL) under argon at -
78 ˚C, and 2 M LDA in THF/n-heptane/ethylbenzene (12.6 mL, 25.09 mmol) was added drop 
wise. The mixture was stirred at -78 ˚C for 20 min then allowed to warm to room temperature for 
3 hr. A solution of 1-phenethylpiperidin-4-one (4.25 g, 20.91 mmol) in anhydrous THF (11 mL) 
was added drop wise to the reaction vessel. The reaction was stirred at room temperature 
overnight. The reaction was quenched with H2O, extracted with DCM, dried over Na2SO4, and 
concentrated in vacuo. The crude material was purified using a Combiflash RF system under 
gradient conditions with hexane and ethyl acetate as eluents. Fractions were collected and 
concentrated in vacuo to provide 174 as a red oil (0.83 g, 2.57 mmol, 12.3%). 1H NMR (500 
MHz, CDCl3) δ 8.10 – 8.06 (m, 2H), 7.26 – 7.24 (m, 2H), 7.22 – 7.18 (m, 6H), 7.15 – 7.11 (m, 
9H), 6.26 (s, 1H), 2.79 – 2.72 (m, 18H), 2.67 – 2.62 (m, 6H), 2.43 – 2.37 (m, 12H). 13C NMR 
(126 MHz, CDCl3) δ 146.08, 144.72, 140.24, 129.63 (2C), 128.77 (3C), 128.52 (2C), 126.22, 
123.61 (2C), 121.92, 60.33, 54.99, 54.32, 36.61, 33.77, 29.37. MS(ESI) m/z calcd. for 
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C20H22N2O2 322.17, found 323.38 [M]+, 324.38 [M+1]+, 325.40 [M+2]+. *The 1H NMR analysis 
contains overlap with starting material, 1-phenethylpiperidin-4-one. The regions of: 7.22 – 7.18 
has 6H reported: 2H are to intermediate 175 and 4H are to 1-phenethylpiperidin-4-one; 7.15 – 
7.11 has 9H reported: 3H are to intermediate 175 and 6H are to 1-phenethylpiperidin-4-one; 2.79 
– 2.72 has 18H: 6H are to intermediate 175 and 12H are to 1-phenethylpiperidin-4-one, 2.67 – 
2.62 has 6H: 2H are to intermediate 175 and 4H are to 1-phenethylpiperidin-4-one, 2.43 – 2.37 
has 12H: 4H are to intermediate 175 and 8H are to 1-phenethylpiperidin-4-one. The 13C NMR 
spectra contains 1-phenethylpiperidin-4-one carbon impurity overlap: the carbonyl carbon is 
located at 209.11; the aromatic carbons are at 140.08, 128.76 (2C), 128.55 (2C), and 126.78; the 
aliphatic spacer carbons are at 59.37 and 34.24; and the aliphatic piperidine carbons are at 53.18 
(2C) and 41.34 (2C). 
4-(Bromo(4-Nitrophenyl)methylene)-1-phenethylpiperidine (176, KGM02084). 
Compound 174 (0.79 g, 2.46 mmol) was dissolved in DCM (10.6 mL) under argon at -78 ˚C. Br2 
(0.19 mL, 3.69 mmol) diluted in DCM (30 mL) was added to the solution drop wise using an 
addition funnel and stirred at -78 ˚C until the solution was fully added. The mixture was allowed 
to warm to room temperature until the complete conversion to the dibromo intermediate 175, 
which was determined by LC/MS. NaOH (0.59 g, 14.76 mmol) was dissolved in MeOH (24 mL) 
and added drop wise using an addition funnel. The mixture was heated to reflux (70 ˚C) until the 
full conversion to the monobromo, determined via LC/MS. The reaction was quenched with 
H2O, extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material 
was purified using a Combiflash RF system under gradient conditions with hexane and ethyl 
acetate as eluents. Fractions were collected and concentrated in vacuo to provide 176 as a red 
wax (0.14 g, 0.36 mmol, 14.6%). 1H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 8.7 Hz, 2H), 7.39 
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(d, J = 8.7 Hz, 2H), 7.24 – 7.18 (m, 3H), 7.14 – 7.12 (m, 2H), 2.82 – 2.78 (m, 2H), 2.75 – 2.72 
(m, 2H), 2.68 – 2.61 (m, 4H), 2.50 – 2.44 (m, 2H), 2.32 – 2.27 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 147.31, 146.56, 130.57 (2C), 128.78 (2C), 128.64 (2C), 128.36, 127.22, 126.42, 
123.76 (2C), 107.80, 55.11, 54.00, 53.72, 34.22, 33.50, 31.63. MS(ESI) m/z calcd. for 
C29H21BrN2O2 400.08, found 401.35 [M]+, 402.37 [M+1]+, 403.33 [M+2]+, 404.34 [M+3]+ , 
405.38 [M+4]+. 
6.10.3: Experimental Data for compounds in Figure 69. 
4-((4-Nitrophenyl)(1-phenethylpiperidin-4-ylidene)methyl)phenol (177). 
Reaction 1 (KGM02085) 
Under argon (g), a mixture of 176 (0.12 g, 0.31 mmol), 4-hydroxyphenylboronic acid (0.05 g, 
0.37 mmol) and K2CO3 (0.11 g, 0.76 mmol) in toluene (4.4 mL)/ethanol (1.5 mL) (3:1 ratio) and 
4 drops of H2O were added to the reaction vessel. The mixture was degassed prior to the addition 
of Pd(PPh3)4 (13 mg). The reaction was wrapped in aluminum foil and heated to reflux (80 ˚C) 
overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, extracted with 
DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was purified using a 
Combiflash RF system under gradient conditions with hexane and ethyl acetate as eluents. 
Fractions were collected and concentrated in vacuo to provide 177 as a brown wax (22.7 mg, 
0.06 mmol, 18.0%). Starting material 176 was recovered and used for reaction 2. 1H NMR (500 
MHz, CDCl3) δ 8.08 – 8.04 (m, 2H), 7.21 – 7.17 (m, 4H), 7.13 – 7.08 (m, 3H), 6.85 (d, J = 8.1 
Hz, 2H), 6.71 (d, J = 8.1 Hz, 2H), 2.84 – 2.78 (m, 2H), 2.68 – 2.59 (m, 6H), 2.49 – 2.44 (m, 2H), 
2.42 – 2.37 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 155.61, 149.58, 146.45, 139.57, 136.43, 
134.72, 132.80, 131.24 (2C), 130.74 (2C), 128.77 (2C), 128.66 (2C), 126.47, 123.52 (2C), 
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115.57 (2C), 60.22, 55.00, 54.89, 33.18, 31.19 (2C). MS(ESI) m/z calcd. for C29H26N2O3 414.19, 
found 415.45 [M]+, 416.46 [M+1]+, 418.33 [M+3]+. 
Reaction 2 (KGM02100) 
Under argon (g), a mixture of 176 (75.1 mg, 0.19 mmol), 4-hydroxyphenylboronic acid (31 mg, 
0.23 mmol) and K2CO3 (64.7 mg, 0.47 mmol) in toluene (0.49 mL)/ethanol (0.33 mL)/ H2O 
(0.33 mL) (3:2:2 ratio) were added to the reaction vessel. The mixture was degassed prior to the 
addition of Pd(PPh3)4 (7.5 mg). The reaction was wrapped in aluminum foil and heated to reflux 
(80 ˚C) overnight. The reaction was cooled, filtered through Celite®, quenched with H2O, 
extracted with DCM, dried over Na2SO4, and concentrated in vacuo. The crude material was 
purified using a Combiflash RF system under gradient conditions with hexane and ethyl acetate 
as eluents. Fractions were collected and concentrated in vacuo and did not provide 177, but 
reverted back to its Wittig form (174) as a brown wax (31.7 mg). 1H NMR (500 MHz, CDCl3) δ 
8.09 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.23 – 7.18 (m, 2H), 7.15 – 7.10 (m, 3H), 6.26 
(s, 1H), 2.80 – 2.75 (m, 2H), 2.63 – 2.56 (m, 4H), 2.53 – 2.47 (m, 4H), 2.42 (s, 2H). 13C NMR 
(126 MHz, CDCl3) δ 146.08, 144.73, 143.62, 140.20, 129.65, 128.79, 128.55, 126.25, 123.64, 
121.98, 60.36, 54.98, 54.32, 36.56, 33.73, 29.33. MS(ESI) m/z calcd. for C29H26N2O3 414.19, 
found 323.38, 324.39, 325.47. 
6.11: Binding and Functional Assays 
 Materials. All chemicals used were bought from Sigma-Aldrich (St. Louis, MO; 
Burlington, MA, USA) or Thermo Fisher Scientific (Hampton, NH, USA) with the following 
exceptions. For the binding experiments, [3H]DAMGO, [3H]U-69,593, [3H]Enkephalin(DPDPE), 
[3H]CP-55,940, and MicroScint were purchased from PerkinElmer Life Sciences (Waltham, MA, 
USA); [3H]-EYWSLAAPQRF and [3H]NPVF were custom synthesized by RC TRITEC AG 
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(Teufen, Switzerland). DAMGO, U-69,593, DPDPE, CP-55,940, AM251, AM630, and NPFF 
were obtained from Tocris Bioscience (Minneapolis, MN, USA). 
 Cell Culture and Membrane Preparation. HEK293 cells (ATCC) were stably 
transfected with opioid receptor subtypes (µ, δ, κ) or plasmids containing cloned human 
cannabinoid (CB) receptor subtypes 1 and 2 (Origene; Rockville, MD, USA) were maintained at 
37 ºC and 5% CO2 in a Dulbecco’s Modified Eagle’s Medium (DMEM) nutrient mixture 
supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 1000 IU/mL penicillin, 1000 
µg/mL of streptomycin, and either 0.5 mg/mL (CB1, CB2, κ) or 0.2 mg/mL (δ and µ) G418 
antibiotic solution. 
CHO cells stably expressing human neuropeptide FF receptors 1 and 2 were harvested in 
phosphate buffer saline (PBS), frozen at -70 ºC for a minimum of 1 hour, then homogenized in 
50 mM Tris-HCl, pH 7.4, in a Potter Elvehjem tissue grinder. Centrifugation at 1000g at 4 ºC for 
15 minutes, discarded the nuclear pellet, whereas centrifugation of the supernatant at 100,000g 
for 30 minutes at 4 ºC provided the membrane fractions, which were collected, aliquoted, and 
stored at -80 ºC in 50 mM Tris-HCl, pH 7.4. Protein concentration was calculated using the 
Lowry method. 
 Membranes were prepared by scraping the cells in cold 50 mM Tris-HCl, pH 7.4, and 
centrifuged at 4 ºC for 10 minutes at 5200g. The supernatant was discarded, the pellet 
resuspended in cold 50 mM Tris-HCl, pH 7.4, homogenized via sonication for 30 seconds, then 
centrifuged at 1000g at 4  ºC for and additional 10 minutes. The supernatant and pellet were 
separated; the supernatant saved and the pellet underwent two additional suspensions, 
homogenizations, and centrifugations using the same conditions as previously stated. The pellet 
was resuspended and aliquoted into 2 mL vials and was preserved at -80 ºC. Protein 
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concentration was calculated through the utilization of a Pierce BCA protein assay kit (Thermo 
Scientific, Rockford IL, USA) according to the manufacturers protocol. 
6.11.1: Binding assay protocol 
6.11.1.1: Radioligand Binding 
6.11.1.1.1: Opioid Receptor Subtypes 
Opioid binding assays were performed under the following conditions: independent 
triplicate dilutions of 10 µM of compound and incubated with 5.28 nM [3H]DPDPE (δ), 1.08 nM 
[3H]U-69-593 (κ), or 0.46 nM [3H]DAMGO (µ) for 60 minutes in a 96-well plate in a 0.2 mL 
final volume of 50 mM Tris-HCl, pH 7.4, with a membrane concentration of 15 µg/well. The 
reaction was terminated via rapid vacuum filtration through Unifilter-96 GF/B filter 
(PerkinElmer Life Sciences Inc.; Boston, MA, USA) pretreated with 0.3% BSA followed by 10 
washes of 4 ºC 50 mM Tris-HCl buffer. The filters were dried and 50 µL of MicroScint20 was 
added. Plates were read using a PerkinElmer TopCount NXT™ Microplate Scintillation Counter. 
Total binding is defined as binding in the presence of 0.1% DMSO. Binding in the presence of 
10 µM the control (DAMGO, U-69-593, DPDPE) is defined as nonspecific binding and the 
difference between total and nonspecific binding is the specific binding. The total binding, 
specific binding, and percent displacement were calculated using the below formula:  
Radioligand % Binding 
= 100− 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝑜𝑓 𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝑁𝑜𝑛𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 ∗ 100𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 
6.11.1.1.2: Neuropeptide FF Receptor Subtypes 
 Compounds were tested against [3H]-EYWSLAAPQRF (NPFF2R) for NPFF receptor 
binding using a previously described method in Mollereau et al.347 Binding of NPFF2R subtypes 
were performed under the following conditions: independent triplicate dilutions of 10 µM of 
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compound incubated with 1.73 nM [3H]-EYWSLAAPQRF and a membrane concentration of 5 
µg/well for 60 minutes at 25 ºC in a 96-well plate in a 0.2 mL final volume of 50 mM Tris-HCl, 
60 mM NaCl, and 0.1% BSA, pH 7.4. The reaction was terminated via rapid vacuum filtration 
through Whatman GF/B filter pretreated with 0.3% PEI followed by 3 washes of cold 50 mM 
Tris-HCl buffer containing 0.1% BSA. The filters were dried and 25 µL of MicroScint20 was 
added. The radioactivity was calculated using a liquid scintillation spectrophotometric counter 
(50% efficiency, Packard). 
6.11.1.1.3: Cannabinoid Receptor Subtypes 
 Cannabinoid receptor binding assays were performed run in competition binding with 
both CB1 and CB2 subtypes under the following conditions: independent triplicate dilutions of 10 
µM of compound incubated with 1.81 nM (CB1) or 1.22 nM (CB2) of [3H]CP-55,940 and a 
membrane concentration of 3 µg/well (CB1) or 1 µg/well (CB2) for 90 minutes at 37 ºC with 
gentile agitation in a 96-well plate in a 0.2 mL final volume of 50 mM Tris-HCl, 20 mM EDTA, 
154 mM NaCl, and 0.2% BSA, pH 7.4. The reaction was terminated via rapid vacuum filtration 
through Unifilter-96 GF/C filter pretreated with 0.2% PEI followed by 10 washes of 50 mM 
Tris-HCl buffer containing 0.2% BSA. The filters were dried and 25 µL of MicroScint20 was 
added. Plates were read using a PerkinElmer TopCount NXT™ Microplate Scintillation Counter. 
Total binding is defined as binding in the presence of 1.0% DMSO (vehicle). Binding in the 
presence of 10 µM CP-55,940 is defined as nonspecific binding. The total binding, specific 
binding, and percent displacement were calculated using the aforementioned formula. 
6.11.2: GTPγS Assay Protocol 
 The assay buffer consisted of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 9 mM MgCl2, 0.2 
mM EGTA, and 1.4 mg/mL RIA BSA, pH 7.4. Aliquots (with membrane concentration of 25 
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µg/well) were incubated in 96-well plates for 60 minutes at room temperature in 0.25 mL final 
volume of buffer, 40 µM GTPγS, compound to be tested, and 50 pM of [35S]GTPγS radioligand. 
The reaction was terminated by rapid vacuum filtration through Unifilter-96 GF/C filter 
pretreated with 0.3% RIA BSA followed by 10 washes (300 µL) of cold 50 mM Tris-HCl buffer. 
Following overnight extraction of the filters in Ready Protein scintillation fluid (Beckman 
Coulter; Brea, CA, USA), liquid scintillation spectrophotometry (94% efficiency, Packard) 
determined the retained amount of membrane-bound reactivity. 
6.12: In Vivo Assays 
Animal Housing. Male C57BL/6J mice (20-25 g; Jackson Labs; Bar Harbor, ME, 
U.S.A.) were housed in a temperature-controlled vivarium, with 4 per cage. Mice were 
maintained under a 12-hour dark/light cycle with lights on at 6 pm. Food and water were 
available as desired. All experimental procedures were approved and carried out in accordance 
with the Institutional Animal Care and Use Committee (IACUC) at the University of Florida as 
specified by the 2008 National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. 
Injection Techniques. In accordance with the method of Haley and McCormick, all 
intracerebroventricular (i.c.v.) injections were made directly into the lateral ventricle.348 The 
i.c.v. route was employed for compound delivery in order to initially measure the inherent 
pharmacological activity in vivo to prevent complications associated with distribution (i.e. blood 
brain barrier penetration) that could affect activity following systemic administration. Using 
isoflurane as a light anesthetic, mice had an incision made in the scalp, and the injection made 2 
mm lateral and 2 mm caudal to bregma at a depth of 3 mm. Using a 10 µL Hamilton microliter 
syringe, a 5 µL injection with 50% DMSO/50% sterile saline was used as the vehicle. All tested 
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compounds were dissolved in 6% DMSO/94% sterile saline (0.9%), with the exception of 
compounds tested at 100 nmol, which were dissolved in 20% DMSO/80% sterile saline. 
Data Analysis. All data from antinociceptive and hyperalgesic tail-withdrawal assays are 
reported as percent antinociception or percent baseline response to control for each animal’s 
baseline latency, ±SEM. Through the utilization by one-way ANOVA, responses to treatment 
over time were analyzed, followed by Tukey’s post hoc test as appropriate. Percent baseline is 
calculated by the below formula: 
 % Baseline Response = 100 𝑡𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑎𝑡𝑒𝑛𝑐𝑦  
6.12.1: Tail-Withdrawal Assay 
 The warm-water tail-withdrawal assays were performed to quantify antinociception (55 
ºC) and hyperalgesic (48 ºC) activity. 
6.12.1.1: Antinociception Assay 
Water was heated and maintained at 55 ºC in a 2L water bath. Mice were gently 
restrained for each testing and their tails were submerged 2 cm into the water bath. The latency 
to curl or flick the tail was recorded and served as the dependent measure to determine the 
baseline tail-withdrawal latencies. Mice that did not respond within 5 seconds during baseline 
testing were excluded from the experiment. Mice were administered compounds i.c.v. and tail-
withdrawal latencies were measured every 10 minutes, for 1 hour following administration or 
until latencies were restored to the baseline values. The maximum response time was limited to 
15 seconds; the tail was removed from the water if the mouse failed to display a tail-withdrawal 
response in the time period and the animal was assigned a maximum antinociceptive score of 
100%. After each time point, antinociception was calculated according to the following formula: 
% Antinociception = 100 ∗ !"#! !"#$%&'!!"#$%"& !"#$%&'!"!!"#$%"& !"#$%&'  
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6.12.1.2: Antinociception Receptor Selectivity Assay 
 In order to determine the agonist receptor selectivity, the same conditions as the 
antinociception assay were utilized. MOP knockout (KO) mice, KOP KO mice, and wild-type 
mice were used in this experiment. Baseline responses of the wild-type mice (alone) were 
recorded. MOP KO and KOP KO mice were subjected to the same conditions as previously 
mentioned. Wild-type mice were pretreated with the highly selective DOP antagonist, naltrindole 
(20 mg/kg, i.p.) 20 minutes prior to administration of tested compound. Antinociception 
produced by the synthesized compounds post-treatment was then measured 40 minutes following 
their administration.349 
6.12.1.3: Hyperalgesic Assay 
 Water was heated and maintained at 48 ºC in a 2L water bath. 48 ºC was the chosen water 
temperature to ensure moderate tail-withdrawal response, but also acting as a significant 
temperature for hyperalgesic mice. Mice were gently restrained for each testing and their tails 
were submerged 2 cm into the water bath. The latency to curl or flick the tail was recorded and 
served as the dependent measure to determine the baseline tail-withdrawal latencies. Mice were 
administered a single dose (i.c.v.) of vehicle (50% DMSO) or novel compound pretreatment. A 
30 nmol dose (i.c.v.) of NPFF was administered 90-120 minutes after compound treatment. 
Animals that had an initial baseline latency <4 or >15 seconds were excluded from the study.  
Tail-withdrawal latencies were measured every 10 minutes for 80 minutes following 
administration of NPFF. The maximum response time was limited to 30 seconds; the tail was 
removed from the water if the mouse failed to display a tail-withdrawal response to minimize 
tissue damage. Experimentally induced decreases in tail-withdrawal latency indicate 
hyperalgesic effects, but increases in latency provide a measure of anti-hyperalgesic effect.  
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APPENDIX A: 1H AND 13C NMR SPECTRA FOR COMPOUNDS. 
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Spectra for compounds in Figure 26. 
Compound 13, KGM01085. 
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Spectra for compounds in Figure 27. 
Compound 17, KGM01091.  
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Spectra for compounds in figure 28. 
Compound 22, KL[16]. 
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Spectra for compounds in Figure 29. 
Compound 26, KGM01075. 
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Spectra for Compounds in Figure 30. 
Compound 30, KGM01073. 
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Compound 33, KGM01082.  
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Spectra for compounds in Figure 31. 
Compound 34, KL[22]. 
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Compound 36, KGM02001. 
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Spectra for compounds in Figure 32. 
Compound 37, KL[27]. 
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Compound 40, KGM02004. 
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Spectra for compounds in Figure 33. 
Compound 42, KGM01088. 
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Compound 49, KGM01094. 
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Compound 50, KGM01093. 
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Compound 52, KGM02002.  
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Spectra for compounds in Figure 36. 
Compound 53, KGM01100. 
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Compound 56, KGM02008. 
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Spectra for compounds in Figure 37. 
Compound 57, KGM01099. 
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Compound 59, KGM02009. 
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Spectra for compounds in Figure 38. 
Compound 61, KGM02006. 
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Spectra for compounds in Figure 39. 
Compound 65, KGM02011. 
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Compound 68, KGM02018. 
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Spectra for compounds in Figure 40. 
Compound 69, KGM02015.  
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Compound 70, KGM02019.  
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Compound 73, KGM02012. 
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N
H3C
H
N
H
N
N
Boc
Boc
 342 
Spectra for compounds in Figure 42. 
Compound 76, KGM02016. 
 
 
 
N
H3C NH2
 343 
Compound 77, KGM02020. 
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Spectra for compounds in Figure 43. 
Compound 80, KGM02017.  
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Compound 83, KGM02025. 
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 Spectra for compounds in Figure 44. 
Compound 84, KGM02027.  
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Compound 85, KGM02031.  
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Spectra for compounds in Figure 45. 
Compound 88, KGM02030.  
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Compound 91, KGM02035.  
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Spectra from compounds in Figure 46. 
Compound 92, KGM02026.  
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Compound 94, KGM02036.  
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Spectra for compounds in Figure 47. 
Compound 95, KGM02029.  
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Compound 96, KGM02032. 
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Compound 97, KGM02037. 
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Spectra for compounds in Figure 48. 
Compound 99, KGM02042.  
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Compound 100, KGM02046. 
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Spectra for compounds in Figure 49. 
Compound 103, KGM02065. 
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Compound 104, KGM02069. 
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Compound 105, KGM02089. 
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Spectra for compound in Figure 50. 
Compound 106, KGM02082. 
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Spectra for compounds in Figure 51. 
Compound 107, KGM02088. 
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Compound 108, KGM03001. 
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Spectra for compounds in Figure 52. 
Compound 109, KGM02066. 
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Compound 110, KGM02073. 
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Compound 112, KGM03002. 
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Spectra for compounds in Figure 53. 
Compound 113, KGM02064. 
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Compound 114, KGM02072. 
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Compound 116, KGM03003. 
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Spectra for compounds in Figure 54. 
Compound 118, KGM02043/KGM02061. 
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Compound 119, KGM02047/KGM02062. 
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Spectra for compounds in Figure 55. 
Compound 122, KGM02070. 
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Compound 123, KGM02077. 
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Compound 124, KGM02092. 
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Spectra for compounds in Figure 56. 
Compound 125, KGM02067. 
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Compound 126, KGM02076. 
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Compound 127, KGM02093. 
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Spectra for compounds in Figure 57. 
Compound 128, KGM02068. 
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Compound 129, KGM02074. 
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Compound 131, KGM02096. 
 
 
 
 
N
H3C
HCl
HCl
NH2
NH
 386 
Spectra for compounds in Figure 58. 
Compound 132, KGM02071. 
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Compound 133, KGM02075. 
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Compound 135, KGM02097. 
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Spectra for compounds in Figure 59. 
Compound 137, KGM02039. 
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Compound 138, KGM02041. 
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Compound 140, KGM02045. 
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Spectra for compounds in Figure 60. 
Compound 141, KGM02053. 
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Compound 142, KGM02055. 
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Compound 143, KGM02090. 
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Spectra for compounds in Figure 61. 
Compound 144, KGM02057. 
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Compound 145, KGM02060. 
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Compound 146, KGM02091. 
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Spectra for compounds in Figure 62. 
Compound 147, KGM02058. 
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Compound 148, KGM02059. 
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Compound 150, KGM03010. 
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Spectra for compounds in Figure 63. 
Compound 151, KGM02054. 
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Compound 152, KGM02056. 
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Compound 154, KGM03011. 
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Spectra for compounds in Figure 64. 
Compound 156, KGM02086. 
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Compound 157, KGM02087. 
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Compound 159, KGM02094. 
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Spectra for compounds in Figure 65. 
Compound 160, KGM02098. 
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Compound 161, KGM03004/KGM03005. 
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Compound 162, KGM03006. 
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Compound 163, KGM03012. 
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Spectra for compounds in Figure 66. 
Compound 164, KGM02099. 
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Compound 165, KGM03007/KGM03008. 
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Compound 166, KGM03009. 
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Compound 167, KGM03013. 
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Spectra for compounds in Figure 67. 
Compound 169, KGM02038. 
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Compound 170, KGM02040. 
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Spectra for compounds in Figure 68. 
Compound 174, KGM02083. 
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Compound 177, KGM02084. 
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Spectra for compounds in Figure 69. 
Compound 177, KGM02085. 
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Compound 177, KGM02100. 
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Mass spectra data for compound 45, KGM01090. 
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Mass Spectra and HPLC data for compound 72, KGM02022. 
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Mass spectra and HPLC data for compound 75, KGM02023. 
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Mass spectra and HPLC data for compound 78, KGM02024. 
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Table 27: Compound Identification Numbers. 
Derivative (Color 
Coded to Notebook) 
Compound Name in 
Lab Notebook 
Notebook 
Number(s) 
Notebook 
Page(s) 
Dissertation 
Number 
Phenyl KL[1] 1 81 2 
Phenyl KL[2] 1 83 3 
Phenyl KL[3] 1 84 5 
Phenyl KL[11] 1 22, 51 6 
Phenyl KL[12] 1 23, 51 7 
Phenyl KL[13] 1 65 8 
Phenyl KL[4] 1 54 9 
Phenyl KL[5] 1 55 10 
Phenyl KL[14] 1 69 11 
Phenyl KL[15] 1 78 12 
Phenyl KGM01085 1 85 13 
Phenyl KGM01086 1 86 14 
Phenyl KGM01087 1 87 16 
Phenyl KGM01091 1 91 17 
Phenyl KGM01092 1 92 18 
Phenyl KGM01095 1 95 20 
Naphthyl KL[16] 1 57 22 
Naphthyl KL[20] 1 59 23 
Naphthyl KL[21] 1 60, 64, 74 25 
Naphthyl KGM01075 1 75 26 
Naphthyl KGM01077 1 77 27 
Naphthyl KGM01080 1 80 29 
Naphthyl KGM01073 1 73 30 
Naphthyl KGM01076 1 76 31 
Naphthyl KGM01082 1, 3 82, 29 33 
Naphthyl KL[22] 1 61 34 
Naphthyl KL[23] 1 62, 72 35 
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Dissertation 
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Naphthyl KGM02001/KL[24] 2 1 36 
Naphthyl KL[27] 1 67 37 
Naphthyl KL[28] 1 70 38 
Naphthyl KL[29] 1 71 39 
Naphthyl KGM02004/KL[30] 2 4 40 
4-Chlorophenyl KGM01088 1 88 42 
4-Chlorophenyl KGM01089 1 89 43 
4-Chlorophenyl KGM01090 1 90 45 
4-Chlorophenyl KGM01094 1 94 46 
4-Chlorophenyl KGM01096 1 96 47 
4-Chlorophenyl KGM01098 1 98 49 
4-Chlorophenyl KGM01093 1 93 50 
4-Chlorophenyl KGM01097 1 97 51 
4-Chlorophenyl KGM02002 2 2 52 
4-Chlorophenyl KGM01100 1 100 53 
4-Chlorophenyl KGM02005 2 5 54 
4-Chlorophenyl KGM02008 2, 3 8, 30 56 
4-Chlorophenyl KGM01099 1 99 57 
4-Chlorophenyl KGM02003 2 3 58 
4-Chlorophenyl KGM02009 2 9 59 
4-Methylphenyl KGM02006 2 6 61 
4-Methylphenyl KGM02007 2 7 62 
4-Methylphenyl KGM02010 2 10 64 
4-Methylphenyl KGM02011 2 11 65 
4-Methylphenyl KGM02013 2 13 66 
4-Methylphenyl KGM02018 2 18 67 
4-Methylphenyl KGM02015 2 15 68 
4-Methylphenyl KGM02019 2 19 69 
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Derivative (Color 
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Compound Name in 
Lab Notebook 
Notebook 
Number(s) 
Notebook 
Page(s) 
Dissertation 
Number 
4-Methylphenyl KGM02022 2 22 70 
4-Methylphenyl KGM02012 2 12 71 
4-Methylphenyl KGM02014 2 14 72 
4-Methylphenyl KGM02023 2 23 74 
4-Methylphenyl KGM02016 2 16 75 
4-Methylphenyl KGM02020 2 20 76 
4-Methylphenyl KGM02024 2 24 78 
3,4-Dichlorophenyl KGM02017 2 17 80 
3,4-Dichlorophenyl KGM02021 2 21 81 
3,4-Dichlorophenyl KGM02025 2 25 83 
3,4-Dichlorophenyl KGM02027 2 27 84 
3,4-Dichlorophenyl KGM02031 2 31 85 
3,4-Dichlorophenyl KGM02034 2 34 86 
3,4-Dichlorophenyl KGM02030 2 30 87 
3,4-Dichlorophenyl KGM02033 2 33 88 
3,4-Dichlorophenyl KGM02035 2 35 89 
3,4-Dichlorophenyl KGM02026 2 26 90 
3,4-Dichlorophenyl KGM02028 2 28 91 
3,4-Dichlorophenyl KGM02036 2 36 93 
3,4-Dichlorophenyl KGM02029 2 29 94 
3,4-Dichlorophenyl KGM02032 2 32 95 
3,4-Dichlorophenyl KGM02037 2 37 97 
3-Chlorophenyl KGM02042; KGM02078 2 42, 78 99 
3-Chlorophenyl KGM02046; KGM02079 2 46, 79 100 
3-Chlorophenyl KGM02048; KGM02080 2 48, 80 102 
3-Chlorophenyl KGM02065 2 65 103 
3-Chlorophenyl KGM02069 2 69 104 
3-Chlorophenyl KGM02089 2 89 105 
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Derivative (Color 
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Lab Notebook 
Notebook 
Number(s) 
Notebook 
Page(s) 
Dissertation 
Number 
3-Chlorophenyl 
KGM02063; 
KGM02081; KGM02082 
2 63, 81, 82 106 
3-Chlorophenyl KGM02088 2 88 107 
3-Chlorophenyl KGM03001 3 1 108 
3-Chlorophenyl KGM02066 2 66 109 
3-Chlorophenyl KGM02073 2 73 110 
3-Chlorophenyl KGM03002 3 2, 27 112 
3-Chlorophenyl KGM02064 2 64 113 
3-Chlorophenyl KGM02072 2 72 114 
3-Chlorophenyl KGM03003 3 3, 28 116 
3-Methylphenyl KGM02043 2 43 118 
3-Methylphenyl KGM02047; KGM02062 2 47, 62 119 
3-Methylphenyl KGM02049 2 49 121 
3-Methylphenyl KGM02070 2 70 122 
3-Methylphenyl KGM02077 2 77 123 
3-Methylphenyl KGM02092 2 2 124 
3-Methylphenyl KGM02067 2 67 125 
3-Methylphenyl KGM02076 2 76 126 
3-Methylphenyl KGM02093 2 93 127 
3-Methylphenyl KGM02068 2 68 128 
3-Methylphenyl KGM02074 2 74 129 
3-Methylphenyl KGM02096 2, 3 96, 25 131 
3-Methylphenyl KGM02071 2 71 132 
3-Methylphenyl KGM02075 2 75 133 
3-Methylphenyl KGM02097 2, 3 97, 26 135 
3-Methoxyphenyl KGM02039 2 39 137 
3-Methoxyphenyl KGM02041 2 41 138 
3-Methoxyphenyl KGM02045 2 45 140 
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Lab Notebook 
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Page(s) 
Dissertation 
Number 
3-Methoxyphenyl KGM02053 2 53 141 
3-Methoxyphenyl KGM02055 2 55 142 
3-Methoxyphenyl KGM02090 2 90 143 
3-Methoxyphenyl KGM02057 2 57 144 
3-Methoxyphenyl KGM02060 2 60 145 
3-Methoxyphenyl KGM02091 2 91 146 
3-Methoxyphenyl KGM02058 2 58 147 
3-Methoxyphenyl KGM02059 2 59 148 
3-Methoxyphenyl KGM03010 3 10 150 
3-Methoxyphenyl KGM02054 2 54 151 
3-Methoxyphenyl KGM02056 2 56 152 
3-Methoxyphenyl KGM03011 3 11 154 
 KGM02086 2 86 155 
 KGM02087 2 87 157 
 KGM02094 2 94 159 
4-Methoxyphenyl KGM02098 2 98 160 
4-Methoxyphenyl KGM03004, KGM03005 3 4, 5 161 
4-Methoxyphenyl KGM03006 3 6 162 
4-Methoxyphenyl KGM03012 3 12 163 
4-Hydroxyphenyl KGM02099 2 99 164 
4-Hydroxyphenyl KGM03007, KGM03008 3 7, 8 165 
4-Hydroxyphenyl KGM03009 3 9 166 
4-Hydroxyphenyl KGM03013 3 13 167 
*Bolded compound name = final compound 
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Table 28: In vitro screening results from Core C. 
Cmpd Name Number DOPa KOPb MOPc NPFF1d NPFF2e CB1 CB2h 
KL[13] 8 97.6 91.7 101.4 93.2 76.4 54.1f 27.1 
KL[15] 12 82.4 70.8 100.0 88.0 86.8 63.3f 28.9 
KGM01086 14 59.2 13.4 74.1 20.1 11.6 38.6f 16.1 
KGM01087 16 92.3 89.5 98.7 79.6 65.4 88.1f 51.8 
KGM01092 18 94.6 82.3 97.7 64.8 41.4 26.0f 31.5 
KGM01095 20 94.4 98.1 99.8 99.7 89.2 39.6f 35.8 
KGM01080 29 92.0 93.3 99.4 93.4 70.6 47.2f 59.6 
KGM01082 33 67.4 57.2 97.5 28.4 16.0 41.7f 39.1 
KGM02001 36 55.8 2.9 94.3 22.4 38.0 51.9g 53.9 
KGM02004 40 85.5 75.9 96.0 84.2 78.5 82.0g 80.5 
KGM01096 47 84.8 79.8 100.4 69.4 33.8 64.4f 48.0 
KGM01098 49 88.0 89.6 97.8 98.7 88.9 65.6g 46.3 
KGM02002 52 74.1 68.0 96.9 70.3 45.8 46.2g 16.2 
KGM02005 54 46.4 21.0 65.8 29.7 11.4 81.5g 41.7 
KGM02008 56 68 55 97 34.9 21.3 55f 22 
KGM02009 59 76.2 35.0 83.6 71.9 60.4 79.6g 49.8 
KGM02013 66 92 92 97 51.7 17.1 95f 58 
KGM02018 67 63 59 97 31.9 49.2 0f 10 
KGM02019 69 55 32 49 15.1 3.2 45f 26 
KGM02022 70 77 72 98 77.4 61.8 73f 65 
KGM02023 74 10 0 80 46.2 0 14f 8 
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KGM02024 78 13 0 28 0.0 2.1 3f 9 
KGM02031 85 78.6 83.1 97.2 53.7 49.3 34.3f 54.0 
KGM02034 86 87.5 90.1 98.1 91.2 73.9 49.0f 45.4 
KGM02033 88 51.5 54.0 43.1 26.6 23.9 55.7f 43.9 
KGM02035 89 68.3 72.9 97.5 59.1 36.0 55.2f 41.0 
KGM02036 93 93.6 93.5 98.2 93.1 86.6 70.1f 66.3 
KGM02037 97 92.5 93.0 95.4 75.5 66.6 78.6f 81.9 
**Data obtained in-house from COBRE Core C. 
aReflects the % Displacement of [3H]DPDPE from HEKhDOR receptor membrane. 
bReflects the % Displacement of [3H]U-69,593 from HEKhKOR receptor membrane. 
cReflects the % Displacement of [3H]DAMGO from HEKhMOR receptor membrane. 
dReflects the % Displacement of [3H]-NPVF from CHOhNPFF1 receptor membrane. 
eReflects the % Displacement of [3H] -EYW from CHOhNPFF2 receptor membrane. 
fReflects the % Displacement of [3H]CP-55,940  from CHOhCB1 receptor membrane. 
gReflects the % Displacement of [3H]CP-55-940 from HEKhCB1 receptor membrane 
hReflects the % Displacement of [3H]CP-55,940 from HEKhCB2 receptor membrane. 
 
Table 29: In vitro CB1 and CB2 binding data. 
Cmpd Name Number CB1 Ki (nM)† CB2 Ki (nM)† 
KL[13] 8 N.A. N.A. 
KL[15] 12 N.A. N.A. 
KGM01086 14 N.A. N.A. 
KGM01087 16 985.2 ± 330.1 N.A. 
KGM01092 18 N.A. N.A. 
KGM01095 20 N.A. N.A. 
KGM01080 29 N.A. N.A. 
KGM01082 33 N.A. N.A. 
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KGM02001 36 N.A. N.A. 
KGM02004 40 544.6 ± 185.2 1,527 ± 336 
KGM01096 47 N.A. N.A. 
KGM01098 49 N.A. N.A. 
KGM02002 52 N.A. N.A. 
KGM02005 54 23.68 ± 13.71 N.A. 
KGM02008 56 N.A. N.A. 
KGM02009 59 223.4 ± 83.4 N.A. 
KGM02013 66 * N.A. 
KGM02018 67 N.A. N.A. 
KGM02019 69 N.A. N.A. 
KGM02022 70 * N.A. 
KGM02023 74 N.A. N.A. 
KGM02024 78 N.A. N.A. 
KGM02031 85 N.A. N.A. 
KGM02034 86 N.A. N.A. 
KGM02033 88 N.A. N.A. 
KGM02035 89 N.A. N.A. 
KGM02036 93 * N.A. 
KGM02037 97 * * 
**Data obtained in-house from COBRE Core C. 
Ki values, expressed as mean ± S.E.M. 
†Reflects displacement of [3H] of CP-55,940. 
*Not tested, awaiting testing. 
N.A., no affinity as determined by a primary screen. 	
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